User Image Cart Icon 0 Search Image

Neuroprotective Agents

  1. Neuroprotection by estradiol
  2. Neuroprotection by the inhibition of apoptosis
  3. The problem of assessing effective Neuroprotection in experimental cerebral ischemia
  4. Perinatal brain injury: from pathogenesis to Neuroprotection
  5. Nerve growth factor signaling, Neuroprotection , and neural repair
  6. Neuroprotection by the metabolic antioxidant α-lipoic acid
  7. Adenosine and Neuroprotection
  8. Estrogens and Neuroprotection
  9. Erythropoietin–a novel concept for Neuroprotection
  10. Antioxidant Neuroprotection in Alzheimer’s disease as preventive and therapeutic approach
  11. Neuroprotection against oxidative stress by estrogens: structure-activity relationship
  12. Innate immunity: the missing link in Neuroprotection and neurodegeneration?
  13. Estrogen-mediated Neuroprotection after experimental stroke in male rats
  14. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of Neuroprotection
  15. Neuroprotection in relation to retinal ischemia and relevance to glaucoma
  16. Bilobalide and Neuroprotection
  17. Endocannabinoids and Neuroprotection
  18. Hibernation, a model of Neuroprotection
  19. Neuroprotection and the ischemic cascade
  20. Is Neuroprotection a viable therapy for glaucoma?
  21. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition
  22. Neuroprotection : heat shock proteins
  23. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
  24. Endogenous Neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy
  25. Drug-mediated Neuroprotection and antiepileptogenesis: animal data
  26. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
  27. Glycine antagonist (gavestinel) in Neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
  28. Experimental stroke and Neuroprotection in the aging rat brain
  29. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant
  30. Erythropoietin-mediated Neuroprotection involves cross-talk between Jak2 and NF-κ B signalling cascades
  31. Neuroprotection by a caspase inhibitor in acute bacterial meningitis
  32. Testosterone‐mediated Neuroprotection through the androgen receptor in human primary neurons
  33. Glycine antagonist in Neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial
  34. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies
  35. Nonproteolytic Neuroprotection by human recombinant tissue plasminogen activator
  36. Cannabinoids and Neuroprotection in global and focal cerebral ischemia and in neuronal cultures
  37. brain cooling during transient focal ischemia provides complete Neuroprotection
  38. Current status and perspectives of Neuroprotection in ischemic stroke treatment
  39. Neuroprotection with noninvasive neurotrophin delivery to the brain
  40. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat
  41. Cytokines in CNS disorders: neurotoxicity versus Neuroprotection
  42. Caspase inhibitor affords Neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury.
  43. Assessment of the retinal nerve fiber layer in clinical trials of glaucoma Neuroprotection
  44. Glaucoma, apoptosis, and Neuroprotection .
  45. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep
  46. Neuroprotection by (−)-deprenyl and related compounds
  47. A new concept in the pharmacology of Neuroprotection
  48. Neuroprotection by memantine against neurodegeneration induced by β-amyloid (1–40)
  49. The mitogen-activated protein kinase pathway mediates estrogen Neuroprotection after glutamate toxicity in primary cortical neurons
  50. The role of the complement cascade in ischemia/reperfusion injury: implications for Neuroprotection
  51. Current status of Neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies
  52. Neuroprotection by a bile acid in an acute stroke model in the rat
  53. Neuroprotection and traumatic brain injury: the search continues
  54. Neuroprotection by brain -derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase
  55. Neuroprotection by bromocriptine against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice1
  56. Reaction of uric acid with peroxynitrite and implications for the mechanism of Neuroprotection by uric acid
  57. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia
  58. NOS knockouts and Neuroprotection
  59. Glycogen synthase kinase‐3β, mood stabilizers, and Neuroprotection
  60. The potential of Neuroprotection in glaucoma treatment
  61. The pharmacological manipulation of glutamate receptors and Neuroprotection
  62. Interactions of estrogens and insulin-like growth factor-I in the brain : implications for Neuroprotection
  63. Nuclear estrogen receptor-independent Neuroprotection by estratrienes: a novel interaction with glutathione
  64. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β
  65. Pathways of neuron-astrocyte interactions and their possible role in Neuroprotection
  66. Role of sodium channel inhibition in Neuroprotection : effect of vinpocetine
  67. Neuroprotection for acute stroke: making clinical trials work
  68. Neurotrophins, Neuroprotection and the blood-brain barrier
  69. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt
  70. The future of Neuroprotection
  71. Evaluation of memantine for Neuroprotection in dementia
  72. Neuroprotection in cerebrovascular disease
  73. Subthalamic nucleus‐mediated excitotoxicity in Parkinson’s disease: a target for Neuroprotection
  74. Erythropoietin and the brain : from neurodevelopment to Neuroprotection
  75. Central nicotinic receptors, neurotrophic factors and Neuroprotection
  76. Potential treatment modalities for glaucomatous neuropathy: Neuroprotection and neuroregeneration.
  77. Hematopoietic factor erythropoietin fosters Neuroprotection through novel signal transduction cascades
  78. Hyperalgesia, anxiety, and decreased hypoxic Neuroprotection in mice lacking the adenosine A1 receptor
  79. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease
  80. RGC death in mice after optic nerve crush injury: oxidative stress and Neuroprotection
  81. Inhibition of p38 mitogen‐activated protein kinase provides Neuroprotection in cerebral focal ischemia
  82. Cannabinoids and Neuroprotection
  83. Impact of progestins on estrogen-induced Neuroprotection : synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate
  84. Glia-dependent neurotoxicity and Neuroprotection in mesencephalic cultures
  85. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease
  86. Dopamine agonists and Neuroprotection in Parkinson’s disease
  87. Caspase activation and Neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation
  88. New horizons in Neuroprotection
  89. Magnesium for Neuroprotection in ischaemic stroke
  90. GABA and Neuroprotection
  91. Vitamin D hormone confers Neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons
  92. Neuroprotection : is it already applicable to glaucoma therapy?
  93. Minocycline provides Neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia
  94. Neuroprotection by the α2-Adrenoreceptor Agonist Dexmedetomidine in a Focal Model of Cerebral Ischemia
  95. Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors
  96. Neuroprotection is unlikely to be effective in humans using current trial designs
  97. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients
  98. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers Neuroprotection during chemical ischemia
  99. Action of Glucocorticoids on Survival of Nerve Cells: Promoting Neurodegeneration or Neuroprotection ?1
  100. Detailed characterization of Neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults
  101. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension
  102. Epilepsy and Neuroprotection : an illustrated review
  103. … system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and Neuroprotection
  104. Monosialogangliosides, Neuroprotection , and neuronal repair processes.
  105. Nuclear factor κB is a critical determinant in N‐methyl‐d‐aspartate receptor‐mediated Neuroprotection
  106. Melatoninergic Neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge
  107. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia.
  108. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for Neuroprotection
  109. Neuroprotection and dopamine agonists
  110. Vaccination for Neuroprotection in the mouse optic nerve: implications for optic neuropathies
  111. Vitamin E and other antioxidants in Neuroprotection
  112. Mechanisms of Neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein
  113. A putative role for platelet-derived growth factor in angiogenesis and Neuroprotection after ischemic stroke in humans
  114. Caspases and Neuroprotection .
  115. Preconditioning-induced Neuroprotection is mediated by reactive oxygen species
  116. Modeling of acute spinal cord injury in the rat: Neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673
  117. The therapeutic potential of the cannabinoids in Neuroprotection
  118. The protease thrombin is an endogenous mediator of hippocampal Neuroprotection against ischemia at low concentrations but causes degeneration at high …
  119. Apoptosis, Neuroprotection , and retinal ganglion cell death: an overview
  120. Endogenous mechanisms of Neuroprotection : role of zinc, copper, and carnosine
  121. The novel β-blocker, carvedilol, provides Neuroprotection in transient focal stroke
  122. Propofol Neuroprotection in a rat model of ischaemia reperfusion injury
  123. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes
  124. Glial cell survival is enhanced during melatonin‐induced Neuroprotection against cerebral ischemia
  125. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack
  126. Neuroprotection by dehydroepiandrosteronesulfate: role of an NFκB-like factor
  127. REVIEW■: Neuroprotection in brain Ischemia: An Update (Part I
  128. Differential mechanisms of Neuroprotection by 17 β-estradiol in apoptotic versus necrotic neurodegeneration
  129. On the mechanisms of Neuroprotection by creatine and phosphocreatine
  130. Current understanding of Neuroprotection in glaucoma
  131. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson’s disease
  132. Neuroprotection by S‐nitrosoglutathione of brain dopamine neurons from oxidative stress
  133. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and Neuroprotection
  134. Cellular and molecular mechanisms of estrogen regulation of memory function and Neuroprotection against Alzheimer’s disease: recent insights and remaining …
  135. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons
  136. Estrogen provides Neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats
  137. Partial Neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats
  138. Molecular Pathology of Cerebral Ischemia: Delayed Gene Expression and Strategies for Neuroprotection a
  139. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal
  140. Marked age‐dependent Neuroprotection by brain ‐derived neurotrophic factor against neonatal hypoxic—ischemic brain injury
  141. Modest hypothermia provides partial Neuroprotection for ischemic neonatal brain
  142. Stimulation of β-adrenoceptors activates astrocytes and provides Neuroprotection
  143. Indefatigable CA1 sector Neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats
  144. Differential Neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions
  145. Dopamine agonists and Neuroprotection in Parkinson’s disease
  146. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos
  147. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for Neuroprotection in stroke and trauma
  148. Inducible nitric oxide synthase expression after traumatic brain injury and Neuroprotection with aminoguanidine treatment in rats
  149. Dopaminergic Neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive …
  150. Medical treatment and Neuroprotection in traumatic brain injury
  151. Autoimmune maintenance and Neuroprotection of the central nervous system
  152. Cellular basis for progesterone Neuroprotection in the injured spinal cord
  153. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats
  154. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism
  155. Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal hypoxia-ischemia
  156. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
  157. Alpha-lipoic acid provides Neuroprotection from ischemia-reperfusion injury of peripheral nerve
  158. CDP‐choline: Neuroprotection in transient forebrain ischemia of gerbils
  159. Lithium induces brain -derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for Neuroprotection against glutamate excitotoxicity
  160. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795
  161. Ca2+ channel antagonists and Neuroprotection from cerebral ischemia
  162. Recombinant human erythropoietin for Neuroprotection : what is the evidence?
  163. Association of serum estrogen level and ischemic Neuroprotection in female rats
  164. Antioxidant property of pramipexole independent of dopamine receptor activation in Neuroprotection
  165. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization
  166. Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in Neuroprotection
  167. Amphiphilic, tri‐block copolymers provide potent, membrane‐targeted Neuroprotection
  168. Neuroprotection by the α2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia
  169. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to Neuroprotection in Parkinson’s disease
  170. Does Neuroprotection improve stroke outcome?
  171. Preconditioning‐induced Neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor‐κB
  172. Neuroprotection of glial cell line‐derived neurotrophic factor in damaged spinal cords following contusive injury
  173. Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia
  174. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity
  175. Death and Neuroprotection of retinal ganglion cells after different types of injury
  176. Neuroprotection for ischaemic stroke
  177. Neuroprotection of acute ischemic stroke: where are we?
  178. Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and Neuroprotection
  179. Adenosine A2A Receptors and Neuroprotection
  180. Glaucomatous neurodegeneration and the concept of Neuroprotection .
  181. Neuroprotection of S (+) ketamine isomer in global forebrain ischemia
  182. Neuroprotection by melatonin from kainate‐induced excitotoxicity in rats
  183. Neuroprotection by T-cells depends on their subtype and activation state
  184. Neuroprotection at Drosophila synapses conferred by prior heat shock
  185. Prophylactic Neuroprotection for cerebral ischemia.
  186. Relationship between the increased cell surface α7 nicotinic receptor expression and Neuroprotection induced by several nicotinic receptor agonists
  187. brain -derived neurotrophic factor-mediated Neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase …
  188. Neuroprotection after several days of mild, drug-induced hypothermia
  189. Estrogen‐mediated Neuroprotection against β‐amyloid toxicity requires expression of estrogen receptor α or β and activation of the MAPK pathway
  190. Progesterone Neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease
  191. Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity
  192. Cerebrolysin® reduces microglial activation in vivo and in vitro: a potential mechanism of Neuroprotection
  193. Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP‐choline Neuroprotection
  194. σ Receptor-mediated Neuroprotection against glutamate toxicity in primary rat neuronal cultures
  195. Hyperbaric oxygen preconditioning induces Neuroprotection against ischemia in transient not permanent middle cerebral artery occlusion rat model.
  196. Dendritic spines for Neuroprotection : a hypothesis
  197. Ginkgo biloba Neuroprotection : Therapeutic implications in Alzheimer’s disease
  198. Discovery of endocannabinoids and some random thoughts on their possible roles in Neuroprotection and aggression
  199. brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide Neuroprotection implicates edema‐based mechanism
  200. Neuroprotection
  201. Conjugation of brain -derived neurotrophic factor to a blood–brain barrier drug targeting system enables Neuroprotection in regional brain ischemia following …
  202. Physiological approaches to Neuroprotection : boosting of protective autoimmunity
  203. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein …
  204. Modest hypothermia provides partial Neuroprotection when used for immediate resuscitation after brain ischemia
  205. Differential damage to auditory neurons and hair cells by ototoxins and Neuroprotection by specific neurotrophins in rat cochlear organotypic cultures
  206. Persistent Neuroprotection with prolonged postischemic hypothermia in adult rats subjected to transient middle cerebral artery occlusion
  207. Drug-induced Neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor-kappaB in rats
  208. Erythropoietin exerts Neuroprotection in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production
  209. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector
  210. Differential Neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability …
  211. Combination of intraischemic and postischemic hypothermia provides potent and persistent Neuroprotection against temporary focal ischemia in rats
  212. Accelerated functional recovery and Neuroprotection by agmatine after spinal cord ischemia in rats
  213. Valproate and Neuroprotection
  214. Neuroprotection in acute ischemic stroke
  215. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington’s disease
  216. Is pharmacological Neuroprotection dependent on reduced glutamate release?
  217. Neuroprotection against CA1 injury with metalloporphyrins.
  218. Neuroprotection by methanol extract of Uncaria rhynchophylla against global cerebral ischemia in rats
  219. Symposium overview: the role of glutathione in Neuroprotection and neurotoxicity.
  220. Survival signaling and selective Neuroprotection through glutamatergic transmission
  221. Future of Neuroprotection in Parkinson’s disease
  222. Caffeine’s Neuroprotection against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice
  223. Microglial reaction induced by noncytotoxic methylmercury treatment leads to Neuroprotection via interactions with astrocytes and IL‐6 release
  224. Selective mGluR5 receptor antagonist or agonist provides Neuroprotection in a rat model of focal cerebral ischemia
  225. Neuroprotection in ischemia–reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor
  226. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia
  227. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia
  228. Hypoxic-ischemic brain injury in the newborn: cellular mechanisms and potential strategies for Neuroprotection
  229. Oxidative changes in brain pyridine nucleotides and Neuroprotection using nicotinamide
  230. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral …
  231. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of Neuroprotection in major depression?
  232. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration
  233. Neuroimmunophilin ligands exert neuroregeneration and Neuroprotection in midbrain dopaminergic neurons
  234. Quantitative assessment of Neuroprotection against NMDA-induced brain injury
  235. Retrograde cerebral perfusion as a method of Neuroprotection during thoracic aortic surgery
  236. Neuroprotection by pigment epithelial‐derived factor against glutamate toxicity in developing primary hippocampal neurons
  237. Group I and group III metabotropic glutamate receptor subtypes provide enhanced Neuroprotection
  238. Nimodipine Neuroprotection in cardiac valve replacement: report of an early terminated trial
  239. Electroencephalographic burst suppression is not required to elicit maximal Neuroprotection from pentobarbital in a rat model of focal cerebral ischemia
  240. Oxidative stress in the pathogenesis of Alzheimer’s disease and antioxidant Neuroprotection
  241. Treatment of acute ischemic stroke: Part II: Neuroprotection and medical management
  242. NMDA recepter-mediated Neuroprotection by essential oils from the rhizomes of Acorus gramineus
  243. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and Neuroprotection by antioxidants
  244. Nitric oxide is involved in anoxic preconditioning Neuroprotection in rat hippocampal slices
  245. The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
  246. Mechanism of Action and Persistence of Neuroprotection by Cell-Permeant Ca2+ Chelators
  247. Neuroprotection in Alzheimer’s disease—new strategies for treatment
  248. KATP channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal Neuroprotection
  249. Neuroprotection by propofol in acute mechanical injury: role of GABAergic inhibition
  250. Neuroprotection by ketamine at the cellular level
  251. Preconditioning‐mediated Neuroprotection : role of nitric oxide, cGMP, and new protein expression
  252. A specific inhibitor of calcium/calmodulin-dependent protein kinase-II provides Neuroprotection against NMDA-and hypoxia/hypoglycemia-induced cell death
  253. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in Neuroprotection against excitotoxicity
  254. Estrogen and Neuroprotection : from clinical observations to molecular mechanisms
  255. Pharmacologic Neuroprotection in experimental spinal cord ischemia: a systematic review
  256. Isoflurane Neuroprotection : a passing fantasy, again?
  257. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity
  258. Estrogen-astrocyte interactions: implications for Neuroprotection
  259. Rapid preconditioning Neuroprotection following anoxia in hippocampal slices: role of the K+ ATP channel and protein kinase C
  260. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers Neuroprotection
  261. Preconditioning-mediated Neuroprotection through erythropoietin?
  262. Nitric oxide in acute ischaemic stroke: a target for Neuroprotection
  263. Transient ischemia of the retina results in altered retrograde axoplasmic transport: Neuroprotection with brimonidine
  264. Delayed sclerosis, Neuroprotection , and limbic epileptogenesis after status epilepticus in the rat
  265. Animal and culture models of glaucoma for studying Neuroprotection
  266. Neuroprotection in acute ischaemic stroke
  267. Characterization of postischemic behavioral deficits in gerbils with and without hypothermic Neuroprotection
  268. Neuroprotection due to irrigation during bipolar cautery
  269. Corticotropin-releasing hormone-mediated Neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid β …
  270. Is there a rationale for Neuroprotection against dopamine toxicity in Parkinson’s disease?
  271. Dose‐ and time‐dependence of l‐NAME Neuroprotection in transient focal cerebral ischaemia in rats
  272. Nicotine blocks TNF‐α‐mediated Neuroprotection to NMDA by an α‐bungarotoxin‐sensitive pathway
  273. Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3 …
  274. Neuroprotection : a new treatment modality for glaucoma?
  275. Potential signalling pathways underlying corticotrophin‐releasing hormone‐mediated Neuroprotection from excitotoxicity in rat hippocampus
  276. New conceptual approaches for pharmacological Neuroprotection in glaucomatous neuronal degeneration
  277. Hypothermic Neuroprotection : a global ischemia study using 18-to 20-month-old gerbils
  278. Glucose deprivation and chemical hypoxia: Neuroprotection by P2 receptor antagonists
  279. Ischemic preconditioning acts upstream of GluR2 down-regulation to afford Neuroprotection in the hippocampal CA1
  280. N-methyl-D-aspartate receptor-mediated Neuroprotection in cerebellar granule cells requires new RNA and protein synthesis
  281. An improved survival model of hypoxia/ischaemia in the piglet suitable for Neuroprotection studies
  282. Intravenous agents and intraoperative Neuroprotection : beyond barbiturates
  283. p75-mediated Neuroprotection by NGF against glutamate cytotoxicity in cortical cultures
  284. Statins and Neuroprotection
  285. Group I metabotropic glutamate receptors in spinal cord injury: roles in Neuroprotection and the development of chronic central pain
  286. Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats
  287. Janus kinase 2, an early target of α7 nicotinic acetylcholine receptor-mediated Neuroprotection against Aβ-(1–42) amyloid
  288. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco
  289. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis
  290. Anti-oxidative Neuroprotection by estrogens in mouse cortical cultures.
  291. Morphological aspects of spinal cord autoimmune Neuroprotection : colocalization of T cells with B7‐2 (CD86) and prevention of cyst formation
  292. Hypoxia and hypoxia-inducible factor modulated gene expression in brain : involvement in Neuroprotection and cell death
  293. Enoxaparin in experimental stroke: Neuroprotection and therapeutic window of opportunity
  294. Investigations of neurotoxicity and Neuroprotection within the nucleus basalis of the rat
  295. Insulin-like growth factor-1-mediated Neuroprotection against oxidative stress is associated with activation of nuclear factor κB
  296. Neuroprotection is associated with β-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients
  297. Neuroprotection . Models and basic principles
  298. Modulation of neuronal and glial cell function by adenosine and Neuroprotection in vascular demential
  299. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation
  300. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
  301. Where do we stand on Neuroprotection ? Where do we go from here?
  302. Neuroprotection from glutamate toxicity with ultra-low dose glutamate
  303. Estrogen attenuates tumor necrosis factor-α expression to provide ischemic Neuroprotection in female rats
  304. Cellular delivery of trophic factors for the treatment of Huntington’s disease: is Neuroprotection possible?
  305. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: conditioned central neurogenic Neuroprotection
  306. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers Neuroprotection that exceeds the transduced population
  307. Inflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α impart Neuroprotection to an excitotoxin through distinct pathways
  308. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil
  309. Hypoglycaemia-induced cell death: features of Neuroprotection by the P2 receptor antagonist basilen blue
  310. The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson’s Disease with Iron …
  311. Age‐and concentration‐dependent Neuroprotection and toxicity by TNF in cortical neurons from β‐amyloid
  312. Head trauma and Neuroprotection
  313. Neuroprotection by estrogen via extracellular signal‐regulated kinase against quinolinic acid‐induced cell death in the rat hippocampus
  314. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion®)
  315. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons
  316. Corticostriatopallidal Neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration
  317. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-β
  318. The dopamine agonist cabergoline provides Neuroprotection by activation of the glutathione system and scavenging free radicals
  319. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides Neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma
  320. Improved Neuroprotection with hypothermia delayed by 6 hours following cerebral hypoxia-ischemia in the 14-day-old rat
  321. T cell immunity to copolymer 1 confers Neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies
  322. The estrogen receptor is not essential for all estrogen Neuroprotection : new evidence from a new analog
  323. Evidence that brain ‐derived neurotrophic factor Neuroprotection is linked to its ability to reverse the NMDA‐induced inactivation of protein kinase C in cortical neurons
  324. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide
  325. Attempts to obtain Neuroprotection in Parkinson’s disease
  326. Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor
  327. Stress‐inducible protein 1 is a cell surface ligand for cellular prion that triggers Neuroprotection
  328. Combined argatroban and edaravone caused additive Neuroprotection against 15 min of forebrain ischemia in gerbils
  329. Hypoxia, excitotoxicity, and Neuroprotection in the hippocampal slice preparation
  330. Advances in Neuroprotection trials
  331. Stimulus-dependent activation of NF-κB specifies apoptosis or Neuroprotection in cerebellar granule cells
  332. Traumatic Neuroprotection with inhibitors of nitric oxide and ADP-ribosylation
  333. … : an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in Neuroprotection
  334. Acute administration of Ginkgo biloba extract (EGb 761) affords Neuroprotection against permanent and transient focal cerebral ischemia in Sprague‐Dawley rats
  335. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members
  336. Estrogen Neuroprotection : the involvement of the Bcl-2 binding protein BNIP2
  337. Unexpected Neuroprotection observed with the adenosine A2A receptor agonist CGS 21680
  338. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide Neuroprotection in the MPTP‐mouse model of Parkinson’s disease
  339. Phosphatidylinositol 3‐kinase mediates Neuroprotection by estrogen in cultured cortical neurons
  340. Long-term Neuroprotection by benzodiazepine: full versus partial agonists after transient cerebral ischemia in the gerbil
  341. Role of calcium in sigma-mediated Neuroprotection in rat primary cortical neurons
  342. Dose-dependent Neuroprotection with tiagabine in a focal cerebral ischemia model in rat
  343. Pharmacology of AMPA antagonists and their role in Neuroprotection
  344. Nitric-oxide synthase and neurodegeneration/Neuroprotection
  345. Comparative optic nerve physiology: implications for glaucoma, Neuroprotection , and neuroregeneration.
  346. Design and application of HSV vectors for Neuroprotection
  347. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA‐074: a novel strategy for Neuroprotection based on ‘calpain–cathepsin …
  348. Monitoring for Neuroprotection : new technologies for the new millennium
  349. Assessment of cannabinoid induced gene changes: tolerance and Neuroprotection
  350. Neuroprotection by ATP-dependent potassium channels in rat neocortical brain slices during hypoxia
  351. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships.
  352. Opportunities for Neuroprotection in traumatic brain injury
  353. Strategies for Neuroprotection
  354. Prolonged induction of neuronal NOS expression and activity following cortical spreading depression (SD): implications for SD-and NO-mediated Neuroprotection
  355. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting Neuroprotection in cerebral ischemia through apoptosis reduction …
  356. Neuroprotection by the pyridoindole stobadine: a minireview
  357. Expectations in the treatment of retinal diseases: Neuroprotection
  358. Immortalized dopamine neurons: A model to study neurotoxicity and Neuroprotection
  359. Neuroprotection : the role of neuroglia.
  360. Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for Neuroprotection
  361. Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation.
  362. Strategies for Neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies.
  363. Neuroprotection in brain Ischemia: An Update (Part II
  364. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity
  365. Felbamate Neuroprotection against CA1 traumatic neuronal injury
  366. BDNF and NGF afford in vitro Neuroprotection against ethanol combined with acute ischemia and chronic hypoglycemia
  367. Neuroprotection by scatter factor/hepatocyte growth factor and FGF‐1 in cerebellar granule neurons is phosphatidylinositol 3‐kinase/akt‐dependent and MAPK/CREB …
  368. A dose-response study of Neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
  369. Clinical trial update: Neuroprotection against acute ischaemic stroke
  370. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation
  371. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view
  372. Harnessing the immune system for Neuroprotection : therapeutic vaccines for acute and chronic neurodegenerative disorders
  373. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX)
  374. Monitoring Neuroprotection and restorative therapies in Parkinson’s disease with PET
  375. Dose‐related Neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of Neuroprotection in α4 nicotinic receptor subunit knockout mice
  376. Neuroprotection by corticotropin releasing factor during hypoxia in rat brain .
  377. Evaluation of Neuroprotection by lithium and valproic acid against ouabain‐induced cell damage
  378. Do statins afford Neuroprotection in patients with cerebral ischaemia and stroke?
  379. … audiogenic seizures (MDDASs) in adult mice: a nutritional model for discriminatory screening of anticonvulsant drugs and original assessment of Neuroprotection …
  380. Multiple pathways of Neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons
  381. Optic nerve degeneration and potential Neuroprotection : implications for glaucoma
  382. Gene therapeutic strategies for Neuroprotection : implications for Parkinson’s disease
  383. Toxicity of CSF in motor neurone disease: a potential route to Neuroprotection
  384. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat
  385. AP-1 proteins in the adult brain : facts and fiction about effectors of Neuroprotection and neurodegeneration
  386. Intrinsic neurons of fastigial nucleus mediate neurogenic Neuroprotection against excitotoxic and ischemic neuronal injury in rat
  387. Lidocaine for Neuroprotection : more evidence of efficacy
  388. -Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion
  389. Neurotoxicity of polyamines and pharmacological Neuroprotection in cultures of rat cerebellar granule cells
  390. Feasibility and efficacy of balloon-based Neuroprotection during carotid artery stenting in a single-center setting
  391. Oestrogen and nerve growth factor–Neuroprotection and repair in Alzheimer’s disease
  392. brain antioxidant regulation in mammals and anoxia-tolerant reptiles: balanced for Neuroprotection and neuromodulation
  393. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and Neuroprotection in the central nervous system
  394. Interactions between Hypothermia and the Latency to Ischemic Depolarization Implications for Neuroprotection
  395. Bone morphogenetic proteins are involved in fetal kidney tissue transplantation-induced Neuroprotection in stroke rats
  396. Neuroprotection with anaesthetic agents
  397. Enhanced Neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate
  398. Cellular basis of steroid Neuroprotection in the wobbler mouse, a genetic model of motoneuron disease
  399. Neuroprotection for Parkinson’s disease
  400. Diazepam-induced Neuroprotection : dissociating the effects of hypothermia following global ischemia
  401. Cyclic guanosine 3′, 5′-monophosphate-mediated Neuroprotection by nitric oxide in dissociated cultures of rat dorsal root ganglion neurones
  402. Neuroprotection for Parkinson’s disease: a new approach for a new millennium
  403. Hypothermic Neuroprotection of peripheral nerve of rats from ischaemia–reperfusion injury
  404. Conus peptides and Neuroprotection .
  405. Activation of σ1 receptor subtype leads to Neuroprotection in the rat primary neuronal cultures
  406. Review of clinical trials of Neuroprotection in acute spinal cord injury
  407. Postischemic hypothermia and IL-10 treatment provide long-lasting Neuroprotection of CA1 hippocampus following transient global ischemia in rats
  408. Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia
  409. Spectrin proteolysis in the hippocampus: a biochemical marker for neuronal injury and Neuroprotection
  410. Neuroprotection in acute ischaemic stroke
  411. Neuroprotection by 2-h postischemia administration of two free radical scavengers, α-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN …
  412. Neonatal ischemic Neuroprotection by modest hypothermia is associated with attenuated brain acidosis
  413. Neuroprotection by recombinant thrombomodulin
  414. Iron and neurodegeneration: prospects for Neuroprotection
  415. Neurodegeneration and Neuroprotection in Parkinson’s disease
  416. Neuroprotection in Parkinson’s disease: love story or mission impossible?
  417. Nitric oxide synthase expression in the transient ischemic rat retina: Neuroprotection of betaxolol
  418. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives
  419. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment
  420. Injury mechanisms in the ischaemic penumbra–approaches to Neuroprotection in acute ischaemic stroke
  421. Calcium antagonists: their role in Neuroprotection
  422. Discovery of molecular mechanisms of Neuroprotection using cell-based bioassays and oligonucleotide arrays
  423. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C
  424. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat
  425. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats.
  426. Role of alpha-2 adrenergic receptors in Neuroprotection and glaucoma
  427. Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides Neuroprotection
  428. Studies of damaged processes in the nervous system and possibilities of Neuroprotection
  429. NMDA antagonists: their role in Neuroprotection
  430. cDNA microarray to study gene expression of dopaminergic neurodegeneration and Neuroprotection in MPTP and 6-hydroxydopamine models: implications for …
  431. The rapid effects of estrogen are implicated in estrogen-mediated Neuroprotection
  432. Metallothionein induction in human CNS in vitro: Neuroprotection from ionizing radiation
  433. Neuroprotection and intracellular Ca2+ modulation with fructose-1, 6-bisphosphate during in vitro hypoxia–ischemia involves phospholipase C-dependent signaling
  434. Cerebral Neuroprotection and ketamine
  435. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia
  436. … 4-aryl-3-aminoquinolin-2-ones: a new class of calcium-Dependent, large conductance, potassium (maxi-K) channel openers targeted for post-stroke Neuroprotection
  437. Beneficial autoimmune T cells and posttraumatic Neuroprotection
  438. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model
  439. Neuronal cell death and strategies for Neuroprotection
  440. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3β pathway: Implications for Neuroprotection
  441. Neurogenesis and Neuroprotection in the Adult brain : A Putative Role for 5‐Lipoxygenase?
  442. … (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in Neuroprotection
  443. … precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: Neuroprotection by Ca2+ antagonist …
  444. Neuroprotection with felbamate: a 7-and 28-day study in transient forebrain ischemia in gerbils
  445. Neuroprotection and antiepileptogenesis: overview, definitions, and context
  446. Neuroprotection in neuroanesthesia: current practices in Germany
  447. Selegiline: current perspectives on issues related to Neuroprotection and mortality
  448. Early and late molecular events in neurodegeneration and Neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
  449. Usefulness of postischemic thrombolysis with or without Neuroprotection in a focal embolic model of cerebral ischemia
  450. Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile
  451. Role of potassium channels in the central neurogenic Neuroprotection elicited by cerebellar stimulation in rat
  452. Sodium and potassium channel modulators: their role in Neuroprotection
  453. Liposome-mediated transfer of the bcl-2 gene results in Neuroprotection after in vivo transient focal cerebral ischemia in an animal model
  454. Neuroprotection disappointment yet aGAIN
  455. Les leucomalacies périventriculaires. IL Diagnostic, séquelles et Neuroprotection
  456. Excitotoxicity and Neuroprotection
  457. Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N …
  458. Inhibition of glutamate release: a possible mechanism of hypothermic Neuroprotection
  459. Glutamate-induced excitotoxicity in retina: Neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers
  460. Neuroprotection by melatonin from glutamate‐induced excitotoxicity during development of the cerebellum in the chick embryo
  461. HU-211, a nonpsychotropic cannabinoid, produces short-and long-term Neuroprotection after optic nerve axotomy
  462. Neuroprotection —rationale for pharmacological modulation of Na+-channels
  463. The effect of oedema and tissue swelling on the measurement of Neuroprotection ; a study using chlormethiazole and permanent middle cerebral artery occlusion in …
  464. Neuroprotection : establishing proof of concept in human stroke
  465. Strategies for Neuroprotection against L‐trans‐2,4‐pyrrolidine dicarboxylate‐induced neuronal damage during energy impairment in vitro
  466. Is there Neuroprotection in Parkinson syndrome?
  467. Amyloid protein precursor stimulates excitatory amino acid transport: implications for roles in Neuroprotection and pathogenesis
  468. Neuroprotection failure in stroke
  469. Hypothermia and metabolic stress: narrowing the cellular site of early Neuroprotection .
  470. Neuroprotection with Bcl-220–34 peptide against trauma
  471. In glaucoma, should enthusiasm about Neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?
  472. Therapeutic coma or Neuroprotection by anaesthetics
  473. Cellular and molecular basis of estrogen’s Neuroprotection
  474. VIP Neuroprotection against excitotoxic lesions of the developing mouse brain
  475. Combined Neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia.
  476. No additional Neuroprotection provided by barbiturate-induced burst suppression under mild hypothermic conditions in rats subjected to reversible focal ischemia
  477. … as a stressor in mice:: Against the dopaminergic neurotoxicity of d-mdma, low body weight mitigates restraint-induced hypothermia and consequent Neuroprotection
  478. Modeling pediatric head trauma: mechanisms of degeneration and potential strategies for Neuroprotection
  479. Characterization of Neuroprotection from excitotoxicity by moderate and profound hypothermia in cultured cortical neurons unmasks a temperature-insensitive …
  480. Imaging technologies for assessing Neuroprotection in glaucomatous optic neuropathy
  481. ATP-dependent potassium channel mediates Neuroprotection by chemical preconditioning with 3-nitropropionic acid in gerbil hippocampus
  482. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia
  483. Neurotoxic action of veratridine in rat brain neuronal cultures: mechanism of Neuroprotection by Ca++ antagonists nonselective for slow Ca++ channels.
  484. Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)‐4‐phosphonophenylglycine
  485. A global hypoxia preconditioning model: Neuroprotection against seizure-induced specific gravity changes (edema) and brain damage in rats
  486. Do dopamine agonists provide Neuroprotection ?
  487. T cell-mediated Neuroprotection involves antithrombin activity
  488. Selective blockade of type-1 metabotropic glutamate receptors induces Neuroprotection by enhancing gabaergic transmission
  489. Transgenic glutathione peroxidase mouse models for Neuroprotection studies.
  490. Metallothionein, neurotrophins and selegiline in providing Neuroprotection in Parkinson’s disease
  491. Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT
  492. Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats
  493. Retinal neuronal cell death: molecular mechanism and Neuroprotection
  494. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for Neuroprotection studies
  495. Neuroprotection during cardiac surgery: strategies to reduce cognitive decline
  496. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in Neuroprotection
  497. Vasoprotection as Neuroprotection for the optic nerve
  498. Practical importance of Neuroprotection in Parkinson’s disease
  499. Structure/function in Neuroprotection and apoptosis
  500. Neuroprotection by a novel compound, NS521
  501. A model of ‘epileptic tolerance’for investigating Neuroprotection , epileptic susceptibility and gene expression-related plastic changes
  502. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl (R) salsolinol, and Neuroprotection by propargylamines
  503. Ketamine racemate and S-(+)-ketamine. Cerebrovascular effects and Neuroprotection following focal ischemia
  504. Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF
  505. Neuroprotection induced by stimulating A1 or blocking A2A adenosine receptors: an apparent paradox
  506. In vitro Neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH2 (EEP)
  507. Ketamine and Neuroprotection . Clinical outlook
  508. Intravenous Magnesium for Neuroprotection in Acute Stroke: Clinical Hope Versus Basic
  509. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
  510. Neuroprotection : past successes and future challenges
  511. T cell mediated Neuroprotection is a physiological response to central nervous system insults
  512. Neuroprotection in acute ischaemic stroke. II: Clinical potential
  513. Extradural compression of sensorimotor cortex: a useful model for studies on ischemic brain damage and Neuroprotection
  514. Neuroprotection and antiepileptogenesis: Where are we now?
  515. ACTH/MSH-derived peptides and peripheral nerve plasticity: neuropathies, Neuroprotection and repair
  516. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke
  517. Neuroprotection by the N‐Methyl‐d‐Aspartate Receptor Antagonist CGP 40116: In Vivo and In Vitro Studies
  518. MCI-186: further histochemical and biochemical evidence of Neuroprotection
  519. Neuroprotection in aortic surgery
  520. Cocaine dependence. A clinical syndrome requiring Neuroprotection .
  521. The effect of reperfusion on Neuroprotection using an inhibitor of poly (ADP-ribose) polymerase
  522. Preclinical studies with modafinil. Evidence for vigilance enhancement and Neuroprotection .
  523. Deleterious effects of IL-9–activated mast cells and Neuroprotection by antihistamine drugs in the developing mouse brain
  524. Neuroprotection against ischemic brain injury conferred by a novel nitrate ester
  525. Hypothermic Neuroprotection of peripheral nerve of rats from ischemia–reperfusion injury: intraischemic vs. reperfusion hypothermia
  526. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites
  527. Chemokines released from astroglia by vasoactive intestinal peptide. Mechanism of Neuroprotection from HIV envelope protein toxicity.
  528. Neuroprotection in HIV-positive drug users: implications for antioxidant therapy
  529. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug-induced Neuroprotection ?
  530. Possible role of microglial prostanoids and free radicals in Neuroprotection and neurodegeneration
  531. Glutamate-mediated Neuroprotection against N-methyl-D-aspartate toxicity: a role for metabotropic glutamate receptors
  532. Neuroprotection by caspase inhibitors
  533. Opioids: Epilepsy and Neuroprotection
  534. Assessment of neurotoxicity and “Neuroprotection ”
  535. Evaluation of Neuroprotection and behavioral recovery by the kappa-opioid, PD117302 following transient forebrain ischemia
  536. Neuroprotection by selegiline and other MAO inhibitors
  537. Calcium channel blockers and Neuroprotection
  538. Transcriptional pharmacology of neurodegenerative disorders: novel venue towards Neuroprotection against excitotoxicity?
  539. NO-Related species: Neuroprotection verses neurodestruction
  540. Hydroxyl radicals and nitric oxide in neurotoxicity and Neuroprotection
  541. Neuroprotection in stroke: is it time to consider large-molecule drugs?
  542. Gene transfer for Neuroprotection in animal models of Parkinson’s disease and amyotrophic lateral sclerosis
  543. Neuroprotection of grafted neurons with a GDNF/caspase inhibitor cocktail
  544. Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, Neuroprotection , and adrenomedullary secretion
  545. Clinical trials of Neuroprotection in Parkinson’s disease: long-term selegiline and alpha-tocopherol treatment.
  546. Neuroprotection by memantine as increased by hypothermia and nimodipine
  547. Immunosuppressant Analogs in Neuroprotection
  548. Prophylactic pharmacologic Neuroprotection against focal cerebral ischemia.
  549. The pursuit of effective Neuroprotection during infant cardiac surgery
  550. Correlates of delayed neuronal damage and Neuroprotection in a rat model of cardiac-arrest-induced cerebral ischemia
  551. In vitro Neuroprotection against glutamate toxicity provided by novel non‐competitive N‐methyl‐d‐aspartate antagonists
  552. Neuroprotection in idiopathic Parkinson’s disease
  553. Human retina contains polyamine sensitive [3H]-ifenprodil binding sites: implications for Neuroprotection ?
  554. Neuroprotection by dextromethorphan in acute experimental subdural hematoma in the rat
  555. Neuroprotection by anti-oxidant strategies in Parkinson’s disease
  556. Neuroprotection with herpes simplex vectors expressing virally derived anti-apoptotic agents
  557. Emerging strategies in Neuroprotection
  558. Neuroprotection in stroke: Analysis of failure, and alternative strategies
  559. Neuroprotection in ischemia of the retina in an animal model
  560. Neuroprotection by MK-801 in temperature maintained gerbils
  561. … class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and Neuroprotection
  562. Neuroprotection by A2A receptor antagonists
  563. Neuroprotection by R (−)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus …
  564. Neuroprotection for the new millennium: matchmaking pharmacology and technology
  565. Corticosteroid hormones in Neuroprotection and brain damage
  566. Neuroprotection to the retina: relevance in glaucoma
  567. Quantitative and dynamic MRI of Neuroprotection in experimental stroke
  568. Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative …
  569. Azulenyl nitrones: Colorimetric detection of oxyradical end products and Neuroprotection in the gerbil transient forebrain ischemia/reperfusion model
  570. Delayed multidose treatment with nicotinamide extends the degree and duration of Neuroprotection by reducing infarction and improving behavioral scores up to two …
  571. Cell Death in Spinal Cord Injury (SCI) Requires de Novo Protein Synthesis: Calpain Inhibitor E‐64‐d Provides Neuroprotection in SCI Lesion and Penumbra
  572. Neuroprotection and stroke
  573. Basic neurobiochemical mechanisms of brain Neuroprotection
  574. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides Neuroprotection in the aged parkinsonian rat.
  575. Neuroprotection : fact or fantasy?
  576. Synthesis, brain antihypoxic activity and cell Neuroprotection of 1-substituted-3, 7-dimethylxanthines
  577. Neuroprotection of mild hypothermia: differential effects
  578. Mild hypothermia: an alternative to deep hypothermia for achieving Neuroprotection
  579. Temporal dependent Neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model
  580. Oxidation of N-methyl (R) salsolinol: involvement to neurotoxicity and Neuroprotection by endogenous catechol isoquinolines
  581. Stereoselective effects of 2, 3-benzodiazepines in vivo: electrophysiology and Neuroprotection studies
  582. The Role of the Metabolism of (−)-Deprenyl in Neuroprotection
  583. Grand prematurity, risk of neuropsychic handicaps and Neuroprotection
  584. Glycosaminoglycans boost insulin-like growth factor-I-promoted Neuroprotection : blockade of motor neuron death in the wobbler mouse
  585. Cell culture models of neuronal degeneration and Neuroprotection
  586. Neuroprotection role of adenosine under hypothermia in the rat global ischemia involves inhibition of not dopamine release but delayed postischemic hypoperfusion
  587. Neuroprotection during hypoxic insults: role of adenosine
  588. Neuroprotection in Parkinson’s disease; a commentary
  589. Neuroprotection (including hypothermia)
  590. Inflammation in stroke—a potential target for Neuroprotection ?
  591. Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats
  592. Alcohol Blocks TNFα but Not Other Cytokine‐Mediated Neuroprotection to NMDA
  593. Neuroprotection by LY341122, a novel inhibitor of lipid peroxidation, against focal ischemic brain damage in rats
  594. Unilateral Hypoxic-Ischemic Injury in the Neonatal Rat brain Evaluated by In Vivo MRI: Correlation with Histopathology and Neuroprotection by MK-801
  595. Cellular delivery of trophic factors for the treatment of Huntington’s disease: is Neuroprotection possible?
  596. The environmental estrogenic compound bisphenol A exerts estrogenic effects on mouse hippocampal (HT-22) cells: Neuroprotection against glutamate and amyloid …
  597. Neuroprotection in stroke. A critical overview
  598. Prophylactic Neuroprotection to improve stroke outcome
  599. Learning may provide Neuroprotection against dementia.
  600. Excitotoxicity and Neuroprotection
  601. … motor system: Analyses of motoneuron cell death, motility, and target trophic factor activity and in vitro analyses of neurotoxicity and trophic factor Neuroprotection
  602. Positive modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits Neuroprotection after trimethyltin exposure in …
  603. Dopamine receptor agonists mediate Neuroprotection in malonate-induced striatal lesion in the rat
  604. Participation of manganese-superoxide dismutase in the Neuroprotection exerted by copper sulfate against 1-methyl 4-phenylpyridinium neurotoxicity
  605. Neuroprotection against excitotoxicity by N-alkylglycines in rat hippocampal neurons
  606. European Stroke Prevention Study-2 results: serendipitous demonstration of Neuroprotection induced by endogenous adenosine accumulation?
  607. Clinical aspects of Neuroprotection in Parkinson’s disease.
  608. Mechanisms of 1S, 3R-ACPD-induced Neuroprotection in rat hippocampal slices subjected to oxygen and glucose deprivation
  609. Dual effect of cerebrolysin in children with attention deficit syndrome with hyperactivity: Neuroprotection and immunomodulation.
  610. Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing
  611. Metabolism of dehydroepiandrosterone by rat hippocampal cells in culture: possible role of aromatization and 7-hydroxylation in Neuroprotection
  612. The case for Neuroprotection with dopamine agonists
  613. Neuroprotection and perinatal brain care: the field of the future, currently going nowhere!?
  614. Introduction to the special issue on Neuroprotection by steroids: new perspectives
  615. Neurotrophin-mediated Neuroprotection by solid fetal telencephalic graft in middle cerebral artery occlusion: a preventive approach
  616. Hypothermic Neuroprotection in cerebral ischemia
  617. SOD‐1 Transgenic Mice as a Model for Studies of Neuroprotection in Stroke and brain Traumaa
  618. Neuroprotection as initial therapy in acute stroke
  619. Neuroprotection , neuroregeneration, and interaction with insulin‐like growth factor‐I: novel non‐anticoagulant action of glycosaminoglycans
  620. Neuroprotection against ischemia by metabolic inhibition revisited: A comparison of hypothermia, a pharmacologic cocktail and magnesium plus mexiletine
  621. Metallothionein provides ubiquinone-mediated Neuroprotection in Parkinson’s disease
  622. Correlation of CGS 19755 Neuroprotection against in vitro excitotoxicity and focal cerebral ischemia
  623. Immunohistochemical evidence of Neuroprotection by R(−)‐deprenyl and N‐(2‐hexyl)‐N‐methylpropargylamine on DSP‐4‐induced degeneration of rat brain …
  624. Neuroprotection after cardiac arrest
  625. Neuroprotection of completely lacerated spinal cord of adult rats by homotopic and heterotopic transplantation
  626. Acidic fibroblast growth factor delays in vitro ischemia-induced intracellular calcium elevation in gerbil hippocampal slices: a sign of Neuroprotection
  627. Noise, Calpain, Calpain Inhibitors, and Neuroprotection : A Preliminary Report of Tinnitus Control.
  628. Current situation of Neuroprotection in stroke
  629. Peptidic endothelin-1 receptor antagonist, BQ-123, and Neuroprotection
  630. Neuroprotection by caffeine and pentoxifylline during experimental cerebral ischaemia.
  631. Neuroprotection against oxidative stress by serum from heat acclimated rats
  632. Central neurogenic Neuroprotection : Protection of brain from focal ischemia by cerebellar stimulation
  633. Stereoselective Neuroprotection by novel 2, 3-benzodiazepine non-competitive AMPA antagonists against non-NMDA receptor-mediated excitotoxicity in primary rat …
  634. Characterization of mianserin Neuroprotection in experimental spinal trauma: dose/route response and late treatment.
  635. Workshop II:“Neuroprotection ”–the Lugano consensus
  636. Neurotrophins and Neuroprotection improve axonal regeneration into Schwann cell transplants placed in transected adult rat spinal cord
  637. Neuroprotection afforded by some hindered phenols and α-tocopherol in guinea-pig detrusor strips subjected to anoxia-glucopenia and reperfusion-like conditions
  638. Increase of ATP levels by glutamate antagonists is unrelated to Neuroprotection .
  639. RS-100642-198, a novel sodium channel blocker, provides differential Neuroprotection against hypoxia/hypoglycemia, veratridine or glutamate-mediated neurotoxicity …
  640. Neuroprotection by aspirin in cerebrovascular pathology
  641. Failure of Neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy)
  642. Intraoperative Neuroprotection
  643. Motor, cytoarchitectural and biochemical assessment of pharmacological Neuroprotection against CNS damage induced by neonatal exposure to ionizing radiation
  644. Prospects for improved Neuroprotection trials in stroke
  645. In vitro Neuroprotection by substituted guanidines with varying affinities for the N-methyl-D-aspartate receptor ionophore and for sigma sites.
  646. Neuroprotection in Acute Stroke: Is there Still Hope?
  647. Heme oxygenase 1 transgenic mice as a model to study Neuroprotection .
  648. Neuroprotection in selective focal ischemia in rats by nitrates, an alternative redox manipulation on nitric oxide: experimental model
  649. Is MK-801 Neuroprotection mediated by systemic hypothermia in the immature rat?
  650. Pharmacological strategies for Neuroprotection and rehabilitation
  651. Blockade of voltage-sensitive Na+ channels by the 5-HT1A receptor agonist 8-OH-DPAT: possible significance for Neuroprotection
  652. Neuroprotection after spinal cord injury: state of the science.
  653. For ischemic brain damage, is preclinical evidence of Neuroprotection by presynaptic blockade of glutamate release enough?
  654. Mechanisms of the Neuroprotection of astrocyte during cerebral ischemic disease
  655. Nitric oxide-mediated mitochondrial impairment in neural cells: a role for glucose metabolism in Neuroprotection
  656. Neuroprotection in acute stroke
  657. Neuroprotection afforded by MK-801 against L-2-chloropropionic acid-induced cerebellar granule cell necrosis in the rat
  658. Neuroprotection , anaesthesia, and the brain
  659. Transforming Growth Factor-β Signaling and Neuroprotection
  660. Neuroprotection in vitro and in vivo by cell membrane-permeant Ca2+ chelators.
  661. Parkinson therapy yesterday, today, tomorrow. Neuroprotection gains in importance
  662. Acid–base management–is it relevant for the study design of hypothermic Neuroprotection ?
  663. Neuroprotection and selective vulnerability of neurons within the nucleus basalis magnocellularis
  664. Physiologic roles for the heme oxygenase products carbon monoxide, bilirubin and iron: links to Neuroprotection in stroke and Alzheimer’s disease
  665. Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment
  666. IGF-I in neuronal differentiation and Neuroprotection
  667. Periventricular leukomalacia and brain protection. II. Diagnosis, sequelae and Neuroprotection
  668. Primary dissociated cultures of human brain stem cells: a useful tool for their characterization and Neuroprotection study
  669. Excitatory amino acids and Neuroprotection
  670. The glycine binding site of the NMDA receptor: involvement in neurodegeneration and new approach for Neuroprotection .
  671. Membrane-derived lipid second messengers as targets for Neuroprotection : Platelet-activating factor
  672. Strategies and Techniques for Neuroprotection in Coronary Artery Surgery
  673. Neuroprotection for acute ischemic stroke: an overview
  674. Induced mild hypothermia: the spearhead strategy for effective neonatal Neuroprotection ?
  675. Neuroprotection by NMDA and non-NMDA glutamate antagonists
  676. β2‐Adrenoceptor Agonist Clenbuterol Causes NGF Expression and Neuroprotection
  677. ARL-15896, a NovelN-Methyl-D-aspartate Receptor Ion Channel Antagonist: Neuroprotection against Mitochondrial Metabolic Toxicity and Regional Pharmacology
  678. Isoflurane preconditioning induces Neuroprotection against middle cerebral artery occlusion damage in rat
  679. Cannabinoids and Neuroprotection in stroke
  680. Lipid peroxidation blockade: Neuroprotection from cell membranes to humans
  681. Studies on the interaction between 1, 2, 3, 4-tetrahydro-β-carboline and cigarette smoke: a potential mechanism of Neuroprotection for Parkinson’s disease
  682. Neuroprotection reduces the risk of peri-procedural major strokes and death in octogenarians
  683. Neuroprotection of mild hypothermia beginning at different time intervals on cerebral ischemia/reperfusion injury
  684. Pharmacological Characterization of [3H]-Ifenprodil Binding to Polyamine Binding Sites on Rabbit and Rat Retinal Homogenates: Role in Neuroprotection ?
  685. “Low-Tech” Neuroprotection for brain Injury
  686. Neurotrophic factors, Neuroprotection and hypothalamic function
  687. Excitatory and inhibitory pathways for anoxic preconditioning Neuroprotection in hippocampal slices
  688. CNS Neuroprotection
  689. Biomarkers of 3‐nitropropionic acid (3‐NPA)‐induced mitochondrial dysfunction as indicators of Neuroprotection
  690. … -Ischemic (HI) Hypothermia (Ht) Reduces Necrosis and Apoptosis Correspondingly in the Newborn Rat However Restraint Stress Ameliorates Neuroprotection
  691. Neuroprotection in neuro-ophthalmic disease
  692. Excitotoxic cascade and Neuroprotection in various stages of cerebral development
  693. Perioperative Neuroprotection
  694. Molecular mechanisms of Neuroprotection from neuronal death by trophic factor deprivation
  695. Neuroprotection by High Dose Magnesium in CABG Patients: Preliminary Data
  696. Neuroprotection as Initial Therapy in Acute Stroke: Third Report of an Ad Hoc Consensus Group Meeting
  697. Estrogens and other antioxidants in Neuroprotection : implications for Alzheimer’s disease
  698. Neuroprotection for ischemic stroke
  699. Theoretical aspects of Neuroprotection in acute ischaemic stroke. I: basic mechanisms
  700. Neuroprotection EFFECT OF TAURINE IN YOUNG RATS AND THE MECHANISM INVOLVED
  701. Neuroprotection by free radical scavengers and other antioxidants
  702. Neuroprotection during carotid endarterectomy
  703. Hydroxyl radical generation and post-ischemic reperfusion brain damage implications for Neuroprotection
  704. Mild hypothermia as a clinical strategy for Neuroprotection
  705. Neuroprotection by 21-aminosteroids: insights from latencies of anoxic terminal negativity in hippocampus slices of guinea pig
  706. Mitochondrial approaches to Neuroprotection
  707. Antiepileptics and Neuroprotection
  708. Neuroprotection and antiepileptogenesis
  709. Vaccination for T cell‐mediated Neuroprotection : Dream or reality?
  710. Sights set on Neuroprotection for glaucoma
  711. Future perspectives of gender hormones in Neuroprotection
  712. Hyperbaric oxygen preconditioning induces Neuroprotection against ischemia in transient not permanent middle cerebral artery occlusion rat model
  713. Results of two controlled studies on estrogen: avenue to Neuroprotection in schizophrenia
  714. Neuroprotection by neurotrophic factors in apoptosis
  715. Regulation of cyclic AMP synthesis in microglial cells and possible role of cyclic AMP in Neuroprotection
  716. Mild hypothermia provides Neuroprotection in an in vitro model of fetal cerebral ischemia.
  717. Current situation of experimental studies of glaucomatous optic Neuroprotection therapy [J]
  718. Mitochondria: Aspects for Neuroprotection
  719. No Naip: naff Neuroprotection
  720. gp120-Neuroprotection by mernantine
  721. Selective estrogen receptor modulator LY353381. HCl-mediated Neuroprotection and Bcl-2 expression after experimental stroke
  722. Monoamine oxidase inhibition and Neuroprotection by N1‐propargylphenelzine
  723. Plasma and CSF levels of dizocilplne (MK-801) required for Neuroprotection in the quinolinate-injected rat striatum
  724. Neuroprotection in glaucoma. Where is the clinical evidence?
  725. Modeling neurodegeneration and Neuroprotection in hippocampal slices
  726. Treatment of laser-induced retinal injuries by Neuroprotection
  727. Deleterious consequences of corticosteroid exposure: possible therapeutic Neuroprotection
  728. Neuroprotection in cerebral ischemia
  729. Pharmacological treatment of laser eye injuries by Neuroprotection
  730. HIGH PROSTAGLANDIN (PG) LEVELS IN THE PERINATAL PERIOD CONFER Neuroprotection .† 1218
  731. Free radical scavengers in Neuroprotection
  732. Rationale for the use of soy phytoestrogens for Neuroprotection
  733. Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection?
  734. Excitotoxicity, cerebral ischemia, and Neuroprotection by competitive NMDA receptor antagonists
  735. Neuroprotection IN ICU
  736. Effect of fractalkine on Neuroprotection
  737. Neuronal death mode switch and neurogenesis as in vivo Neuroprotection
  738. LONG-TERM Neuroprotection BY MATERNALLY-ADMINISTERED MAGNESIUM SULFATE (MgSO 4) IN PRETERM INFANTS IS RELATED TO INITIAL POST …
  739. Experimental and Clinical Neuroprotection : An Update
  740. KN-62 provides Neuroprotection against glutamate-induced excitotoxicity in neurons.
  741. Intraoperative Neuroprotection
  742. … inhibitors in Alzheimer’s disease: An experimental study on mechanisms of interatcion with muscarinic and nicotinic receptors and Neuroprotection
  743. A model of neonatal cerebral ischemia in rats (“levine”) to study Neuroprotection and neuroregeneration,”
  744. Beyond Neuroprotection : the protection of axons and oligodendrocytes in cerebral ischemia
  745. The approach of Neuroprotection for the new millennium
  746. Caroverine Depressesthe Activity of Cochlear Glutamate Receptors (in vivo Model for Drug-Induced Neuroprotection )
  747. Mitochondrial dysfunction in neurodegeneration: prospects for Neuroprotection
  748. Mild and moderate hypothermia for Neuroprotection
  749. Immune-mediated cell death and Neuroprotection in neurodegenerative diseases
  750. Molecular mechanism underlying Neuroprotection by rasagiline
  751. of Neuroprotection in the CNS
  752. Trophic factors, Neuroprotection and spinal cord repair
  753. The Pathophysiology of Stroke: Neuroprotection Following Stroke and Head Injury
  754. Neuroprotection in rabbit retina with N-acetyl-aspartylglutamate and 2-phosphonyl-methyl pentanedioic acid
  755. The role of estrogen receptor subtypes alpha and beta in developmental Neuroprotection and neurotrophism.
  756. Neuroprotection in Neuro-Ophthalmology-Introduction
  757. EARLY CEREBRAL Neuroprotection BY MATERNALLY-ADMINISTERED MAGNESIUM SULFATE (MgSO 4) IN PRETERM INFANTS IS RELATED TO INITIAL …
  758. Central neurogenic regulation of regional cerebral blood flow (rCBF) and relationship to Neuroprotection
  759. Neuroprotection of selective brain hyprothermia to neonates with the hypoxic-ischemic brain damage
  760. Neuroprotection with tetracyclines in brain ischemia models
  761. Lack of Neuroprotection by glutamate antagonist lubeluzole after transient global cerebral ischemia in fetal sheep
  762. Head Cooling and Neuroprotection
  763. Preservation Of Ganglion Cells In Adult Retinal Tissue Cultures-An In Vitro-Model For Neuroprotection
  764. prophylactic Neuroprotection • Design of clinical trials for prophylactic Neuroprotection • Conclusion
  765. Neuroprotection During CPB: From Mechanisms to Interventions
  766. Quantitative DWI analysis of Neuroprotection against soman-induced neuropathology
  767. The Endocannabinoid Anandamide: Metabolism & Neuroprotection
  768. 2 Understanding cerebral energy metabolism: a key to successful Neuroprotection
  769. An inhibitor of injury-induced COX-2 transcriptional activation elicits Neuroprotection in a brain damage model
  770. Substrate and mechanism of central neurogenic Neuroprotection .
  771. Neuroprotection in Parkinson’s Disease
  772. Neuroprotection as a possible therapy in glaucoma
  773. Neuroprotection in cerebral ischemia
  774. Poster Sessions CP11: Neurotoxicity and Neuroprotection
  775. Lubeluzole pretreatment does not provide Neuroprotection against transient global cerebral ischemia in fetal sheep near term
  776. Head Injuries: A Target for Neuroprotection
  777. Neuroprotection and Stroke: Neuroprotectants as initial therapy
  778. New evidence for Neuroprotection by estrogen
  779. Nitric oxide-induced neurotoxicity versus Neuroprotection ; relationship with selective motor neuronal death
  780. Neuroprotection of Excitotoxic brain Lesions in the Newborn Mouse by Glycine Antagonist and Inhibitor of No°. 159
  781. Sex hormones, Neuroprotection and cognition
  782. Neuregulins, Neuroprotection and Parkinson’s Disease
  783. Cerebral ischemia and Neuroprotection from the viewpoint of the neurosurgeon
  784. Hypothermia for Neuroprotection
  785. Probing into signaling transduction mechanisms of ischemic preconditioning based on generality of cardioprotection and Neuroprotection
  786. PPARγ: a new avenue to Neuroprotection
  787. Global cerebral ischemia and Neuroprotection .
  788. Early detection of paracentral defects: Implications for Neuroprotection in primary open-angle glaucoma
  789. Mechanisms of reversible injury and Neuroprotection
  790. Reactive oxygen species mediate Neuroprotection induced by mitochondrial ATP-sensitive potassium channel opener in rat hippocampal slices during hypoxia
  791. Neuroprotection and neurotransplantation strategies in models of Parkinson’s disease
  792. Electrocortical concomitants of Neuroprotection and ischemic damage following cerebral circulatory arrest.
  793. Is Neuroprotection the Next Wave In Glaucoma Management?
  794. NEURODEGENRATION AND Neuroprotection IN SEVERE RETINAL DYSFUNCTION
  795. Possible Mechanisms of Neuroprotection in Response to Diverse Insults
  796. Deep brain Stimulation and Neuroprotection
  797. Neuroprotection in optic neuropathy: assessment of effect
  798. Medical management of head injury and Neuroprotection
  799. Cerebral Ischemia: Pathophysiology and Neuroprotection
  800. An experimental study on the Neuroprotection of magnesium sulfate.
  801. Serum from patients with diabetic neuropathy impairs laminin Neuroprotection by altering laminin receptor integrin expression
  802. Correlation between 5‐HT Content and Uptake Site Density following (S)‐MDMA and Dexfenfluramine‐induced Depletion, and with Neuroprotection by the Glycine …
  803. Neuroprotection : the next step in glaucoma therapy
  804. Neuroprotection in schizophrenia-What does it mean?-What means do we have?
  805. Neuroprotection : Rescuing the brain from endogenous assassins
  806. Physical and Pharmacological Neuroprotection in Cardiac Surgery
  807. Dual-action drug gives good Neuroprotection
  808. Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson’s Disease
  809. Milestones in Neurotoxicity and Neuroprotection : A Tribute to Professor Toshiharu Nagatsu
  810. Neuroprotection : ion flux and receptor mechanisms
  811. Effects of oxidative stress and Neuroprotection in apoptosis in neuronal cell models
  812. Minocycline Provides Neuroprotection
  813. Limiting Apoptosis as a Strategy for CNS Neuroprotection
  814. Neuroprotection : The Next Breakthrough in Glaucoma?
  815. Neuroprotection for acute ischemic stroke: Who is most to blame for current failure?
  816. Angiotensin II receptors: New targets for Neuroprotection
  817. Neuroprotection in an animal model of retinal ischemia
  818. Carotid artery stenting with Neuroprotection : a single center experience
  819. Pay attention to the study and clinical application of Neuroprotection for retinal diseases
  820. Combined Neuroprotection /Thrombolysis in Acute Stroke
  821. Partial Neuroprotection to oxidative stress by selective antioxidants in culture
  822. Insulin, Hypoglycemia, and Ischemic Neuroprotection
  823. Neuroprotection From Op-Induced Seizures and Neuropathology.
  824. Neuroprotection effect of taurine in young rats and the mechanism involved
  825. Blood perfusion-independent Neuroprotection induced by antiplatelet agents and its gender-difference
  826. Expression and Neuroprotection of Vascular Endothelial Growth Factor in an in vitro Ischemia
  827. Neuroprotection by Drug-Induced Neurotrophic Factors
  828. The study of Neuroprotection of bcl-2 gene by transfecting it into PC12 cell line
  829. Novel mediators of ischemic preconditioning induced Neuroprotection
  830. c‐DNA Microarray to determine molecular events in neurodegeneration and Neuroprotection
  831. Combining Neuroprotection with thrombolysis: how to translate laboratory success to our clinical trials
  832. Neuroprotection and Stroke: Stroke and the role of the emergency physician
  833. Transcriptional mechanisms of Neuroprotection by iron chelators
  834. Neuroprotection IN CNS DISEASES. 1997. Edited by PR Bar and M. Flint Beal. Published by Marcel Dekker Publishers. 585 pages. $ C241. 00
  835. Neuroprotection With NPS1506, A Novel NMDA Receptor Antagonist: 605
  836. Novel players in Neuroprotection and tissue reorganisation after hippocampal lesion
  837. Neuroprotection for Nerve Agent-Induced brain Damage
  838. Putative mechanisms of cortical spreading depression-induced Neuroprotection .
  839. Neurochemical Changes Following Stroke: Role in Neuroprotection and Cardiac Susceptibility
  840. Blood perfusion-independent Neuroprotection induced by antiplatelet agents and its gender-difference
  841. Neuroprotection and Functional Alterations in Mice Over-Expressing Heat Shock Protein 70i
  842. An investigation into the mechanism responsible for clomethiazole-induced Neuroprotection in a rat model of severe global ischemia.
  843. Neuroprotection : A Society of Cardiovascular Anesthesiologists Monograph
  844. Molecules for Neuroprotection and Regeneration in Animal Models of Parkinson’s Disease
  845. Neuroprotection from brain Injury by Novel Estrogens
  846. Neuroprotection of retinal ganglion cells in experimental models of glaucoma. A review
  847. Results of two controlled studies on estrogen: avenue to Neuroprotection in schizophrenia
  848. Neuroprotection by Progesterone Through Simulation of Mitochondrial Gene Expression
  849. Postmortem interval and anesthetic Neuroprotection in regenerating cortical neuron cultures used as a model for TNF Neuroprotection from beta-amyloid toxicity.
  850. Assessment of ischemic damage and Neuroprotection in an experimental model of forebrain ischemia
  851. Diltiazem-Induced Neuroprotection in an In Vitro Model of Photoreceptor Degeneration
  852. Neuroprotection from delayed post-ischemic administration of a metalloporphyrin catalytic antioxidant in the rat
  853. Neuroprotection Profile of the High Affinity NMDA Receptor Antagonist Conantokin-G
  854. Neuroprotection by heat shock protein 27 in sensory and motor neurons
  855. The Neuroprotection effects of basic fibroblast growth factor on focal cerebral ischemia in rats and the expression of bax
  856. Neuroprotection of Propofol during an In Vitro Cerebral Ischemia: Glutamate Transporters Are a Major Target
  857. Interactions Between Hypothermia and the Latency to Ischemic Depolarization: Implications for Neuroprotection
  858. Prenatal Choline Supplementation Modifies brain Development: Improved cognition and Neuroprotection
  859. East of England Neonatal Neuroprotection Guideline Diagnosis & Management of Neonatal Seizures in the Term Infant
  860. Delayed post ischemic hypothermia: A six month survival study using behavioral and histological assessments of Neuroprotection
  861. Neuroprotection of Hypothermia in Full Term Neonates After Asphyxia: a Safety Study
  862. The Neuroprotection effects of basic fibroblast growth factor on focal cerebral ischemia in rats and the expression of bax
  863. Neuroprotection with the N-methyl-D-aspartate antagonist dizocilpine (MK-801) in a model of focal ischaemia
  864. Estrogen provides Neuroprotection in focal cerebral ischemia modulation and bcl-2 protein expression
  865. Role of intracellular calcium in neuronal death following cerebral ischemica: Neuroprotection by dantrolene and BCL-2.
  866. Neuroprotection by Selective Nitric Oxide Synthase Inhibition at 24 Hours After Perinatal Hypoxia-Ischemia
  867. Electrophysiologic Evidence of Functional Neuroprotection of Photoreceptors by X-Linked Inhibitor of Apoptosis (XIAP) in a Chemotoxic Model of Retinal …
  868. Hippocampal Expression of a Human GRINL1A Complex Transcription Unit (CTU) Splice Variant Suggests a Role in Neuroprotection
  869. Apoptotic degeneration induction in retinal cells by acute ocular hypertension and Neuroprotection by troxolol
  870. The Neuroprotection effect of acute infective brain edema induced by pertussis bacilli in rat
  871. MODULATION OF CEREBRAL BLOOD FLOW IS NOT THE MECHANISM OF Neuroprotection IN TRANSGENIC MICE OVER EXPRESSING HUMAN …
  872. Tumor necrosis factor appear the Neuroprotection through the enhancement of transient outward potassium currents in cultured rat cortical neurons
  873. … family is the largest and fastest-growing family of ion channels. Evidence is accumulating that modulation of potassium channels is a new approach to Neuroprotection …
  874. Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF
  875. Nimodipine Neuroprotection does not decrease thromboxane release following global cerebral ischemia
  876. ESTROGEN PROVIDES PERFUSION-INDEPENDENT Neuroprotection IN RAT TRANSIENT FOREbrain ISCHEMIA
  877. Mechanisms of dopamine D2-induced Neuroprotection against glutamate neurotoxicity in rat mesencephalon
  878. Neuroprotection of 1400W, a Selective Inhibitor of Inducible Nitric Oxide Synthetase in Rat after Traumatic brain Injury
  879. Chromosome Mapping of the Human Homologue of a New Glutamate Receptor Gene Suggests Roles in Neuroprotection and Autism
  880. Investigation of sigma and dextromethorphan-like Neuroprotection using glutamate-induced LDH release, cellular morphology and dynamic calcium signaling.
  881. 11 Beyond NMDA antagonists: looking to the future of Neuroprotection
  882. Neuroprotection of Progesterone on the Hippocampal Neurons of Gerbil Following Transient Forebrain Ischemia
  883. Delayed neurodegeneration induced by extracellular lactacidity and Neuroprotection by basic fibroblast growth factor in rat hippocampal neurons
  884. Neuroprotection effects of exogenous adrenomedullin against hypoxic-ischemia reperfusion brain damage in neonatal rats
  885. Outcome From Temporary brain Artery Clipping Using Etomidate or Desflurane for Neuroprotection
  886. Mechanisms of cerebral injury and strategies for Neuroprotection following deep hypothermic circulatory arrest in the neonatal piglet
  887. Poster Sessions CP11: Neurotoxicity and Neuroprotection . Secretory phospholipase A2 signalling partly overlaps glutamate‐mediated events
  888. Roles of hypoxia regulated genes/protein in Neuroprotection against hypoxia injury in differentiated SH-SY5Y cells preconditioned with CoCl_2
  889. Nitric oxide synthase is required for nerve growth factor-mediated Neuroprotection in cerebellar granule cell cultures [J]
  890. Neuroprotection in the hibernating brain : tissue trauma and glutamate studied by microdialysis
  891. DEXAMETHASONE Neuroprotection IS ASSOCIATED WITH PRESERVED EXPRESSION OF BCL-2 AND SUPPRESSION OF GLIAL FIBRILLARY ACID …
  892. Development of novel treatment against glaucoma; Intraocular pressure-lowering by cytoskeletal drugs and Neuroprotection by neurotrophic factors.
  893. … of mild hypothermia-assisted stereotactic hematoma puncture and catheter drainage on postoperative intracranial pressure and Neuroprotection in elderly patients …
  894. Alzheimer’s Disease–Neuroprotection
  895. Blockade of the N-methyl-D-aspartate-type glutamate receptor in the animal: Target for Neuroprotection in head trauma and brain ischemia
  896. Low-dose dipyridamole infusion acutely increases exercise capacity in angina pectoris-serendipitous demonstration of Neuroprotection induced by endogenous …
  897. Serotonin (5-HT)1A Receptor Agonists and Neuroprotection
  898. Acidosis and Neuroprotection in two types of acidosis model rats under isoflurane anesthesia: evaluation of blood flow, pH and amino acid levels in the cortex
  899. GABA and Neuroprotection : Do GABAergic circuitries play a critical role in the regulation of seizure-induced neuronal damage and synaptic reorganization in the rat …
  900. Enhancement of entorhinal-dentate evoked potentials following repeated electroconvulsive shock seizures in the rat, Neuroprotection studies
  901. Akerud P, Canals JM, Snyder EY, et al. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of …
  902. α‐Amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid‐mediated Neuroprotection requires TRKB receptor activation
  903. … Resource Utilization in the Three Months after Acute Stroke: A Report on 1604 Patients from the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial
  904. Erratum: Sheardown MJ, Knutsen LJS (1996): Unexpected Neuroprotection observed with the adenosine A2A receptor agonist CGS 21680. Drug Dev Res 39:108 …
  905. Posthypoxic hypothermia for 24 hrs in unsedated newborn pigs gives no Neuroprotection
  906. 5 Selective modulation of voltage-gated sodium channels: a rational approach for Neuroprotection
  907. Identification of a novel synergistic interaction between 17 B-estradiol and glutathione in Neuroprotection .
  908. Neurotoxicity and clonal mouse hippocampal cell line (HT-22): Neuroprotection by tamoxifen, bisphenol-A and pregnenalone.
  909. … ICAM-1 MONOCLONAL ANTIBODY DECREASES LEUKOCYTE RECRUITMENT AND INFILTRATION AND OFFERS Neuroprotection AFTER SPINAL CORD …
  910. 398. Non-Viral Gene Delivery to the Primate CNS: A Model for Pre-Operative Neuroprotection
  911. 21 Neuroprotection IN HEAD INJURY
  912. … of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
  913. 907 Potent O1-Receptor Ligand, PPBP [4-Phenyl-1-(4-Phenylbutyl) piperidine] Affords Neuroprotection From Focal Ischemia and Prolonged Reperfusion
  914. Neuroprotection by flavonoids
  915. Ischemic tolerance and endogenous Neuroprotection
  916. Neuroprotection and neurodegenerative disease
  917. Neurosphere-derived multipotent precursors promote Neuroprotection by an immunomodulatory mechanism
  918. Neuroprotection for ischemic stroke: two decades of success and failure
  919. Neuroprotection in cerebral ischaemia: facts and fancies–the need for new approaches
  920. Estrogen and ischemic Neuroprotection : an integrated view
  921. Neuroprotection in glaucoma.
  922. Astrocyte apoptosis: implications for Neuroprotection
  923. Mechanisms of radiation injury to the central nervous system: implications for Neuroprotection
  924. Neuroprotection in experimental stroke with targeted neurotrophins
  925. Multifunctional activities of green tea catechins in Neuroprotection
  926. Heat shock proteins and Neuroprotection
  927. VEGF: once regarded as a specific angiogenic factor, now implicated in Neuroprotection
  928. Neuroprotection and acute spinal cord injury: a reappraisal
  929. Neuroprotection by tetracyclines
  930. Molecular and cellular mechanisms of Neuroprotection by vascular endothelial growth factor
  931. β-Lactam antibiotics offer Neuroprotection by increasing glutamate transporter expression
  932. Optic nerve and Neuroprotection strategies
  933. Neurodegeneration and Neuroprotection in Parkinson disease
  934. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions
  935. Bioenergetic approaches for Neuroprotection in Parkinson’s disease
  936. Lithium Neuroprotection : molecular mechanisms and clinical implications
  937. Critical appraisal of Neuroprotection trials in head injury: what have we learned?
  938. A focus on the synapse for Neuroprotection in Alzheimer disease and other dementias
  939. From clinical evidence to molecular mechanisms underlying Neuroprotection afforded by estrogens
  940. Microglia and Neuroprotection : implications for Alzheimer’s disease
  941. Neuroprotection by KATP channels
  942. Fibroblast growth factors and Neuroprotection
  943. Hypothermia for Neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis
  944. (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and Neuroprotection
  945. Cannabinoid receptors and their role in Neuroprotection
  946. Effect of magnesium sulfate given for Neuroprotection before preterm birth: a randomized controlled trial
  947. Quinol-based cyclic antioxidant mechanism in estrogen Neuroprotection
  948. VEGF-induced Neuroprotection , neurogenesis, and angiogenesis after focal cerebral ischemia
  949. Mechanisms of hyperbaric oxygen and Neuroprotection in stroke
  950. Neuroprotection by osteopontin in stroke
  951. The TREK K2P channels and their role in general anaesthesia and Neuroprotection
  952. Neuroprotection in Parkinson’s disease: clinical trials
  953. Neuroprotection from the collateral perspective.
  954. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels
  955. Neuroprotection by crocetin in a hemi-parkinsonian rat model
  956. Lost in translation: taking Neuroprotection from animal models to clinical trials
  957. Mitochondria in cell death: novel targets for Neuroprotection and cardioprotection
  958. Neuroprotection by adenosine in the brain : From A1 receptor activation to A2A receptor blockade
  959. Lipid signaling in neural plasticity, brain repair, and Neuroprotection
  960. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
  961. Neuroprotection associated with running: is it a result of increased endogenous neurotrophic factors?
  962. Catechin polyphenols: neurodegeneration and Neuroprotection in neurodegenerative diseases
  963. Pharmacological inhibition of AMP-activated protein kinase provides Neuroprotection in stroke
  964. Erythropoietin: a candidate compound for Neuroprotection in schizophrenia
  965. Neuroprotection by bioactive components in medicinal and food plant extracts
  966. Lipid signaling: sleep, synaptic plasticity, and Neuroprotection
  967. Activation of complement in the central nervous system: roles in neurodegeneration and Neuroprotection
  968. Molecular mechanisms of light-induced photoreceptor apoptosis and Neuroprotection for retinal degeneration
  969. Control of nerve agent-induced seizures is critical for Neuroprotection and survival
  970. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, Neuroprotection : the 2002 Thomas Willis Lecture
  971. Mechanisms of ischemic Neuroprotection by acetyl-L-carnitine
  972. A role for hypoxia-inducible factor-1α in desferoxamine Neuroprotection
  973. The mechanism of Neuroprotection by topiramate in an animal model of epilepsy
  974. Xenon and hypothermia combine to provide Neuroprotection from neonatal asphyxia
  975. Inhibition of GSK3β is a common event in Neuroprotection by different survival factors
  976. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for Neuroprotection in stroke
  977. Antiepileptic drugs and Neuroprotection : current status and future roles
  978. Neurogenic Neuroprotection
  979. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical‐scavenging activity
  980. Immunomodulation in multiple sclerosis: from immunosuppression to Neuroprotection
  981. Dual effects of nicotine on oxidative stress and Neuroprotection in PC12 cells
  982. Akt contributes to Neuroprotection by hypothermia against cerebral ischemia in rats
  983. Neuroprotection by estrogen in animal models of global and focal ischemia
  984. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage
  985. Prion protein accumulation and Neuroprotection in hypoxic brain damage
  986. Anaesthesia induced Neuroprotection
  987. Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation
  988. Nanotechnology approaches for the regeneration and Neuroprotection of the central nervous system
  989. The potential of minocycline for Neuroprotection in human neurologic disease
  990. Mechanism of estrogen-mediated Neuroprotection : regulation of mitochondrial calcium and Bcl-2 expression
  991. Organotypic hippocampal slice cultures for studies of brain damage, Neuroprotection and neurorepair
  992. Participation of adenosine receptors in Neuroprotection .
  993. Erythropoietin: novel approaches to Neuroprotection in human brain disease
  994. Neuroprotection in ophthalmology: a review
  995. Mechanisms of hyperbaric oxygen-induced Neuroprotection in a rat model of subarachnoid hemorrhage
  996. Antiepileptic drugs in Neuroprotection
  997. Regulation of body temperature and Neuroprotection by endogenous interleukin-6 in cerebral ischemia
  998. Cell cycle inhibition provides Neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury
  999. The role of α‐synuclein in both Neuroprotection and neurodegeneration
  1000. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
  1001. Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members
  1002. brain edema induced by in vitro ischemia: causal factors and Neuroprotection
  1003. Effect of two different Neuroprotection systems on microembolization during carotid artery stenting
  1004. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
  1005. Estrogen activates classical and alternative mechanisms to orchestrate Neuroprotection
  1006. Neuroprotection by a selective estrogen receptor β agonist in a mouse model of global ischemia
  1007. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways
  1008. Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity
  1009. Protective autoimmunity and Neuroprotection in inflammatory and noninflammatory neurodegenerative diseases
  1010. Interactions between the cells of the immune and nervous system: neurotrophins as Neuroprotection mediators in CNS injury
  1011. Carotid artery stenting with Neuroprotection : assessing the learning curve and treatment outcome
  1012. Purines and Neuroprotection
  1013. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia
  1014. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis
  1015. α2-Adrenoceptor agonists: shedding light on Neuroprotection ?
  1016. Optimal delivery of minocycline to the brain : implication for human studies of acute Neuroprotection
  1017. Physiological roles of hydrogen sulfide: synaptic modulation, Neuroprotection , and smooth muscle relaxation
  1018. Prophylactic creatine administration mediates Neuroprotection in cerebral ischemia in mice
  1019. Neurogenesis and Neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis
  1020. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in Neuroprotection
  1021. Forebrain -specific neuronal inhibition of nuclear factor-κB activity leads to loss of Neuroprotection
  1022. Signal transduction pathways implicated in neural recognition molecule L1 triggered Neuroprotection and neuritogenesis
  1023. Incipient neurovulnerability and Neuroprotection in early psychosis
  1024. Rasagiline: neurodegeneration, Neuroprotection , and mitochondrial permeability transition
  1025. Neuroprotection in Huntington’s disease: a 2-year study on minocycline
  1026. Role of mitochondria in neuronal cell death induced by oxidative stress; Neuroprotection by Coenzyme Q10
  1027. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons
  1028. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke
  1029. Targeting mitochondrial ATP-sensitive potassium channels—a novel approach to Neuroprotection
  1030. Choroid plexus megalin is involved in Neuroprotection by serum insulin-like growth factor I
  1031. A preclinical view of cholinesterase inhibitors in Neuroprotection : do they provide more than symptomatic benefits in Alzheimer’s disease?
  1032. Transforming Growth Factor-β1-Mediated Neuroprotection against Excitotoxic Injury in Vivo
  1033. Indicators of Neuroprotection with galantamine
  1034. Erythropoietin exerts Neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings
  1035. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for Neuroprotection
  1036. CB1 cannabinoid receptors are involved in Neuroprotection via NF-κB inhibition
  1037. Calpain in the pathophysiology of spinal cord injury: Neuroprotection with calpain inhibitors
  1038. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive Neuroprotection induced by chronic fenofibrate treatment
  1039. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease
  1040. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin
  1041. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic Neuroprotection
  1042. Methodological quality of animal studies on Neuroprotection in focal cerebral ischaemia
  1043. Astrocyte mitochondrial mechanisms of ischemic brain injury and Neuroprotection
  1044. Paraquat induces oxidative stress and neuronal cell death; Neuroprotection by water-soluble Coenzyme Q10
  1045. Estrogen activates protein kinase C in neurons: role in Neuroprotection
  1046. Pharmacologic Neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma
  1047. Blockade of gap junctions in vivo provides Neuroprotection after perinatal global ischemia
  1048. Clinical perspectives: Neuroprotection lessons from hypoxia-tolerant organisms
  1049. Isoflurane preconditioning induces Neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases
  1050. Signal transduction pathways involved in melatonin‐induced Neuroprotection after focal cerebral ischemia in mice
  1051. Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI
  1052. Creatine therapy provides Neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice
  1053. Antiepileptogenesis, Neuroprotection , and disease modification in the treatment of epilepsy: focus on levetiracetam
  1054. Effect of Antioxidant Flavanone, Naringenin, from Citrus junos on Neuroprotection
  1055. Is white matter involved in patients entered into typical trials of Neuroprotection ?
  1056. Some current ideas on the pathogenesis and the role of Neuroprotection in glaucomatous optic neuropathy
  1057. A novel mechanism of FK506‐mediated Neuroprotection : downregulation of cytokine expression in glial cells
  1058. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for Neuroprotection /neurodegeneration …
  1059. Magnesium Neuroprotection is limited in humans with acute brain injury
  1060. Isoflurane preconditioning induces Neuroprotection that is inducible nitric oxide synthase–dependent in neonatal rats
  1061. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for Neuroprotection in Alzheimer’s disease.
  1062. Activin: an important regulator of wound repair, fibrosis, and Neuroprotection
  1063. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia
  1064. Endogenous Neuroprotection in the retina
  1065. Involvement of tyrosine kinases and STAT3 in Humanin-mediated Neuroprotection
  1066. Neuroprotection by Brazilian green propolis against in vitro and in vivo ischemic neuronal damage
  1067. Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and Neuroprotection
  1068. Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐) …
  1069. Effects of estrogen on brain development and Neuroprotection —implications for negative symptoms in schizophrenia
  1070. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for Neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative …
  1071. Neuroprotection in hypothermia linked to redistribution of oxygen in brain
  1072. Melatonin‐induced Neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late‐phase activation of NF‐κB and AP‐1
  1073. CD4-positive T cell-mediated Neuroprotection requires dual compartment antigen presentation
  1074. Neuroprotection in brain and spinal cord trauma
  1075. TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: Neuroprotection by NFκB inhibition
  1076. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia
  1077. brain nitric oxide and its dual role in neurodegeneration/Neuroprotection : understanding molecular mechanisms to devise drug approaches
  1078. Nicotinic acetylcholine receptor-mediated Neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
  1079. Thioredoxin as a neurotrophic cofactor and an important regulator of Neuroprotection
  1080. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: Potential strategies for Neuroprotection 1
  1081. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: Neuroprotection of dopaminergic neurons
  1082. Topiramate extends the therapeutic window for hypothermia-mediated Neuroprotection after stroke in neonatal rats
  1083. Neurodegeneration and Neuroprotection in glaucoma: development of a therapeutic Neuroprotective vaccine: the Friedenwald lecture
  1084. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious Neuroprotection in the postischemic brain
  1085. Rise and fall of minocycline in Neuroprotection : need to promote publication of negative results
  1086. Free radical trapping as a therapeutic approach to Neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers
  1087. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway
  1088. Pharmacology update/Neuroprotection for ischemic stroke
  1089. Differential effects of ethanol antagonism and Neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity
  1090. Neuroprotection against transient cerebral ischemia by exercise pre-conditioning in rats
  1091. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease
  1092. … hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, Neuroprotection , and synaptic plasticity
  1093. BDNF-induced white matter Neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge
  1094. Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration
  1095. Stroke units, tissue plasminogen activator, aspirin and Neuroprotection : which stroke intervention could provide the greatest community benefit?
  1096. α-Tocotrienol provides the most potent Neuroprotection among vitamin E analogs on cultured striatal neurons
  1097. Melatonin provides Neuroprotection in the late-gestation fetal sheep brain in response to umbilical cord occlusion
  1098. Estrogen-like compounds for ischemic Neuroprotection
  1099. Different levels of Neuroprotection by two insulin-like growth factor-I splice variants
  1100. Preconditioning with isoflurane produces dose-dependent Neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral …
  1101. Metallothionein-mediated Neuroprotection in genetically engineered mouse models of Parkinson’s disease
  1102. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
  1103. Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFκB
  1104. Simultaneous Neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
  1105. Intracerebral transplantation of porcine choroid plexus provides structural and functional Neuroprotection in a rodent model of stroke
  1106. Neuroprotection in glaucoma: a model for Neuroprotection in optic neuropathies
  1107. Glutathione monoethyl ester provides Neuroprotection in a rat model of stroke
  1108. Enhancement of glutamate uptake mediates the Neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes
  1109. Activity-dependent Neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB …
  1110. Significant Neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with …
  1111. IGF‐I Neuroprotection in the immature brain after hypoxia‐ischemia, involvement of Akt and GSK3β?
  1112. Glycogen synthase kinase 3β links Neuroprotection by 17β-estradiol to key Alzheimer processes
  1113. Neuroprotection by NGF in the PC12 In Vitro OGD Model: Involvement of Mitogen‐Activated Protein Kinases and Gene Expression
  1114. The Neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation
  1115. Estrogen receptor-mediated Neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway
  1116. Tumor necrosis factor (TNF)-mediated Neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation …
  1117. Propofol Neuroprotection in cerebral ischemia and its effects on low-molecular-weight antioxidants and skilled motor tasks
  1118. Progesterone Neuroprotection in spinal cord trauma involves up-regulation of brain -derived neurotrophic factor in motoneurons
  1119. A potent antioxidant, lycopene, affords Neuroprotection against microglia activation and focal cerebral ischemia in rats
  1120. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression
  1121. Coactivation of GABAA and GABAB Receptor Results in Neuroprotection During In Vitro Ischemia
  1122. Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia
  1123. Mechanisms of progesterone‐induced Neuroprotection
  1124. Reconstituted high-density lipoprotein exhibits Neuroprotection in two rat models of stroke
  1125. Uric acid administration for Neuroprotection in patients with acute brain ischemia
  1126. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases
  1127. Neuronal growth‐promoting and inhibitory cues in Neuroprotection and neuroregeneration
  1128. β-Synuclein Regulates Akt Activity in Neuronal Cells: A POSSIBLE MECHANISM FOR Neuroprotection IN PARKINSON′ S DISEASE
  1129. Immunosuppressants: Neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions
  1130. Sensory Neuroprotection , mitochondrial preservation, and therapeutic potential of N-acetyl-cysteine after nerve injury
  1131. Pharmacological Neuroprotection
  1132. Cannabinoids produce Neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores
  1133. Role of PPAR-γ ligands in Neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells
  1134. Valproic acid-mediated Hsp70 induction and anti-apoptotic Neuroprotection in SH-SY5Y cells
  1135. Local saline infusion into ischemic territory induces regional brain cooling and Neuroprotection in rats with transient middle cerebral artery occlusion
  1136. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to Neuroprotection in Parkinson’s disease and other …
  1137. … low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides Neuroprotection and induces behavioral …
  1138. Neuroprotection and regeneration in glaucoma.
  1139. Insulin Neuroprotection against oxidative stress in cortical neurons—involvement of uric acid and glutathione antioxidant defenses
  1140. Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation
  1141. Neuroprotection by transforming growth factor-β1 involves activation of nuclear factor-κB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein …
  1142. A responsive outcome for Parkinson’s disease Neuroprotection futility studies
  1143. Neuroprotection from complement‐mediated inflammatory damage
  1144. Unequal Neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic …
  1145. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation
  1146. Microglial NADPH oxidase is a novel target for femtomolar Neuroprotection against oxidative stress
  1147. Neuroprotection after Transient Global Cerebral Ischemia in Wlds Mutant Mice
  1148. Blood-brain barrier drug targeting enables Neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins
  1149. Wide therapeutic time window for nimesulide Neuroprotection in a model of transient focal cerebral ischemia in the rat
  1150. T-cell-based vaccination for morphological and functional Neuroprotection in a rat model of chronically elevated intraocular pressure
  1151. Prospects for Neuroprotection in multiple sclerosis.
  1152. Novel role for gabapentin in Neuroprotection of central nervous system in streptozotocine-induced diabetic rats
  1153. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration
  1154. The mitochondrial permeability transition as a target for Neuroprotection
  1155. Tenascin-R plays a role in Neuroprotection via its distinct domains that coordinate to modulate the microglia function
  1156. Erythropoietin and Neuroprotection : a therapeutic perspective
  1157. Preclinical evidence for Neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease
  1158. Neuroprotection by human neural progenitor cells after experimental contusion in rats
  1159. Behavioral and histological Neuroprotection by tamoxifen after reversible focal cerebral ischemia
  1160. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of Neuroprotection by an ERα agonist
  1161. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration
  1162. Local brain hypothermia for Neuroprotection in stroke treatment and aneurysm repair
  1163. Neuroprotection by α-lipoic acid in streptozotocin-induced diabetes
  1164. Neuroprotection of catalpol in transient global ischemia in gerbils
  1165. The c‐Raf inhibitor GW5074 provides Neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism
  1166. … brain -derived neurotrophic factor gene: a portal to transform mesenchymal stem cells into advantageous engineering cells for neuroregeneration and Neuroprotection
  1167. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for Neuroprotection
  1168. Clinical trials of Neuroprotection for Parkinson’s disease
  1169. Neuroprotection with angiotensin receptor antagonists
  1170. L-DOPA treatment from the viewpoint of Neuroprotection
  1171. Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen
  1172. Cannabinoids and Neuroprotection in CNS inflammatory disease
  1173. The kinder side of killer proteases: caspase activation contributes to Neuroprotection and CNS remodeling
  1174. Retinal Neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor
  1175. Gene activation and protein expression following ischaemic stroke: strategies towards Neuroprotection
  1176. Voluntary running provides Neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle
  1177. Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides Neuroprotection after transient focal cerebral ischemia
  1178. Central nervous system–targeted complement inhibition mediates Neuroprotection after closed head injury in transgenic mice
  1179. Neuroprotection and regeneration strategies for spinal cord repair
  1180. Hypothesis for a common basis for Neuroprotection in glaucoma and Alzheimer’s disease: anti-apoptosis by alpha-2-adrenergic receptor activation
  1181. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease?
  1182. The intracerebral application of the PPARγ‐ligand pioglitazone confers Neuroprotection against focal ischaemia in the rat brain
  1183. Neuroprotection trek—the next generation: neuromodulation I. Techniques—deep brain stimulation, vagus nerve stimulation, and transcranial magnetic stimulation
  1184. Structural and functional Neuroprotection in a rat model of Huntington’s disease by viral gene transfer of GDNF
  1185. Functional aspects of estrogen Neuroprotection
  1186. Neuroprotection with carotenoids in glaucoma
  1187. Optical coherence tomography: measuring in-vivo axonal survival and Neuroprotection in multiple sclerosis and optic neuritis
  1188. … colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated Neuroprotection against Alzheimer’s disease …
  1189. Vascular aspects of Neuroprotection
  1190. Isoflurane Neuroprotection in Hypoxic Hippocampal Slice Cultures Involves Increases in Intracellular Ca2+and Mitogen-activated Protein Kinases
  1191. Insulin exerts Neuroprotection by counteracting the decrease in cell‐surface GABAA receptors following oxygen–glucose deprivation in cultured cortical neurons
  1192. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase
  1193. Adenosine, neurodegeneration and Neuroprotection
  1194. Neuroprotection and neurodegenerative diseases: from biology to clinical practice
  1195. Provoking Neuroprotection by peroxynitrite
  1196. Zinc-induced apoptosis in substantia nigra of rat brain : Neuroprotection by vitamin D3
  1197. Neuroprotection of naloxone against ischemic injury in rats: role of mu receptor antagonism
  1198. Rubia cordifolia, Fagonia cretica linn and Tinospora cordifolia exert Neuroprotection by modulating the antioxidant system in rat hippocampal slices subjected …
  1199. Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes
  1200. Neuroprotection following fluid percussion brain trauma: a pilot study using quercetin
  1201. Role of insulin-like growth factors in neuronal plasticity and Neuroprotection
  1202. Timing of neutrophil depletion influences long-term Neuroprotection in neonatal rat hypoxic-ischemic brain injury
  1203. NF-E2-related factor-2 mediates Neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary …
  1204. Neuroprotection in acute ischemic stroke
  1205. Empirical evidence of Neuroprotection by dual cholinesterase inhibition in Alzheimer’s disease
  1206. Clomethiazole: mechanisms underlying lasting Neuroprotection after hypoxia‐ischemia
  1207. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced Neuroprotection in transgenic R6/2 mouse model of Huntington’s …
  1208. In vitro Gender Differences in Neuronal Survival on Hypoxia and in 17β-Estradiol-Mediated Neuroprotection
  1209. Estrogen provides Neuroprotection against activated microglia‐induced dopaminergic neuronal injury through both estrogen receptor‐α and estrogen receptor‐β in …
  1210. What can adenosine neuromodulation do for Neuroprotection ?
  1211. Novel Diketopiperazine Enhances Motor and cognitive Recovery after Traumatic brain Injury in Rats and Shows Neuroprotection In Vitro and In Vivo
  1212. Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches
  1213. Depth of delayed cooling alters Neuroprotection pattern after hypoxia‐ischemia
  1214. Long-term Neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats
  1215. Neuroprotection and enhancement of learning and memory by BF-7
  1216. Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats
  1217. Inhibition of mitochondrial respiration by nitric oxide: its role in glucose metabolism and Neuroprotection
  1218. Neuroprotection trek—the next generation: neuromodulation II. Applications—epilepsy, nerve regeneration, neurotrophins
  1219. NF-κB factor c-Rel mediates Neuroprotection elicited by mGlu5 receptor agonists against amyloid β-peptide toxicity
  1220. Dual role of DENN/MADD (Rab3GEP) in neurotransmission and Neuroprotection
  1221. The role of the estrogen in Neuroprotection : implications for neurodegenerative diseases.
  1222. Circulatory arrest as a model for studies of global ischemic injury and Neuroprotection
  1223. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm
  1224. Perioperative Neuroprotection : are we asking the right questions?
  1225. Estrogen and Neuroprotection : higher constitutive expression of glutaredoxin in female mice offers protection against MPTP‐mediated neurodegeneration
  1226. Challenges of Neuroprotection and neurorestoration in ischemic stroke treatment
  1227. Imaging end points for monitoring Neuroprotection in Parkinson’s disease
  1228. Neuroprotection by tempol in a model of iron-induced oxidative stress in acute ischemic stroke
  1229. Protease-activated receptors in neuronal development, neurodegeneration, and Neuroprotection : thrombin as signaling molecule in the brain
  1230. Neuroprotection and enhanced recovery with edaravone after acute spinal cord injury in rats
  1231. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term Neuroprotection with brimonidine
  1232. A3 receptors in cortical neurons: Pharmacological aspects and Neuroprotection during hypoxia
  1233. Neurotrophin-based strategies for Neuroprotection
  1234. Estrogen Neuroprotection against the neurotoxic effects of ethanol withdrawal: potential mechanisms
  1235. Cannabinoids in neurodegeneration and Neuroprotection
  1236. Possible sources of Neuroprotection following subretinal silicon chip implantation in RCS rats
  1237. Asymptomatic ischemic cerebrovascular disorders and Neuroprotection with vinpocetine.
  1238. Mitochondria are involved in the neurogenic Neuroprotection conferred by stimulation of cerebellar fastigial nucleus
  1239. γ-Aminobutyric acid-A receptors contribute to isoflurane Neuroprotection in organotypic hippocampal cultures
  1240. Heat acclimation increases hypoxia-inducible factor 1α and erythropoietin receptor expression: implication for Neuroprotection after closed head injury in mice
  1241. Glucagon-like peptide-1 receptor is involved in learning and Neuroprotection
  1242. Dose-dependent Neuroprotection by 17β-estradiol after cardiac arrest and cardiopulmonary resuscitation
  1243. TREK‐1, a K+ channel involved in Neuroprotection and general anesthesia
  1244. Cellular strategies of estrogen-mediated Neuroprotection during brain development
  1245. Advances in stroke Neuroprotection : hyperoxia and beyond
  1246. Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington’s disease
  1247. Models of epilepsy in the developing and adult brain : implications for Neuroprotection
  1248. Glial‐mediated Neuroprotection : Evidence for the protective role of the NO‐cGMP pathway via neuron–glial communication in the peripheral nervous system
  1249. Neuroprotection and peptide toxins
  1250. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase‐2 inhibitor APHS can be reversed by a prostanoid
  1251. Plasma membrane oestrogen receptor mediates Neuroprotection against β‐amyloid toxicity through activation of Raf‐1/MEK/ERK cascade in septal‐derived …
  1252. Multiple calcium channels and kinases mediate α7 nicotinic receptor Neuroprotection in PC12 cells
  1253. Neuroprotection against Aβ and glutamate toxicity by melatonin: Are GABA receptors involved?
  1254. Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning‐induced cardioprotection and Neuroprotection
  1255. l‐Carnitine and Neuroprotection in the Animal Model of Mitochondrial Dysfunction
  1256. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides Neuroprotection in a rat model of Parkinson’s disease
  1257. NO stimulation of ATP-sensitive potassium channels: involvement of Ras/mitogen-activated protein kinase pathway and contribution to Neuroprotection
  1258. Synaptophysin enhances the Neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells
  1259. A “cure” for Parkinson’s disease: can Neuroprotection be proven with current trial designs?
  1260. Role of protein phosphatases in estrogen-mediated Neuroprotection
  1261. Galantamine and memantine produce different degrees of Neuroprotection in rat hippocampal slices subjected to oxygen–glucose deprivation
  1262. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo …
  1263. Neuroprotection in ischemic stroke—combination drug therapy and mild hypothermia in a rat model of permanent focal cerebral ischemia
  1264. Combining insulin-like growth factor derivatives plus caffeinol produces robust Neuroprotection after stroke in rats
  1265. Neuroprotection of immortalized hippocampal neurones by brain ‐derived neurotrophic factor and Raf‐1 protein kinase: role of extracellular signal‐regulated protein …
  1266. Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient Neuroprotection against ischemic stroke
  1267. Corticotropin-releasing factor (CRF) and related peptides confer Neuroprotection via type 1 CRF receptors
  1268. Aging blunts ischemic-preconditioning-induced Neuroprotection following transient global ischemia in rats
  1269. Immune-mediated neurodegeneration and Neuroprotection in MS.
  1270. Expression of apoptosis inhibitor protein Mcl1 linked to Neuroprotection in CNS neurons
  1271. Neuroprotection in PD—a role for dopamine agonists?
  1272. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and Neuroprotection by distinct signaling pathways
  1273. Dexamethasone downregulates chemokine receptor CXCR4 and exerts Neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats
  1274. Caspase 3 activation is essential for Neuroprotection in preconditioning
  1275. Prolonged opportunity for ischemic Neuroprotection with selective κ-opioid receptor agonist in rats
  1276. Neuroprotection by fructose-1, 6-bisphosphate involves ROS alterations via p38 MAPK/ERK
  1277. Neuroprotection in Parkinson disease
  1278. Partial characterization of retina-derived cone Neuroprotection in two culture models of photoreceptor degeneration
  1279. Neuroprotection by Na+ channel blockade
  1280. Ionotropic glutamate receptors: still a target for Neuroprotection in brain ischemia? Insights from in vitro studies
  1281. Role of nonfeminizing estrogen analogues in Neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity
  1282. Neuroprotection by D-securinine against neurotoxicity induced by beta-amyloid (25–35)
  1283. Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts Neuroprotection in autoimmune encephalomyelitis
  1284. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for Neuroprotection in the central nervous system
  1285. … element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced Neuroprotection
  1286. Kappa-opioid receptor selectivity for ischemic Neuroprotection with BRL 52537 in rats
  1287. Signaling cascades involved in Neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38
  1288. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury
  1289. Mitochondrial ATP-sensitive potassium channel: a novel site for Neuroprotection
  1290. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels
  1291. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker
  1292. Role of alpha-2 agonists in Neuroprotection
  1293. Consensus review. Pharmacological Neuroprotection in cerebral ischemia: is it still a therapeutic option?
  1294. Mechanisms of neuronal death and Neuroprotection
  1295. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease?
  1296. FGF-2 promotes neurogenesis and Neuroprotection and prolongs survival in a transgenic mouse model of Huntington’s disease
  1297. Lack of Neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia
  1298. Reduction of calcium release from the endoplasmic reticulum could only provide partial Neuroprotection against beta‐amyloid peptide toxicity
  1299. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to Neuroprotection
  1300. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in Neuroprotection against N-methyl-D-aspartate receptor-mediated …
  1301. Nicotine‐induced Neuroprotection against N‐methyl‐d‐aspartic acid or β‐amyloid peptide occur through independent mechanisms distinguished by pro …
  1302. Mechanisms involved in prostaglandin E2-mediated Neuroprotection against TNF-α: possible involvement of multiple signal transduction and β-catenin/T-cell factor
  1303. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents
  1304. Molecular mechanisms of cytokine-induced Neuroprotection : NFκB and neuroplasticity
  1305. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis: a key role for glucose-6-phosphate dehydrogenase activity in Neuroprotection
  1306. Single-dose ebselen does not afford sustained Neuroprotection to rats subjected to severe focal cerebral ischemia
  1307. Phosphatidylinositol 3‐kinase and Akt effectors mediate insulin‐like growth factor‐I Neuroprotection in dorsal root ganglia neurons
  1308. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia
  1309. Retinal detachment neuropathology and potential strategies for Neuroprotection
  1310. SOD1 overexpression and female sex exhibit region-specific Neuroprotection after global cerebral ischemia due to cardiac arrest
  1311. First clinical experiences with an endovascular clamping system for Neuroprotection during carotid stenting
  1312. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector
  1313. Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17β-estradiol-mediated Neuroprotection
  1314. Neuroprotection in cardiac surgery.
  1315. Neurotoxicity of lidocaine: implications for spinal anesthesia and Neuroprotection
  1316. Neuroprotection in brain ischemia–doubts and hopes
  1317. Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion-and T2-weighted magnetic resonance imaging
  1318. Mitochondrial medicine: Neuroprotection and life extension by the new amphiphilic nitrone LPBNAH1 acting as a highly potent antioxidant agent
  1319. … derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand‐mediated Neuroprotection in a model of …
  1320. Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models.
  1321. Regulation of c‐Jun N‐terminal kinase, p38 kinase and AP‐1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium Neuroprotection
  1322. Levodopa therapy from the Neuroprotection viewpoint
  1323. Pharmacological strategies to block rod photoreceptor apoptosis caused by calcium overload: a mechanistic target-site approach to Neuroprotection
  1324. Severe hypotension is not essential for isoflurane Neuroprotection against forebrain ischemia in mice
  1325. The Neuroprotection of resveratrol in the experimental cerebral ischemia
  1326. Neuroprotection in progressive brain disorders
  1327. Inhibition of release of taurine and excitatory amino acids in ischemia and Neuroprotection
  1328. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma
  1329. Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study
  1330. Designing Neuroprotection trials in Parkinson’s disease
  1331. Neuroprotection in Parkinson’s disease: an elusive goal
  1332. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following Neuroprotection by FK506 in the ischemic rat brain
  1333. Mediation of BMP7 Neuroprotection by MAPK and PKC IN rat primary cortical cultures
  1334. Microglial NADPH oxidase mediates leucine enkephalin dopaminergic Neuroprotection
  1335. Prenatal hypoxia-induced adaptation and Neuroprotection that is inducible nitric oxide synthase-dependent
  1336. Polycyclic phenols, estrogens and Neuroprotection : a proposed mitochondrial mechanism
  1337. Electroacupuncture provides a new approach to Neuroprotection in rats with induced glaucoma
  1338. Female-specific Neuroprotection against transient brain ischemia observed in mice devoid of prion protein is abolished by ectopic expression of prion protein-like …
  1339. Gonadotropins and Alzheimer’s disease: the link between estrogen replacement therapy and Neuroprotection
  1340. An in vitro model of inflammatory neurodegeneration and its Neuroprotection
  1341. Neuroprotection and epilepsy
  1342. Time for a cool head—Neuroprotection becomes a reality
  1343. Targeting Neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy
  1344. Long-term Neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system
  1345. Signaling pathways involved with serotonin1A agonist-mediated Neuroprotection against ethanol-induced apoptosis of fetal rhombencephalic neurons
  1346. Retinal ganglion cell death and Neuroprotection : involvement of the CaMKIIα gene
  1347. Opportunities for Neuroprotection in ALS using cell death mechanism rationales
  1348. Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist
  1349. … brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of ΔFosB and galectin-1 in Neuroprotection …
  1350. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides Neuroprotection , and reduces inflammation in a rat model of traumatic brain injury
  1351. A novel mechanism for pergolide-induced Neuroprotection : inhibition of NF-κB nuclear translocation
  1352. Atrial natriuretic peptide expression is increased in rat cerebral cortex following spreading depression: possible contribution to sd-induced Neuroprotection
  1353. Neuroprotection against hypoxia-ischemia by insulin-like growth factor-I (IGF-I).
  1354. Modulation of calcium/calmodulin kinase‐II provides partial Neuroprotection against beta‐amyloid peptide toxicity
  1355. Glutathione peroxidase-1 contributes to the Neuroprotection seen in the superoxide dismutase-1 transgenic mouse in response to ischemia/reperfusion injury
  1356. A comparison of carotid artery stenting with Neuroprotection versus carotid endarterectomy under local anesthesia
  1357. Challenge of conducting trials of Neuroprotection in the asphyxiated term infant
  1358. VPAC2 receptors mediate vasoactive intestinal peptide-induced Neuroprotection against neonatal excitotoxic brain lesions in mice
  1359. Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring Neuroprotection in experimental focal cerebral ischemia in the rat …
  1360. Monoamine oxidase B inhibition and Neuroprotection : studies on selective adenosine A2A receptor antagonists
  1361. Neuroprotection for Parkinson’s disease: a call for clinically riven experimental design
  1362. Involvement of γ protein kinase C in estrogen‐induced Neuroprotection against focal brain ischemia through G protein‐coupled estrogen receptor
  1363. 681. Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma
  1364. Mechanism of electrical stimulation-induced Neuroprotection : effects of verapamil on protection of primary auditory afferents
  1365. Failure of ischemic Neuroprotection by potentiators of gamma-aminobutyric acid
  1366. Neuroprotection induced by the adenosine A 2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways
  1367. The dual role of prostaglandin E2 in excitotoxicity and preconditioning-induced Neuroprotection
  1368. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4. 1) motoneurons exposed to glutamate: calpain inhibition provides functional Neuroprotection
  1369. Long-term Neuroprotection induced by regional brain cooling with saline infusion into ischemic territory in rats: a behavioral analysis
  1370. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring Neuroprotection
  1371. Oxidative injury to the locus coeruleus of rat brain : Neuroprotection by melatonin
  1372. What is the learning curve for carotid artery stenting with Neuroprotection ? Analysis of 200 consecutive cases at an academic institution
  1373. Cerebral ischemia-hypoxia and biophysical mechanisms of neurodegeneration and Neuroprotection effects
  1374. Lack of Neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma
  1375. Synthesis and evaluation of peptidic metal chelators for Neuroprotection in neurodegenerative diseases
  1376. 17β‐Estradiol activates ICI 182,780‐sensitive estrogen receptors and cyclic GMP‐dependent thioredoxin expression for Neuroprotection
  1377. An alternative Ca2+‐dependent mechanism of Neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics
  1378. Anesthetic mediated Neuroprotection : established fact or passing fancy?
  1379. Combination of early perinatal factors to identify near-term and term neonates for Neuroprotection
  1380. Biological and molecular mechanisms of hypothermic Neuroprotection
  1381. In vitro Neuroprotection by novel antioxidants in guinea-pig urinary bladder subjected to anoxia-glucopenia/reperfusion damage
  1382. nNOS is involved in estrogen mediated Neuroprotection in neuroblastoma cells
  1383. Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction
  1384. Diltiazem-induced Neuroprotection in glutamate excitotoxicity and ischemic insult of retinal neurons
  1385. Humanin antagonists: mutants that interfere with dimerization inhibit Neuroprotection by Humanin
  1386. Antisense oligonucleotide against GTPase Rab5b inhibits metabotropic agonist DHPG-induced Neuroprotection
  1387. The use of hypothermia as a method of Neuroprotection during neurosurgical procedures and after traumatic brain injury: a survey of clinical practice in Great Britain …
  1388. The Ras Inhibitor S-Trans, Trans-Farnesylthiosalicylic Acid Exerts Long-Lasting Neuroprotection in a Mouse Closed Head Injury Model
  1389. Dopamine transporter as a marker of Neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol
  1390. STN stimulation and Neuroprotection in Parkinson’s disease—when beautiful theories meet ugly facts
  1391. Mechanisms of Neuroprotection by polyphenols
  1392. Neuroprotection in the PNS: erythropoietin and immunophilin ligands
  1393. Postischemic Neuroprotection in the ischemia-tolerant state gerbil hippocampus is associated with increased ligand binding to inhibitory GABA A receptors
  1394. Reactive oxygen species mediate the Neuroprotection conferred by a mitochondrial ATP-sensitive potassium channel opener during ischemia in the rat hippocampal …
  1395. Single intravenous injection of naked plasmid DNA encoding erythropoietin provides Neuroprotection in hypoxia–ischemia rats
  1396. Ischemic Neuroprotection with selective κ-opioid receptor agonist is gender specific
  1397. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to Neuroprotection
  1398. Neuroprotection with delayed initiation of prolonged hypothermia after in vitro transient global brain ischemia
  1399. Neuroprotection against hypoxia-ischemia in neonatal rat brain by novel superoxide dismutase mimetics
  1400. Caffeinol confers cortical but not subcortical Neuroprotection after transient focal cerebral ischemia in rats
  1401. Estrogen receptor alpha mediates neuronal differentiation and Neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
  1402. In vitro model of neurotoxicity of Aβ 1–42 and Neuroprotection by a pentapeptide: irreversible events during the first hour
  1403. Neurochemical correlates of differential Neuroprotection by long-term dietary creatine supplementation
  1404. Adenosine A2A Receptor Antagonism and Neuroprotection : Mechanisms, Lights, and Shadows
  1405. Morphinan Neuroprotection : new insight into the therapy of neurodegeneration
  1406. Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration
  1407. Detailed in vitro pharmacological analysis of FK506-induced Neuroprotection
  1408. Hypothermia for 24 hours after asphyxic cardiac arrest in piglets provides striatal Neuroprotection that is sustained 10 days after rewarming
  1409. Neuroprotection and protein damage prevention by estradiol replacement in rat hippocampal slices exposed to oxygen-glucose deprivation
  1410. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: Neuroprotection with brimonidine
  1411. Neuroprotection in cardiac surgery
  1412. Inhibition of neuronal nitric oxide synthase-mediated activation of poly (ADP-ribose) polymerase in traumatic brain injury: Neuroprotection by 3-aminobenzamide
  1413. Transactivation in astrocytes as a novel mechanism of Neuroprotection
  1414. Poly (ADP‐Ribose) polymerase‐1 in acute neuronal death and inflammation: a strategy for Neuroprotection
  1415. Effects of neonatal and prepubertal hormonal manipulations upon estrogen Neuroprotection of the nigrostriatal dopaminergic system within female and male mice
  1416. Mechanisms of Neuroprotection against glaucoma
  1417. Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells
  1418. Health care resource use after acute stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas trial
  1419. The therapeutic window of hypothermic Neuroprotection in experimental ischemic neuropathy: protection in ischemic phase and potential deterioration in later …
  1420. Potent ς1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats
  1421. Neuroprotection
  1422. … deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38α and p38β activation and confers Neuroprotection in the pheochromocytoma …
  1423. Nicotinic receptor modulation for Neuroprotection and enhancement of functional recovery following brain injury or disease
  1424. The lipid‐activated two‐pore domain K+ channel TREK‐1 is resistant to hypoxia: implication for ischaemic Neuroprotection
  1425. Uncoupling protein 2: a novel player in Neuroprotection
  1426. Cannabinoid‐mediated Neuroprotection following interferon‐gamma treatment in a three‐dimensional mouse brain aggregate cell culture
  1427. Angiotensin II blocks nicotine-mediated Neuroprotection against β-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1
  1428. Neuroprotection and regeneration after traumatic lesion of the optic nerve
  1429. Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration
  1430. Clinical trials in Neuroprotection
  1431. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson’s disease and Neuroprotection ; are there links?
  1432. Neuroprotection assessment by topographic electroencephalographic analysis: effects of a sodium channel blocker to reduce polymorphic delta activity following …
  1433. In vitro Neuroprotection against oxidative stress by pre-treatment with a combination of dihydrolipoic acid and phenyl-butyl nitrones
  1434. Transplantation of fetal kidney cells: Neuroprotection and neuroregeneration
  1435. Neuroprotection by the caspase-1 inhibitor Ac-YVAD-(acyloxy) mk in experimental neuroAIDS is independent from IL-1 β generation
  1436. No magic bullets: the ephemeral nature of anesthetic-mediated Neuroprotection
  1437. How to keep injured CNS neurons viable—strategies for Neuroprotection and gene transfer to retinal ganglion cells
  1438. Strategies for Neuroprotection in the newborn
  1439. The immunophilin‐ligands FK506 and V‐10,367 mediate Neuroprotection by the heat shock response
  1440. The prospects for Neuroprotection in MS.
  1441. Neuroprotection of adult rat dorsal root ganglion neurons by combined hypothermia and alkalinization against prolonged ischemia
  1442. Post-ischemic diazepam does not reduce hippocampal CA1 injury and does not improve hypothermic Neuroprotection after forebrain ischemia in gerbils
  1443. Neuroprotection : Where Are We Going?
  1444. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation
  1445. Does Neuroprotection prevent epileptogenesis?
  1446. Neuroprotection in traumatic brain injury
  1447. The inhibition of glycogen synthase kinase 3β by a metabotropic glutamate receptor 5 mediated pathway confers Neuroprotection to Aβ peptides
  1448. Neuroprotection mediated by subtoxic dose of NMDA in SH-SY5Y neuroblastoma cultures: activity-dependent regulation of PSA-NCAM expression
  1449. Molecular targets for Neuroprotection
  1450. Rapid Report: Acute hypoxia occludes hTREK‐1 modulation: re‐evaluation of the potential role of tandem P domain K+ channels in central Neuroprotection
  1451. Neuroprotection in Glaucoma
  1452. Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide Neuroprotection against multiple consequences of vitamin …
  1453. Lens epithelium-derived growth factor: Neuroprotection on rat retinal damage induced by N-methyl-D-aspartate
  1454. Possible involvement of astrocytes in Neuroprotection by the cognitive enhancer T-588
  1455. VEGF–mediated Neuroprotection in ischemic retina
  1456. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis
  1457. Calcineurin and cyclophilin D are differential targets of Neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage
  1458. Angiotensin receptor gene expression in candesartan mediated Neuroprotection
  1459. Neuroprotection possibilities in epileptic children
  1460. Angiotensin type 2 receptor Neuroprotection against chemical hypoxia is dependent on the delayed rectifier K+ channel, Na+/Ca2+ exchanger and Na+/K+ ATPase in …
  1461. Clinical trials in Neuroprotection . 23-25 January 2003, Key Biscayne, FL, USA.
  1462. Inhibition of nitric oxide production and protein tyrosine nitration contribute to Neuroprotection by a novel calmodulin antagonist, DY-9760e, in the rat microsphere …
  1463. Endogenously expressed estrogen receptors mediate Neuroprotection in hippocampal cells (HT22)
  1464. Astrocytic cytochromes p450: an enzyme subfamily critical for brain metabolism and Neuroprotection
  1465. Small molecule activators of the heat shock response and Neuroprotection from stroke
  1466. Clinical pharmacology and Neuroprotection in Parkinson’s disease
  1467. Retinal ganglion cell Neuroprotection in culture
  1468. Remyelination as Neuroprotection
  1469. Strategies of Neuroprotection for intracranial aneurysms
  1470. Suppression of protein kinase Cε mediates 17β‐estradiol‐induced Neuroprotection in an immortalized hippocampal cell line
  1471. In the rostral ventrolateral medulla, the 70-kDa heat shock protein (HSP70), but not HSP90, confers Neuroprotection against fatal endotoxemia via augmentation of …
  1472. P2 receptor antagonist PPADS confers Neuroprotection against glutamate/NMDA toxicity
  1473. C5b‐9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and Neuroprotection
  1474. Neuroprotection of vestibular sensory cells from gentamicin ototoxicity obtained using nitric oxide synthase inhibitors, reactive oxygen species scavengers, brain …
  1475. Introduction: A2A receptors in Neuroprotection of dopaminergic neurons
  1476. Con: Retrograde cerebral perfusion is not an optimal method of Neuroprotection in thoracic aortic surgery
  1477. Perioperative cerebral ischemia and the possibility of Neuroprotection by inhalational anesthetics
  1478. Neuronal injury and Neuroprotection
  1479. Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and Neuroprotection by antioxidants and selective NOS inhibitors
  1480. Assessment and explorations on the mechanism of Neuroprotection of patients in ischemic stroke by traditional Chinese medicine
  1481. Perinatal brain damage–from Neuroprotection to neuroregeneration using cord blood stem cells
  1482. Gene therapy and Neuroprotection for cerebral infarction
  1483. Neuroprotection by the stable nitroxide 3-carbamoyl-proxyl during reperfusion in a rat model of transient focal ischemia
  1484. Neuroprotection in epilepsy: the Holy Grail of antiepileptogenic therapy.
  1485. Secondary Neuroprotection
  1486. New directions in Neuroprotection : Basic mechanisms, molecular targets and treatment strategies
  1487. Neuroprotection Becomes Reality
  1488. Delayed transient ischemic attacks kill some CA1 neurons previously salvaged with postischemic hypothermia: Neuroprotection undone
  1489. … effects of hypothermia ranging from 34 degrees C to 31 degrees C on brain ischemia in gerbils and determination of the mechanism of Neuroprotection .
  1490. Neuroprotection and dopamine agonists
  1491. Neuroprotection
  1492. Poly (ADP-ribosyl) ation enzyme-1 as a target for Neuroprotection in acute central nervous system injury
  1493. Monoamine oxidase inhibitors, their structural analogues, and Neuroprotection
  1494. Neuroprotection : A realistic goal for aged brain ?
  1495. Current status of Neuroprotection in cerebrovascular disease
  1496. Erythropoiesis and Neuroprotection : two sides of the same coin?
  1497. … expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent Neuroprotection
  1498. Ocular Neuroprotection
  1499. Neuroprotection against glaucoma remains a concept
  1500. Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke Neuroprotection
  1501. Neuro-overprotection? A functional evaluation of clomethiazole-induced Neuroprotection following hypoxic-ischemic injury
  1502. Cell-permeant calcium buffer induced Neuroprotection after cortical devascularization
  1503. Gap junction-mediated intercellular communication in astrocytes and Neuroprotection
  1504. Low molecular weight compounds with affinity to melanocortin receptors exert Neuroprotection in spinal cord injury—an experimental study in the rat
  1505. Neuroprotection or Neurotoxicity
  1506. Limiting iron availability confers Neuroprotection from chronic mild carbon monoxide exposure in the developing auditory system of the rat
  1507. CAI is a potent inhibitor of neovascularization and imparts Neuroprotection in a mouse model of ischemic retinopathy
  1508. Neuroprotection by estrogen in animal models of ischemia and Parkinson’s disease
  1509. Time Window of Fibroblast Growth Factor-18—Mediated Neuroprotection after Occlusion of the Middle Cerebral Artery in Rats
  1510. Involvement of phosphatidylinositol 3-kinase and insulin-like growth factor-I in YXLST-mediated Neuroprotection
  1511. The risks of extending the controversial use of tocolytic magnesium sulfate for the purpose of Neuroprotection in preterm labor
  1512. The role of BF-7 on Neuroprotection and enhancement of cognitive function
  1513. The synthetic estrogen 4-estren-3α, 17β-diol (estren) induces estrogen-like Neuroprotection
  1514. COMT inhibition in the treatment of Parkinson’s disease: Neuroprotection and future perspectives
  1515. Pontine cholinergic neurons depend on three Neuroprotection systems to resist nitrosative stress
  1516. Fenfluramine‐induced serotonergic neurotoxicity in mice: lack of Neuroprotection by inhibition/ablation of nNOS
  1517. Neuroprotection in Ischemic/Hypoxic Disorders
  1518. Magnesium sulfate for preterm Neuroprotection
  1519. Postischemic nitrous oxide alone versus intraischemic nitrous oxide in the presence of isoflurane: What it may change for Neuroprotection against cerebral stroke in …
  1520. Neuroprotection trek—the next generation: the measurement is the message
  1521. Vasopressin mediates Neuroprotection in mice by stimulation of V1 vasopressin receptors: Influence of PI-3 kinase and gap junction inhibitors
  1522. Neuroprotection against focal ischemia in the hyperbilirubinemic rat model
  1523. Microwave‐assisted synthesis and chiral HPLC separation of 18F‐labeled MaxiPost™. An agent for post‐stroke Neuroprotection
  1524. Advances in neuroregulation and Neuroprotection
  1525. Effect of magnesium sulfate given for Neuroprotection before preterm birth
  1526. Multi-organ protection and the kidney. From nephroprotection, cardioprotection, Neuroprotection to multi-organ protection
  1527. Magnesium sulfate and Neuroprotection
  1528. Monounsaturated fatty acids and Neuroprotection . The results of a study of cognitive decline in old age. Is there a case for this treatment in multiple sclerosis?
  1529. Transfert cérébral et Neuroprotection
  1530. N-methyl-D-aspartate attenuates CXCR2-mediated Neuroprotection through enhancing the receptor phosphorylation and blocking the receptor recycling
  1531. Role of erythropoietin in brain homeostasis, neurodevelopment and Neuroprotection
  1532. Characteristic features of optic nerve ganglion cells and approaches for Neuroprotection . From intracellular to capillary processes and therapeutic considerations
  1533. Neuroprotection in Hungtington’s disease
  1534. Neuroprotection in the peripheral nervous system
  1535. Neuroprotection of nerve growth factor in experiment retinal detachment
  1536. Neuroprotection against Apoptosis
  1537. Ca2+-ATPase isoforms are expressed in Neuroprotection in rat, but not human, neurons
  1538. Oxidative Toxicity in BV‐2 Microglia Cells: Sesamolin Neuroprotection of H2O2 Injury Involving Activation of p38 Mitogen‐Activated Protein Kinase
  1539. Nanoceria particles confer Neuroprotection in retinal cells in vitro
  1540. The Gtx homeodomain transcription factor exerts Neuroprotection using its homeodomain
  1541. Neuroprotection of photoreceptor cells in rod-cone dystrophies: from cell therapy to cell signalling
  1542. Progestins and antiprogestins: mechanisms of action, Neuroprotection and myelination
  1543. Inhibition of brain phospholipase A2 by antimalarial drugs: Implications for Neuroprotection in neurological disorders
  1544. Green tea catechins Neuroprotection mediated by nAChR
  1545. Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in Neuroprotection and neurotherapy.
  1546. Neuroprotection by cAMP
  1547. Neurotoxicity and Neuroprotection , two aspects of microglial activation in human immunodeficiency virus (HIV) infection
  1548. Perinatal Neuroprotection by muscle relaxants against hypoxic-ischemic lesions: Is it a possible hypothesis?
  1549. A viable Neuroprotection strategy following soman-induced status epilepticus
  1550. Advances in studies on Neuroprotection of natural medicines
  1551. Neuronal nicotinic receptors and Neuroprotection : newer ligands may help us understand their role in neurodegeneration
  1552. Neuroprotection with Aminoguanidine treatment after brain injury in rats
  1553. Possible role of cerebellar fastigial nucleus in preconditioned Neuroprotection
  1554. International Journal of Neuroprotection and Neuroregeneration: IJNN
  1555. … 14C labeled (S)‐3‐(5‐chloro‐2‐methoxyphenyl)‐1, 3‐dihydro‐3‐fluoro‐6‐(trifluoromethyl)‐2H‐indol‐2‐one, maxipost™. An agent for post‐stroke Neuroprotection
  1556. Advances in Neuroprotection research for neurodegenerative diseases
  1557. Magnesium Sulfate for Preterm Neuroprotection —Reply
  1558. Neuroprotection by resveratrol against cytotoxicity of oxidized low density lipoprotein in PC12 cells
  1559. Seizure-Induced Neuroprotection
  1560. Neuroprotection by ketamine
  1561. Experimental Neuroprotection : translation to human stroke trials
  1562. brain atrophy as a measure of neurodegeneration and Neuroprotection
  1563. Primary Neuroprotection
  1564. Polycyclic aminoguanidines: novel entities for Neuroprotection
  1565. Neuroprotection and neurodegenerative parkinsonian syndromes
  1566. Evolution of the Neuroprotection concept
  1567. An improved quantitative method for evaluation of ischemic injury and Neuroprotection in mouse brain slices
  1568. Effect of magnesium sulfate given for Neuroprotection before preterm birth: a randomized, controlled trial
  1569. Proceedings of the Perioperative Neuroprotection Symposium
  1570. Neuroprotection of lithium and the antagonism of lithium to toxic effects of lead on primary culturing cerebrocortical neurons in vitro
  1571. Cholecystokinin and Neuroprotection
  1572. Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
  1573. White matter Neuroprotection in preterm infants
  1574. Neuroprotection induced by Estrogen Against Focal Cerebral Ischemic-reperfusion Injury in Ovariectomized Rats
  1575. Neutrophil elastase: a target of Neuroprotection
  1576. Molecular mechanisms of neurodegeneration and Neuroprotection -experimental approaches and the diseased brain .
  1577. Soyisoflavones provide Neuroprotection in focal cerebral ischemia of ovariectmized female rats
  1578. Xenon Exhibits Its Neuroprotection Through an Anti-Apoptotic Mechanism
  1579. Clinical Trials Promote treatment and Neuroprotection in Parkinson Disease
  1580. Neuroprotection in Hungtington’s Disease: RESPONSE FROM THE AUTHORS
  1581. Estratriene Neuroprotection through Antioxidant, Non-Estrogen Receptor Mediated Mechanisms
  1582. Mechanisms of Neuroprotection in hippocampal organotypic culture
  1583. Incipient neurovulnerability and Neuroprotection in early psychosis: A proton spectroscopy study of the anterior hippocampus at 3Tesla
  1584. Carbon dioxide provides Neuroprotection in fluid percussion injured rats
  1585. Neuroprotection for Ischemic Injury in the immature brain
  1586. Neuroprotection in Stroke
  1587. Session IV: Role of Carnitines and Other agents in Neuroprotection
  1588. Perioperative Neuroprotection Symposium
  1589. Role of Akt1 in estrogen-mediated Neuroprotection
  1590. Neuroprotection of Hypothermia Combined with Salvia Miltiorrhiza Bunge on brain Damage in the Immature Rat
  1591. Neuroprotection of Veratrum nigrum var. ussurience alkaloids on focal cerebral ischemia-reperfusion injury in rats
  1592. Apoptosis and glaucoma: new insight from basic research to the development of novel strategies for Neuroprotection
  1593. … of N-type Ca2+ currents. An increase in the isoflurane blocking potency of N-type Ca2+ currents may contribute to the known Neuroprotection action of isoflurane …
  1594. Blocking the axonal injury cascade: Neuroprotection in multiple sclerosis and its models
  1595. Effects of aging on hypothermic Neuroprotection in acute stroke
  1596. Neuroprotection by the α2-adrenoceptor agonist, dexmedetomidine, in experimental stroke models
  1597. Mechanism of isoflurane preconditioning’s Neuroprotection against global cerebral ischemia in rat [J]
  1598. Endogenous mechanisms of Neuroprotection and neuroregeneration
  1599. Nicotinic acetylcholine receptor-mediated mechanisms of Neuroprotection in AD
  1600. Lithium and Neuroprotection
  1601. Effect of two different Neuroprotection systems on microembolization during carotid artery stenting
  1602. … CHRONIC OCULAR HYPERTENSION RESULTS IN DEGENERATION OF RETINO–TECTAL AFFERENTS: Neuroprotection WITH TOPICAL BRIMONIDINE.
  1603. Neuroprotection in Parkinson’s Disease
  1604. Neuroprotection Therapeutics: Part 2-Companies & Drugs in Development
  1605. Neuroprotection and the anesthesiologist
  1606. The functional change in the 5-HT1A receptor induced by stress and the role of the 5-HT1A receptor in Neuroprotection
  1607. ELECTRIC MAGNETIC NEUROSTIMULA-TIONS ARE REALLY Neuroprotection
  1608. Intravenous Magnesium for Neuroprotection in Acute Stroke: Neuropharmacology Supports Clinical Hope: Response
  1609. Persistent Neuroprotection Against Focal Cerebral Ischemia Induced By Cortical Spreading Depression In Mice
  1610. Preventive Neuroprotection : from experimental data to therapeutic
  1611. The role of neuregulins in Neuroprotection following acute stroke
  1612. Cerebral transfer and Neuroprotection
  1613. Long-lasting Neuroprotection induced in mouse retina by repeated hypoxic preconditioning
  1614. Glycosaminoglycans and Neuroprotection : effect on cholinergic neurodegeneration
  1615. Anesthesia for neurosurgery Neuroprotection 2005
  1616. 17 The Essentiality of Iron Chelation in Neuroprotection : A Potential Role of Green Tea Catechins
  1617. Development of sleep therapeutic instrument based on the mechanism of Neuroprotection
  1618. Updating the Dual Role of brain Nitric Oxide in Neurodegeneration/Neuroprotection : Understanding Molecular Mechanisms to Devise Drug Approaches
  1619. Regulation of immune-dependent Neuroprotection for arresting neuronal degeneration in optic neuropathies
  1620. Preconditioning Neuroprotection afforded by xenon requires new protein synthesis in an vitro nodel of neuronal injury
  1621. Society for Neuroscience–34th Annual Meeting. Neuroprotection and Anxiety. 23-27 October 2004, San Diego, CA, USA
  1622. Neuroprotection in Parkinson’s Disease
  1623. Quality of preclinical evidence for Neuroprotection in stroke
  1624. Ketamine and Neuroprotection : hemodynamic and metabolic effects in severe traumatic brain injury
  1625. Molecular Mechanisms of Dopaime Receptor Mediated Neuroprotection
  1626. Neuroprotection by Brimonidine Treatment in a Rat Model of Anterior Ischemic Optic Neuropathy
  1627. Neuroprotection in Progressive brain Disorders
  1628. The Neuroprotection of polysaccharidesulfate in the experimental cerebral ischemia
  1629. Neuroprotection Therapeutics: Part 1-New Scientific Strategies & Broader Clinical Applications
  1630. Lamotrigine Neuroprotection in the rabbit retina after pars plana vitrectomy with silicone oil tamponade
  1631. Modulators of endogenous Neuroprotection : Estrogen, corticotropin-releasing hormone and endocannabinoids
  1632. Approaches to Neuroprotection and Recovery Enhancement After Acute Stroke
  1633. Endovanilloid and endocannabinoid mechanism in Neuroprotection
  1634. Neuroprotection in Huntington; s Disease
  1635. Apoptosis and Neuroprotection an exciting and rapidly expanding field of research in ophthalmology
  1636. From a cage to a model, from the heart to the brain : novel concepts in Neuroprotection
  1637. Adenosine-induced Neuroprotection
  1638. Mechanisms underlying in vivo Neuroprotection by the endocannabinoid anandamide and the cannabinoid/vanilloid receptor agonist, arvanil
  1639. … ) on Retinal Ganglion Cells (RGCs) Survival After Optic Nerve Crush, and the Role of brain Derived Neurotrophic Factor (BDNF) in Immune Mediated Neuroprotection
  1640. Anti-apoptotic mechanism of androgen Neuroprotection
  1641. Neuroprotection by drug-induced growth factors
  1642. The müller glia: role in Neuroprotection
  1643. Adaptation of different Neuroprotection devices during carotid stenting procedures
  1644. Mechanisms of Neuroprotection by acetyl-L-carnitine
  1645. Neuroprotection and ageing in sensory neurons.
  1646. Immuno-pharmacological properties of panaxadiol and panaxatriol and their potential effects in Neuroprotection in vitro
  1647. Assessment of functional Neuroprotection in a rat model of neonatal stroke
  1648. Preface [Hot Topic: Current Status of Neuroprotection in Traumatic brain Injury (Executive Editors: Maria Mataro and Juan Sahuquillo)]
  1649. Neuroprotection against ischemic stroke by early or delayed treatment with MC4 receptor-stimulating melanocortins
  1650. Erythropoietin: A Beneficial Approach to Neuroprotection in Stroke
  1651. Acid–base management during hypothermic Neuroprotection
  1652. A-type potassium currents and Neuroprotection after ischemia
  1653. Correlation between Mitochondrial Membrane Potential and Topiramate′ s Neuroprotection
  1654. Low stroke rates during carotid artery stenting with Neuroprotection
  1655. Neuroprotection Effect of Ascorbic Acid in Model of Ischemic Retinal Injury
  1656. Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy.
  1657. Postischemic Hypothermia Provides Long-Term Neuroprotection in Rodents
  1658. Modern Therapeutic Approaches to Acute Focal brain Ischemia. Basic Strategies for Neuroprotection
  1659. Neuroprotection During Acute Oxidative Stress: Role of the PKG
  1660. Neuroprotection in Acute Ischemic Stroke: Lessons for Early Treatment in Multiple Sclerosis
  1661. Cell Death and Neuroprotection of Retinal Ganglion (RGC–5) Cells
  1662. In vivo Neuroprotection of melatonin against focal cerebral
  1663. Parkinson’s Disease: Possible Mechanisms of Neurodegeneration and Strategies for Neuroprotection
  1664. Perspectives on Neuroprotection . Could acid-sensing ion channels be a target of new treatments?
  1665. Albumin therapy for Neuroprotection in ischemic stroke: Alias I trial
  1666. WHAT CAUSES RETINAL GANGLION CELLS TO DIE? NEUROTOXICITY AND Neuroprotection
  1667. Neuroprotection in acute cerebral ischemia by acetylsalicylic acid
  1668. Metallothionein is Implicated in Zn” Neuroprotection of
  1669. Combined Neuroprotection by Xenon and Dexmedetomidine in vitro
  1670. Mechanism of isoflurane preconditioning’s Neuroprotection against global cerebral ischemia in rat
  1671. Neurodegeneration and Neuroprotection in transient cerebral ischemic stroke
  1672. Tenascin-R plays a role in Neuroprotection via its distinct
  1673. Neurodegeneration and Neuroprotection : epilepsy and Parkinsonism
  1674. Molecular Basis of Neuroprotection in a Mouse Model of Focal Cerebral Ischaemia
  1675. Developmental effects of gonadal steriod hormones upon Neuroprotection of the nigrostriatal dopaminergic system
  1676. Estrogen Regulate Neuroprotection and PDI Gene Expression in Ischemic Rat brain
  1677. Estrogen Regulate Neuroprotection and PDI Gene Expression in Ischemic Rat brain
  1678. Therapeutic T-cell-based vaccination versus pharmacological intervention for Neuroprotection : restoring lost homeostasis
  1679. Mechanisms of HBO-induced Neuroprotection in a Neonatal Hypoxia-ischemia Model
  1680. Neuroprotection BY TEMPOL IN A MODEL OF IRON INDUCED
  1681. Neuroprotection of zinc against apoptotic cell death in model of anoxia in vitro
  1682. The role of activin in Neuroprotection and long-term potentiation
  1683. Neuroprotection of ginsenoside Rg3 and signal evidences in neuroblastom a cell line (SK-N-MC)
  1684. Evaluation of Early and Prolonged Effects of Acute Neurotoxicity and Neuroprotection Using Novel Functional Imaging Techniques
  1685. Gene expression and spinal cord injury: Using microarrays to find genes associated with Neuroprotection and regeneration.
  1686. In vitro modelling of neurodegeneration and Neuroprotection specific for Alzheimer’s disease in cell cultures
  1687. Sigma Agonists Afford Neuroprotection via a Post-Synaptic Mechanism
  1688. Neuroprotection by 3-CP During Reperfusion in a Rat Model of Transient Focal Ischemia
  1689. Ischemic preconditioning promotes Neuroprotection via cyclooxygenase-2 induction in vitro
  1690. Organ Cultures of Adult Porcine Retina: A Model for Studing Neuroprotection in the Retina
  1691. The role of glia cells in purine receptor-induced Neuroprotection
  1692. CAI Appears to Provide Neuroprotection in Mouse Model of Ischemia Induced Retinal Neovascularization
  1693. Is tumor necrosis factor-α-converting enzyme (TACE) a therapeutic target for Neuroprotection ?
  1694. Neuroprotection of sini decoction after focal cerebral ischemia in rat and mechanism
  1695. Mechanisms of dantrolene‐induced Neuroprotection against excitotoxic injury
  1696. Neuroprotection of Fructose-1, 6-bisphosphate Modifying ROS through p38 MAPK/ERK
  1697. Survivin expression after traumatic brain injury: Potential roles in Neuroprotection
  1698. Progress in study on Neuroprotection of erythropoietin against hypoxic-ischemic brain damage
  1699. Neuroprotection following acute spinal cord injury through inhibition of the Fas apoptotic pathway.
  1700. Adenosine-induced Neuroprotection : involvement of glia cells and cytokines
  1701. Ischemic preconditioning and erythropoietin Neuroprotection share common downstream pathways
  1702. The multiple effects of mood stabilizers and antidepressants on Neuroprotection : translating basic findings into clinical practice
  1703. Mechanisms of Neuroprotection by estrogen and selective estrogen receptor modulators
  1704. Neuroprotection induced by delta-9-THC in a model of transient global cerebral ischemia
  1705. Uptake of Tavocept™ in dorsal root ganglia (DRG) cells: Evidence for pharmacological effects of Neuroprotection
  1706. Neuroprotection Following Acute Spinal Cord Injury Through Inhibition of the Fas Apoptotic
  1707. Transgenic VEGF induces post-ischemic Neuroprotection , but facilitates hemodynamic steal phenomena
  1708. Cannabinoids and Neuroprotection in mouse models of demyelination.
  1709. Glia-regulated, apolipoprotein E specific mechanisms of Neuroprotection and neurodegeneration
  1710. Pathological study on the Neuroprotection effect of mikvetch and memantine against hypoxic-ischemic reperfusion damage in neonatal rats
  1711. Sexual dimorphism and Neuroprotection by sex steroids in an animal model of Parkinson
  1712. A quantitative measurement of formazan for evaluating ischemic injury and Neuroprotection in mouse brain slices
  1713. Sigma-Receptor Mediated Neuroprotection Occurs by a Post-Synaptic Mechanism in Neuronal Cell Culture
  1714. Prolonged Therapeutic Window for Ischemic Neuroprotection with Selective Kappa-Opioid Receptor Agonist, BRL 52537 in Rat
  1715. Neuroprotection of estrogen against injury induced by?-amyloid protein (25-35) in rat cortical neurons
  1716. Isoflurane Neuroprotection is dependent on post-ischemic hypothermia in rats subjected to severe global forebrain ischemia, Alex
  1717. Neuroprotection of retinal ganglion cells in BDNF over–expression mice with induced elevated intraocular pressure
  1718. Peroxisome proliferator-activated receptor-γ activation as a mechanism of preventive Neuroprotection induced by pioglitazone treatment
  1719. Neuroprotection in Ischemic Stroke Mediated by Intracerebral Transplantation of Human Umbilical Cord Cells
  1720. Role of microtubule-associated kinases and phosphatases in Neuroprotection against amyloid-beta toxicity.
  1721. Distribution, Expression, and Inflammatory Response after Non-Viral Gene Delivery to the Primate CNS: A Model for Operative Neuroprotection
  1722. Neuroprotection of MK-801 and magnesium sulfate in 7-day rats with hypoxic ischemic encephalathy (HIE)
  1723. Sigma receptors mediate potent Neuroprotection in vivo and inhibit neuronal depolarisation and swelling in rat brain slices
  1724. Neuroprotection action of Aspirin on cerebral ischemia-reperfusion rats with different treatment time-window and its effect on ATP levels
  1725. Estrogen mediates Neuroprotection via estrogen receptor α, not β, in a neuronal in vitro model
  1726. Caffeine, adenosine A2A receptors, and Neuroprotection in PD Schwarzschiid MA Massacusetts General Hospital, Boston, USA
  1727. Analogous Neuroprotection induced by resveratrol and ischemic preconditioning in CA1 region of hippocampus after ischemia
  1728. Strategies for Neuroprotection Using Passive (Neurotrophin-Deprivation) and Active (Virotoxin Exposure) Models of Neuronal Cell Death
  1729. SPONTANEOUS HYPOTHERMIA PROVIDES ENDOGENOUS Neuroprotection FROM CARDIAC ARREST AND CARDIOPULMONARY RESUSCITATION (CPR …
  1730. Neuroprotection From Calcineurin–Mediated Retinal Ganglion Cell Apoptosis by FK506 in Experimental Glaucoma
  1731. Neuroprotection by LAU–0901 in light–induced retinal damage: rod and cone photoreceptor sparing
  1732. ACh Receptor Activation Links Two Separate Signaling Proteins to Neuroprotection Against Glutamate–Induced Excitotoxicity in Isolated Pig Retinal Ganglion Cells
  1733. Neuroprotection by Native Wild Vegetable Extract against Oxidative Damage in the Mouse brain Induced by Kainic Acid
  1734. Stroke units, tissue plasminogen activator, aspirin and Neuroprotection : which stroke intervention could provide the greatest community benefit?
  1735. Ketamine Neuroprotection in the Rabbit Retina after Pars Plana Vitrectomy with Silicone Oil Tamponade
  1736. Understanding apoptosis: the key to Neuroprotection in glaucoma; As researchers unlock the secrets of programmed cell death, they shed new light on optic …
  1737. Secreted Proteins from Retinal Mueller Glia Enhance Photoreceptor Survival: An Approach to Detection of New Candidates for Neuroprotection
  1738. … Protein Co-Localizes with an NMDA Receptor Subunit in Transfected Cells and Is Detectable in brain Extracts: Prerequisites for a Possible Role in Neuroprotection
  1739. Isoflurane Neuroprotection in Hypoxic Hippocampal Slice Cultures Involves Increases in Intracellular Ca2+ and MAP Kinases
  1740. Pretreament with repeated electroacupuncture induced Neuroprotection against spinal cord ischemia-reperfusion injury in rabbits
  1741. Metabotropic glutamate receptors in spinal cord injury: Roles in Neuroprotection , chronic central pain, and locomotor recovery.
  1742. Aggravation of ischemic brain injury by prion protein deficiency, but lack of Neuroprotection by elevated prion protein levels: Role of tyrosine kinases
  1743. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against In Vivo excitoxicity in the rat: Role of vanilloid receptors and lipoxygenases
  1744. Transient Ischemia of the Retina Results in Altered Retrograde Axonal Transport by Retinal Ganglion Cells: Neuroprotection With Brimonidine
  1745. Correlative Electrophysiological and Anatomical Studies on the Effects of Retinal Ischemia on the ERG and Orthograde Axonal Transport: Neuroprotection with …
  1746. Mechanism of Apoptosis in Rat Retinal Ganglion Cell Line RGC–5 Involves Calpain–Mediated Proteolysis: Calpain Inhibition Provides Functional Neuroprotection
  1747. … AND ANATOM-ICAL STUDIES ON THE EFFECTS OF RETINAL ISCHEMIA ON THE ERG AND ORTHOGRADE AXONAL TRANSPORT: Neuroprotection WITH …
  1748. NF-B factor c-Rel mediates Neuroprotection elicited by mGlu5 receptor agonists against amyloid-peptide toxicity
  1749. Neuroprotection against ischemic CA1 neurodegeneration by pituitary adenylate cyclase activating polypeptide via cAMP-response-element-binding protein-mediated …
  1750. Neuroprotection in hippocampal slices from the hibernating species Arctic ground squirrel, Spermophilus parryii
  1751. Hypothermia Prolongs the Viability of Ischemic brain Tissue Due to Neuroprotection Linked to Redistribution of Oxygen in brain : Positron Emission Tomography Study …
  1752. … in the brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of ΔFosB and galectin-1 in Neuroprotection …
  1753. 4 Cellular brain Ischemia and Stroke: Neuroprotection , Metabolism, and New Strategies for brain
  1754. … Three Months Later in Altered Erg, Degeneration of Inner Retinal Layers, and Deafferentation of the Contralateral Superior Colliculus: Long–Term Neuroprotection …
  1755. Copolymer-1 vaccination regimens for Neuroprotection in laser-induced retinal injuries
  1756. Uncoupling Proteins: Regulation by IGF-1 and Neuroprotection during Hyperglycemia in Vitro
  1757. 155 Combined Inhibition of Neuronal and Inducible Nos Provides Neuroprotection After Hypoxia-Ischaemia in P3 and P7 Rat Pups
  1758. … Meeting of the American Society for Experimental Neurotherapeutics, Washington, DC, March 13-15, 2003—Editor’s Note: Neuroprotection : Translation of Mechanism …
  1759. The role of cyclooxygenase-2 in neurotoxicity and preconditioning-induced Neuroprotection .
  1760. 234 Magnesium Sulphate Given for Neuroprotection Before Preterm Birth
  1761. Optimization of Copolymer–1 Vaccination regimen for Neuroprotection in Laser–Induced Retinal Injuries
  1762. LINGO–1 Exerts Neuroprotection in a Rat Glaucoma Model
  1763. 17 valerate regulates Protein Disulfide Isomerase, c-fos and Nrf2 gene expressions to provide ischemic Neuroprotection in ovariectomized rat
  1764. … BETWEEN THE NEURONAL TRANSCRIPTION FACTOR NOct-3 AND THE HIV-1 TAR AND RRE RNAS: ARationale FOR Neuroprotection ?
  1765. Metallothionein is implicated in zinc (2+) Neuroprotection of cultured rat dopaminergic neurons.
  1766. Age-associated biochemical changes, Alzheimer’s disease and Neuroprotection
  1767. Oxidative Toxicity in BV-2 Microglia Cells: Sesamolin Neuroprotection of H2O2 Injury Involving Activation of p38 Mitogen-Activated Protein Kinase
  1768. PB-007 Memantine Provides Neuroprotection in Animal Models at Therapeutically Relevant Doses
  1769. Neuroprotection : challenges and opportunities
  1770. Pathologically activated therapeutics for Neuroprotection
  1771. Hypothermic Neuroprotection
  1772. Future of Neuroprotection for acute stroke: in the aftermath of the SAINT trials
  1773. Glaucoma Neuroprotection : What is it? Why is it needed?
  1774. Mechanisms of Neuroprotection by estrogen
  1775. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity
  1776. Neuroprotection and stroke: time for a compromise
  1777. Microglia provide Neuroprotection after ischemia
  1778. Pharmacological Neuroprotection for glaucoma
  1779. Minocycline for short‐term Neuroprotection
  1780. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and Neuroprotection
  1781. Cell survival matters: docosahexaenoic acid signaling, Neuroprotection and photoreceptors
  1782. Kynurenine pathway in major depression: evidence of impaired Neuroprotection
  1783. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature
  1784. PPAR: a new pharmacological target for Neuroprotection in stroke and neurodegenerative diseases
  1785. Paradigm shift in Neuroprotection by NMDA receptor blockade: memantine and beyond
  1786. Neuroprotection targets after traumatic brain injury
  1787. Neuroprotection by ovarian hormones in animal models of neurological disease
  1788. Neuroprotection and neuroplasticity–a holistic approach and future perspectives
  1789. Magnesium sulfate for Neuroprotection after traumatic brain injury: a randomised controlled trial
  1790. Novel mechanisms for estrogen-induced Neuroprotection
  1791. Estrogen action in Neuroprotection and brain inflammation
  1792. brain aromatase: roles in reproduction and Neuroprotection
  1793. The role of T helper cells in Neuroprotection and regeneration
  1794. Autophagy, bafilomycin and cell death: the “aB-cs” of plecomacrolide-induced Neuroprotection
  1795. Neuroprotection by resveratrol against traumatic brain injury in rats
  1796. Role of astrocytes in reproduction and Neuroprotection
  1797. Molecular and cellular immune mediators of Neuroprotection
  1798. Prolonged activation of ASIC1a and the time window for Neuroprotection in cerebral ischaemia
  1799. Progesterone: therapeutic opportunities for Neuroprotection and myelin repair
  1800. Neuroprotection by pharmacologic blockade of the GAPDH death cascade
  1801. Auto-catalytic ceria nanoparticles offer Neuroprotection to adult rat spinal cord neurons
  1802. Lymphocytes: potential mediators of postischemic injury and Neuroprotection
  1803. brain Neuroprotection by scavenging blood glutamate
  1804. Preconditioning doses of NMDA promote Neuroprotection by enhancing neuronal excitability
  1805. Neuroprotection by histone deacetylase-related protein
  1806. Aspects of growth hormone and insulin-like growth factor-I related to Neuroprotection , regeneration, and functional plasticity in the adult brain
  1807. Activation of the Keap1/Nrf2 pathway for Neuroprotection by electrophillic phase II inducers
  1808. PPARs: a new target for Neuroprotection
  1809. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia
  1810. Role of astrocytes in estrogen-mediated Neuroprotection
  1811. On the hypes and falls in Neuroprotection : targeting the NMDA receptor
  1812. Cell biology and clinical promise of G‐CSF: immunomodulation and Neuroprotection
  1813. A systematic review of cooling for Neuroprotection in neonates with hypoxic ischemic encephalopathy–are we there yet?
  1814. Role of δ‐opioid receptor function in neurogenesis and Neuroprotection
  1815. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia
  1816. Dopamine in neurotoxicity and Neuroprotection : what do D2 receptors have to do with it?
  1817. Neuroprotection by erythropoietin administration after experimental traumatic brain injury
  1818. Nicotine Neuroprotection against nigrostriatal damage: importance of the animal model
  1819. A select combination of neurotrophins enhances Neuroprotection and functional recovery following spinal cord injury
  1820. Neurorepair versus Neuroprotection in stroke
  1821. Progesterone-induced Neuroprotection
  1822. Inhibition of mitochondrial function in astrocytes: implications for Neuroprotection
  1823. Dual effects of antioxidants in neurodegeneration: direct Neuroprotection against oxidative stress and indirect protection via suppression of gliamediated inflammation
  1824. Inflammation, demyelination, neurodegeneration and Neuroprotection in the pathogenesis of multiple sclerosis
  1825. Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats
  1826. The ischemic penumbra: a new opportunity for Neuroprotection
  1827. Cystine/glutamate exchange modulates glutathione supply for Neuroprotection from oxidative stress and cell proliferation
  1828. Neuroprotection in emerging psychotic disorders
  1829. Peptide Neuroprotection through specific interaction with brain tubulin
  1830. Transplantation of human neural stem cells exerts Neuroprotection in a rat model of Parkinson’s disease
  1831. Chinese herbs and herbal extracts for Neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease
  1832. Erythropoietin enhances long-term Neuroprotection and neurogenesis in neonatal stroke
  1833. Xenon provides short-term Neuroprotection in neonatal rats when administered after hypoxia-ischemia
  1834. Improved reperfusion and Neuroprotection by creatine in a mouse model of stroke
  1835. Cannabinoids and Neuroprotection in basal ganglia disorders
  1836. SIRT1 activation confers Neuroprotection in experimental optic neuritis
  1837. Human neural stem cells over-expressing VEGF provide Neuroprotection , angiogenesis and functional recovery in mouse stroke model
  1838. Neuro (active) steroids actions at the neuromodulatory sigma1 (σ1) receptor: biochemical and physiological evidences, consequences in Neuroprotection
  1839. Pleiotropic functions of PACAP in the CNS: Neuroprotection and neurodevelopment
  1840. Eicosapentaenoic acid confers Neuroprotection in the amyloid-β challenged aged hippocampus
  1841. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats
  1842. Dissecting the signaling pathway of nicotine‐mediated Neuroprotection in a mouse Alzheimer disease model
  1843. Adenosine A2A receptors and brain injury: broad spectrum of Neuroprotection , multifaceted actions and “fine tuning” modulation
  1844. Modulation of interleukin-1β mediated inflammatory response in human astrocytes by flavonoids: implications in Neuroprotection
  1845. Suppression of mitochondrial oxidative stress provides long-term Neuroprotection in experimental optic neuritis
  1846. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with Neuroprotection
  1847. Protease-activated receptors in the brain : receptor expression, activation, and functions in neurodegeneration and Neuroprotection
  1848. Parkin mediates Neuroprotection through activation of IκB kinase/nuclear factor-κB signaling
  1849. Mitochondrial mechanism of Neuroprotection by CART
  1850. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated Neuroprotection
  1851. Structure–nongenomic Neuroprotection relationship of estrogens and estrogen-derived compounds
  1852. Neuroprotection by endogenous and exogenous PACAP following stroke
  1853. Hypothermia for Neuroprotection after cardiac arrest: mechanisms, clinical trials and patient care
  1854. Calcium: a role for Neuroprotection and sustained adaptation
  1855. Life after cerovive: a personal perspective on ischemic Neuroprotection in the post–NXY-059 era
  1856. Valproic acid-mediated Neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation
  1857. Neuroprotection and free radical scavenging effects of Osmanthus fragrans
  1858. Estrogen, neuroinflammation and Neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration
  1859. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/Neuroprotection
  1860. Novel Neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson’s disease
  1861. A novel role for Sema3A in Neuroprotection from injury mediated by activated microglia
  1862. Pathologically-activated therapeutics for Neuroprotection : mechanism of NMDA receptor block by memantine and S-nitrosylation
  1863. Gender-Specific Neuroprotection by 2-Iminobiotin after Hypoxia—Ischemia in the Neonatal Rat via a Nitric Oxide Independent Pathway
  1864. The seek of Neuroprotection : introducing cannabinoids
  1865. The dynamics of statins: from event prevention to Neuroprotection
  1866. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in Neuroprotection
  1867. Estrogen receptor α and β differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen Neuroprotection in hippocampal neurons
  1868. T lymphocyte trafficking: a novel target for Neuroprotection in traumatic brain injury
  1869. Neuroprotection at the nanolevel—Part I: Introduction to nanoneurosurgery
  1870. The role of erythropoietin in Neuroprotection : therapeutic perspectives.
  1871. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing Neuroprotection
  1872. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
  1873. Fractalkine: moving from chemotaxis to Neuroprotection
  1874. New insights into the roles of metalloproteinases in neurodegeneration and Neuroprotection
  1875. Cross-talk between IGF-I and estradiol in the brain : focus on Neuroprotection
  1876. Role of cocaine-and amphetamine-regulated transcript in estradiol-mediated Neuroprotection
  1877. Antenatal magnesium sulphate Neuroprotection in the preterm infant
  1878. Serotonin and Neuroprotection in functional bowel disorders
  1879. Mechanisms of cell death and Neuroprotection by poloxamer 188 after mechanical trauma
  1880. Neuroprotection in the peripheral nervous system: rationale for more effective therapies
  1881. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and Neuroprotection by PSD-95 inhibitors
  1882. Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal Neuroprotection in vivo and in vitro
  1883. … in epigenetic modulators superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron Neuroprotection studies
  1884. Peroxisome proliferator‐activated receptor‐γ agonists induce Neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as …
  1885. Induction of multiple heat shock proteins and Neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis
  1886. Extensive Neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys
  1887. Distinct mechanisms underlie distinct polyphenol-induced Neuroprotection
  1888. Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence
  1889. Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 Neuroprotection
  1890. Tumor necrosis factor α but not interleukin 1β mediates Neuroprotection in response to acute nitric oxide excitotoxicity
  1891. Neuroprotection against neurodegenerative diseases
  1892. Neuroprotection against surgically induced brain injury
  1893. Transient Neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or …
  1894. Deterioration in acute ischemic stroke as the target for Neuroprotection
  1895. Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the Neuroprotection in rat focal cerebral ischemia
  1896. Physiological Neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson’s disease
  1897. Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis
  1898. Neurodegeneration and Neuroprotection in multiple sclerosis and other neurodegenerative diseases
  1899. Cardiac glycosides provide Neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform
  1900. Neurotoxicity of reactive aldehydes: the concept of “aldehyde load” as demonstrated by Neuroprotection with hydroxylamines
  1901. Neuroprotection : a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
  1902. Activation of cerebral peroxisome proliferator‐activated receptors gamma promotes Neuroprotection by attenuation of neuronal cyclooxygenase‐2 overexpression …
  1903. G-CSF and Neuroprotection : a therapeutic perspective in cerebral ischaemia
  1904. Estrogen prevents Neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease
  1905. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in Neuroprotection against glutamate-induced …
  1906. Can imaging techniques measure Neuroprotection and remyelination in multiple sclerosis?
  1907. The function of microglia, either Neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro
  1908. Intrinsic and extrinsic erythropoietin enhances Neuroprotection against ischemia and reperfusion injury in vitro
  1909. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington’s disease
  1910. Neuroprotection in multiple sclerosis
  1911. Preclinical evidence of Neuroprotection by cholinesterase inhibitors
  1912. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia
  1913. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α7 nicotinic receptor knockout mice
  1914. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in Neuroprotection
  1915. Neuroprotection of nicotiflorin in permanent focal cerebral ischemia and in neuronal cultures
  1916. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke
  1917. Axonal loss and Neuroprotection in optic neuropathies
  1918. Mechanisms of Neuroprotection during ischemic preconditioning: lessons from anoxic tolerance
  1919. Pregnane X receptor (PXR) activation: a mechanism for Neuroprotection in a mouse model of Niemann–Pick C disease
  1920. Post‐trauma Lipitor treatment prevents endothelial dysfunction, facilitates Neuroprotection , and promotes locomotor recovery following spinal cord injury
  1921. Neuroprotection in cerebral infarction: the opportunity of new studies
  1922. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and Neuroprotection
  1923. Cell signaling pathways in the mechanisms of Neuroprotection afforded by bergamot essential oil against NMDA‐induced cell death in vitro
  1924. Sigma receptor agonists provide Neuroprotection in vitro by preserving bcl-2
  1925. Vanilloid VR1 receptor is involved in rimonabant‐induced Neuroprotection
  1926. Role of the Fas-signaling pathway in photoreceptor Neuroprotection
  1927. Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia: a mechanism for Neuroprotection
  1928. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres
  1929. Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion
  1930. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat
  1931. Neuroprotection in epilepsy
  1932. Neuroprotection in Parkinson models varies with toxin administration protocol
  1933. Methamphetamine‐induced alterations in monoamine transport: implications for neurotoxicity, Neuroprotection and treatment
  1934. Issues in Neuroprotection clinical trials in Parkinson’s disease
  1935. Gene transfer of insulin-like growth factor–I providing Neuroprotection after spinal cord injury in rats
  1936. Opioid preconditioning induces opioid receptor-dependent delayed Neuroprotection against ischemia in rats
  1937. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor κB (NF-κB), inflammatory gene expression, and …
  1938. Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity
  1939. Aldehyde load in ischemia–reperfusion brain injury: Neuroprotection by neutralization of reactive aldehydes with phenelzine
  1940. Neuroprotection from secondary injury by polyethylene glycol requires its internalization
  1941. Calpeptin provides functional Neuroprotection to rat retinal ganglion cells following Ca2+ influx
  1942. Nonredundant role of Akt2 for Neuroprotection of rod photoreceptor cells from light-induced cell death
  1943. Wide therapeutic time window for fasudil Neuroprotection against ischemia-induced delayed neuronal death in gerbils
  1944. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or Neuroprotection
  1945. Mechanism of progesterone Neuroprotection of rat cerebellar Purkinje cells following oxygen–glucose deprivation
  1946. Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins
  1947. A novel immune-based therapy for stroke induces Neuroprotection and supports neurogenesis
  1948. Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, Neuroprotection , food application and chemoprevention …
  1949. Gender-dependent pathways of hypoxia-ischemia-induced cell death and Neuroprotection in the immature P3 rat
  1950. Role of Nrf2-dependent ARE-driven antioxidant pathway in Neuroprotection
  1951. Immune control by endocannabinoids—new mechanisms of Neuroprotection ?
  1952. Erythropoietin: a new paradigm for Neuroprotection
  1953. Reduction in oxidative stress and cell death explains hypothyroidism induced Neuroprotection subsequent to ischemia/reperfusion insult
  1954. Neuroprotection during chemotherapy: a systematic review
  1955. Prevention of inflammation is a mechanism of preconditioning-induced Neuroprotection against focal cerebral ischemia
  1956. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
  1957. Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson’s disease
  1958. Tryptophan, adenosine, neurodegeneration and Neuroprotection
  1959. Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways
  1960. Zinc attenuates malathion-induced depressant-like behavior and confers Neuroprotection in the rat brain
  1961. Preventing clinical deterioration in the course of schizophrenia: the potential for Neuroprotection .
  1962. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent Neuroprotection
  1963. Enhancement of Neuroprotection of mulberry leaves (Morus alba L.) prepared by the anaerobic treatment against ischemic damage
  1964. The role of nitric oxide in the Neuroprotection of limb ischemic preconditioning in rats
  1965. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice
  1966. Clinical trials for Neuroprotection in Parkinson’s disease: overcoming angst and futility?
  1967. Broad spectrum Neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation
  1968. Dose-dependent Neuroprotection of delta opioid peptide [D-Ala2, D-Leu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats
  1969. An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF Neuroprotection
  1970. Neuroprotection and neurosupplementation in ischaemic brain
  1971. Polyphenol amentoflavone affords Neuroprotection against neonatal hypoxic‐ischemic brain damage via multiple mechanisms
  1972. Neuroprotection by cAMP
  1973. Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic Neuroprotection conferred by the slow …
  1974. Melanocortins defend their territory: multifaceted Neuroprotection in cerebral ischemia
  1975. Age-related changes in Neuroprotection
  1976. Cannabinoids and Neuroprotection in motor-related disorders
  1977. Neuroprotection by GDNF-secreting stem cells in a Huntington’s disease model: optical neuroimage tracking of brain -grafted cells
  1978. Overexpression of APP provides Neuroprotection in the absence of functional benefit following middle cerebral artery occlusion in rats
  1979. Ischaemic brain damage after stroke: new insights into efficient therapeutic strategies: International Symposium on Neurodegeneration and Neuroprotection
  1980. Dexmedetomidine and Neuroprotection
  1981. Immune-mediated Neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4+ T cells
  1982. Experimental models of Neuroprotection relevant to multiple sclerosis
  1983. XIAP-mediated Neuroprotection in retinal ischemia
  1984. NO‐induced Neuroprotection in ischemic preconditioning stimulates mitochondrial Mn‐SOD activity and expression via RAS/ERK1/2 pathway
  1985. Edaravone Neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats
  1986. The role of extracellular signal-regulated kinases in the Neuroprotection of limb ischemic preconditioning
  1987. The Neuroprotection conferred by activating the mitochondrial ATP-sensitive K+ channel is mediated by inhibiting the mitochondrial permeability transition pore
  1988. Slit modulates cerebrovascular inflammation and mediates Neuroprotection against global cerebral ischemia
  1989. Neuroprotection : a therapeutic strategy to prevent deterioration associated with schizophrenia.
  1990. Galantamine postischemia provides Neuroprotection and memory recovery against transient global cerebral ischemia in gerbils
  1991. Neuroprotection during cardiac surgery
  1992. Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants
  1993. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of …
  1994. Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth
  1995. Transplants of encapsulated rat choroid plexus cells exert Neuroprotection in a rodent model of Huntington’s disease
  1996. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in Neuroprotection afforded by 17β‐estradiol
  1997. Evolving paradigms for Neuroprotection : molecular identification of ischemic penumbra
  1998. Why hasn’t Neuroprotection worked in Parkinson’s disease?
  1999. Neuroprotection by estradiol: a role of aromatase against spine synapse loss after blockade of GABAA receptors
  2000. Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked Neuroprotection against stroke injury
  2001. Omega-3 fatty acids, pro-inflammatory signaling and Neuroprotection
  2002. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window
  2003. The application of proteomics and genomics to the study of age-related neurodegeneration and Neuroprotection
  2004. Stroke: the dashed hopes of Neuroprotection .
  2005. Neuroprotection of G-CSF in cerebral ischemia.
  2006. Neuroprotection of Tat-GluR6-9c against neuronal death induced by kainate in rat hippocampus via nuclear and non-nuclear pathways
  2007. Neuroprotection by sodium ferulate against glutamate‐induced apoptosis is mediated by ERK and PI3 kinase pathways1
  2008. Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis
  2009. Role of estrogen receptors in Neuroprotection by estradiol against MPTP toxicity
  2010. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to Neuroprotection against cerebral infarction in rats
  2011. Impact of Neuroprotection on incidence of Alzheimer’s disease
  2012. New insights into purinergic receptor signaling in neuronal differentiation, Neuroprotection , and brain disorders
  2013. Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway1
  2014. Behavioral and histologic Neuroprotection of aqueous garlic extract after reversible focal cerebral ischemia
  2015. Peripheral inflammation and Neuroprotection : systemic pretreatment with complete Freund’s adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of …
  2016. Neurogenesis and Neuroprotection in the CNS—fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders
  2017. Neuroprotection in the juvenile rat model of light-induced retinopathy: evidence suggesting a role for FGF-2 and CNTF
  2018. Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances Neuroprotection by increasing astrocyte mitochondrial metabolism during aging
  2019. Neuroprotection for Parkinson’s disease
  2020. Group I metabotropic receptor Neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and β-catenin during oxidative stress
  2021. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased Neuroprotection after chronic cerebral hypoperfusion in …
  2022. Neuronal death and Neuroprotection : a review
  2023. Currently evaluated calpain and caspase inhibitors for Neuroprotection in experimental brain ischemia
  2024. Deprenyl: from chemical synthesis to Neuroprotection
  2025. Synergistic Neuroprotection by bis (7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase
  2026. Selective cerebral hypothermia for post-hypoxic Neuroprotection in neonates using a solid ice cap
  2027. NMDA Neuroprotection against a phosphatidylinositol‐3 kinase inhibitor, LY294002 by NR2B‐mediated suppression of glycogen synthase kinase‐3β‐induced …
  2028. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional Neuroprotection and neurorestoration in MPTP‐treated monkeys
  2029. Evidence for Neuroprotection and remyelination using imaging techniques
  2030. In vitro and in vivo Neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson’s disease
  2031. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
  2032. Neuroprotection by extract of Petasites japonicus leaves, a traditional vegetable, against oxidative stress in brain of mice challenged with kainic acid
  2033. Evidence of GLP-1-mediated Neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy
  2034. Thrombolysis and Neuroprotection in cerebral ischemia
  2035. Enhancement of Neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia
  2036. Testosterone induces Neuroprotection from oxidative stress. Effects on catalase activity and 3-nitro-L-tyrosine incorporation into alpha-tubulin in a mouse …
  2037. Endogenous α2-adrenergic receptor-mediated Neuroprotection after severe hypoxia in preterm fetal sheep
  2038. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERα in primary cultures of mouse mesencephalon
  2039. The role of CaMKII in BDNF-mediated Neuroprotection of retinal ganglion cells (RGC-5)
  2040. ERK 1/2 signaling pathway is involved in nicotine‐mediated Neuroprotection in spinal cord neurons
  2041. Non-pharmacological Neuroprotection : role of emergency stroke management
  2042. Neuroprotection in Parkinson’s disease: an elusive goal
  2043. Multimodal assessment of Neuroprotection applied to the use of MK-801 in the endothelin-1 model of transient focal brain ischemia
  2044. What constitutes clinical evidence for Neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
  2045. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers
  2046. Akt phosphorylation is required for heat acclimation‐induced Neuroprotection
  2047. Neuroprotection via inhibition of nitric oxide synthase by bis (7)-tacrine
  2048. Molecular mechanisms of Neuroprotection in the eye
  2049. Neuroprotection for ischemic stroke using hypothermia
  2050. … -traumatic application of brain -derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances Neuroprotection and improves motor …
  2051. Neuroprotection and stroke rehabilitation: modulation and enhancement of recovery
  2052. Prophylactic Neuroprotection
  2053. Complement activation in autoimmune demyelination: dual role in neuroinflammation and Neuroprotection
  2054. Neuroprotection by taurine and taurine analogues
  2055. A critical appraisal of the NXY-059 Neuroprotection studies for acute stroke: a need for more rigorous testing of Neuroprotective agents in animal models of stroke
  2056. Dopaminergic Neuroprotection by neurturin-expressing c17. 2 neural stem cells in a rat model of Parkinson’s disease
  2057. Exogenous erythropoietin provides Neuroprotection of grafted dopamine neurons in a rodent model of Parkinson’s disease
  2058. Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation
  2059. Neuroprotection : A new strategy in the treatment of schizophrenia
  2060. Sex, Neuroprotection , and neonatal ischemia’/’Johnston and Hagberg reply’
  2061. Estimation of the hypothermic component in Neuroprotection provided by cannabinoids following cerebral ischemia
  2062. Neuroprotection and enhanced recovery with hypericum perforatum extract after experimental spinal cord injury in mice
  2063. Gene expression in cerebral ischemia: a new approach for Neuroprotection
  2064. Evidence to implicate early modulation of interleukin‐1β expression in the Neuroprotection afforded by 17β‐Estradiol in male rats undergone transient middle cerebral …
  2065. Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus
  2066. Conventional protein kinase C isoforms mediate Neuroprotection induced by phorbol ester and estrogen
  2067. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new Neuroprotection target
  2068. Neuroprotection of insulin against oxidative stress‐induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3‐kinase/Akt signal pathway
  2069. Neuroprotection of retinal ganglion cell function and their central nervous system targets
  2070. Neuroprotection by small molecule activators of the nerve growth factor receptor
  2071. Estrogen receptor beta agonist diarylpropiolnitrile (DPN) does not mediate Neuroprotection in a rat model of permanent focal ischemia
  2072. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated Neuroprotection through increased levels of glutathione …
  2073. Substance P provides Neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium …
  2074. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces Neuroprotection in cerebral ischemia
  2075. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat
  2076. … oxidative stress mediated by 2, 2-azobis (2-amidino-propane) dihydrochloride (AAPH) or Fe2+/H2O2: Insight into mechanisms of Neuroprotection and relevance to …
  2077. Rab‐mediated endocytosis: linking neurodegeneration, Neuroprotection , and synaptic plasticity?
  2078. Neuroprotection in vascular dementia
  2079. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain : Neuroprotection versus neurotoxicity
  2080. Acetylcholine Neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through α4 nAChRs
  2081. Sustained Neuroprotection and facilitation of behavioral recovery by the Ginkgo biloba extract, EGb 761, after transient forebrain ischemia in rats
  2082. Recent advances in Neuroprotection for treating traumatic brain injury
  2083. Perfusing the cold brain : optimal Neuroprotection for aortic surgery
  2084. Direct evidence for calpain involvement in apoptotic death of neurons in spinal cord injury in rats and Neuroprotection with calpain inhibitor
  2085. Pharmacologic Neuroprotection : the search continues
  2086. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms
  2087. Selective γ-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic Neuroprotection
  2088. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin
  2089. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated Neuroprotection against hippocampal neuronal death after transient global …
  2090. Neuroprotection of rat hippocampal slices exposed to oxygen–glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of …
  2091. The mechanism of 1, 2, 3, 4‐tetrahydroisoquinolines Neuroprotection : the importance of free radicals scavenging properties and inhibition of glutamate‐induced …
  2092. Neuroprotection : models, mechanisms and therapies
  2093. nPKCε and NMDA receptors participate in Neuroprotection induced by morphine pretreatment
  2094. Glioblastoma in a boy with fragile X: an unusual case of Neuroprotection
  2095. Role of signal transducer and activator of transcription-3 in estradiol-mediated Neuroprotection
  2096. Clinical trials aimed at detecting Neuroprotection in Parkinson’s disease
  2097. Isoflurane Neuroprotection in Rat Hippocampal Slices Decreases with Aging: Changes in Intracellular Ca2+ Regulation and N-methyl-d-aspartate Receptor–mediated …
  2098. Neuroprotection : lessons from a spectrum of neurological disorders
  2099. Bcl-2 upregulation and Neuroprotection in guinea pig brain following chronic simvastatin treatment
  2100. Intracarotid injection of granulocyte–macrophage colony-stimulating factor induces Neuroprotection in a rat transient middle cerebral artery occlusion model
  2101. The limits of viability and the uncertainty of Neuroprotection : challenges in optimizing outcomes in extreme prematurity
  2102. Amine oxidases and their inhibitors: what can they tell us about Neuroprotection and the development of drugs for neuropsychiatric disorders?
  2103. Neuroprotection afforded by diazepam against oxygen/glucose deprivation-induced injury in rat cortical brain slices
  2104. Coenzyme Q 10 provides Neuroprotection in iron-induced apoptosis in dopaminergic neurons
  2105. Gender, sex steroids, and Neuroprotection following traumatic brain injury
  2106. … Heat Stress–Induced cognitive Dysfunction and brain Pathology: An Experimental Study in the Rat, Using Growth Hormone Therapy for Possible Neuroprotection
  2107. … tea polyphenol (–)‐epigallocatechin‐3‐gallate promotes the rapid protein kinase C‐and proteasome‐mediated degradation of Bad: implications for Neuroprotection
  2108. … of new 4H-pyrano [2, 3-b] quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause Neuroprotection against calcium overload and free …
  2109. Estrogen-mediated Neuroprotection in the cortex may require NMDA receptor activation
  2110. Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector
  2111. Dual effect of adenovirus‐mediated transfer of BMP7 in mixed neuron‐glial cultures: Neuroprotection and cellular differentiation
  2112. Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21Waf1/Cip1 as a novel mechanism of Neuroprotection by glucocorticoids
  2113. Erythropoietin depletes iron stores: antioxidant Neuroprotection for ischemic stroke?
  2114. Hippocampal vulnerability following traumatic brain injury: A potential role for neurotrophin‐4/5 in pyramidal cell Neuroprotection
  2115. Transient expression of Nxf, a bHLH–PAS transactivator induced by neuronal preconditioning, confers Neuroprotection in cultured cells
  2116. Neuroprotection in schizophrenia
  2117. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis
  2118. Farnesyl transferase inhibitors induce Neuroprotection by inhibiting Ha‐Ras signalling pathway
  2119. Global hypothermia for Neuroprotection after cardiac arrest
  2120. Cannabinoids in microglia: a new trick for immune surveillance and Neuroprotection
  2121. Bench to bedside strategies for optimizing Neuroprotection following perinatal hypoxia–ischaemia in high and low resource settings
  2122. Neuroprotection –STAIR-way to the future?
  2123. Macrophage-mediated Neuroprotection and neurogenesis in the olfactory epithelium
  2124. Traumatic brain injury induced Neuroprotection of retinal ganglion cells to optic nerve crush
  2125. Nerve growth factor Neuroprotection of ethanol-induced neuronal death in rat cerebral cortex is age dependent
  2126. T cell independent mechanism for copolymer‐1‐induced Neuroprotection
  2127. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to Neuroprotection during cardiac surgery
  2128. Delta opioid receptors stimulation with [D-Ala2, D-Leu5] enkephalin does not provide Neuroprotection in the hippocampus in rats subjected to forebrain ischemia
  2129. Trypanosome trans-sialidase mediates Neuroprotection against oxidative stress, serum/glucose deprivation, and hypoxia-induced neurite retraction in Trk-expressing …
  2130. Induced hypothermia for Neuroprotection : understanding the underlying mechanisms
  2131. Glycogen synthase kinase-3 in neurodegeneration and Neuroprotection : lessons from lithium
  2132. Neuroprotection in primary brain tumors: sense or nonsense?
  2133. … the base-excision repair pathway after focal ischemic brain injury: a protein phosphorylation-dependent mechanism reversed by hypothermic Neuroprotection
  2134. I can’t get no satisfaction: still no Neuroprotection for Parkinson disease
  2135. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for Neuroprotection ?
  2136. Role of CDK5 in Neuroprotection from serum deprivation by μ-opioid receptor agonist
  2137. Neurotrophin-mediated Neuroprotection of hippocampal neurons following traumatic brain injury is not associated with acute recovery of hippocampal function
  2138. Neuroprotection of α-phenyl-n-tert-butyl-nitrone on the neonatal white matter is associated with anti-inflammation
  2139. Exercise-induced Neuroprotection in SMA model mice: a means for determining new therapeutic strategies
  2140. Neuroprotection by a central nervous system–type prostacyclin receptor ligand demonstrated in monkeys subjected to middle cerebral artery occlusion and …
  2141. Translational vehicles for Neuroprotection
  2142. Adenosine in the central nervous system: effects on neurotransmission and Neuroprotection
  2143. … during adolescence changes brain -derived neurotrophic factor and TrkB levels in the rat visual system but does not offer Neuroprotection to retinal ganglion cells …
  2144. Neuroprotection for acute ischaemic stroke: hope reignited.
  2145. Time course of changes in pyridoxal 5′-phosphate (vitamin B6 active form) and its Neuroprotection in experimental ischemic damage
  2146. Oestrogen receptor subtype‐specific repression of calpain expression and calpain enzymatic activity in neuronal cells – implications for Neuroprotection against Ca2+ …
  2147. A call for clinically driven experimental design in assessing Neuroprotection in experimental Parkinsonism
  2148. Effect of cyclosporin a on immediate early gene in rat global ischemia and its Neuroprotection
  2149. New approaches to clinical trials in Neuroprotection : introduction
  2150. Can clinical outcomes be used to detect Neuroprotection in multiple sclerosis?
  2151. Lost in translation: again, another failed Neuroprotection trial
  2152. How to improve Neuroprotection in Parkinson’s disease?
  2153. Model of acute injury to study Neuroprotection
  2154. Mechanisms of VIP‐induced Neuroprotection against neonatal excitotoxicity
  2155. Plasticity of the central nervous system (CNS) following perinatal asphyxia: does nicotinamide provide Neuroprotection ?
  2156. Blockade of PARP activity attenuates poly (ADP‐ribosyl) ation but offers only partial Neuroprotection against NMDA‐induced cell death in the rat retina
  2157. Neuronal cell culture from human embryonic stem cells as in vitro model for Neuroprotection
  2158. Oxidative Stress and Neuroprotection
  2159. Evidence for a role of Hsp70 in the Neuroprotection induced by heat shock pre‐treatment against 3, 4‐methylenedioxymethamphetamine toxicity in rat brain
  2160. Progestins and Neuroprotection : are all progestins created equal?
  2161. Cannabinoid CB 1 receptor stimulation affords Neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro
  2162. Pharmacological Neuroprotection during cardiac surgery
  2163. Marker for a preclinical diagnosis of Parkinson’s disease as a basis for Neuroprotection
  2164. Therapeutic time window of Neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats
  2165. Neuroprotection at the nanolevel—Part II: Nanodevices for neuromodulation—Deep brain stimulation and spinal cord injury
  2166. Effects of long-term adrenalectomy on apoptosis and Neuroprotection in the rat hippocampus
  2167. Neuroprotection with or without erythropoiesis; sometimes less is more
  2168. Neuroprotection in Parkinson’s disease: clinical trials
  2169. Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its Neuroprotection for the PC12 cells damaged by …
  2170. Acute implantation of an avulsed lumbosacral ventral root into the rat conus medullaris promotes Neuroprotection and graft reinnervation by autonomic and motor …
  2171. Perturbed synaptosomal calcium homeostasis and behavioral deficits following carbofuran exposure: Neuroprotection by N-acetylcysteine
  2172. Glutamate-related excitotoxicity Neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular …
  2173. Activations of nPKCε and ERK1/2 were involved in oxygen-glucose deprivation-induced Neuroprotection via NMDA receptors in hippocampal slices of mice
  2174. Lead and Neuroprotection by iron in ADHD
  2175. Molecular mechanism of ischemic brain injuries and perspectives of drug therapies for Neuroprotection
  2176. Polysialylation of NCAM is upregulated by hyperthermia and participates in heat shock preconditioning-induced Neuroprotection
  2177. Simultaneous bilateral carotid stenting under the circumstance of Neuroprotection device: a retrospective analysis
  2178. … pressure augmentation during retrograde cerebral perfusion under moderate hypothermia provides adequate Neuroprotection : An experimental study
  2179. Quantitative EEG assessment of brain injury and hypothermic Neuroprotection after cardiac arrest
  2180. Potentiation of in vivo Neuroprotection by BclX L and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons
  2181. Effects of Pravastatin on Neuroprotection and neurogenesis after cerebral ischemia in rats.
  2182. Assessing Neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo
  2183. 1, 1′-Xylyl bis-1, 4, 8, 11-tetraaza cyclotetradecane: a new potential copper chelator agent for Neuroprotection in Alzheimer’s disease. Its comparative effects with …
  2184. Transcervical carotid stenting with flow reversal for Neuroprotection : technique, results, advantages, and limitations
  2185. Neuroprotection in glaucoma
  2186. Vitamin E in the Neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity
  2187. Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in Neuroprotection (GAIN) Americas trial
  2188. Back to basics—ephrins, axonal guidance, Neuroprotection and glaucoma
  2189. Neuroprotection : present and future
  2190. Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons
  2191. Increases in expression of 14‐3‐3 eta and 14‐3‐3 zeta transcripts during Neuroprotection induced by Δ9‐tetrahydrocannabinol in AF5 cells
  2192. Carotid artery stenting with distal protection using the carotid wallstent and filterwire Neuroprotection : single-center experience of 380 cases with midterm outcomes
  2193. … immunodeficiency virus–induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and Neuroprotection mediated by insulin …
  2194. Nefopam is more potent than carbamazepine for Neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical …
  2195. Neuroprotection by 7-nitroindazole against iron-induced hippocampal neurotoxicity
  2196. Inhibition of MLK3‐MKK4/7‐JNK1/2 pathway by Akt1 in exogenous estrogen‐induced Neuroprotection against transient global cerebral ischemia by a non‐genomic …
  2197. Neuroprotection in perinatal hypoxic-ischemic encephalopathy. Effective treatment and future perspectives
  2198. Bacterial DNA confers Neuroprotection after optic nerve injury by suppressing CD4+ CD25+ regulatory T-cell activity
  2199. Optimising clinical trial design for proof of Neuroprotection in acute ischaemic stroke: the SAINT clinical trial programme
  2200. Neuroprotection of photoreceptors in the RCS rat after implantation of a subretinal implant in the superior or inferior retina
  2201. Development of non-erythropoietic erythropoietin variants for Neuroprotection
  2202. 4th Global College of Neuroprotection and Neuroregeneration meeting
  2203. Retrograde cerebral perfusion with intermittent pressure augmentation provides adequate Neuroprotection : diffusion-and perfusion-weighted magnetic …
  2204. Neuroanesthesia and Neuroprotection : where are we now?
  2205. Identification of Fasting‐induced Genes in the Rat Hypothalamus: Relationship with Neuroprotection
  2206. Neuroprotection induced by mucosal tolerance is epitope-dependent: conflicting effects in different strains
  2207. The combination of isoflurane and caspase 8 inhibition results in sustained Neuroprotection in rats subject to focal cerebral ischemia
  2208. Neuroprotection in malignant mca infarction
  2209. Injections of vehicle, but not cyclosporin A or tacrolimus (FK506) afford Neuroprotection following injury in the developing rat brain
  2210. Competing approaches to excitotoxic Neuroprotection by inert and catalytic antioxidant porphyrins
  2211. Lithium-mediated Neuroprotection during cranial irradiation: a phase I trial
  2212. Adenylyl cyclase isoforms as novel therapeutic targets: an exciting example of excitotoxicity Neuroprotection
  2213. The direct and indirect effects of serofendic acid on Neuroprotection
  2214. Preconditioning with estradiol abolishes its Neuroprotection in cerebellar neurons
  2215. Up-regulation of Bcl-2 in APP transgenic mice is associated with Neuroprotection
  2216. Perinatal Neuroprotection
  2217. Neuroprotection and enhancement of neurite outgrowth with small molecular weight compounds from screens of chemical libraries
  2218. PAN-811 provides Neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK
  2219. Heat shock proteins and Neuroprotection
  2220. Neuroprotection : where to now?
  2221. Neuroprotection : new pharmacological targets
  2222. Unconventional Neuroprotection against Ca2+‐dependent insults by metalloporphyrin catalytic antioxidants
  2223. Insulin-like growth factor-I and Neuroprotection
  2224. Neuroprotection by diazoxide in animal models for cerebrovascular disorders
  2225. Neuroprotection and neurogenesis: modulation of cornus ammonis 1 neuronal survival after transient forebrain ischemia by prior fimbria-fornix deafferentation
  2226. Neuroprotection of adult human neurons against ischemia by hypothermia and alkalinization
  2227. A clinical trial studying Neuroprotection in low-pressure glaucoma
  2228. Short-and long-term outcome after carotid artery stenting with Neuroprotection : single-center experience within a prospective registry
  2229. EndothelinA receptor antagonist BSF-208075 causes immune modulation and Neuroprotection after stroke in gerbils
  2230. Inhibition of caspase-9 activation and apoptosis is involved in ischemic preconditioning-induced Neuroprotection in rat brain
  2231. Prospects for Neuroprotection in Parkinson’s disease
  2232. Involvement of purα gene in Neuroprotection effects of estrogen in rat ischemic brain model
  2233. How to judge animal models of Parkinson’s disease in terms of Neuroprotection
  2234. Hypertension, vascular cognitive disorders and Neuroprotection
  2235. Breathing, Feeding, and Neuroprotection
  2236. Heparan sulfate mediates Neuroprotection from degeneration in experimental glutaric aciduria
  2237. Motoneurons and CD4+ effector T cell subsets: Neuroprotection and repair
  2238. 15 Lipidomic Approaches to Neuroprotection Signaling in the Retinal Pigment Epithelium
  2239. Rasagiline preclinical studies: Implications for Neuroprotection
  2240. The role of vasoactive intestinal peptide in Neuroprotection : Professor Illana Gozes is interviewed by Emma Quigley.
  2241. Estrogen, neuroinflammation and Neuroprotection in Parkinson’s disease: key role of neuron-glia crosstalk
  2242. Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson’s Disease—Research Focus in the Department of Alternative Medicine and Experimental …
  2243. Assessment of the optic disc to measure Neuroprotection
  2244. Neuroprotection by dexmedetomidine
  2245. Study on Chemical and Optic Neuroprotection Components of Erigeron breviscapus
  2246. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and Neuroprotection
  2247. Cleft-type cyclophanes confer Neuroprotection against excitatory neurotoxicity in vitro and in vivo through inhibition of NMDA receptors
  2248. Neuroprotection during carotid angioplasty and stenting: Comparison of no protection, occlusion, or filters
  2249. Neuroprotection and repair by using adult-derived neural stem cell grafting for neurological disorders
  2250. Neuroprotection of Baicalin on brain Damage Following Experimental Intracerebral Hemorrhage in Rats
  2251. Effects of selective head mild hypothermia on endogenous Neuroprotection in brain following global cerebral ischemia/reperfusion injury: experiment with dogs
  2252. Neuroprotection and drugs used to treat psychiatric disorders
  2253. Anesthetic Neuroprotection : some things do last
  2254. Are cinnamic acids responsible for in vitro Neuroprotection exerted by Bryothamnion triquetrum (SG Gmelin) Howe aqueous extract?
  2255. Neuroprotection : A valuable goal in glaucoma management?
  2256. THE Neuroprotection OF DIETHYLSTILBESTROL ON MESENCEPHALIC NEURONS IN VITRO [J]
  2257. Glutamate transport modulation: a possible role in retinal Neuroprotection
  2258. NXY-059 for acute ischemic stroke: the promise of Neuroprotection is finally realized?
  2259. Mild hypothermia for Neuroprotection after cardiac arrest
  2260. Neuroprotection AND NEUROPLASTICITY IN CRANIOCEREBRAL TRAUMA.
  2261. Shc proteins and brain functions: Possible implications for Neuroprotection
  2262. Detecting the effects of Neuroprotection in living cells
  2263. Neuroprotection with methylaminochroman and lazaroid of embryonic ventral mesencephalic tegmental dopaminergic neurons in cold storage
  2264. Neuroprotection methods and protocols
  2265. Neurodegeneration, Neuroprotection , glial cells, and myelin in multiple sclerosis
  2266. Understanding optic nerve degeneration: key to Neuroprotection in glaucoma
  2267. Superoxide dismutase participates in p38 MAPK-mediated Neuroprotection of limb ischemic preconditioning in global brain ischemic rats
  2268. What have we learned about Neuroprotection in the lab?
  2269. The study on the Neuroprotection of cerebrospinal fluid containing LDP components [J]
  2270. Neuroprotection : Promise and Pitfalls
  2271. Approaches to Neuroprotection and Recovery
  2272. Pharmacologic Neuroprotection in patients with spinal cord injury and the efficacy of early decompressive surgery
  2273. The role of the estrogen in Neuroprotection : Implications for neurodegenerative diseases
  2274. Preface–Special Issue: Molecular mechanisms of CNS injury and Neuroprotection : new roles of amino acids, heme oxygenase system, stress proteins and …
  2275. In vivo tomographic imaging studies of neurodegeneration and Neuroprotection : a review
  2276. Neuroprotection in traumatic brain injury: practical implications for Papua New Guinea and some research developments
  2277. Erythropoietin and Neuroprotection in the central nervous system: intracellular signaling pathways
  2278. Genetical character of CNS injury and autoimmune Neuroprotection [J]
  2279. TRANSCRIPTIONS AND Neuroprotection
  2280. Role of Exercise and GDNF in an Animal Model of Parkinson’s Disease: Implications for Neuroprotection
  2281. Neuroprotection of chloride channel blockers against NMDA-induced apoptosis of cultured rat hippocampal neurons
  2282. Effects of acupuncture at the LU8· KI7 on Anti-apoptotic cell death and Neuroprotection in Rat hippocampus following focal brain ischemic injury induced by …
  2283. ECT and Neuroprotection : a review and proposed study
  2284. Neuronal plasticity as an evolutionary strategy: Implications for Neuroprotection in response to hypoxic challenge
  2285. MHP-133, a drug with multiple CNS targets: potential for Neuroprotection and enhanced cognition
  2286. Global hypothermia for Neuroprotection after cardiac arrest
  2287. Neuroprotection , the role of iron in photoreceptor toxicity induced by subretinal hemorrhage
  2288. Polycyclic indole derivatives as novel structures for Neuroprotection
  2289. Erythropoietin and Neuroprotection in the Peripheral Nervous System: In Vivo Studies
  2290. Novel Endocannabinoids Confer Neuroprotection in NMDA Rat Model
  2291. Pharmacological Neuroprotection against experimental acute cerebral ischemia of neurons of sensomotor area of frontal cortex and hippocampus in rats
  2292. ACUTE STROKE Neuroprotection MODEL
  2293. Selective β1-adrenoreceptor antagonists provide Neuroprotection after focal ischemia in rats
  2294. Neuroprotection in Glaucoma: Is It Possible?
  2295. Neuroprotection strategies from the research lab (’cause there aren’t any ready for prime time yet)
  2296. Recent progress in Neuroprotection of humanin against Alzheimer’s disease-relevant neurotoxicity
  2297. Nitric oxide and histamine in hibernation and Neuroprotection
  2298. Possible sources of Neuroprotection following subretinal silicon chip implantation in RCS rats
  2299. Pharmacological Neuroprotection for glaucoma
  2300. Neuronal restoration of memory disturbances and Neuroprotection for fall in vegetation after cardiac arrest
  2301. Neuroprotection after stroke
  2302. Neuregulins, Neuroprotection and Parkinson’s Disease
  2303. Behavioural aspects of neurodegeneration and Neuroprotection
  2304. Interaction of prion protein with divalent metals: possible role in Neuroprotection and neurodegeneration in prion disease model
  2305. Thyroid hormone regulation of neural and oligodendrocyte precursors in the mature brain : a possibility for remyelination and Neuroprotection
  2306. Phytocannabinoids and Neuroprotection : mechanisms of action and in vitro models
  2307. NT2N cell transplantation and GDNF treatment in stroke: Linking neurotrophic factor therapy and Neuroprotection
  2308. Timecourse of haloperidol-induced midbrain tyrosine hydroxylase downregulation and interventions for Neuroprotection
  2309. Insulin Confers Neuroprotection Against Hyperglycemic Stress-Induced Apoptosis Through PI3K/Akt/mTOR/Nrf2/GCL/Redox Signaling.
  2310. Neuroprotection IN brain HYPOXIA
  2311. Visual Cycle Controls Neuroprotection Switch in the Eye
  2312. Mechanisms of Neuroprotection by Erythropoietin
  2313. A New Dawn for Neuroprotection : NXY-059 for Acute Ischemic Stroke
  2314. Regulation of Calcium Influx in Retinal Ganglion Cells by Sigma-1 Receptor Ligands and Neuroprotection Relevance
  2315. The proteomic study of Ras-induced Neuroprotection
  2316. Cellular and molecular studies of ciliary neurotrophic factor receptor alpha expression and ciliary neurotrophic factor mediated Neuroprotection in the canine retina
  2317. Role of MAPK in Neuroprotection by cart in ischemic stroke
  2318. Neurogeneration and Neuroprotection by Copolymer 1 and Therapeutic Vaccines
  2319. Reduced Neuroprotection by aged astrocytes
  2320. Receptor abuse-dependent antagonism for Neuroprotection
  2321. The role of vasoactive intestinal peptide in Neuroprotection : interview with Professor Illana Gozes
  2322. Does Neuroprotection with NXY-059 improve patient outcome after acute ischemic stroke?
  2323. Erythropoietin signaling and Neuroprotection
  2324. CATHEPSIN B, ANTIAMYLOIDOGENESIS, AND Neuroprotection
  2325. Ginkgo biloba extract and Alzheimer’s disease: Is the Neuroprotection explained merely by antioxidant action
  2326. GROWTH FACTORS AND Neuroprotection OF THE PERINATAL brain
  2327. Neurotoxicity in oncology: Is Neuroprotection (NP) attainable? A critical review
  2328. Neuroprotection by N-methyl-D-aspartate antagonists
  2329. Initiation mechanism of estrogen Neuroprotection pathway
  2330. Exercise induced Neuroprotection in spontaneuosly running rats
  2331. Neurodegenerazione, neuroprotezione e sclerosi multipla [Neurodegeneration, Neuroprotection and multiple sclerosis]
  2332. Cellular and Molecular Mechanisms that Distinguish the Effects of Progestorone and Medroxyprogesterone Acetate on Neuroprotection
  2333. Mechanisms underlying Neuroprotection by PARP inhibitors
  2334. Introduction-Neuroprotection : A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia
  2335. Erythropoietin Neuroprotection in the Retina
  2336. In vitro models to investigate the role of PI-TPα in Neuroprotection and neurodegeneration
  2337. Role of Serine/Threon protein Phosphateases in Estrogen Mediated Neuroprotection
  2338. Neuroprotection in aortic arch surgery: A risk factor analysis
  2339. Molecular Mechanisms of Neuroprotection in the Anoxia Tolerant
  2340. Molecular mechanisms of Homer protein in ischemic Neuroprotection
  2341. James C. Grotta: Best Stroke Advances in Prevention, Treatment, and Neuroprotection
  2342. Cysteamine metabolism: Relevance to Neuroprotection .
  2343. Perioperative Neuroprotection : is it possible to prevent brain injury in high risk patients?
  2344. 17β-Estradiol Fails To Provide Neuroprotection during Cardiac Surgery
  2345. VIP-and PACAP-Related Neuroprotection
  2346. HOPE FOR BETTER TREATMENTS FOR PARKINSON DISEASE THROUGH ADVANCES IN GENETICS, EPIDEMIOLOGY, AND Neuroprotection
  2347. Genetical character of CNS injury and autoimmune Neuroprotection
  2348. Promising Early Candidates for Neuroprotection Against HIV-Dementia
  2349. Assessing Neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo
  2350. Study of Neuroprotection of 17 beta-estradiol after spinal cord injury in rats
  2351. Neuroprotection of Ischemic Injury in Pig Retina, Part III–Functional Assessment
  2352. Developing New Neuroprotection and Neural Regeneration Strategies Using Mouse Models of Neurological Diseases
  2353. Targeting Cell Cycle in a Coordinated Strategy for Anticancer Treatment and Neuroprotection
  2354. Sex Hormone Modulation of Mitochondrial Function: A Possible Mechanism for Neuroprotection
  2355. Neuroprotection of Ischemic Injury in Pig Retina, Part I: The Injury Model
  2356. Macrophage-mediated Neuroprotection and neurogenesis
  2357. Dynamics of neural stem cell-mediated Neuroprotection in the presence of oxidative stress: studies in vitro and in vivo
  2358. Neuroprotection and sudden infant death. A robust Brussels–Paris collaboration and future perspectives
  2359. Two Signaling Proteins Linked to ACh–Induced Neuroprotection in Isolated Pig Retinal Ganglion Cells
  2360. The activation of ERK1/2 participates in Neuroprotection induced by sevoflurane preconditioning on oxygen-glucose deprivation injury in rat hippocampal slices
  2361. MECHANISMS OF NEURODEGENERATION IN MULTIPLE SCLEROSIS: PREMISE FOR Neuroprotection ?
  2362. Radiated-induced brain injury: advance of molecular mechanisms and Neuroprotection strategies
  2363. S9 CANNABINOID RECEPTORS AND THEIR ROLE IN Neuroprotection
  2364. Duplicate Anesthetic Preconditioning Improves Neuroprotection In Vitro
  2365. The Neuroprotection effect of edaravone on spinal cord injury in rats
  2366. Double Isoflurane Preoconditioning Improves Neuroprotection Againt OGD Injury in Rat brain
  2367. Transferrin in Müller Cells and Neuroprotection in the Retina
  2368. Isoflurane Provides Sustained Neuroprotection in Rats Subjected to Focal Ischemia
  2369. A New Transgenic Mouse Model of Neuroprotection in Ischemic Optic Neuropathy
  2370. Estrogen Neuroprotection in Anterior Ischemic Optic Neuropathy (AION)
  2371. Signaling events in activity dependent Neuroprotection , neurodegeneration, and synaptic plasticity
  2372. A role for uncoupling proteins in Neuroprotection following recurrent hypoglycemia?
  2373. Soluble epoxide hydrolase: Sex differences and role in estrogen-mediated Neuroprotection
  2374. Systematic Pharmacotherapy for Sensory Neuroprotection After Peripheral Nerve Injury
  2375. Erythropoietin Neuroprotection in the Term and Preterm Infant: Safety and Efficacy
  2376. The role of excitatory amino acid transporters in Neuroprotection and neuropathology
  2377. VEGF‐based therapeutic angiogenesis for ischemic stroke is associated with damage of nervous tissue and loss of Neuroprotection
  2378. Does Neuroprotection Still Have a Role in Injured brain Following Aneurysmal Subarachnoid Haemorrhage?
  2379. Preconditioning Triggers Neuroprotection Against Excitotoxicity in Pig Retinal Ganglion Cells
  2380. Neuroprotection by delayed high dose Aspirin treatment in cerebral ischemia
  2381. Molecular Mechanisms of Dietary Restriction on the Neuroprotection and Hippocampal Neurogenesis
  2382. The Neuroprotection of Mild hypothermia in the Acute Phase of Subarachnoid Hemorrhage
  2383. Comparative Neuroprotection of Multi-Dose Lidocaine in a Rabbit Model of Subarachnoid Hemorrhage
  2384. Opioid Preconditioning Induces an Opioid Receptor-Dependent Delayed Neuroprotection
  2385. Estrogen-induced Neuroprotection is Mediated by an Increase in Caspase-12-associated Apoptosis Following MCAO.
  2386. Creatine mediates Neuroprotection towards excitoxicity in an in vitro model of neurodegeneration
  2387. Neuroprotection of AG490 in Oxidative Stress-induced Neuronal Death
  2388. Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection
  2389. Neuroprotection in Non-Arteritic Anterior Ischemic Optic Neuropathy
  2390. Overactivation of NMDA receptors in ammonia neurotoxicity: a target for Neuroprotection ?
  2391. Cell cycle regulation provides Neuroprotection after focal cerebral ischemia brain damage
  2392. P20 NEURODEGENERATION AND Neuroprotection ON MODEL OF PHOTOCHEMICALLY INDUCED ISCHEMIA OF RAT brain CORTEX
  2393. Exercise-induced Neuroprotection against kainic acid-induced seizures in the rat
  2394. 599. Neuron Loss Mediated by HIV-1 gp120 In Vivo: Neuroprotection Using SV40 Gene Transfer of Antioxidant Enzymes
  2395. CELL CYCLE INHIBITOR PROVIDES Neuroprotection IN RATS AFTER FOCAL CEREBRAL ISCHEMIA
  2396. Neuroprotection of Ischemic Injury in Pig Retina, Part II: Ganglion Cell Rescue
  2397. Role of cocaine and amphetamine regulated transcript in estradiol-mediated Neuroprotection .
  2398. Long lasting Neuroprotection by JNK activity blockade in severe cerebral ischemia
  2399. Metabolism of Primary Astrocytes Studied by NMR Metabolic Trafficking and Neuroprotection
  2400. Metabolism of primary astrocytes studied by NMR: metabolic trafficking and Neuroprotection
  2401. CHAPTER III. Neuroprotection FROM OXIDATIVE STRESS IN THE STEM CELL NICHE: CELLULAR NETWORKS AND REGULATION OF ANTIOXIDANT …
  2402. Neuroprotection of spinal cord by application of an extract from Paeonin Lactiflora, animal studies
  2403. Role of LIFR-gp130 Activation in Endogenous Neuroprotection of Retinal Photoreceptors
  2404. Studies into The Mechanisms of Neurodegeneration and Neuroprotection in Rd1 Mouse Retina.
  2405. Neuroprotection by granulocyte colony-stimulating factor (G-CSF) after focal cerebral ischemia
  2406. Anxiety Reactions as a Neuroprotection Strategy: Acetylcholinesterase modulations under stress and neurodegenerative diseases as a case study
  2407. Neuroprotection by 20 (S) Protopanaxadiol in Focal Cerebral Ischemia Mouse Model
  2408. Prophylaxis against nerve agent toxicity: Physiological, behavioral, and Neuroprotection of current and novel treatments
  2409. Neuroprotection by Nicotine in Hippocampal Slices Subjected to Oxygen-Glucose Deprivation: Involvement of the α7…
  2410. Carotid Artery Stenting with Neuroprotection : the first percutaneous revascularization technique shown to be clinically superior to surgery in a randomized trial
  2411. A pilot study of Neuroprotection with umbilical cord blood cell transplantation for preterm very low birth weight infants
  2412. Bacterial DNA Confers Neuroprotection Following Optic Nerve Injury by Suppressing CD4+ CD25+ Regulatory T Cell Activity
  2413. HPLC-based activity profiling of Erigeron breviscapus for optic Neuroprotection
  2414. Neuroprotection in Parkinson’s disease: modafinil and Δ9-tetrahydrocannabinol
  2415. Autoimmune Uveitis Induces Loss of Retinal Ganglion Cells: Immune Modulation Rather Than Suppression for Neuroprotection
  2416. Erythropoietin exerts Neuroprotection during Deep Hypothermic Circulatory Arrest
  2417. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α7 nicotinic receptor knockout mice
  2418. Neuroprotection of progesterone on retinal ganglion cells in chronic ocular hypertension model rats
  2419. Neuroprotection following repeated hypoxia preconditioning (RHP): pivotal role of brain -derived erythropoietin
  2420. A Perfusion Culture System for Whole Retina From Adult Rat: An in–vitro Model for Neuroprotection on Retinal Ganglion Cells
  2421. Conditional Knock Out of HIF-La and the Consequences for Hypoxia Induced Retinal Neuroprotection in a Model of Light Induced Retinal Degeneration
  2422. PUFA-induced Neuroprotection against cerebral or spinal cord ischemia via the TREK-1 channel
  2423. Assessment of Longterm Neuroprotection by CNTF Gene Transfer in a Mouse Inherited Retinal Degeneration
  2424. Correlation between the repair of oxidative DNA damage and the Neuroprotection in mice after forebrain ischemia
  2425. Pharmacokinetic properties of selective and non-selective AMPA-receptor antagonists and their role in Neuroprotection
  2426. Neuroprotection by 1, 25 (OH) 2-Vitamin D3 Against Kainic Acid-Induced Excitotoxicity in the Rat Hippocampus
  2427. THE Neuroprotection OF OLPRINONE, A PHOSPHODIESTERASE 3 INHIBITOR, ON GLOBAL CEREBRAL ISCHEMIA IN RATS.: 149
  2428. Molecular mechanisms of Neuroprotection by extract from Rosmarinus officinalis (Rosemary) in dopaminergic cell line, SH-SY5Y
  2429. Neuroprotection of Green Tea Derived EGCG: Implications for HIV associated dementia
  2430. Noscapine is synergistic with vincristine and provides Neuroprotection of myelin in cell culture.
  2431. The Insulin Sensitizer Rosiglitazone Decreases Inflammatory Pattern and Improves Vascular Neuroprotection in Insulin-Resistant Type 2 Diabetic Subjects with …
  2432. Neuroinflammation and excitotoxicity in neurobiology of HIV-1 infection and AIDS: targets for Neuroprotection
  2433. Glycogen synthase kinase 3: role in neurodegeneration and Neuroprotection
  2434. Neuroprotection by pharmacological preconditioning, the role of the mitochondrial ATP-sensitive K+ channel
  2435. Leukocyte Anti-adhesion Therapy Provides Neuroprotection after Transient Global Cerebral Ischemia in the Mouse
  2436. GLP-1 secreting encapsulated human mesenchymal stem cells for Neuroprotection
  2437. Riluzole confers Neuroprotection by increasing the amount of HSF1 for a more robust heat shock response
  2438. Erythropoietin Exerts Endogenous Neuroprotection After Ocular Hypertension Induced Glaucoma and Optic Nerve Transection Injuries
  2439. Neuroprotection by sodium ferulate against glutamate-induced apoptosis is mediated by ERK and PI3 kinase pathways1
  2440. Modulation of the endocannabinoid system is implicated in the Neuroprotection afforded by 17Beta-estradiol (E2) against brain damage caused by transient middle …
  2441. … ultrastructural damage in the neurons of hippocampal CA_3 subarea during kainic acid induced status epilepticus and the Neuroprotection of topiramate in rats
  2442. Testosterone-mediated Neuroprotection in NO Induced Cell Death of Motor Neuron Cells Expressing Wild Type or Mutant Cu/Zn Superoxide Dismutase
  2443. The Neuropeptide NAP Provides Neuroprotection of Retinal Ganglion Cells After Optic Nerve Crush and Retinal Ischemia in vivo
  2444. Reversal of Cerebral Vasospasm and Neuroprotection by Injecting Magnesium Sulfate into Cisterna Magna in Rabbit with Subarachnoid Hemorrhage
  2445. … Colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of Colivelin-mediated Neuroprotection against Alzheimer’s disease …
  2446. S07H5 Fuctional analysis of tripartite synapses using membrane potential imaging: memory enhancement and Neuroprotection by neurosteroids (Leading Edge in …
  2447. The Beneficial Role of Extracellular Signal-regulated Kinases 1 and 2 in Exercise-induced Neuroprotection after Stroke
  2448. Concurrent Treatment with Lovastatin and 5‐Aminoimidazole‐4‐Carboxamide‐1‐Beta‐D‐Ribofuranoside provides Neuroprotection and alleviate Neurodegeneration …
  2449. Decrease in Rate of NMDA-induced Ca^ 2^+ Entry May Explain Neuroprotection by Anti-GRINL1A Antibodies
  2450. AM 404 leads to Neuroprotection against ischemia-induced neuronal injury
  2451. Anaesthesia for thoracic and thoraco-abdominal aortic disease—Part 2: Anaesthetic management and Neuroprotection
  2452. Metabotropic glutamate receptor 3 Neuroprotection
  2453. 354 MECHANISMS OF ENDOGENOUS SEX HORMONE MEDIATED Neuroprotection IN THE AGING brain : A SYSTEMATIC REVIEW.
  2454. S20 DIFFERENTIAL ROLES OF 1, 2, 3, 4-TETRAHYDROISOQUINOLINES IN NEURODEGENERATION AND Neuroprotection
  2455. EVIDENCE TO IMPLICATE EARLY MODULATION OF INTERLEUKIN-1 EXPRESSION IN THE Neuroprotection AFFORDED BY 17-ESTRADIOLIN MALE RATS …
  2456. Journal of Neuroal Transmission Suppplement 71: Oxidative Stress and Neuroprotection
  2457. Cytotoxicity of Levodopa on c17. 2 neural stem cell and Neuroprotection of Pergolide
  2458. 8 Erythropoietin Signaling Pathways in Neuroprotection
  2459. 2 Diagnosis and Neuroprotection in Parkinson’s Disease
  2460. Metabotropic glutamate receptor 3 Neuroprotection A. Berent-Spillson and JW Russell Received June 12, 2006; revised manuscript received October 3, 2006; …
  2461. Neurotox-98 Neuroprotection by Progesterones Through Stimulation of Mitochondrial Gene Expression
  2462. Neurone and astrocyte response to Aβ25-35: Role in glutathione in Neuroprotection
  2463. n-3 poly-unsaturated fatty Acid (n-3PUFA) and Neuroprotection : Is docosahexaenoic acid (DHA) involved in glutamate uptake by astrocytes?
  2464. A~ 2-adrenergic system: From neurotransmitans to Neuroprotection
  2465. The role of astroglia in Neuroprotection
  2466. Neuroprotection for ischemic stroke: past, present and future
  2467. Mitochondrial approaches for Neuroprotection
  2468. Statins: mechanisms of Neuroprotection
  2469. Neuroinflammation in Parkinson’s disease: a target for Neuroprotection ?
  2470. Targets for Neuroprotection in Parkinson’s disease
  2471. Metabolic downregulation: a key to successful Neuroprotection ?
  2472. Neuroprotection does not work!
  2473. Current status of Neuroprotection for cerebral ischemia: synoptic overview
  2474. Imaging outcomes for Neuroprotection and repair in multiple sclerosis trials
  2475. Why have we failed to achieve Neuroprotection in Parkinson’s disease?
  2476. The role of kynurenines in disorders of the central nervous system: possibilities for Neuroprotection
  2477. Progress in Neuroprotection in Parkinson’s disease
  2478. The specificity of Neuroprotection by antioxidants
  2479. Magnesium sulphate for women at risk of preterm birth for Neuroprotection of the fetus
  2480. Neuroprotection (and lack of Neuroprotection ) afforded by a series of noble gases in an in vitro model of neuronal injury
  2481. Steroids and Neuroprotection : new advances
  2482. Wnt signaling in Neuroprotection and stem cell differentiation
  2483. Neuroprotection in glaucoma: drug-based approaches
  2484. AMPK in the brain : its roles in energy balance and Neuroprotection
  2485. Antioxidants and Neuroprotection in the adult and developing central nervous system
  2486. Molecular mechanisms of Neuroprotection by two natural antioxidant polyphenols
  2487. Toll-like receptor signaling in endogenous Neuroprotection and stroke
  2488. Mitochondrial mechanisms of estrogen Neuroprotection
  2489. Autophagy and the ubiquitin-proteasome system: collaborators in Neuroprotection
  2490. The multiple faces of quercetin in Neuroprotection
  2491. Assessment of Neuroprotection in the retina with DARC
  2492. Inflammation and its role in Neuroprotection , axonal regeneration and functional recovery after spinal cord injury
  2493. Toll-like receptors: roles in Neuroprotection ?
  2494. Biochemical, molecular and epigenetic mechanisms of valproic acid Neuroprotection
  2495. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
  2496. Neuroprotection by the NR3A subunit of the NMDA receptor
  2497. Citicoline: update on a promising and widely available agent for Neuroprotection and neurorepair
  2498. Autophagy in Neuroprotection and neurodegeneration: a question of balance
  2499. Estrogen therapy: is time of initiation critical for Neuroprotection ?
  2500. Fluoxetine affords robust Neuroprotection in the postischemic brain via its anti‐inflammatory effect
  2501. Neuroprotection : extrapolating from neurologic diseases to the eye
  2502. History of Neuroprotection and rationale as a therapy for glaucoma
  2503. Alcohol in moderation, cardioprotection, and Neuroprotection : epidemiological considerations and mechanistic studies
  2504. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, Neuroprotection possibly
  2505. Can we achieve Neuroprotection with currently available anti-parkinsonian interventions?
  2506. Recent trends in erythropoietin-mediated Neuroprotection
  2507. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and Neuroprotection
  2508. Neuroprotection in the newborn infant
  2509. Leptin Neuroprotection in the CNS: mechanisms and therapeutic potentials
  2510. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis
  2511. Therapeutic targets and limits of minocycline Neuroprotection in experimental ischemic stroke
  2512. More than a decade of estrogen Neuroprotection
  2513. Forced, not voluntary, exercise effectively induces Neuroprotection in stroke
  2514. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons
  2515. Estrogen and SERM Neuroprotection in animal models of Parkinson’s disease
  2516. Vitagenes, dietary antioxidants and Neuroprotection in neurodegenerative diseases (498 views visite)
  2517. Delayed post-ischaemic Neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms
  2518. Mechanisms of disease: sodium channels and Neuroprotection in multiple sclerosis—current status
  2519. Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration
  2520. Neuroprotection trials in Parkinson’s disease: systematic review
  2521. Endogenous Neuroprotection : mitochondria as gateways to cerebral preconditioning?
  2522. All-you-can-eat: autophagy in neurodegeneration and Neuroprotection
  2523. The role of Wnt signaling in Neuroprotection
  2524. CD4+ T cells support glial Neuroprotection , slow disease progression, and modify glial morphology in an animal model of inherited ALS
  2525. Experimental and clinical evidence of Neuroprotection by nerve growth factor eye drops: Implications for glaucoma
  2526. Targeting post-mitochondrial effectors of apoptosis for Neuroprotection
  2527. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy
  2528. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement
  2529. Two different molecular mechanisms underlying progesterone Neuroprotection against ischemic brain damage
  2530. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and Neuroprotection
  2531. Recent clinical findings with memantine should not mean that the idea of Neuroprotection in glaucoma is abandoned
  2532. Progesterone Neuroprotection in traumatic CNS injury and motoneuron degeneration
  2533. Neuroinflammation in spinal cord injury: therapeutic targets for Neuroprotection and regeneration
  2534. Effects of antenatal exposure to magnesium sulfate on Neuroprotection and mortality in preterm infants: a meta-analysis
  2535. Cellular stress response: a novel target for chemoprevention and nutritional Neuroprotection in aging, neurodegenerative disorders and longevity
  2536. Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of Neuroprotection
  2537. Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid Neuroprotection
  2538. Taurine increases mitochondrial buffering of calcium: role in Neuroprotection
  2539. Endocannabinoids in the retina: from marijuana to Neuroprotection
  2540. Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury
  2541. Mitochondrial mechanisms of cell death and Neuroprotection in pediatric ischemic and traumatic brain injury
  2542. Immunomodulation and Neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other …
  2543. A review of published reports on Neuroprotection in spinal cord injury
  2544. An approach to using recombinant erythropoietin for Neuroprotection in very preterm infants
  2545. Robust docosahexaenoic acid–mediated Neuroprotection in a rat model of transient, focal cerebral ischemia
  2546. Nrf2-mediated Neuroprotection in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte
  2547. Adaptive immune Neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice
  2548. Metallothionein‐I+ II in Neuroprotection
  2549. PPAR‐gamma‐mediated Neuroprotection in a chronic mouse model of Parkinson’s disease
  2550. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired Neuroprotection induced by synaptic activity
  2551. Neuroprotection in diet-induced ketotic rat brain after focal ischemia
  2552. Randomized, double-blinded, placebo controlled study of Neuroprotection with lidocaine in cardiac surgery
  2553. Nicotinic receptor-mediated Neuroprotection in neurodegenerative disease models
  2554. Neuroprotection by radical avoidance: search for suitable agents
  2555. Glucocorticoid receptors modulate mitochondrial function: A novel mechanism for Neuroprotection
  2556. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for Neuroprotection and tissue repair
  2557. Sex differences in minocycline-induced Neuroprotection after experimental stroke
  2558. Targeting oxidative stress for Neuroprotection
  2559. Molecular and cell-based approaches for Neuroprotection in glaucoma
  2560. Neuronal death after peripheral nerve injury and experimental strategies for Neuroprotection
  2561. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards Neuroprotection
  2562. A core review of temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2563. Transcribe to survive: transcriptional control of antioxidant defense programs for Neuroprotection in Parkinson’s disease
  2564. Mesenchymal stem cells therapy exerts Neuroprotection in a progressive animal model of Parkinson’s disease
  2565. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for Neuroprotection and neuroregeneration in Parkinson’s disease?
  2566. Nano-drug delivery and Neuroprotection in spinal cord injury
  2567. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced Neuroprotection
  2568. Dantrolene: mechanisms of Neuroprotection and possible clinical applications in the neurointensive care unit
  2569. Regulation of Mn-superoxide dismutase activity and Neuroprotection by STAT3 in mice after cerebral ischemia
  2570. Angiotensin AT2 receptor stimulation causes Neuroprotection in a conscious rat model of stroke
  2571. A Nurr1 pathway for Neuroprotection
  2572. Cooling Combined with Immediate or Delayed Xenon Inhalation Provides Equivalent Long-Term Neuroprotection after Neonatal Hypoxia—Ischemia
  2573. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate
  2574. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated Neuroprotection is independent of its deacetylase activity
  2575. Study of Neuroprotection of donepezil, a therapy for Alzheimer’s disease
  2576. Propofol: Neuroprotection in an in vitro model of traumatic brain injury
  2577. Uric acid administration in patients with acute stroke: a novel approach to Neuroprotection
  2578. Disease progression and the need for Neuroprotection in glaucoma management
  2579. Matrix metalloproteinases inhibition provides Neuroprotection against hypoxia‐ischemia in the developing brain
  2580. Insulin Neuroprotection against oxidative stress is mediated by Akt and GSK-3β signaling pathways and changes in protein expression
  2581. Xenon and hypothermia combine additively, offering long-term functional and histopathologic Neuroprotection after neonatal hypoxia/ischemia
  2582. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in Neuroprotection
  2583. Neuroprotection by pravastatin in acute ischemic stroke in rats
  2584. Erythropoietin modulation of astrocyte water permeability as a component of Neuroprotection
  2585. Cannabinoid-mediated Neuroprotection , not immunosuppression, may be more relevant to multiple sclerosis
  2586. Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of Neuroprotection
  2587. Optimal Neuroprotection by erythropoietin requires elevated expression of its receptor in neurons
  2588. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial
  2589. Is it time to definitely abandon Neuroprotection in acute ischemic stroke?
  2590. Novel anti-Alzheimer’s dimer bis (7)-cognitin: cellular and molecular mechanisms of Neuroprotection through multiple targets
  2591. Neuroprotection by estrogen in the brain : the mitochondrial compartment as presumed therapeutic target
  2592. Research into Neuroprotection must continue… But with a different approach
  2593. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway
  2594. Neuroprotection for diabetic retinopathy
  2595. Physical activity and Neuroprotection in amyotrophic lateral sclerosis
  2596. Secretoneurin promotes Neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke
  2597. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis
  2598. Pathogenesis of ganglion “cell death” in glaucoma and Neuroprotection : focus on ganglion cell axonal mitochondria
  2599. Strong Neuroprotection by inhibition of NF-κB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines
  2600. The impact of neuroimmune dysregulation on Neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment
  2601. Methylene blue provides behavioral and metabolic Neuroprotection against optic neuropathy
  2602. Endocannabinoids mediate Neuroprotection after transient focal cerebral ischemia
  2603. Cellular NAD replenishment confers marked Neuroprotection against ischemic cell death: role of enhanced DNA repair
  2604. Intranasal delivery of erythropoietin plus insulin-like growth factor–I for acute Neuroprotection in stroke
  2605. Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors
  2606. Progesterone and progestins: Neuroprotection and myelin repair
  2607. Ferulic acid provides Neuroprotection against oxidative stress-related apoptosis after cerebral ischemia/reperfusion injury by inhibiting ICAM-1 mRNA expression in …
  2608. TNF receptor I sensitizes neurons to erythropoietin-and VEGF-mediated Neuroprotection after ischemic and excitotoxic injury
  2609. Neuroprotection and repair
  2610. Neuroprotection for Huntington’s disease: ready, set, slow
  2611. Should amplitude-integrated electroencephalography be used to identify infants suitable for hypothermic Neuroprotection ?
  2612. Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the …
  2613. Striatal Neuroprotection with methylene blue
  2614. NAP and D-SAL: Neuroprotection against the β amyloid peptide (1–42)
  2615. Neural stem/progenitor cells initiate the formation of cellular networks that provide Neuroprotection by growth factor‐modulated antioxidant expression
  2616. Neuroprotection by co-treatment and post-treating with calcitriol following the ischemic and excitotoxic insult in vivo and in vitro
  2617. Progesterone reverses 17β‐estradiol‐mediated Neuroprotection and BDNF induction in cultured hippocampal slices
  2618. Phylogeny of proteolipid proteins: divergence, constraints, and the evolution of novel functions in myelination and Neuroprotection
  2619. Bioenergetic‐based Neuroprotection and glaucoma
  2620. P2Y1 receptor signaling enhances Neuroprotection by astrocytes against oxidative stress via IL‐6 release in hippocampal cultures
  2621. New targets of Neuroprotection in ischemic stroke
  2622. Nasal administration of osteopontin peptide mimetics confers Neuroprotection in stroke
  2623. The past and future of Neuroprotection in cerebral ischaemic stroke
  2624. Neuroprotection by nitrous oxide: Facts and evidence.
  2625. Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for Neuroprotection ?
  2626. Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson model using lactoferrin‐modified nanoparticles
  2627. Carotid Artery Stenting with Patient-and Lesion-Ta ilo r ed Selection of the Neuroprotection System and Stent Type: Early and 5-Year Results from a Prospective …
  2628. New insight into the molecular pathways of metallothionein‐mediated Neuroprotection and regeneration
  2629. Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13
  2630. Stromal cell-derived factor-1α promotes Neuroprotection , angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats
  2631. Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and Neuroprotection
  2632. Uracil nucleotides: from metabolic intermediates to Neuroprotection and neuroinflammation
  2633. Effects of optic nerve injury, glaucoma, and Neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina
  2634. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1
  2635. … complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent Neuroprotection
  2636. Stem cells for Neuroprotection in glaucoma
  2637. Leptin is induced in the ischemic cerebral cortex and exerts Neuroprotection through NF-κB/c-Rel–dependent transcription
  2638. TGF-β in dopamine neuron development, maintenance and Neuroprotection
  2639. In search of clinical Neuroprotection after brain ischemia: the case for mild hypothermia (35 C) and magnesium
  2640. Human neural stem cells genetically modified to overexpress Akt1 provide Neuroprotection and functional improvement in mouse stroke model
  2641. Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to Neuroprotection
  2642. The yellow fluorescent protein (YFP-H) mouse reveals Neuroprotection as a novel mechanism underlying chondroitinase ABC-mediated repair after spinal cord injury
  2643. CNTF induces photoreceptor Neuroprotection and Müller glial cell proliferation through two different signaling pathways in the adult zebrafish retina
  2644. Marked calpastatin (CAST) depletion in Alzheimer’s disease accelerates cytoskeleton disruption and neurodegeneration: Neuroprotection by CAST overexpression
  2645. Molecular and clinical pathways to Neuroprotection of dopaminergic drugs in Parkinson disease
  2646. Dimethyl sulfoxide provides Neuroprotection in a traumatic brain injury model
  2647. Neuroprotection by Spirulina platensis protean extract and phycocyanin against iron-induced toxicity in SH-SY5Y neuroblastoma cells
  2648. Progesterone with vitamin D affords better Neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone
  2649. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia
  2650. Lovastatin induces Neuroprotection through tumor necrosis factor receptor 2 signaling pathways
  2651. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic Neuroprotection in a model of Parkinson’s disease
  2652. Long-term Neuroprotection from a potent redox-modulating metalloporphyrin in the rat
  2653. Current controversies in hypothermic Neuroprotection
  2654. Acute Neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome
  2655. TNF‐α‐mediates Neuroprotection against glutamate‐induced excitotoxicity via NF‐κB‐dependent up‐regulation of KCa2.2 channels
  2656. Progesterone attenuates oestrogen Neuroprotection via downregulation of oestrogen receptor expression in cultured neurones
  2657. Modeling axonal degeneration within the anterior visual system: implications for demonstrating Neuroprotection in multiple sclerosis
  2658. P2X7 receptors in oligodendrocytes: a novel target for Neuroprotection
  2659. Neuroprotection during cardiac surgery
  2660. Acetyl-L-carnitine provides effective in vivo Neuroprotection over 3, 4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain
  2661. The seed extract of Cassia obtusifolia offers Neuroprotection to mouse hippocampal cultures
  2662. DHEA-Neuroprotection and-neurotoxicity after transient cerebral ischemia in rats
  2663. TAT-Hsp70-mediated Neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice
  2664. Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for Neuroprotection
  2665. Nrf2 activators provide Neuroprotection against 6‐hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures
  2666. Involvement of TRPC channels in CCL2-mediated Neuroprotection against tat toxicity
  2667. Multifunction of myricetin on Aβ: Neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases
  2668. Retinal ganglion cell Neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments
  2669. Possible involvement of P2X7 receptor activation in microglial Neuroprotection against focal cerebral ischemia in rats
  2670. Functional mechanism of Neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease
  2671. Neuroprotection of aucubin in primary diabetic encephalopathy
  2672. A closed-circuit neonatal xenon delivery system: a technical and practical Neuroprotection feasibility study in newborn pigs
  2673. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for Neuroprotection
  2674. Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway
  2675. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit Neuroprotection properties
  2676. Neuroprotection of ginsenoside Re in cerebral ischemia–reperfusion injury in rats
  2677. Tamoxifen Neuroprotection in cerebral ischemia involves attenuation of kinase activation and superoxide production and potentiation of mitochondrial superoxide …
  2678. Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and …
  2679. Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by …
  2680. Post-ischemic helium provides Neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia
  2681. A critique of SAINT II: wishful thinking, dashed hopes, and the future of Neuroprotection for acute stroke
  2682. The role of the somatotrophic axis in Neuroprotection and neuroregeneration of the addictive brain
  2683. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts Neuroprotection by inhibiting oxidative stress following pilocarpine-induced status …
  2684. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression
  2685. P2X 7 nucleotide receptor is coupled to GSK-3 inhibition and Neuroprotection in cerebellar granule neurons
  2686. Involvement of ERK1/2 signaling pathway in DJ-1-induced Neuroprotection against oxidative stress
  2687. Lipopolysaccharide preconditioning reduces neuroinflammation against hypoxic ischemia and provides long-term outcome of Neuroprotection in neonatal rat
  2688. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced Neuroprotection and nicotinic receptor up-regulation
  2689. Neuroprotection and neuroregeneration in multiple sclerosis
  2690. Are delayed‐start design trials to show Neuroprotection in Parkinson’s disease fundamentally flawed?
  2691. Docosahexaenoic acid pretreatment confers Neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia
  2692. The APCs of Neuroprotection
  2693. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic Neuroprotection
  2694. Hypoxic-ischemic injury in neonatal brain : involvement of a novel neuronal molecule in neuronal cell death and potential target for Neuroprotection
  2695. Long-term administration of estrogen or tamoxifen to ovariectomized rats affords Neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and …
  2696. Molecular mechanisms leading to Neuroprotection /ischemic tolerance: effect of preconditioning on the stress reaction of endoplasmic reticulum
  2697. Blood–central nervous system barriers: the gateway to neurodegeneration, Neuroprotection and neuroregeneration
  2698. Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K–Akt signaling pathway: A novel …
  2699. Heat shock proteins and the brain : implications for neurodegenerative diseases and Neuroprotection
  2700. Cyclosporine A for Neuroprotection : establishing dosing guidelines for safe and effective use
  2701. Chronic treatment with red wine polyphenol compounds mediates Neuroprotection in a rat model of ischemic cerebral stroke
  2702. Long-term pharmacologic Neuroprotection after birth asphyxia: where do we stand?
  2703. Evidence for Neuroprotection by the fenamate NSAID, mefenamic acid
  2704. Hyperphosphorylation of microtubule-associated tau protein plays dual role in neurodegeneration and Neuroprotection
  2705. Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK
  2706. Pharmacological strategies for Neuroprotection in traumatic brain injury.
  2707. Mechanism of guanosine-induced Neuroprotection in rat hippocampal slices submitted to oxygen–glucose deprivation
  2708. Neuroprotection by melatonin on astrocytoma cell death
  2709. Effects of Vinpocetine on mitochondrial function and Neuroprotection in primary cortical neurons
  2710. Uric acid and Neuroprotection
  2711. Diazepam Neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects
  2712. Pharmacologic Neuroprotection —Is xenon the light at the end of the tunnel?
  2713. Essential role for zinc-triggered p75NTR activation in preconditioning Neuroprotection
  2714. Rho kinase inhibitor Fasudil induces Neuroprotection and neurogenesis partially through astrocyte-derived G-CSF
  2715. Gabapentin Neuroprotection and seizure suppression in immature mouse brain ischemia
  2716. TRPC channel-mediated Neuroprotection by PDGF involves Pyk2/ERK/CREB pathway
  2717. VEGF as a target for Neuroprotection
  2718. Combination therapy of lovastatin and rolipram provides Neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis
  2719. A novel insight into Neuroprotection against hypoxic/ischemic stress
  2720. HIV protease inhibitors provide Neuroprotection through inhibition of mitochondrial apoptosis in mice
  2721. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse
  2722. Nicotinamide treatment provides acute Neuroprotection and GFAP regulation following fluid percussion injury
  2723. Differential Neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity
  2724. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation Neuroprotection with statin therapy for acute recovery trial (NeuSTART)
  2725. Small molecule activators of the Trk receptors for Neuroprotection
  2726. Transplantation of human amniotic cells exerts Neuroprotection in MPTP-induced Parkinson disease mice
  2727. Oleoylethanolamide exerts partial and dose-dependent Neuroprotection of substantia nigra dopamine neurons
  2728. Balancing paediatric anaesthesia: preclinical insights into analgesia, hypnosis, Neuroprotection , and neurotoxicity
  2729. PI3 kinase/Akt activation mediates estrogen and IGF‐1 nigral DA neuronal Neuroprotection against a unilateral rat model of Parkinson’s disease
  2730. Retinal Neuroprotection against ischemia-reperfusion damage induced by postconditioning
  2731. Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes
  2732. The neuropeptide NAP provides Neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush
  2733. Desflurane, isoflurane, and sevoflurane provide limited Neuroprotection against neonatal hypoxia-ischemia in a delayed preconditioning paradigm
  2734. Antioxidant Neuroprotection against ethanol-induced apoptosis in HN2-5 cells
  2735. A global view of Parkinson’s disease pathogenesis: Implications for natural history and Neuroprotection
  2736. Oxidative stress in stroke pathophysiology: Validation of hydrogen peroxide metabolism as a pharmacological target to afford Neuroprotection
  2737. Additive Neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade
  2738. Neuroprotection of brain -derived neurotrophic factor against hypoxic injury in vitro requires activation of extracellular signal-regulated kinase and phosphatidylinositol …
  2739. Lactation is a natural model of hippocampus Neuroprotection against excitotoxicity
  2740. The novel Cholinesterase–Monoamine Oxidase inhibitor and Antioxidant, Ladostigil, confers Neuroprotection in neuroblastoma cells and aged rats
  2741. Neuroprotection of γ‐aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric …
  2742. Melatonin provides Neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats
  2743. GABA synapses mediate Neuroprotection after ischemic and εPKC preconditioning in rat hippocampal slice cultures
  2744. Intranasal bFGF-induced progenitor cell proliferation and Neuroprotection after transient focal cerebral ischemia
  2745. Novel regimen through combination of memantine and tea polyphenol for Neuroprotection against brain excitotoxicity
  2746. Prolonged opportunity for Neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity
  2747. Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer’s disease
  2748. Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia
  2749. Diphenyl diselenide confers Neuroprotection against hydrogen peroxide toxicity in hippocampal slices
  2750. Neuroprotection and imaging studies in Parkinson’s disease
  2751. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute …
  2752. Neuroprotection : VEGF, IL-6, and clusterin: the dark side of the moon
  2753. Neuroprotection against Spinal Cord Ischemia–Reperfusion Injury Induced by Different Ischemic Postconditioning Methods: Roles of Phosphatidylinositol 3-Kinase …
  2754. Neuroprotection of microglial conditioned medium on 6‐hydroxydopamine‐induced neuronal death: role of transforming growth factor beta‐2
  2755. Neuroprotection and functional recovery conferred by administration of kappa-and delta1-opioid agonists in a rat model of global ischemia
  2756. Photoreceptor Neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide
  2757. Apolipoprotein E may be a critical factor in hormone therapy Neuroprotection
  2758. Neuronal nicotinic receptors as novel targets for inflammation and Neuroprotection : mechanistic considerations and clinical relevance
  2759. IGF-IR in Neuroprotection and brain tumors
  2760. … receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK‐3beta: connecting neurotransmission with Neuroprotection
  2761. Targeting Neuroprotection as an alternative approach to preventing and treating neuropathic pain
  2762. Synergistic effect of galantamine on nicotine-induced Neuroprotection in hemiparkinsonian rat model
  2763. 17β-estradiol-mediated Neuroprotection and ERK activation require a pertussis toxin-sensitive mechanism involving GRK2 and β-arrestin-1
  2764. Preconditioning Neuroprotection in global cerebral ischemia involves NMDA receptor-mediated ERK-JNK3 crosstalk
  2765. Clinical trials in Neuroprotection
  2766. Limited minocycline Neuroprotection after balloon-compression spinal cord injury in the rat
  2767. PACAP-mediated Neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration
  2768. L-kynurenine: metabolism and mechanism of Neuroprotection
  2769. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates Neuroprotection against normoxic oxidative death via HIF-and CREB-independent …
  2770. Mechanisms of platelet‐derived growth factor‐mediated Neuroprotection –implications in HIV dementia
  2771. NMDA-induced Neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB (cAMP-response element-binding protein) pathway
  2772. DJ-1 knock-down in astrocytes impairs astrocyte-mediated Neuroprotection against rotenone
  2773. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords Neuroprotection in experimental stroke
  2774. Interaction between neuropeptide Y (NPY) and brain ‐derived neurotrophic factor in NPY‐mediated Neuroprotection against excitotoxicity: a role for microglia
  2775. Small-molecule mediated Neuroprotection in an in situ model of tauopathy
  2776. Therapeutic hypothermia for Neuroprotection
  2777. Sonic hedgehog mediates BDNF-induced Neuroprotection against mitochondrial inhibitor 3-nitropropionic acid
  2778. Mitochondrial localization of DJ‐1 leads to enhanced Neuroprotection
  2779. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway
  2780. Ischemic preconditioning-induced Neuroprotection is associated with differential expression of IL-1β and IL-1 receptor antagonist in the ischemic cortex
  2781. Propofol exerts greater Neuroprotection with disodium edetate than without it
  2782. 5-HT4 receptor-mediated Neuroprotection and neurogenesis in the enteric nervous system of adult mice
  2783. Potential Neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole
  2784. Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1α truncation
  2785. Progesterone blocks estrogen Neuroprotection from kainate in middle-aged female rats
  2786. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate
  2787. Neuroprotection by oxygen in acute transient focal cerebral ischemia is dose dependent and shows superiority of hyperbaric oxygenation
  2788. Mitochondrial Ca 2+ overload underlies Aβ oligomers neurotoxicity providing an unexpected mechanism of Neuroprotection by NSAIDs
  2789. A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides Neuroprotection
  2790. Neuroprotection of GluR5-containing kainate receptor activation against ischemic brain injury through decreasing tyrosine phosphorylation of N-methyl-D …
  2791. Functional characterization of basic helix-loop-helix-PAS type transcription factor NXF in vivo: putative involvement in an “on demand” Neuroprotection system
  2792. Extraluminal cooling of bilateral common carotid arteries as a method to achieve selective brain cooling for Neuroprotection
  2793. Proteomic analysis of differential proteins related to the neuropathic pain and Neuroprotection in the dorsal root ganglion following its chronic compression in rats
  2794. Delta2‐Specific Opioid Receptor Agonist and Hibernating Woodchuck Plasma Fraction Provide Ischemic Neuroprotection
  2795. Role of Dickkopf-1, an antagonist of the Wnt/β-catenin signaling pathway, in estrogen-induced Neuroprotection and attenuation of tau phosphorylation
  2796. Toll‐like receptor 4 is involved in Neuroprotection afforded by ischemic preconditioning
  2797. Allele-specific RNA silencing of mutant ataxin-3 mediates Neuroprotection in a rat model of Machado-Joseph disease
  2798. Neuroprotection by cell permeable TAT-mGluR1 peptide in ischemia: synergy between carrier and cargo sequences
  2799. Atorvastatin enhances hypothermia-induced Neuroprotection after stroke
  2800. Non-conventional MRI techniques for measuring Neuroprotection , repair and plasticity in multiple sclerosis
  2801. Repeated preconditioning with hyperbaric oxygen induces Neuroprotection against forebrain ischemia via suppression of p38 mitogen activated protein kinase
  2802. Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes Neuroprotection and neurite elongation through protein …
  2803. Progesterone, BDNF and Neuroprotection in the injured CNS
  2804. Role of melatonin receptors in the effects of melatonin on BDNF and Neuroprotection in mouse cerebellar neurons
  2805. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons
  2806. CT-guided radiofrequency ablation of spinal osteoid osteomas with concomitant perineural and epidural irrigation for Neuroprotection
  2807. In vivo Neuroprotection by a creatine-derived compound: Phosphocreatine–Mg-complex acetate
  2808. Pharmacological inhibition of mitochondrial membrane permeabilization for Neuroprotection
  2809. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of Neuroprotection
  2810. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy
  2811. Stereo-selective Neuroprotection against stroke with vitamin A derivatives
  2812. Neuroprotection in Parkinson’s disease: myth or reality?
  2813. Oxidative insults induce DJ-1 upregulation and redistribution: implications for Neuroprotection
  2814. Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and allopregnanolone Neuroprotection is associated with GABAA receptor …
  2815. Growth hormone‐induced Neuroprotection in the neural retina during chick embryogenesis
  2816. Mechanism of Neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil
  2817. Parameters of optic nerve electrical stimulation affecting Neuroprotection of axotomized retinal ganglion cells in adult rats
  2818. Essential involvement of the NMDA receptor in ethanol preconditioning‐dependent Neuroprotection from amyloid‐βin vitro
  2819. Retinal Neuroprotection by hypoxic preconditioning is independent of hypoxia‐inducible factor‐1α expression in photoreceptors
  2820. Species‐dependent Neuroprotection by activated protein C mutants with reduced anticoagulant activity
  2821. The 2007 Feinberg lecture: a new road map for Neuroprotection
  2822. Unconventional neurotransmitters, neurodegeneration and Neuroprotection
  2823. DNA damage response and Neuroprotection
  2824. Partial Neuroprotection with low-dose infusion of the α2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep
  2825. Estrogen receptor-mediated Neuroprotection : The role of the Alzheimer’s disease-related gene seladin-1
  2826. Can overexpression of parkin provide a novel strategy for Neuroprotection in Parkinson’s disease?
  2827. Cannabinoids, multiple sclerosis and Neuroprotection
  2828. Activity of adenosine receptors type 1 is required for CX3CL1-mediated Neuroprotection and neuromodulation in hippocampal neurons
  2829. Estrogen receptor-independent Neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation
  2830. Neuroplasticity and Neuroprotection in enteric neurons: role of epithelial cells
  2831. How to study Neuroprotection ?
  2832. A pivotal role for interleukin-4 in atorvastatin-associated Neuroprotection in rat brain
  2833. Induced Neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin
  2834. Oxygen-conserving implications of the trigemino-cardiac reflex in the brain : the molecular basis of Neuroprotection ?
  2835. Multiple molecular pathways are involved in the Neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo
  2836. Neuroprotection of soyabean isoflavone co-administration with folic acid against β-amyloid 1-40-induced neurotoxicity in rats
  2837. Neuroprotection by rasagiline in thiamine deficient rats
  2838. Withdrawal of fenofibrate treatment partially abrogates preventive Neuroprotection in stroke via loss of vascular protection
  2839. Neuroprotection against excitotoxic brain injury in mice after ovarian steroid depletion
  2840. Neuroprotection : still achievable in humans
  2841. Microglial inhibition of Neuroprotection by antagonists of the EP1 prostaglandin E2 receptor
  2842. Neuroprotection and enhancement of spatial memory by herbal mixture HT008-1 in rat global brain ischemia model
  2843. New avenue of research: antiepileptic drug and estradiol Neuroprotection in epilepsy
  2844. Morphine: axon regeneration, Neuroprotection , neurotoxicity, tolerance, and neuropathic pain
  2845. Inhibition of PKCgamma membrane translocation mediated morphine preconditioning-induced Neuroprotection against oxygen–glucose deprivation in the …
  2846. The Neuroprotection of prodromal transient ischaemic attack on cerebral infarction
  2847. Mechanisms of DJ‐1 Neuroprotection in a cellular model of Parkinson’s disease
  2848. … oxygen-glucose deprivation: the role of adenosine triphosphate dependent potassium channels and reactive oxygen species in sevoflurane-induced Neuroprotection
  2849. Sodium channel blockers and Neuroprotection in multiple sclerosis using lamotrigine
  2850. Clearing the brain ‘s cobwebs: the role of autophagy in Neuroprotection
  2851. Endothelial nitric oxide synthase overexpression by neuronal cells in neurodegeneration: a link between inflammation and Neuroprotection
  2852. Therapeutic potential of statins in multiple sclerosis: immune modulation, Neuroprotection and neurorepair
  2853. Sirtuin 1 overexpression mice show a reference memory deficit, but not Neuroprotection
  2854. Strategies for Neuroprotection following spinal cord injury.
  2855. Microglial involvement in Neuroprotection following experimental traumatic brain injury in heat-acclimated mice
  2856. Prevention of glutamate accumulation and upregulation of phospho‐akt may account for Neuroprotection afforded by bergamot essential oil against brain injury …
  2857. Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells
  2858. Antenatal magnesium sulfate for Neuroprotection before preterm birth?
  2859. PRO: Temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2860. Linkage between immunomodulation, Neuroprotection and neurogenesis
  2861. Neuroprotection of hypothermia against neuronal death in rat hippocampus through inhibiting the increased assembly of GluR6‐PSD95‐MLK3 signaling module …
  2862. High-dose propofol triggers short-term Neuroprotection and long-term neurodegeneration in primary neuronal cultures from rat embryos
  2863. Inhaled nitric oxide and Neuroprotection in preterm infants
  2864. Interleukin-6 upregulates neuronal adenosine A 1 receptors: implications for neuromodulation and Neuroprotection
  2865. PHYTOMEDICINES FOR Neuroprotection
  2866. Patents related to therapeutic activation of KATP and K2P potassium channels for Neuroprotection : ischemic/hypoxic/anoxic injury and general anesthetics
  2867. Neuroprotection in Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical findings
  2868. Study of red wine Neuroprotection on astrocytes
  2869. Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation–induced apoptosis involves the Akt pathway and inhibition of cell …
  2870. Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95
  2871. Pharmacology of Neuroprotection in acute ischemic stroke
  2872. The endocannabinoid anandamide: from immunomodulation to Neuroprotection . Implications for multiple sclerosis
  2873. Patterned Neuroprotection in the Inpp4awbl mutant mouse cerebellum correlates with the expression of Eaat4
  2874. Neuroprotection in diabetic encephalopathy
  2875. Repeated exposure to MDMA provides Neuroprotection against subsequent MDMA-induced serotonin depletion in brain
  2876. Effects of simvastatin on Neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington’s disease
  2877. Xenon/hypothermia Neuroprotection regimes in spontaneously breathing neonatal rats after hypoxic-ischemic insult: the respiratory and sedative effects
  2878. Lack of Neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions
  2879. Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced Neuroprotection in the mouse model of surgical brain injury
  2880. The continued promise of Neuroprotection for acute stroke treatment
  2881. CON: Temperature regimens and Neuroprotection during cardiopulmonary bypass: does rewarming rate matter?
  2882. Glaucoma: an open-window to neurodegeneration and Neuroprotection
  2883. Redox activated MAP kinase death signaling cascade initiated by ASK1 is not activated in female mice following MPTP: novel mechanism of Neuroprotection
  2884. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances Neuroprotection from moderate but not severe hypoxia–ischemia
  2885. Hypoxia‐induced deactivation of NGF‐mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl‐L‐carnitine
  2886. Estrogens and Neuroprotection in retinal diseases
  2887. Acute Neuroprotection to pilocarpine-induced seizures is not sustained after traumatic brain injury in the developing rat
  2888. Neuron‐microglia crosstalk up‐regulates neuronal FGF‐2 expression which mediates Neuroprotection against excitotoxicity via JNK1/2
  2889. Neuroprotection of preconditioning against ischemic brain injury in rat hippocampus through inhibition of the assembly of GluR6—PSD95—mixed lineage kinase 3 …
  2890. … advanced glycation end products‐inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and Neuroprotection by UK‐14,304
  2891. Estrogen receptors increased expression during hippocampal Neuroprotection in lactating rats
  2892. Nicotine attenuates iNOS expression and contributes to Neuroprotection in a compressive model of spinal cord injury
  2893. Additive Neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson’s model
  2894. Role of prions in Neuroprotection and neurodegeneration: a mechanism involving glutamate receptors?
  2895. Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the Neuroprotection after embolic stroke
  2896. New possibilities of Neuroprotection in the treatment of ischemic stroke
  2897. … -ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not Neuroprotection
  2898. Neuroprotection Against Transient Focal Cerebral Ischemia and Oxygen–Glucose Deprivation by Interference with GluR6-PSD95 Protein Interaction
  2899. Hypothermia-induced increase in galanin concentrations and ischemic Neuroprotection in the rat brain
  2900. Neuroprotection in infant heart surgery
  2901. Effect of endoplasmic reticulum stress in VEGF-induced Neuroprotection
  2902. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced Neuroprotection of the injured nigrostriatal system in the murine …
  2903. Glaucoma as a neuropathy amenable to Neuroprotection and immune manipulation
  2904. Fibroblast growth factor 9 prevents MPP+‐induced death of dopaminergic neurons and is involved in melatonin Neuroprotection in vivo and in vitro
  2905. Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: implications for estrogen Neuroprotection in HIV dementia
  2906. Optimal dose of aprotinin for Neuroprotection and renal function in a piglet survival model
  2907. Huperzine A provides Neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death
  2908. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and Neuroprotection
  2909. Granulocyte-colony stimulating factor is involved in low-dose LPS-induced Neuroprotection
  2910. … mouse striatum and its modulation in 1-methyl 4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease phenotype and nicotine-mediated Neuroprotection
  2911. Neuroprotection with delayed calpain inhibition after transient forebrain ischemia
  2912. Activation of NF-κB p65/c-Rel dimer is associated with Neuroprotection elicited by mGlu5 receptor agonists against MPP+ toxicity in SK-N-SH cells
  2913. Neuroprotection in glaucoma using calpain-1 inhibitors: regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for …
  2914. Neuroprotection of ethanol against cerebral ischemia/reperfusion induced brain injury through GABA receptor activation
  2915. Cyclic adenosine monophosphate response element-binding protein phosphorylation and Neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP)
  2916. Use of induced hypothermia for Neuroprotection : indications and application
  2917. Neuroprotection by herbal formula FBD and its active compounds
  2918. Neuroprotection and neurotrophism effects of liquiritin on primary cultured hippocampal cells
  2919. Basal ganglia Neuroprotection with anticonvulsants after energy stress: a comparative study
  2920. Regulation of interleukin-1β by the interleukin-1 receptor antagonist in the glutamate-injured spinal cord: endogenous Neuroprotection
  2921. It’s all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke Neuroprotection
  2922. Magnesium sulfate for Neuroprotection : what do we do now?
  2923. Bis (7)-tacrine, a promising anti-Alzheimer’s dimer, affords dose-and time-dependent Neuroprotection against transient focal cerebral ischemia
  2924. Quantitative evaluation of chaperone activity and Neuroprotection by different preparations of a cell-penetrating Hsp70
  2925. Combinatorial-approached Neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is …
  2926. Potential of choroid plexus epithelial cell grafts for Neuroprotection in Huntington’s disease: what remains before considering clinical trials
  2927. Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated Neuroprotection
  2928. Use of endovascular clamping as Neuroprotection during carotid stenting in the presence of a critical ipsilateral stenosis of the external carotid artery.
  2929. Neuroprotection and enhanced neurogenesis by extract from the tropical plant Knema laurina after inflammatory damage in living brain tissue
  2930. Aprotinin confers Neuroprotection by reducing excitotoxic cell death
  2931. Sirt1’s complex roles in Neuroprotection
  2932. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic Neuroprotection
  2933. NMDA preconditioning and Neuroprotection in vivo: delayed onset of kainic acid-induced neurodegeneration and c-Fos attenuation in CA3a neurons
  2934. … a novel anilidoquinoline derivative, 2-(2-methyl-quinoline-4ylamino)-N-(2-chlorophenyl)-acetamide, in Japanese encephalitis: correlation with in vitro Neuroprotection
  2935. Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to Neuroprotection in a mouse model of …
  2936. Co-application of ischemic preconditioning and postconditioning provides additive Neuroprotection against spinal cord ischemia in rabbits
  2937. Neonatal hypertonia: II. Differential diagnosis and proposed Neuroprotection
  2938. Sulfhydryl oxidation: A potential strategy to achieve Neuroprotection during severe hypoxia?
  2939. PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent Neuroprotection in ER stress-induced cell death
  2940. Neuroprotection by neurotrophic factors and membrane depolarization is regulated by calmodulin kinase IV
  2941. Implication of pituitary adenylate cyclase-activating polypeptide (PACAP) for Neuroprotection of nicotinic acetylcholine receptor signaling in PC12 cells
  2942. Neurolological disorders and Neuroprotection after heart surgery
  2943. Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses
  2944. Ischemic postconditioning induces Neuroprotection via up-regulation of endogenous antioxidant enzyme activities: experiment with rabbits
  2945. Moderate alcohol consumption, apolipoprotein E, and Neuroprotection
  2946. Acetaminophen confers Neuroprotection during early cerebral ischemia-reperfusion
  2947. A secretory phospholipase A 2-mediated Neuroprotection and anti-apoptosis
  2948. Sevoflurane preconditioning induced delayed Neuroprotection against focal cerebral ischemia in rats
  2949. Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not Neuroprotection
  2950. Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 β inhibitor produces long-term Neuroprotection in a hypoxia-ischemia …
  2951. … inducer of cellular glutathione and NAD (P) H: quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic Neuroprotection
  2952. Melatonin and its therapeutic potential in Neuroprotection
  2953. Flow reversal for proximal Neuroprotection during endovascular management of critical symptomatic carotid artery stenosis coexisting with ipsilateral external carotid …
  2954. HIF‐1 alpha is an essential effector for purine nucleoside‐mediated Neuroprotection against hypoxia in PC12 cells and primary cerebellar granule neurons
  2955. … strychnine-sensitive glycine receptors modulate N-methyl-d-aspartate–evoked acetylcholine release from rat spinal motoneurons: A possible role in Neuroprotection
  2956. Targeting β2-adrenoceptors for Neuroprotection after cerebral ischemia: is inhibition or stimulation best?
  2957. 5th Annual Global College of Neuroprotection and Neuroregeneration
  2958. Neuroprotection against staurosporine by metalloporphyrins independent of antioxidant capability
  2959. … of some urea and thiourea derivatives of naphtha [1, 2-d] thiazol-2-amine as anti-Parkinsonian agents that cause Neuroprotection against haloperidol-induced …
  2960. Anesthetic drugs and sustained Neuroprotection in acute cerebral ischemia: can we alter clinical outcomes?
  2961. Neuroprotection of microglia conditioned media from apoptotic death induced by staurosporine and glutamate in cultures of rat cerebellar granule cells
  2962. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and Neuroprotection
  2963. The impact of astrocyte mitochondrial metabolism on Neuroprotection during aging
  2964. Hsp70 and Neuroprotection [J]
  2965. Does postmenopausal estrogen use confer Neuroprotection ?
  2966. Research progress of protein kinase C in Neuroprotection
  2967. Nitrous oxide: From neurotoxicity to Neuroprotection ?
  2968. p42/44 MAPK is an essential effector for purine nucleoside-mediated Neuroprotection of hypoxic PC12 cells and primary cerebellar granule neurons
  2969. Effective delivery of Pep-1-cargo protein into ischemic neurons and long-term Neuroprotection of Pep-1-SOD1 against ischemic injury in the gerbil hippocampus
  2970. Neuroprotection in stroke.
  2971. Neuroprotection in Parkinson’s disease: analysis though group of experts’ methodology
  2972. Current trends in glaucoma: what about Neuroprotection ?
  2973. Anesthetic-induced Neuroprotection : a review
  2974. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring Neuroprotection in experimental focal cerebral ischemia in the rat
  2975. Modulation of innate immunity by copolymer‐1 leads to Neuroprotection in murine HIV‐1 encephalitis
  2976. Neuroprotection for Parkinson’s disease: clinically driven experimental design in non-human primates
  2977. 6th Global College of Neuroprotection and Neuroregeneration, annual meeting
  2978. Management of acute stroke: Neuroprotection
  2979. Advancement of therapies for Neuroprotection in multiple sclerosis
  2980. Neuroprotection from diazinon-induced toxicity in differentiating murine N2a neuroblastoma cells
  2981. Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio-and Neuroprotection
  2982. Exploratory analysis about Neuroprotection after ischemic stroke.
  2983. La Neuroprotection est-elle à portée de main?
  2984. Neuroprotection : is it close to us?
  2985. Surgical strategies for Neuroprotection during ascending aortic and arch surgery
  2986. Sustained delivery of NT‐3 from lens fiber cells in transgenic mice reveals specificity of Neuroprotection in retinal degenerations
  2987. Perioperative strategy of Neuroprotection
  2988. Glaucoma Neuroprotection –how far is it from a dream to reality
  2989. Preconditioning with+ Gz acceleration (head-to-foot inertial load) produces Neuroprotection against transient focal cerebral ischemia in rats
  2990. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors
  2991. Antioxidant therapy and Neuroprotection in the newborn
  2992. Neuroprotection of antipsychotic olanzapine [J]
  2993. Perinatal brain damage: from pathogenesis to Neuroprotection
  2994. Neuroprotection of venlafaxine and fluoxetine [J]
  2995. Cannabinoids and Neuroprotection
  2996. Selective over expression of EAAT2 in astrocytes enhances Neuroprotection from moderate but not severe hypoxia-ischemia
  2997. Neuroprotection against ischemic brain injury by knockdown of hematopietic progenitor kinase 1 expression
  2998. The Neuroprotection of kappa opioid receptor agonist BRL52537 is partly through enhancing endogenous GABA function
  2999. Neuroprotection in Glaucoma
  3000. Endogenous Neuroprotection
  3001. Targeting immunophilins for Neuroprotection
  3002. brain damage from soman-induced seizures is greatly exacerbated by dimethyl sulfoxide (DMSO): Modest Neuroprotection by 2-aminoethyl diphenylborinate (2-APB) …
  3003. Neuroprotection in epilepsy: the role of antiepileptic drugs
  3004. The role of Neuroprotection in schizophrenia
  3005. Potential mechanisms of Neuroprotection induced by low dose total-body γ-irradiation in C57 mice administered with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine …
  3006. Neuroprotection with hypothermia for hypoxic ischemic encephalopathy in term newborn: review of the learning
  3007. Kynurenines and Neuroprotection
  3008. Neuroprotection , Neuronal Remodelling, and Anxiety-Like Behavior: The Role of the Teneurin and Teneurin C-Terminal Associated Peptide (TCAP) System in the …
  3009. Neuroprotection using hypothermia after perinatal asphyxia in full-term neonates
  3010. Antioxidants: promising Neuroprotection against cardiotoxin-4b-induced cell death which triggers oxidative stress with early calpain activation
  3011. 11 Adenosine Neuromodulation and Neuroprotection
  3012. Neurodegeneration and Neuroprotection in the epileptic brain
  3013. The future of Neuroprotection in glaucoma therapeutics
  3014. Effect of VEGF-B on Neuroprotection in mouse retinal ganglion cells
  3015. Neuronal and astrocytic mitochondrial dynamics as vulnerability factors and targets for Neuroprotection
  3016. Neuroprotection of sevoflurane against the ischemia injury in hippocampal slices of rat
  3017. Neuroprotection : Pharmacological Approaches
  3018. Neuroprotection of phenolic alkaloids from Menispermum dauricum versus melatonin against oxygen-glucose-serum-deprivation-mediated injury*☆
  3019. Ocular delivery of TUDCA provides Neuroprotection in a mouse model of retinal degeneration
  3020. Neuroprotection against surgically induced brain injury
  3021. Neuroprotection of GST, an extract of traditional Chinese herb, against ischemic brain injury induced by transient brain ischemia and reperfusion in rat hippocampus
  3022. Neuroprotection of recombinant human erythropoietin via modulation of N-methyl-D-aspartate receptors in neonatal rats with hypoxic-ischemic brain injury
  3023. Diagnosis and treatment strategy for Neuroprotection with combined tcm and western medicine in the early stage of Parkinson’s disease
  3024. Lewy body formation in Parkinson’s disease: neurodegeneration or Neuroprotection ?
  3025. Neuroprotection Against Neurodegenerative Diseases: Development of a Novel Hybrid Neuroprotective Peptide Colivelin
  3026. Neurodegeneration and Neuroprotection in multiple sclerosis
  3027. α-Synuclein, CSPα, SNAREs and Neuroprotection in vivo
  3028. Experimental studies on hypoxic preconditioning-induced Neuroprotection against focal ischemic injury of mice and its p38 MAPK mechanism
  3029. Neuroprotection by angiotensin receptor blockers?
  3030. Neuroprotection –DO AEDS PROTECT THE brain ?(NO)
  3031. Intraoperative neuromonitoring, Neuroprotection and preventive carotid endarterectomy in patients with increased risk for development of cerebral ischemia indicated …
  3032. D. Neuroprotection in the PICU
  3033. Preclinical versus clinical Neuroprotection
  3034. Antenatal Magnesium Sulfate for Neuroprotection Before Preterm Birth?
  3035. Deprenyl and its metabolites in Neuroprotection
  3036. Akt activation mediates estrogen-induced Neuroprotection against beta amyloid
  3037. Valproic acid-mediated Neuroprotection and neuroregeneration in optic nerve injury is associated with CREB-induction and activation of pERK1/2
  3038. IGF-I and Neuroprotection
  3039. Advantages of MRI study of normobaric hyperoxia therapy in stroke Neuroprotection
  3040. The Underlying Mechanism (s) of Fasting Induced Neuroprotection After Moderate Traumatic brain Injury
  3041. The time‐dependency of post‐conditioning for Neuroprotection against global cerebral ischemia and reperfusion injury in C57BL/6 mice
  3042. Application of induced hypothermia for Neuroprotection after cardiac arrest: a systematic review
  3043. Neuroprotection of Extraction of Gastrodia Elata for Status Epilepticus Induced by Li-Pilocarpin
  3044. Neuroprotection and Glaucoma.
  3045. Experimental Study of Different Perfusion Methods and Neuroprotection during Deep Hypothermic Circulatory Arrest [J]
  3046. The PERG as a Useful Tool in Demonstrating Functional Neuroprotection in the Mouse
  3047. Neuroprotection in spinal cord injury
  3048. Molecular mechanisms of Neuroprotection in the anoxia tolerant freshwater turtle
  3049. A Model of Sporadic Parkinson’s Disease: Herbicide Induced Parkinson’s Disease in Rat and Neuroprotection by Water Soluble CoQ10
  3050. Non-Amyloid Approaches to Neuroprotection
  3051. CRMP-2 were involved in hypoxic preconditioning-induced Neuroprotection against cerebral ischemic injuries of mice
  3052. Neuroprotection Effect of Aspirin on Neuron Apoptosis Following Chronic Spinal Cord Compressive Injury in Rats [J]
  3053. Neuroprotection against hyperhomocysteinemia-induced selective oxidative stress in brain regions of rats with folic acid or Dioscorea alata supplementation.
  3054. Abstract P28: Early Antioxidant Treatment Does Not Provide Additive Neuroprotection with Delayed Hypothermia after Asphyxic Cardiac Arrest in Newborn Pigs
  3055. … MOLECULAR CHAPERONE HSP90 IN THE HIPPOCAMPAL CA1 NEURONS―A POSSIBLE MECHANISM OF Neuroprotection BY ANGIOTENSIN RECEPTOR …
  3056. Neuroprotection Effect of Fufang Shexiang Injection in Neonates with Hypoxic Ischemic Encephalopathy
  3057. Neuroprotection of Lidocaine by Injecting into Cisterna Magna in a Rabbit Model of Subarachnoid Hemorrhage [J]
  3058. Strategies for ischemic Neuroprotection : learning from mice
  3059. Neuroprotection by DJNKI1 following seizure activity.
  3060. Clinical Neuroprotection and secondary neuronal injury mechanisms
  3061. Downstream signaling of reactive oxygen species, protein kinase C epsilon translocation and delayed Neuroprotection in sevoflurane preconditioned rats following …
  3062. Neuroprotection via activation of glutamate dehydrogenase against cerebral ischemia and reperfusion
  3063. Neuroprotection Against Ischemia-Reperfusion Injury in the Rat Retina by Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Type 1 Receptor Blocker
  3064. Identification of protein markers of Neuroprotection from radiation
  3065. Statins linked with Neuroprotection
  3066. Induced Hypothermia for Neuroprotection Following
  3067. Functional and molecular partitioning of the brain provides Neuroprotection to cardiorespiratory nuclei in ground squirrels during hibernation
  3068. Neuroprotection During Cerebral Aneurysm Surgery
  3069. Protein Kinase C Subytpes and Mechanisms of Endogenous Neuroprotection
  3070. Docosahexaenoic acid Confers Neuroprotection in a Rat Model of Perinatal Hypoxia-ischemia potentiated by E. coli lipopolysaccharide-induced systemic …
  3071. Neuroprotection of Optic Nerve in Glaucoma
  3072. Neuroprotection of adenovirus expressing glutamic acid receptor c-terminal peptide in rat hippocampal CA1 region during brain ischemia and reperfusion
  3073. Redox-Based Therapies for Neuroprotection
  3074. Pharmacological Neuroprotection for spinal cord injury
  3075. Erratum: Neuroprotection and Enhancement of Learning and memory by BF-7 [J. Health Sci. 51 (3): 317-324 (2005)]
  3076. Granolocyte-macrophage clony-stimulating factor and Neuroprotection
  3077. A computational investigation of FTY720P-mediated Neuroprotection in multiple sclerosis
  3078. Neuroprotection of PROG in rat acute ocular hypertention model
  3079. Traumatic Optic Neuropathy: Recommendations and Neuroprotection
  3080. Angiotensin Ⅱ Receptor Blockers and Neuroprotection
  3081. The brain innate immune response in Neuroprotection and repair
  3082. Wnt signaling in Neuroprotection and stem cell differentiation
  3083. EXCITOXIC brain DAMAGE IN CHILDREN WITH EPILEPSY AND POTENTIAL OF Neuroprotection
  3084. Hypothesis-based Screening of Candidate miRNAs in Dopaminergic Neuroprotection
  3085. Mechanisms of Estrogen Receptor Neuroprotection in Dopamine Neurons
  3086. Hypothermia therapy, Neuroprotection and meaningful brain recovery
  3087. Contribution of GDNF to the Estrogen-mediated Neuroprotection
  3088. Apolipoprotein E, hormone therapy, and Neuroprotection
  3089. CD4 T cell‐mediated Neuroprotection : Relevence to ALS and Motoneuron Injury
  3090. 10 Free Radicals and Neuroprotection in Traumatic brain and Spinal Cord Injury
  3091. Molecular mechanisms of Neuroprotection by the herpes simplex virus type 2 gene ICP10PK
  3092. STUDY ON THE Neuroprotection EFFECT OF MAGNESIUM SULFATE ON GLOBAL ISCHEMIA IN RABBITS [J]
  3093. Neuroprotection induced by the adenosine A1-receptor and IL-6: Do they use the same mechanisms?
  3094. Neuroinffammation in spinal cord injury: therapeutic targets for Neuroprotection and regeneration
  3095. Pharmacological Neuroprotection of Photoreceptors in Vigabatrin-Treated Animals
  3096. The role of standardized Mangifera Indica L. leaf extracts in antioxidation and Neuroprotection
  3097. Neuroprotection by hypoxic preconditioning: the role of HIF-1α
  3098. Neuroprotection of Vegf-b by Inhibition of Apoptosis
  3099. Neuroprotection as a treatmeNt for Nerve ageNt survivors
  3100. Study on the Neuroprotection effect of magnesium sulfate on global ischemia in rabbits.
  3101. Evoluation on Neuroprotection of Memantine in acute elevated IOP
  3102. Role of phosphorylation events in Neuroprotection due to ethanol preconditioning
  3103. The Neuroprotection of fusion protein TAT-Flip in MCAO mice models
  3104. The Neuroprotection of Monosialoganglioside on the Middle Cerebral Artery Occlusion Reperfusion in Rats [J]
  3105. Emphasizes the research of diabetic retinal neurons lesions and retinal Neuroprotection
  3106. Neuroprotection by erythropoetin and Darbopoetin-alfa following experimental intracerebral haemorrhage: P 038
  3107. Erythropoietin for Neuroprotection in preterm infants: feasiblity and safety study
  3108. The study of Neuroprotection about erythropoietin on traumatic brain injury in rats
  3109. Pathological study on the Neuroprotection of memantine against cerebral ischemia in SD rats
  3110. Study on the Neuroprotection of HSP72 during brain injury induced by ischemia
  3111. Angiotensin AT2 Receptor-Mediated Neuroprotection and Nitric Oxide–Bioavailability in Stroke
  3112. Survival Pathways Downstream Cyclic Bright Light-Induced Endogenous Neuroprotection
  3113. FGF2, Müller Glia and Neuroprotection in the Chicken Retina
  3114. Neuroprotection by delayed high dose Aspirin treatment in cerebral ischemia
  3115. Toll like receptors in the central nervous system regulators of inflammation, Neuroprotection , development and repair
  3116. Regulation of microvascular endothelial barrier function: a new mechanism for Neuroprotection of statins
  3117. Estrogen, progesterone and BDNF interactions: Roles in Neuroprotection
  3118. Neuroprotection of Laser-Injured Retina by Intravitreal Saline Injection
  3119. Neuroprotection by Leukemia Inhibitory Factor Does Not Require Reduced Phototransduction
  3120. Neuroprotection of Copolymer 1 in glaucoma rats with elevated intraocular pressure
  3121. Effect of Maleate on Blood Scavenging Activity and Neuroprotection in Closed Head Injury in Rats
  3122. Ultrasound-Controlled Therapeutic Gas Delivery Provides Enhanced Neuroprotection Following Hypoxic-Ischemia
  3123. Comparative Neuroprotection of different-dose Lidocaine by injecting into in a rabbit model of subarachnoid hemorrhage
  3124. Neuroprotection of mild brain hypothermia against cerebral ischemic injury
  3125. Uncovering the molecular mechanisms of ischemic tolerance—the role of ATP in depolarization-induced Neuroprotection
  3126. Targeting Cytokine Systems to Achieve Neuroprotection : Experimental Models of Seizures and Neurodegeneration
  3127. No Neuroprotection Afforded by the Noble Gases Neon, Argon and Krypton In Vitro.
  3128. FK506 Binding Protein 51 (FKBP51) mediated Neuroprotection against glutamate excitotoxicity in RGC-5 cells
  3129. Neuroprotection for Acute Spinal Cord Injury-Comparison of Simvastatin and Atorvastatin
  3130. Strategies of Neuroprotection in an in vivo model of retinal degeneration induced by mitochondrial dysfunction
  3131. Flavonoids and Neuroprotection : biochemical and population-based analyses of potential Neuroprotective factors related to dementia.
  3132. Fluocinolone Acetonide-Mediated Neuroprotection in S334-ter-4 Rat Retinal Degeneration
  3133. Cellular Mechanisms for Motor Stimulation and Neuroprotection by A2A Antagonists in PD Model
  3134. Full retraction of Kumar DM, Simpkins JW, Agarwal N. Estrogens and Neuroprotection in retinal diseases. Mol Vis. 2008; 14: 1480-6. Review.
  3135. T cell-mediated Neuroprotection in the injured central nervous system: Gaining insight with the facial nerve axotomy model
  3136. Endogenous Neuroprotection Induced by STAT3 Activation Is Independent of Akt or FGF2
  3137. Androgen-Androgen Receptor Signaling Provides Dose-Dependent Neuroprotection In the Male brain
  3138. Estradiol regulation of cerebral metabolism: Implications for Neuroprotection and mitochondrial bioenergetics
  3139. Excitotoxicity, oxidative stress and Neuroprotection in cerebellar granule neurones
  3140. Strategies for Conferring Neuroprotection and Countering the High Threshold for Induction of the Stress Response in Motor Neurons
  3141. Mitochondrial ATP-sensitive potassium-channel: A novel target of Neuroprotection in cerebral hypoperfusion
  3142. Parameters of optic nerve electrical stimulation affecting Neuroprotection of axotomized retinal ganglion cells in adult rats
  3143. Molecular Analysis of Neuroprotection of Photoreceptor Neurons by RanBP2 Haploinsufficiency Upon Light-Induced Damage
  3144. Müller Cell/Microglia Interactions in CNTF-Mediated Photoreceptor Neuroprotection
  3145. … , ZK238519 and ZK166350: comparison of different potent antagonists of AMPA-type glutamate receptor channels and their potential role for Neuroprotection
  3146. Neuroprotection of dexamethasone prophylaxis on brain damage in neonatal rat with hypoxia-ischemia [J]
  3147. Lovastatin-mediated in vivo Neuroprotection against excitotoxicity is PKB/Akt dependent
  3148. Alpha 7 nicotinic acetylcholine receptors: Molecular pharmacology and role in Neuroprotection
  3149. Neuroprotection from inflammation: Experimental allergic encephalomyelitis facilitates traumatic spinal cord injury recovery
  3150. Human umbilical cord blood collagen-adherent, nestin-positive neurological progenitors mediate Neuroprotection in an oxidative stress-induced ischaemic model
  3151. Molecular mechanisms underlying the Neuroprotection of novel anti-Alzheimer dimers targeting pathologically activated NMDA receptors
  3152. Investigation of neurodevelopment, degeneration and polyphenol induced Neuroprotection in Nothobranchius furzeri.
  3153. Physiological and Biochemical Neuroprotection in Cetaceans: Are Some Marine Mammal Species Safeguarded From Emboli Formation and Barotrauma
  3154. Gene silencing as a promising strategy for Neuroprotection : on the development of a lipid-based system for the delivery of siRNAs to he central nervous system
  3155. Formulation and Characterization of N-Acetyl Cysteine Loaded PLGA Nanoparticles for Neuroprotection to Retinal Ganglion Cells in an in vitro Model of …
  3156. Minocycline reveals Neuroprotection in an accelerated rhesus macaque model of neuroAIDS by 1H MR Spectroscopy
  3157. Strong Neuroprotection by Inhibition of NF-B After Neonatal Hypoxia-Ischemia Involves Apoptotic Mechanisms but Is Independent of Cytokines
  3158. 1H-magnetic resonance spectroscopy of vascular endothelial growth factor-induced Neuroprotection following acute cerebral ischemia and reperfusion***☆
  3159. SB220025 a p38 inhibitor mediates Neuroprotection by inhibiting transcriptional activation and apoptosis in focal cerebral ischemia
  3160. US Army Battlefield Exercise and Combat Related Spinal Cord Injury Research: Neuroprotection and Repair After Spinal Cord Injury. Addendum
  3161. Neuroprotection and neuroplasticity–A short consensus of the concepts: Clinical utility of neurotrophic factor therapy (cerebrolysin) in VaD–Data from a new pilot …
  3162. Neuroprotection effect of Ginsenoside Rb1 and geniposide in rat cultured hippocampal neurons
  3163. Prolonged Neuroprotection of Degenerating Photoreceptors in the S334ter4 rat Retina via Single Intravitreal Injection of Mouse Embryonic Stem Cells Expressing a …
  3164. Interactions of neurons, astrocytes and microglia with HUCB cell populations in stroke models: Migration, Neuroprotection and inflammation
  3165. The Retinal Toxicity of the Antiepileptic Drug, Vigabatrin: In vivo Examination of Retinal Lesions and Pharmacological Neuroprotection
  3166. … PURE OXYGEN VS ROOM-AIR DOWN-REGULATES VEGFR2 AND HIF-1ALPHA IN NEWBORN PIGLETS RETINA AND MAY INDICATE LESS Neuroprotection
  3167. CD4+ T cell responses and the role of IL-10 in T cell-mediated Neuroprotection after facial nerve axotomy
  3168. P3. 065 Nimesulide, a preferential cyclooxygenase-2 inhibitor exhibits Neuroprotection against MPTP-induced striatal lesions in rats: behavioral, biochemical, cellular …
  3169. Preconditioning and postconditioning exert stroke Neuroprotection modulating NCX and ASIC1a expression
  3170. … Neurotrophic Factors, Their Receptors, and Signalling Pathways with Small Molecule Mimetics and Modulators to Achieve Neuroprotection and Regeneration Guest …
  3171. Nicotine Attenuates Both iNOS and nNOS Involved Antioxidative Effects and Contributes to Neuroprotection in Spinal Cord Injury
  3172. Lithium Radioprotection of Hippocampal Neurons: Promotion of NHEJ DNA Repair and Reversal of Neuroprotection with DNA-PK Inhibition
  3173. Lowered set‐point for hypothalamic temperature regulation alters hippocampal activity and may enhance Neuroprotection in hibernating hamsters
  3174. Age-Dependent Neuroprotection of Retinal Ganglion Cells by Tempol C8-acyl Ester in a Rat NMDA Toxicity Model
  3175. Neuroprotection BY 3-(METHYLTHIO)–5, 6–DI-(4–METHOXYPHENYL)–1, 2, 4-TRIAZINE AGAINST OXIDATIVE-INDUCED CELL DEATH: INVOLVEMENT OF …
  3176. Effects of Age-Inductor Glyoxal and H2O2 As Oxidative Stress Factors on Rat Retinal Organ Cultures and Neuroprotection by Brimonidine
  3177. … relevant proteins in neuronal cells through coupled microarray and siRNA screening: Role of a novel selenoprotein in calcium regulation and Neuroprotection
  3178. Reversal of Cerebral Vasospasm and Neuroprotection by Injecting Magnesium Sulfate into Cisterna Magna in Rabbit with Subarachnoid Hemorrhage
  3179. Neuroprotection Induced by Preconditioning with Prolonged and Intermittent Normobaric Hyperoxia Upregulate TNF-α Converting Enzyme and Increase NF-kB …
  3180. Glutathione depletion in neurodegenerative disorders: Cell death mechanisms and Neuroprotection , exacerbation of manganese neurotoxicity, and the role in …
  3181. Neuroprotection of adenovirus expressing glutamic acid receptor c-terminal peptide in brain ischemic injury in rat involved in MLK3
  3182. Neuroprotection of a cocktail therapy involving anti-intercellular adhesion molecule 1 antibody and insulin-like growth factor 1 in treatment of cerebral ischemia …
  3183. Pretreatment is not mandatory for Neuroprotection with 1alpha, 25-dihydroxyvitamin D3 in perinatal hypoxic-ischemic rat brain damage in vivo and in excitotoxic injury …
  3184. 3-Hydroxymorphinan, the Parent Molecule of GCC1290, Provides Neuroprotection against Glutamateinduced Toxicity
  3185. P1-127 LOVASTATIN MEDIATES IN VIVO Neuroprotection AGAINST NMDA-INDUCED EXCITOTOXICITY
  3186. 3-Hydroxymorphinan-Mediated Neuroprotection Against Methamphetamine-lnduced Neuropsychotoxicity: Possible Modulation of Neurotrophic-and …
  3187. 100. Magnesium in a Polyethylene Glycol Formulation Provides Neuroprotection after Acute Spinal Cord Injury
  3188. 116. A novel moderate-affinity metal binding ligand confers Neuroprotection against 6-hydroxydopamine mediated chronic cell death and improves rotational …
  3189. 2 Adrenergic Modulation of NMDA Receptor Function: A Novel Mechanism of Neuroprotection in Experimental Glaucoma
  3190. The Anti-NgR Blocking Protein, NgR (310) ecto-Fc, Has a Potential Role for Neuroprotection in an EVC Rat Model of Glaucoma
  3191. Hypoxia-Inducible-Factor 1 Ablation in a Model of Retinal Neuroprotection by Hypoxic Preconditioning
  3192. Nimodipine Enhances 2 Adrenergic Modulation of NMDA Receptor: A Novel Mechanism of RGC Neuroprotection
  3193. Glucocorticoids, 11 [beta] HSDs and Neuroprotection
  3194. 17-β-estradiol-induced Neuroprotection through ERK activation by G protein-and β-arrestin-dependent mechanisms
  3195. RGC-5 Cells Express Opioid Receptors: Role in Neuroprotection
  3196. Abstract No. 64: Carotid Artery Stenting Without Neuroprotection . Influence of the Learning Curve on Clinical Results
  3197. Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in
  3198. 12 Tocotrienol Neuroprotection
  3199. 5-HT1A receptors are present in the retina and are involved in the outer retina Neuroprotection by 5-HT1A agonists through the activation of MAP kinase …
  3200. Inhibitory effect of lithium tungstate on the secretion of amyloid beta-protein 1-42, and its Neuroprotection
  3201. MRI/MRS of ischemic evolution in mouse brain at 14.1 T and Neuroprotection with lactate
  3202. The handbook of Neuroprotection
  3203. Treatment advances in neonatal Neuroprotection and neurointensive care
  3204. Anaesthetic-related Neuroprotection
  3205. From neuroprogression to Neuroprotection : implications for clinical care
  3206. Neuroprotection in glaucoma–is there a future role?
  3207. Prospects for minocycline Neuroprotection
  3208. Neuroprotection in glaucoma: recent and future directions
  3209. Neuroprotection of sex steroids
  3210. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies
  3211. Neuroprotection in glaucoma
  3212. Mechanisms of hypothermic Neuroprotection
  3213. Neuroprotection in acute ischemic stroke–current status
  3214. Astrocytes: targets for Neuroprotection in stroke
  3215. Education, the brain and dementia: Neuroprotection or compensation? EClipSE Collaborative Members
  3216. Microglia and Neuroprotection : from in vitro studies to therapeutic applications
  3217. Investigational therapies for ischemic stroke: Neuroprotection and neurorecovery
  3218. Neuroprotection by ketamine: a review of the experimental and clinical evidence
  3219. Mitochondrial mechanisms of estrogen Neuroprotection
  3220. Alternative mitochondrial electron transfer as a novel strategy for Neuroprotection
  3221. Autophagy for tissue homeostasis and Neuroprotection
  3222. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for Neuroprotection
  3223. The biological basis of injury and Neuroprotection in the fetal and neonatal brain
  3224. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration
  3225. Cell-mediated Neuroprotection in a mouse model of human tauopathy
  3226. Statins and Neuroprotection : a prescription to move the field forward
  3227. Ethanol and cognition : indirect effects, neurotoxicity and Neuroprotection : a review
  3228. Vision in multiple sclerosis (MS): the story, structure-function correlations, and models for Neuroprotection
  3229. Actions of estrogens on glial cells: implications for Neuroprotection
  3230. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal Neuroprotection .
  3231. Neurodegenerative diseases and Neuroprotection : current views and prospects
  3232. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for Neuroprotection
  3233. Current perspectives on potential role of albumin in Neuroprotection
  3234. Central nervous system agents for ischemic stroke: Neuroprotection mechanisms
  3235. Clinical prediction of Parkinson’s disease: planning for the age of Neuroprotection
  3236. Riluzole, Neuroprotection and amyotrophic lateral sclerosis
  3237. Neuroprotection by spice-derived nutraceuticals: you are what you eat!
  3238. Neuroprotection in subarachnoid hemorrhage
  3239. Perioperative Neuroprotection
  3240. Érythropoïétine et Neuroprotection
  3241. SIRT2 inhibition achieves Neuroprotection by decreasing sterol biosynthesis
  3242. Psychopharmacological Neuroprotection in neurodegenerative disease: assessing the preclinical data
  3243. Clinical trials for Neuroprotection in ALS
  3244. Therapeutic targets for Neuroprotection in acute ischemic stroke: lost in translation?
  3245. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model
  3246. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for Neuroprotection
  3247. Xenon enhances hypothermic Neuroprotection in asphyxiated newborn pigs
  3248. Astrocytic-neuronal crosstalk: implications for Neuroprotection from brain injury
  3249. Vitamin E Neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial
  3250. Neuroprotection mediated through estrogen receptor-α in astrocytes
  3251. Neuroprotection and recovery: recent data at the bench on citicoline
  3252. Effects of caffeine in Parkinson’s disease: from Neuroprotection to the management of motor and non-motor symptoms
  3253. NAP (davunetide) provides functional and structural Neuroprotection
  3254. Curcumin provides Neuroprotection after spinal cord injury
  3255. Clinical evidence for Neuroprotection in glaucoma
  3256. Ocular Neuroprotection by siRNA targeting caspase-2
  3257. Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats
  3258. Autophagy activation is associated with Neuroprotection in a rat model of focal cerebral ischemic preconditioning
  3259. Role of ghrelin system in Neuroprotection and cognitive functions: implications in Alzheimer’s disease
  3260. TGF‐β1 Pathway as a New Target for Neuroprotection in Alzheimer’s Disease
  3261. Bone marrow mesenchymal stem cells: agents of immunomodulation and Neuroprotection
  3262. MicroRNAs as effectors of brain function with roles in ischemia and injury, Neuroprotection , and neurodegeneration
  3263. Valproate administered after traumatic brain injury provides Neuroprotection and improves cognitive function in rats
  3264. Toll-like receptor tolerance as a mechanism for Neuroprotection
  3265. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade
  3266. Dexmedetomidine provides cortical Neuroprotection : impact on anaesthetic‐induced neuroapoptosis in the rat developing brain
  3267. Medical management of Parkinson’s disease: focus on Neuroprotection
  3268. Targeting microvasculature for Neuroprotection after SCI
  3269. Ion channels on microglia: therapeutic targets for Neuroprotection
  3270. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and Neuroprotection
  3271. In vitro antioxidant activities and an investigation of Neuroprotection by six Salvia species from Iran: a comparative study
  3272. Neuroprotection during carotid artery stenting using the GORE flow reversal system: 30‐day outcomes in the EMPiRE Clinical Study
  3273. Oxytocin mediates social Neuroprotection after cerebral ischemia
  3274. Phenobarbital augments hypothermic Neuroprotection
  3275. Niaspan treatment induces Neuroprotection after stroke
  3276. Iron chelation and Neuroprotection in neurodegenerative diseases
  3277. NF-κB inhibitory action of resveratrol: a probable mechanism of Neuroprotection in experimental diabetic neuropathy
  3278. Lamotrigine for Neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
  3279. Pharmacological Neuroprotection after perinatal hypoxic-ischemic brain injury
  3280. Role of the glyoxalase system in astrocyte-mediated Neuroprotection
  3281. Evidence for neuroinflammation and Neuroprotection in HCV infection-associated encephalopathy
  3282. Complement in Neuroprotection and neurodegeneration
  3283. Serum uri acid: Neuroprotection in thrombolysis. The Bergen NORSTROKE study
  3284. Safety and feasibility of a novel transcervical access Neuroprotection system for carotid artery stenting in the PROOF Study
  3285. Clinical Neuroprotection in Parkinson’s disease—still waiting for the breakthrough
  3286. Remyelination—an effective means of Neuroprotection
  3287. Inhibition of c-Jun kinase provides Neuroprotection in a model of Alzheimer’s disease
  3288. miRNA Expression profile after status epilepticus and hippocampal Neuroprotection by targeting miR-132
  3289. Valproic acid–mediated Neuroprotection and regeneration in injured retinal ganglion cells
  3290. Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and Neuroprotection
  3291. Excitotoxic Neuroprotection and vulnerability with CaMKII inhibition
  3292. Magnesium for Neuroprotection in birth asphyxia
  3293. Exercise Neuroprotection in a rat model of binge alcohol consumption
  3294. Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?
  3295. Neuroprotection for optic nerve disorders
  3296. Therapeutic challenges to retinitis pigmentosa: from Neuroprotection to gene therapy
  3297. Antioxidant activity of 7, 8-dihydroxyflavone provides Neuroprotection against glutamate-induced toxicity
  3298. Menstrual blood cells display stem cell–like phenotypic markers and exert Neuroprotection following transplantation in experimental stroke
  3299. A serial study of retinal changes following optic neuritis with sample size estimates for acute Neuroprotection trials
  3300. Neuroprotection of Scutellarin is mediated by inhibition of microglial inflammatory activation
  3301. Mechanisms of Neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of α4 and α7 receptors in Neuroprotection
  3302. Magnesium for fetal Neuroprotection
  3303. Cerebral blood flow alteration in Neuroprotection following cerebral ischaemia
  3304. Decreased cerebrovascular brain -derived neurotrophic factor–mediated Neuroprotection in the diabetic brain
  3305. Chitosan produces potent Neuroprotection and physiological recovery following traumatic spinal cord injury
  3306. Endogenous Neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
  3307. The PPAR-γ agonist pioglitazone modulates inflammation and induces Neuroprotection in parkinsonian monkeys
  3308. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages
  3309. Human microglia transplanted in rat focal ischemia brain induce Neuroprotection and behavioral improvement
  3310. Magnesium sulphate for fetal Neuroprotection
  3311. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study
  3312. Polyphenols and Neuroprotection against ischemia and neurodegeneration
  3313. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease
  3314. Can molecular and cellular Neuroprotection be translated into therapies for patients? Yes, but not the way we tried it before
  3315. Complement protein C1q-mediated Neuroprotection is correlated with regulation of neuronal gene and microRNA expression
  3316. Adaptive Müller cell responses to microglial activation mediate Neuroprotection and coordinate inflammation in the retina
  3317. The RNA-binding protein RBM3 is involved in hypothermia induced Neuroprotection
  3318. Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain
  3319. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires Neuroprotection and reduced soluble tau burden
  3320. GDNF fails to exert Neuroprotection in a rat α-synuclein model of Parkinson’s disease
  3321. Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxidative signaling in ischemic stroke
  3322. Target brain : Neuroprotection and neurorestoration in ischemic stroke.
  3323. Autophagy activation is involved in Neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats
  3324. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite
  3325. Sex differences in Neuroprotection provided by inhibition of TRPM2 channels following experimental stroke
  3326. Sevoflurane preconditioning confers Neuroprotection via anti-inflammatory effects
  3327. The connexin43 C-terminal region mediates Neuroprotection during stroke
  3328. Prolyl hydroxylase domain inhibitors: a route to HIF activation and Neuroprotection
  3329. Human cord blood transplantation in a neonatal rat model of hypoxic–ischemic brain damage: functional outcome related to Neuroprotection in the striatum
  3330. Neuroprotection , regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
  3331. Polycomb group proteins as epigenetic mediators of Neuroprotection in ischemic tolerance
  3332. Caffeine and uric acid mediate glutathione synthesis for Neuroprotection
  3333. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson’s disease
  3334. NR4A orphan nuclear receptors as mediators of CREB-dependent Neuroprotection
  3335. Pharmacological therapy in Parkinson’s disease: focus on Neuroprotection
  3336. Leptin induces proliferation of neuronal progenitors and Neuroprotection in a mouse model of Alzheimer’s disease
  3337. Clinically available iron chelators induce Neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration
  3338. Effective post-insult Neuroprotection by a novel Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor
  3339. Transplantation of BDNF-secreting mesenchymal stem cells provides Neuroprotection in chronically hypertensive rat eyes
  3340. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway
  3341. Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and Neuroprotection
  3342. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and Neuroprotection
  3343. Neuroprotection of midbrain dopaminergic cells in MPTP‐treated mice after near‐infrared light treatment
  3344. Newly synthesized radical-containing nanoparticles enhance Neuroprotection after cerebral ischemia-reperfusion injury
  3345. Free-radical scavenger edaravone treatment confers Neuroprotection against traumatic brain injury in rats
  3346. Sevoflurane preconditioning induces Neuroprotection through reactive oxygen species-mediated up-regulation of antioxidant enzymes in rats
  3347. Rasagiline, Parkinson Neuroprotection , and delayed-start trials: still no satisfaction?
  3348. Microglia-mediated IGF-I Neuroprotection in the rd10 mouse model of retinitis pigmentosa
  3349. Mechanism of Neuroprotection of melatonin against beta-amyloid neurotoxicity
  3350. Recent advances in pharmacologic Neuroprotection
  3351. Docosahexaenoic acid: brain accretion and roles in Neuroprotection after brain hypoxia and ischemia
  3352. Neuroprotection for the warrior: dietary supplementation with omega-3 fatty acids
  3353. A combination immunomodulatory treatment promotes Neuroprotection and locomotor recovery after contusion SCI
  3354. Competitive Inhibition at the Glycine Site of the N -Methyl-d-Aspartate Receptor Mediates Xenon Neuroprotection against Hypoxia–Ischemia
  3355. Human neural stem cells genetically modified to overexpress brain ‐derived neurotrophic factor promote functional recovery and Neuroprotection in a mouse stroke …
  3356. Improving outcomes of Neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice
  3357. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor
  3358. Hypoxic preconditioning induced Neuroprotection against cerebral ischemic injuries and its cPKCγ-mediated molecular mechanism
  3359. In vivo therapeutic gas delivery for Neuroprotection with echogenic liposomes
  3360. ERK activation by the polyphenols fisetin and resveratrol provides Neuroprotection in multiple models of Huntington’s disease
  3361. Insulin, synaptic function, and opportunities for Neuroprotection
  3362. Recombinant Fv-Hsp70 protein mediates Neuroprotection after focal cerebral ischemia in rats
  3363. Propentofylline: glial modulation, Neuroprotection , and alleviation of chronic pain
  3364. Decaffeinated coffee and nicotine-free tobacco provide Neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism
  3365. Low dose methamphetamine mediates Neuroprotection through a PI3K-AKT pathway
  3366. Proteomic analysis of cPKCβII‐interacting proteins involved in HPC‐induced Neuroprotection against cerebral ischemia of mice
  3367. … decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on Neuroprotection in a progressive …
  3368. CSF transthyretin Neuroprotection in a mouse model of brain ischemia
  3369. Nanomolar vitamin E α‐tocotrienol inhibits glutamate‐induced activation of phospholipase A2 and causes Neuroprotection
  3370. Neuroprotection with a brain -penetrating biologic tumor necrosis factor inhibitor
  3371. Oral pelargonidin exerts dose-dependent Neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism
  3372. αB crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and provides Neuroprotection to adjacent cells
  3373. … terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-α and the critical period hypothesis of estrogen Neuroprotection
  3374. Neuronal estrogen receptor-α mediates Neuroprotection by 17β-estradiol
  3375. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+
  3376. Beta-lactam antibiotic offers Neuroprotection in a spinal muscular atrophy model by multiple mechanisms
  3377. Neuroprotection with intraventricular brain -derived neurotrophic factor in rat venous occlusion model
  3378. Neuroprotection : the emerging concept of restorative neural stem cell biology for the treatment of neurodegenerative diseases
  3379. Propofol post‐conditioning induced long‐term Neuroprotection and reduced internalization of AMPAR GluR2 subunit in a rat model of focal cerebral ischemia …
  3380. Benzothiophene selective estrogen receptor modulators provide Neuroprotection by a novel GPR30-dependent mechanism
  3381. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism
  3382. Mitochondria and calcium flux as targets of Neuroprotection caused by minocycline in cerebellar granule cells
  3383. Role of sirtuins and calorie restriction in Neuroprotection : implications in Alzheimer’s and Parkinson’s diseases
  3384. Lithium-mediated long-term Neuroprotection in neonatal rat hypoxia–ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of …
  3385. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2)
  3386. Delayed treatment with systemic (S)-roscovitine provides Neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models
  3387. Neuroprotection and enhanced neurogenesis by tetramethylpyrazine in adult rat brain after focal ischemia
  3388. Potential of edaravone for Neuroprotection in neurologic diseases that do not involve cerebral infarction
  3389. Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced Neuroprotection via an NFκB-mediated increase in interleukin-6 production
  3390. ERK-and Akt-dependent Neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD
  3391. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for Neuroprotection
  3392. Pharmacological Neuroprotection after perinatal asphyxia
  3393. Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy
  3394. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion
  3395. Blockade of acute microglial activation by minocycline promotes Neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week …
  3396. Psychopharmacological Neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research
  3397. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain
  3398. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor
  3399. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells
  3400. Neuroprotection in pediatric cardiac surgery: what is on the horizon?
  3401. New approaches to Neuroprotection in infant heart surgery
  3402. Mechanisms mediating brain and cognitive reserve: experience-dependent Neuroprotection and functional compensation in animal models of neurodegenerative …
  3403. Mitochondria: the missing link between preconditioning and Neuroprotection
  3404. Chitooligosaccharide-mediated Neuroprotection is associated with modulation of Hsps expression and reduction of MAPK phosphorylation
  3405. Neuroprotection by natural polyphenols: molecular mechanisms
  3406. Chitosan nanoparticle-based neuronal membrane sealing and Neuroprotection following acrolein-induced cell injury
  3407. Lymphocytes in Neuroprotection , cognition and emotion: is intolerance really the answer?
  3408. BCG vaccine-induced Neuroprotection in a mouse model of Parkinson’s disease
  3409. Structural and functional Neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors
  3410. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson’s disease: a contribution to sex-specific Neuroprotection by estrogens
  3411. Sex-independent Neuroprotection with minocycline after experimental thromboembolic stroke
  3412. 17β-Estradiol–a new modulator of neuroglobin levels in neurons: role in Neuroprotection against H2O2-induced toxicity
  3413. ERK/MAPK is essential for endogenous Neuroprotection in SCN2. 2 cells
  3414. Targeting the brain : Neuroprotection and neurorestoration in ischemic stroke
  3415. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated Neuroprotection following cerebral ischemia/reperfusion injury
  3416. Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression …
  3417. … profiling of the injured sciatic nerve of mice carrying the Wld (S) mutant gene: identification of genes involved in Neuroprotection , neuroinflammation, and nerve …
  3418. Argon Neuroprotection
  3419. Intracellular mechanisms of N-acylethanolamine-mediated Neuroprotection in a rat model of stroke
  3420. Cardiac and Neuroprotection regulated by α1-adrenergic receptor subtypes
  3421. Endocannabinoid signaling in neurotoxicity and Neuroprotection
  3422. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of α7 nicotinic receptors and internalization of NMDA receptors
  3423. … breakdown, edema formation and brain pathology: a light and electron microscopic study on a new model for neurodegeneration and Neuroprotection in porcine brain
  3424. Neuroprotection signaling pathway of nerve growth factor and brain -derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19 …
  3425. … are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance Neuroprotection
  3426. Effects of propofol on proliferation and anti-apoptosis of neuroblastoma SH-SY5Y cell line: New insights into Neuroprotection
  3427. Xenon preconditioning confers Neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion
  3428. Neuroprotection through stimulation of mitochondrial antioxidant protein expression
  3429. Mechanistic insight into DNA damage and repair in ischemic stroke: exploiting the base excision repair pathway as a model of Neuroprotection
  3430. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson’s disease
  3431. Neuroprotection by taurine in ethanol-induced apoptosis in the developing cerebellum
  3432. Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced Neuroprotection against global cerebral ischemia
  3433. Hepatoprotection and Neuroprotection induced by low doses of IGF-II in aging rats
  3434. Molecular mechanisms underlying hypothermia-induced Neuroprotection
  3435. VIP-induced Neuroprotection of the developing brain
  3436. Optic neuropathy in methylmalonic acidemia: the role of Neuroprotection
  3437. Antenatal exposure to magnesium sulfate and Neuroprotection in preterm infants
  3438. Acute hepatocyte growth factor treatment induces long-term Neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and …
  3439. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain
  3440. Recent findings on Neuroprotection against excitotoxicity in the hippocampus of female rats
  3441. Isoflurane preconditioning Neuroprotection in experimental focal stroke is androgen-dependent in male mice
  3442. Neuroprotection and sensorimotor functional improvement by curcumin after intracerebral hemorrhage in mice
  3443. Neuroprotection in Parkinson’s disease
  3444. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides Neuroprotection in mice transient focal cerebral ischemia
  3445. Role of PPARgamma, a nuclear hormone receptor in Neuroprotection
  3446. Protein changes in CSF of HIV-infected patients: evidence for loss of Neuroprotection
  3447. Leptin induces Neuroprotection neurogenesis and angiogenesis after stroke
  3448. PI3K/Akt signaling pathway is required for Neuroprotection of thalidomide on hypoxic–ischemic cortical neurons in vitro
  3449. Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to Neuroprotection
  3450. Progesterone inhibits estrogen‐mediated Neuroprotection against excitotoxicity by down‐regulating estrogen receptor‐β
  3451. The role of ASIC1a in Neuroprotection elicited by quercetin in focal cerebral ischemia
  3452. Lipoic acid decreases inflammation and confers Neuroprotection in experimental autoimmune optic neuritis
  3453. Hypoxic-preconditioning induces Neuroprotection against hypoxia–ischemia in newborn piglet brain
  3454. The Neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (nrf2)-mediated antioxidant response: role of …
  3455. Isoflurane postconditioning induces Neuroprotection via Akt activation and attenuation of increased mitochondrial membrane permeability
  3456. … modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV Neuroprotection
  3457. Chemical Neuroprotection in the cochlea: the modulation of dopamine release from lateral olivocochlear efferents
  3458. Calcium preconditioning triggers Neuroprotection in retinal ganglion cells
  3459. … Neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged Neuroprotection independent of HIF-1 function
  3460. Wnt1 Neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways
  3461. Neuroprotection induced in vitro by ischemic preconditioning and postconditioning: modulation of apoptosis and PI3K–Akt pathways
  3462. Post-stroke hypothermia provides Neuroprotection through inhibition of AMP-activated protein kinase
  3463. Evaluation of cell damage in organotypic hippocampal slice culture from adult mouse: a potential model system to study Neuroprotection
  3464. Roles of estrogen receptors alpha and beta in sexually dimorphic Neuroprotection against glutamate toxicity
  3465. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice
  3466. Moderate ethanol preconditioning of rat brain cultures engenders Neuroprotection against dementia-inducing neuroinflammatory proteins: possible signaling …
  3467. The NCX3 Isoform of the Na+/Ca2+ Exchanger Contributes to Neuroprotection Elicited by Ischemic Postconditioning
  3468. Meloxicam exerts Neuroprotection on spinal cord trauma in rats
  3469. Neuroprotection against cobalt chloride-induced cell apoptosis of primary cultured cortical neurons by salidroside
  3470. Activation of Akt/FoxO signaling pathway contributes to induction of Neuroprotection against transient global cerebral ischemia by hypoxic pre‐conditioning in adult …
  3471. Neuroprotection in the preterm infant: further understanding of the short-and long-term implications for brain development
  3472. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia
  3473. Sinomenine inhibits microglial activation by Aβ and confers Neuroprotection
  3474. The Akt/GSK-3β pathway mediates flurbiprofen-induced Neuroprotection against focal cerebral ischemia/reperfusion injury in rats
  3475. Astroglial reaction to delta opioid peptide [D-Ala2, D-Leu5] enkephalin confers Neuroprotection against global ischemia in the adult rat hippocampus
  3476. Neuroprotection by local intra-arterial infusion of erythropoietin after focal cerebral ischemia in rats
  3477. Long‐term Neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson’s disease
  3478. p120 catenin/αN‐catenin are molecular targets in the Neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia
  3479. Enhanced delivery of erythropoietin across the blood–brain barrier for Neuroprotection against ischemic neuronal injury
  3480. Hydrogen saline offers Neuroprotection by reducing oxidative stress in a focal cerebral ischemia-reperfusion rat model
  3481. Neuroprotection with hypothermia in the newborn with hypoxic-ischaemic encephalopathy. Standard guidelines for its clinical application
  3482. Selected combination of neurotrophins potentiate Neuroprotection and functional recovery following spinal cord injury in the rat
  3483. Aging alters the expression of genes for Neuroprotection and synaptic function following acute estradiol treatment
  3484. Lack of Neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson’s disease
  3485. Intrastriatal transplantation of GDNF-engineered BMSCs and its Neuroprotection in lactacystin-induced Parkinsonian rat model
  3486. Synthesis and preliminary evaluation of Neuroprotection of celastrol analogues in PC12 cells
  3487. Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis
  3488. Insulin and glucagon share the same mechanism of Neuroprotection in diabetic rats: role of glutamate
  3489. Neuroprotection against retinal ischemia–reperfusion injury by blocking the angiotensin II type 1 receptor
  3490. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent Neuroprotection in aged rats after embolic focal ischemia
  3491. Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for Neuroprotection
  3492. Characterization of neurotoxic effects of NMDA and the novel Neuroprotection by phytopolyphenols in mice.
  3493. GSK-3 as a target for lithium-induced Neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke
  3494. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional Neuroprotection in a rat model of …
  3495. Neuroprotection of interleukin-6 against NMDA-induced apoptosis and its signal-transduction mechanisms
  3496. Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition
  3497. Neuroprotection caused by hyperoxia preconditioning in animal stroke models
  3498. Liposomal-glutathione provides maintenance of intracellular glutathione and Neuroprotection in mesencephalic neuronal cells
  3499. Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain
  3500. Regulation of posttranscriptional modification as a possible therapeutic approach for retinal Neuroprotection
  3501. Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers Neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of …
  3502. Administration of thiazolidinediones for Neuroprotection in ischemic stroke: a pre‐clinical systematic review
  3503. Role of purinergic receptors in CNS function and Neuroprotection
  3504. Omega-3 polyunsaturated fatty acid supplementation confers long-term Neuroprotection against neonatal hypoxic–ischemic brain injury through anti-inflammatory …
  3505. … agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes Neuroprotection after root avulsion injury
  3506. Involvement of brain ‐derived neurotrophic factor and neurogenesis in oestradiol Neuroprotection of the hippocampus of hypertensive rats
  3507. Cell signaling in NMDA preconditioning and Neuroprotection in convulsions induced by quinolinic acid
  3508. Proton magnetic resonance spectroscopy reveals Neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS
  3509. Neuroprotection by melatonin on mercury induced toxicity in the rat brain
  3510. Urban air pollution targets the dorsal vagal complex and dark chocolate offers Neuroprotection
  3511. White Tea (Camellia sinensis Kuntze) Exerts Neuroprotection against Hydrogen Peroxide-Induced Toxicity in PC12 Cells
  3512. Hypoxic preconditioning provides Neuroprotection and increases vascular endothelial growth factor A, preserves the phosphorylation of Akt-Ser-473 and diminishes …
  3513. Neuroprotection and underlying mechanisms of oxymatrine in cerebral ischemia of rats
  3514. Zonisamide: aspects in Neuroprotection
  3515. Neuroprotection in acute ischemic stroke.
  3516. Neuroprotection by valproic acid in mouse models of permanent and transient focal cerebral ischemia
  3517. Insulin-like growth factor-I mediates Neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells
  3518. Levetiracetam in brain ischemia: clinical implications in Neuroprotection and prevention of post-stroke epilepsy
  3519. New insights into the mechanisms of mitochondrial preconditioning-triggered Neuroprotection
  3520. The assessment of non-feminizing estrogens for use in Neuroprotection
  3521. Toxicity of neurons treated with herbicides and Neuroprotection by mitochondria-targeted antioxidant SS31
  3522. ACh receptors link two signaling pathways to Neuroprotection against glutamate‐induced excitotoxicity in isolated RGCs
  3523. Isoflurane preconditioning induces Neuroprotection by attenuating ubiquitin-conjugated protein aggregation in a mouse model of transient global cerebral ischemia
  3524. Inhibition of extracellular signal‐regulated kinases 1/2 provides Neuroprotection in spinal cord ischemia/reperfusion injury in rats: relationship with the nuclear factor …
  3525. Combination treatment with ethyl pyruvate and aspirin enhances Neuroprotection in the postischemic brain
  3526. Neuroprotection induced by vitamin E against oxidative stress in hippocampal neurons: involvement of TRPV1 channels
  3527. Modulation of morphological changes of microglia and Neuroprotection by monocyte chemoattractant protein-1 in experimental glaucoma
  3528. Neuroprotection by melatonin after germinal matrix hemorrhage in neonatal rats
  3529. Magnesium in a polyethylene glycol formulation provides Neuroprotection after unilateral cervical spinal cord injury
  3530. The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust Neuroprotection in the postischemic brain
  3531. Pituitary adenylate cyclase‐activating peptide induces long‐lasting Neuroprotection through the induction of activity‐dependent signaling via the cyclic AMP response …
  3532. ASIC1a contributes to Neuroprotection elicited by ischemic preconditioning and postconditioning
  3533. Neuroprotection by glucagon: role of gluconeogenesis
  3534. Contrasting patterns of Bim induction and Neuroprotection in Bim-deficient mice between hippocampus and neocortex after status epilepticus
  3535. Transplantation of TAT-Bcl-xL-transduced neural precursor cells: long-term Neuroprotection after stroke
  3536. Cochrane corner: hypothermia for Neuroprotection in adults after cardiopulmonary resuscitation.
  3537. Evaluation of Samjunghwan, a traditional medicine, for Neuroprotection against damage by amyloid-beta in rat cortical neurons
  3538. Combined prostaglandin E1 and lithium exert potent Neuroprotection in a rat model of cerebral ischemia
  3539. Role of the c‐Jun N‐terminal kinase pathway in retinal excitotoxicity, and Neuroprotection by its inhibition
  3540. Boosting endogenous Neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial
  3541. Delayed Neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures
  3542. Synergistic effect of selenium and melatonin on Neuroprotection in cerebral ischemia in rats
  3543. Caffeine and CSC, adenosine A2A antagonists, offer Neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells
  3544. Progenitor cells as remote” bioreactors”: Neuroprotection via modulation of the systemic inflammatory response
  3545. … ‐induced blood‐brain barrier breakdown, reduction in cerebral blood flow, edema formation, and brain pathology: Possible Neuroprotection with growth hormone
  3546. Targeting heme oxygenase-1 for Neuroprotection and neuroinflammation in neurodegenerative diseases
  3547. Neuroprotection against hypoxic-ischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway
  3548. Mitochondrial Na+/Ca2+ exchanger, a new target for Neuroprotection in rat hippocampal slices
  3549. Neuroinflammation and Neuroprotection : an update on (future) neurotrophin-related strategies in multiple sclerosis treatment
  3550. Nicotine-and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in Neuroprotection mechanism
  3551. Pathologically activated Neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis …
  3552. Profile of minocycline Neuroprotection in bilirubin-induced auditory system dysfunction
  3553. Sex-specific role of thioredoxin in Neuroprotection against iron-induced brain injury conferred by estradiol
  3554. Signal transducers and activators of transcription: STATs-mediated mitochondrial Neuroprotection
  3555. Lack of Neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice
  3556. Differential Neuroprotection by A1 receptor activation and A2A receptor inhibition following pilocarpine-induced status epilepticus
  3557. Erythropoietin-induced Neuroprotection requires cystine glutamate exchanger activity
  3558. Neuroprotection and regeneration by extracellular metallothionein via lipoprotein-receptor-related proteins
  3559. Neuroglobin, estrogens, and Neuroprotection
  3560. … regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and Neuroprotection
  3561. Neuroprotection of locomotor networks after experimental injury to the neonatal rat spinal cord in vitro
  3562. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) Neuroprotection
  3563. Neuroprotection by human umbilical cord blood-derived progenitors in ischemic brain injuries
  3564. Neuroprotection of erythropoietin and methylprednisolone against spinal cord ischemia-reperfusion injury
  3565. Esmolol and landiolol, selective β1-adrenoreceptor antagonists, provide Neuroprotection against spinal cord ischemia and reperfusion in rats
  3566. Male/female differences in Neuroprotection and neuromodulation of brain dopamine
  3567. Neuroprotection via strychnine-sensitive glycine receptors during post-ischemic recovery of excitatory synaptic transmission in the hippocampus
  3568. Hypothermia and Neuroprotection by sulfide after cardiac arrest and cardiopulmonary resuscitation
  3569. Cold pre‐conditioning Neuroprotection depends on TNF‐α and is enhanced by blockade of interleukin‐11
  3570. Psychopharmacological Neuroprotection in neurodegenerative disease: heuristic clinical applications
  3571. Neuroprotection by the traditional Chinese medicine, Tao-Hong-Si-Wu-Tang, against middle cerebral artery occlusion-induced cerebral ischemia in rats
  3572. Dietary supplementation with tBHQ, an Nrf2 stabilizer molecule, confers Neuroprotection against apoptosis in amyloid β-injected rat
  3573. Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and Neuroprotection in human neuroblastoma cells
  3574. Neuroprotection in stroke in the mouse with intravenous erythropoietin–Trojan horse fusion protein
  3575. Glucagon‐like peptide 1 receptor stimulation as a means of Neuroprotection
  3576. Ethyl pyruvate inhibits peroxynitrite-induced DNA damage and hydroxyl radical generation: implications for Neuroprotection
  3577. Neuroprotection of taurine against bilirubin-induced elevation of apoptosis and intracellular free calcium ion in vivo
  3578. 2-(-2-benzofuranyl)-2-imidazoline induces Bcl-2 expression and provides Neuroprotection against transient cerebral ischemia in rats
  3579. Neuroprotection effects of retained acupuncture in neurotoxin-induced Parkinson’s disease mice
  3580. Cell non-autonomous functions of homeoproteins in Neuroprotection in the brain
  3581. Engineered superparamagnetic Mn0. 5Zn0. 5Fe2O4 nanoparticles as a heat shock protein induction agent for ocular Neuroprotection in glaucoma
  3582. Pigment epithelium-derived factor gene therapy targeting retinal ganglion cell injuries: Neuroprotection against loss of function in two animal models
  3583. The Impact of Subthalamic Deep brain Stimulation on Nigral Neuroprotection —Myth or Reality?
  3584. Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and Neuroprotection
  3585. Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent …
  3586. Corticotropin releasing factor—distribution in rat intestine and role in Neuroprotection
  3587. Field-induced therapeutic hypothermia for Neuroprotection after out-of hospital cardiac arrest: a systematic review of the literature
  3588. Sex difference in sensitivity to allopregnanolone Neuroprotection in mice correlates with effect on spontaneous inhibitory post synaptic currents
  3589. Duplicate preconditioning with sevoflurane in vitro improves Neuroprotection in rat brain via activating the extracellular signal-regulated protein kinase
  3590. Short-term exposure to nickel alters the adult rat brain antioxidant status and the activities of crucial membrane-bound enzymes: Neuroprotection by L-cysteine
  3591. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson’s disease mutations A30P, A53T and …
  3592. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in Neuroprotection and memory function in mouse brain
  3593. Incrementally applied multifaceted therapeutic bundles in Neuroprotection clinical trials… time for change
  3594. Astrocytic glutamate transporter-dependent Neuroprotection against glutamate toxicity: an in vitro study of maslinic acid
  3595. IL-10 within the CNS is necessary for CD4+ T cells to mediate Neuroprotection
  3596. α2-Adrenoceptors do not Mediate Neuroprotection in Acute Ischemic Stroke in Mice
  3597. Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat—possible involvement of kynurenic acid
  3598. Neuroprotection in Parkinson’s disease: a realistic goal?
  3599. Olfactory Ensheathing Cell Transplantation Into Spinal Cord Prolongs the Survival of Mutant SOD1G93A ALS Rats Through Neuroprotection and Remyelination
  3600. The hippocampal fimbria of cuprizone-treated animals as a structure for studying Neuroprotection in multiple sclerosis
  3601. Striatal Neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with EUK-134 or edaravone
  3602. Role of cystatin C in Neuroprotection and its therapeutic implications
  3603. A role for neuronal NF-κB in suppressing neuroinflammation and promoting Neuroprotection in the CNS
  3604. DJ‐1 modulates the expression of Cu/Zn‐superoxide dismutase‐1 through the Erk1/2–Elk1 pathway in Neuroprotection
  3605. Neuroprotection offered by Majun Khadar, a traditional unani medicine, during cerebral ischemic damage in rats
  3606. Rosuvastatin preconditioning provides Neuroprotection against spinal cord ischemia in rats through modulating nitric oxide synthase expressions
  3607. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and Neuroprotection
  3608. … increases resveratrol‐induced heme oxygenase‐1 expression through the inhibition of ubiquitin‐dependent proteasome pathway: a possible role in Neuroprotection
  3609. Omega-3 polyunsaturated fatty acids in the brain : metabolism and Neuroprotection
  3610. Preconditioning and postconditioning for Neuroprotection : the most recent evidence
  3611. NCAM-mediated locomotor recovery from spinal cord contusion injury involves Neuroprotection , axon regeneration, and synaptogenesis
  3612. Gene therapy approaches for Neuroprotection and axonal regeneration after spinal cord and spinal root injury
  3613. Neuroprotection of ethanol against ischemia/reperfusion-induced brain injury through decreasing c-Jun N-terminal kinase 3 (JNK3) activation by enhancing GABA …
  3614. Electrophysiological actions of zonisamide on striatal neurons: selective Neuroprotection against complex I mitochondrial dysfunction
  3615. Ceftriaxone preconditioning confers Neuroprotection in neonatal rats through glutamate transporter 1 upregulation
  3616. Lentivirus-mediated transfer of MMP-9 shRNA provides Neuroprotection following focal ischemic brain injury in rats
  3617. Advanced neuroimaging techniques: their role in the development of future fetal and neonatal Neuroprotection
  3618. Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and Neuroprotection
  3619. … in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of Neuroprotection for striatal neurons
  3620. Strategies for study of Neuroprotection from cold-preconditioning
  3621. Minocycline Neuroprotection in a rat model of asphyxial cardiac arrest is limited
  3622. … -α (TNF-α) regulates shedding of TNF-α receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in Neuroprotection
  3623. Mitochondrial ERK plays a key role in delta-opioid receptor Neuroprotection against acute mitochondrial dysfunction
  3624. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for Neuroprotection
  3625. … Mechanism of Mitochondrial Ferritin on 6-Hydroxydopamine–Induced Dopaminergic Cell Damage: Implication for Neuroprotection in Parkinson’s Disease
  3626. Inhibition of gp91phox contributes towards normobaric hyperoxia afforded Neuroprotection in focal cerebral ischemia
  3627. Mechanisms of Neuroprotection by protein disulphide isomerase in amyotrophic lateral sclerosis
  3628. Treatment with Ginsenoside Rb1, A Component of Panax Ginseng, Provides Neuroprotection in Rats Subjected to Subarachnoid Hemorrhage-Induced brain Injury
  3629. The role of neural stem cells for in vitro models of schizophrenia: Neuroprotection via Akt/ERK signal regulation
  3630. … interacting mediator of cell death (Bim) E3 ligase, tripartite motif-containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced Neuroprotection
  3631. Excitotoxicity‐induced endocytosis mediates Neuroprotection by TAT‐peptide‐linked JNK inhibitor
  3632. Traumatic brain injury: Current endeavours and trends for Neuroprotection and related recovery
  3633. MRI measures of Neuroprotection and repair in multiple sclerosis
  3634. Chronic hypertension aggravates heat stress-induced brain damage: possible Neuroprotection by cerebrolysin
  3635. Neuroprotection in experimental stroke in the rat with an IgG–erythropoietin fusion protein
  3636. Rosuvastatin-induced Neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation
  3637. Bioenergetic homeostasis decides Neuroprotection or neurotoxicity induced by volatile anesthetics: a uniform mechanism of dual effects
  3638. Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid homeostasis of functionally diverse but linked pathways …
  3639. Involvement of glutamate transporter-1 in Neuroprotection against global brain ischemia-reperfusion injury induced by postconditioning in rats
  3640. Success of immunomodulators in MS shifts discovery focus to Neuroprotection
  3641. Post-treatment with selective beta1 adrenoceptor antagonists provides Neuroprotection against transient focal ischemia in rats
  3642. Role of salt-induced kinase 1 in androgen Neuroprotection against cerebral ischemia
  3643. “Won’t you be my neighbor?” Deciphering the mechanisms of Neuroprotection induced by social interaction
  3644. … oxygen species assessed by electron spin resonance spectroscopy in the initial stage of ischemia–reperfusion are not associated with hypothermic Neuroprotection
  3645. Cinnamophilin offers prolonged Neuroprotection against gray and white matter damage and improves functional and electrophysiological outcomes after transient …
  3646. Ibuprofen for Neuroprotection after cerebral ischemia
  3647. … necrosis factor‐α and neuronal nitric oxide synthase antibodies applied topically over the traumatized spinal cord enhances Neuroprotection and functional recovery …
  3648. Astrocytic Neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse
  3649. HspB1 (Hsp 27) expression and Neuroprotection in the retina
  3650. C‐terminal mechano‐growth factor induces heme oxygenase‐1‐mediated Neuroprotection of SH‐SY5Y cells via the protein kinase Cϵ/Nrf2 pathway
  3651. Cystine glutamate exchanger upregulation by retinoic acid induces Neuroprotection in neural stem cells
  3652. Neuroprotection of spinal neurons against blunt trauma and ischemia
  3653. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for Neuroprotection : results from a prospective randomized study
  3654. Citicoline and postconditioning provides Neuroprotection in a rat model of ischemic spinal cord injury
  3655. Assessment of Parkinson disease: what do we need to show Neuroprotection ?
  3656. Targeting individual calpain isoforms for Neuroprotection
  3657. Achyranthes bidentata polypeptides confer Neuroprotection through inhibition of reactive oxygen species production, Bax expression, and mitochondrial dysfunction …
  3658. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide 25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death
  3659. FK506 Neuroprotection after cavernous nerve injury is mediated by thioredoxin and glutathione redox systems
  3660. Studies of locomotor network Neuroprotection by the selective poly(ADP‐ribose) polymerase‐1 inhibitor PJ‐34 against excitotoxic injury to the rat spinal cord in vitro
  3661. Optimizing neurodevelopmental outcomes after prematurity: lessons in Neuroprotection and early intervention.
  3662. Inactivation of GABAA receptor reduces ginsenoside Rb3 Neuroprotection in mouse hippocampal slices after oxygen–glucose deprivation
  3663. In silico theoretical molecular modeling for Alzheimer’s disease: the nicotine-curcumin paradigm in Neuroprotection and neurotherapy
  3664. Distribution of radiolabeled l-glutamate and d-aspartate from blood into peripheral tissues in naive rats: significance for brain Neuroprotection
  3665. Hippocampal damage after intra-amygdala kainic acid-induced status epilepticus and seizure preconditioning-mediated Neuroprotection in SJL mice
  3666. Multi‐targeted Neuroprotection by the HSV‐2 gene ICP10PK includes robust bystander activity through PI3‐K/Akt and/or MEK/ERK‐dependent neuronal release of …
  3667. Mitogen-and stress-activated protein kinase 1-induced Neuroprotection in Huntington’s disease: role on chromatin remodeling at the PGC-1-alpha promoter
  3668. Neuroprotection against excitotoxic and ischemic insults by bis (12)-hupyridone, a novel anti-acetylcholinesterase dimer, possibly via acting on multiple targets
  3669. Estrogen and P2 purinergic receptor systems in microglia: therapeutic targets for Neuroprotection
  3670. Peroxisome proliferator-activated receptor γ promotes Neuroprotection by modulating cyclic D1 expression after focal cerebral ischemia
  3671. Overcoming cell death and tau phosphorylation mediated by PI3KInhibition: a cell assay to measure Neuroprotection
  3672. Cortistatin is induced in brain tissue and exerts Neuroprotection in a rat model of bacterial meningoencephalitis
  3673. Isoflurane preconditioning affords functional Neuroprotection in a murine model of intracerebral hemorrhage
  3674. Neuroprotection by rosiglitazone in transient focal cerebral ischemia might not be mediated by glutamate transporter‐1#
  3675. Neuroprotection of glycyrrhizin against ischemic vascular dementia in vivo and glutamate-induced damage in vitro.
  3676. The critical limiting temperature and selective brain cooling: Neuroprotection during exercise?
  3677. Effects of valsartan on Neuroprotection and neurogenesis after ischemia
  3678. Therapeutic targets for Neuroprotection and/or enhancement of functional recovery following traumatic brain injury
  3679. Donepezil-induced Neuroprotection of acetylcholinergic neurons in olfactory bulbectomized mice
  3680. Acute Neuroprotection by the synaptic blocker botulinum neurotoxin E in a rat model of focal cerebral ischaemia
  3681. Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation confers functional Neuroprotection in global ischemia
  3682. Differential Neuroprotection of selective estrogen receptor agonists against autonomic dysfunction and ischemic cell death in permanent versus reperfusion …
  3683. Stem cell plasticity, Neuroprotection and regeneration in human eye diseases
  3684. Hypoxic preconditioning induces Neuroprotection against transient global ischemia in adult rats via preserving the activity of Na+/K+-ATPase
  3685. Future strategies for Neuroprotection in Parkinson’s disease
  3686. Broad-spectrum Neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors
  3687. The phosphatidylinositol-3 kinase/Akt pathway mediates geranylgeranylacetone-induced Neuroprotection against cerebral infarction in rats
  3688. During glaucoma, α2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor, neutralizing Neuroprotection
  3689. Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic Neuroprotection
  3690. Neuroprotection of Alpinia katsumadai seed extract against neuronal damage in the ischemic gerbil hippocampus is linked to altered brain -derived neurotrophic …
  3691. Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced Neuroprotection in hypoxia ischemia
  3692. Docosahexaenoic acid confers Neuroprotection in a rat model of perinatal hypoxia-ischemia potentiated by Escherichia coli lipopolysaccharide-induced systemic …
  3693. Past, present and future of Neuroprotection
  3694. Potential role of IL-13 in Neuroprotection and cortical excitability regulation in multiple sclerosis
  3695. The multimodal prospects for Neuroprotection and disease modification in epilepsy: relationship to its challenging neurobiology
  3696. Iptakalim, an ATP-sensitive potassium channel opener, confers Neuroprotection against cerebral ischemia/reperfusion injury in rats by protecting neurovascular unit …
  3697. Magnetic resonance spectroscopy of the brain under mild hypothermia indicates changes in Neuroprotection -related metabolites
  3698. Human embryonic stem cell-derived neurons as a tool for studying Neuroprotection and neurodegeneration
  3699. Trypanosoma cruzi-derived neurotrophic factor: role in neural repair and Neuroprotection
  3700. Inhibition of hexokinase leads to Neuroprotection against excitotoxicity in organotypic hippocampal slice culture
  3701. Involvement of ERK1/2 pathway in Neuroprotection by salidroside against hydrogen peroxide-induced apoptotic cell death
  3702. A subchronic application period of glucocorticoids leads to rat cognitive dysfunction whereas physostigmine induces a mild Neuroprotection
  3703. Potent Neuroprotection induced by remote preconditioning in a rat model of neonatal cerebral hypoxic–ischemic injury
  3704. Hypothermia for Neuroprotection in adults after cardiopulmonary resuscitation
  3705. Adhesion molecules as potential targets for Neuroprotection in a rodent model of Parkinson’s disease
  3706. Stem cells and Neuroprotection : understanding the players
  3707. Expression of heat shock protein (HSP 72 kDa) during acute methamphetamine intoxication depends on brain hyperthermia: neurotoxicity or Neuroprotection ?
  3708. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides Neuroprotection after embolic stroke in rats
  3709. Primary Neuroprotection : the Holy Grail of multiple sclerosis therapy
  3710. Magnesium sulfate for Neuroprotection in patients at risk for early preterm delivery: not yet
  3711. Blood–CNS barrier, neurodegeneration and Neuroprotection : recent therapeutic advancements and nano-drug delivery
  3712. LPS-induced iNOS expression in Bv-2 cells is suppressed by an oxidative mechanism acting on the JNK pathway—a potential role for Neuroprotection
  3713. α-Synuclein Promotes Neuroprotection Through NF-κB–Mediated Transcriptional Regulation of Protein Kinase Cδ
  3714. Davunetide (NAP) pharmacology: Neuroprotection and tau
  3715. Magnesium sulfate for fetal Neuroprotection .
  3716. Partial Neuroprotection by 17-β-estradiol in neonatal gamma-irradiated rat cerebellum
  3717. Interleukin‐6‐type cytokines in Neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A1 receptor …
  3718. Neuroprotection by estradiol: some important considerations
  3719. The use of antenatal magnesium sulfate for Neuroprotection for infants born prematurely
  3720. Small temperature variations alter edaravone-induced Neuroprotection of cortical cultures exposed to prolonged hypoxic episodes
  3721. … PDZ1 domain of PSD-95 decreases Src phosphorylation and increases nNOS (Ser847) phosphorylation contributing to Neuroprotection after cerebral ischemia
  3722. The c‐Jun N‐terminal kinase (JNK) inhibitor XG‐102 enhances the Neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats
  3723. Epileptic tolerance is associated with enduring Neuroprotection and uncoupling of the relationship between CA3 damage, neuropeptide Y rearrangement and …
  3724. Y-P30 confers Neuroprotection after optic nerve crush in adult rats
  3725. Neuroprotection by S-PBN in hyperglycemic ischemic brain injury in rats
  3726. Pharmacological Neuroprotection against brain damage in ischemiai/reperfusion experiment
  3727. Strongylophorine-8, a pro-electrophilic compound from the marine sponge Petrosia (Strongylophora) corticata, provides Neuroprotection through Nrf2/ARE pathway
  3728. Passive immunization with LINGO-1 polyclonal antiserum afforded Neuroprotection and promoted functional recovery in a rat model of spinal cord injury
  3729. Editorial [Hot topic: VIP and PACAP: Novel Approaches to brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]
  3730. Aroclor1254 interferes with estrogen receptor-mediated Neuroprotection against beta-amyloid toxicity in cholinergic SN56 cells
  3731. Granulocyte colony-stimulating factor treatment provides Neuroprotection in surgically induced brain injured mice
  3732. Vasodilation and Neuroprotection : the magnesium saga in subarachnoid hemorrhage
  3733. … , intrinsic propensity/pathological processes–causes of self recovery limits and also, subtle related targets for Neuroprotection /pleiotropicity/multimodal actions …
  3734. Neuroprotection and brain cholesterol biosynthesis in Huntington’s disease
  3735. Unilateral brain hypothermia as a method to examine efficacy and mechanisms of Neuroprotection against global ischemia
  3736. The activation of β2-adrenergic receptors in naïve rats causes a reduction of blood glutamate levels: Relevance to stress and Neuroprotection
  3737. Phytoceramide shows Neuroprotection and ameliorates scopolamine-induced memory impairment
  3738. Neuroprotection in glaucoma: a review
  3739. Lack of Neuroprotection of inhibitory peptides targeting Jun/JNK after transient focal cerebral ischemia in spontaneously hypertensive rats
  3740. Glial cell-line derived neurotrophic factor is essential for electroconvulsive shock-induced Neuroprotection in an animal model of Parkinson’s disease
  3741. Neuroprotection of selective brain cooling after penetrating ballistic-like brain injury in rats
  3742. Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis
  3743. Acetylcholinesterase variants in Alzheimer’s disease: from Neuroprotection to programmed cell death
  3744. Neuroprotection of retinal ganglion cells with GDNF-Loaded biodegradable microspheres in experimental glaucoma
  3745. New perspectives on molecular and cellular mechanisms of Neuroprotection and neuroregeneration: part I
  3746. Ironing out neurodegeneration: iron chelation for Neuroprotection
  3747. Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity
  3748. Posttreatment but not pretreatment with selective β-adrenoreceptor 1 antagonists provides Neuroprotection in the hippocampus in rats subjected to transient forebrain …
  3749. Magnesium sulphate for fetal Neuroprotection
  3750. Joongpoongtang 05 (JP05) confers Neuroprotection via anti-apoptotic activities in Neuro-2a cells during oxygen–glucose deprivation and reperfusion
  3751. Endogenous Neuroprotection in multiple sclerosis.
  3752. Sevoflurane‐induced post‐conditioning has no beneficial effects on Neuroprotection after incomplete cerebral ischemia in rats
  3753. “Therapeutic Hypercapnia” after Ischemic brain Injury: Is There a Potential for Neuroprotection ?
  3754. Therapeutic time window of YGY-E Neuroprotection of cerebral ischemic injury in rats
  3755. Clinical Neuroprotection and secondary neuronal injury mechanisms
  3756. Neuroprotection of paclitaxel against cerebral ischemia/reperfusion-induced brain injury through JNK3 signaling pathway
  3757. Overestimating Neuroprotection in congenital heart disease: problems with Bayley III outcomes
  3758. Refining Neuroprotection strategies in the era of therapeutic hypothermia.
  3759. Hormones in neurodegeneration, Neuroprotection , and neurogenesis
  3760. Molecular Aspects of Neurodegeneration and Neuroprotection
  3761. … -activated protein kinase and peroxisome proliferator-activated receptor gamma coactivator 1α signaling provides Neuroprotection in status epilepticus in rats
  3762. … R-Pia reduces the imbalance between cerebral glucose metabolism and blood flow during status epilepticus: could this mechanism be involved with Neuroprotection ?
  3763. Further assessment of neuropathology in retinal explants and Neuroprotection by human neural progenitor cells
  3764. Expression of pancreatitis-associated protein after traumatic brain injury: a mechanism potentially contributing to Neuroprotection in human brain
  3765. Indirect measures of Neuroprotection are parameters to avoid: examples from research on neonatal rat hypoxia-ischemia
  3766. Prostaglandin E2 EP1 Receptor Inhibition Fails to Provide Neuroprotection in Surgically Induced brain -Injured Mice
  3767. Mesenchymal Stem Cell Transplantation Confers Neuroprotection in Experimental Glaucoma
  3768. Study on the Neuroprotection components of ethnomedicine Erigeron breviscapus [J]
  3769. Involvement of histamine 1 receptor in seizure susceptibility and Neuroprotection in immature mice
  3770. Neuroprotection , SCHIZOPHRÉNIE ET ANTIPSYCHOTIQUES: REVUE SYSTÉMATIQUE DE LA LITTÉRATURE.
  3771. Hypothermia for Neuroprotection in adults after cardiopulmonary resuscitation
  3772. Magnesium for Neuroprotection
  3773. Neuroprotection by hypothermia plus alkalinization of dorsal root ganglia neurons through ischemia
  3774. Translati onal challenges of Neuroprotection strategy in ischemic stroke
  3775. Aprotinin confers Neuroprotection by reducing apoptotic cell death
  3776. Neonatal hypothermia: a method to provide Neuroprotection after hypoxic ischemic encephalopathy
  3777. Effects of hominis placenta pharmacopuncture and electroacupuncture Neuroprotection in contused spinal cord of rats
  3778. Neuroprotection of a neotype transactivating-brain -derived neurotrophic factor fusion protein with penetrating activity of blood-brain barrier
  3779. Discovering Neuroprotection in Parkinson’s disease, or getting to haphazard
  3780. Combinatorial techniques for enhancing Neuroprotection : hypothermia and alkalinization
  3781. Neuroprotection by IL-6 is mediated by STAT3 and antioxidative signaling in ischemic stroke
  3782. Neuroprotection in neonatal hypoxic ischemic encephalopathy: Therapeutic hypothermia and beyond
  3783. Pharmacological preconditioning with GYKI 52466: a prophylactic approach to Neuroprotection
  3784. Neuroprotection in bipolar depression
  3785. Complement protein 6 deficiency in PVG/c rats does not lead to Neuroprotection against seizure induced cell death
  3786. Beyond Neuroprotection to brain repair: exploring the next frontier in clinical neuroscience to expand the therapeutic window for stroke
  3787. Low-molecular-mass peptides from the venom of the Amazonian viper Bothrops atrox protect against brain mitochondrial swelling in rat: potential for Neuroprotection
  3788. The role of MSUT-2 in tau neurotoxicity: a target for Neuroprotection in tauopathy?
  3789. Dual isoflurane-induced preconditioning improves Neuroprotection in rat brain in vitro and the role of extracellular signal-regulated protein kinase
  3790. Hypertonic mannitol in mice poisoned by a convulsive dose of soman: Antilethal activity without Neuroprotection
  3791. Calcium transport mechanisms in Neuroprotection and neurotoxicity
  3792. Towards a new paradigm in Neuroprotection and neuroplasticity
  3793. Autophagy and its Neuroprotection in neurodegenerative diseases
  3794. New possibilities of Neuroprotection in ischemic stroke
  3795. Forsythiae fructus and its active component, arctigenin, provide Neuroprotection by inhibiting neuroinflammation
  3796. Effects of minocycline on the expression of NGF and HSP70 and its Neuroprotection role following intracerebral hemorrhage in rats
  3797. Past, present and future of hypothermic Neuroprotection for neonatal encephalopathy in Japan: time to say good-by to the old remedies.
  3798. New perspectives on molecular and cellular mechanisms of Neuroprotection and neuroregeneration: part II
  3799. The delayed-start study in Parkinson disease: Can’t satisfy everyone: Rasagiline, Parkinson Neuroprotection , and delayed-start trials: Still no satisfaction?
  3800. … regulation of FGF-2 in neurons and reactive astrocytes of axotomized rat hypoglossal nucleus. A possible therapeutic target for Neuroprotection in peripheral nerve …
  3801. Oestrogen and Neuroprotection
  3802. Retinal Neuroprotection
  3803. Neuroprotection of Maslinic Acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats
  3804. Marine toxins, neurodegeneration and Neuroprotection
  3805. Prospects for Neuroprotection in glaucoma
  3806. Dopaminergic Neuroprotection of Poacynum hendersonni in MPTP mouse
  3807. Improved Neuroprotection with melatonin-augmented hypothermia vs hypothermia alone in a perinatal asphyxia model: a randomized study
  3808. What’s new in Neuroprotection
  3809. How effective is hypothermia for Neuroprotection in adults after cardiopulmonary resuscitation?
  3810. Copper and Prion Protein Function: A Brief Review of Emerging Theories of Neuroprotection
  3811. Uncoupling Neuroprotection from immunosuppression: The discovery of ILS-920
  3812. Mechanism of NMDA receptor-dependent neuronal survival and Neuroprotection
  3813. Neuroprotection of the newborn brain : therapeutic targets & behavioral outcome
  3814. The impact of Neuroprotection on brain metabolism during carotid endarterectomy
  3815. Developments in Neuroprotection
  3816. News and views of Neuroprotection in complete traumatic spinal cord injuries
  3817. Comparing Different Erigerontis Preparations on the Neuroprotection Activity and Chemical Constituents
  3818. Hypothermia for Neuroprotection in the newborn
  3819. The conundrum of Neuroprotection in Parkinson’s disease.
  3820. Mechanisms of social Neuroprotection after cerebral ischemia
  3821. Neuroprotection in Glaucoma
  3822. Progenitor cell therapies as a novel treatment for traumatic brain injury: A pathway towards Neuroprotection
  3823. Neuroprotection of retinal degenerative disease by ciliary neurotrophic factor
  3824. Neuroprotection in Parkinson’s disease: a multi-directional genetic strategy for maximum protection of dopaminergic neurons against Parkinsonian toxicity
  3825. Recombinant human erythropoietin: novel approach to Neuroprotection and neuroregeneration in schizophrenia
  3826. Development of intravenous topiramate for Neuroprotection and seizure control in neonates.
  3827. Synthesis of Indolylquinones as a Potential Therapy for Diabetes and as Candidates for Neuroprotection
  3828. Magnesium sulfate Neuroprotection : time to start?
  3829. Fetal Cardiac Arrest Due to Asphyxia in Late Preterm Lambs: Propofol Mediates Neuroprotection for the Fetus When Administered During Emergency Caesarean …
  3830. From bone marrow to brain : stem cells in Neuroprotection , plasticity, and neuroregeneration
  3831. Does anesthetic provide similar Neuroprotection to therapeutic hypothermia after cardiac arrest?
  3832. Clinical analysis on Neuroprotection of transient ischemic attacks
  3833. Citicoline: a promising agent for Neuroprotection and neurorepair
  3834. Dimethyl-carbamic acid 2, 3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine-1-Carbonyl)-phenyl ester: A novel multi-target therapeutic approach to Neuroprotection
  3835. Medical Treatment: Neuroprotection
  3836. Sustained Neuroprotection after a single intravitreal injection of PGJ2 in a rodent model of NAION
  3837. Impact of belief in Neuroprotection on therapeutic intervention in Parkinson’s disease
  3838. Strategies to Promote Neuroprotection and Repair in Multiple Sclerosis
  3839. How right is the righting reflex? The risk of false positives in Neuroprotection studies using behavioral measures to certify forebrain ischemia
  3840. Enhance effort for study of Neuroprotection of degenerative fundus disease
  3841. Expression of liquoral Neuroprotection markers in children with acute lymphoblastic leukemia
  3842. The fabulous Neuroprotection of selegiline: memoir and prospectus
  3843. Reply to Valenza and Cattaneo: SIRT2-mediated Neuroprotection and cholesterol dyshomeostasis in Huntington’s disease
  3844. Neuroprotection and neuroregeneration: what to expect from a stem cell-based therapy of acute brain injury
  3845. Somatostatin and Neuroprotection in Retina
  3846. Effect of sivelestat on neutrophil elastase and Neuroprotection in rats with craniocerebral injury at simulated high altitude
  3847. Erythropoietic Neuroprotection : Holy Grail or potential to fail?
  3848. Transpupillary thermotherapy: New observations on Neuroprotection of retinal ganglion cells
  3849. Frontiers in Perinatal Neuroprotection
  3850. Role of CX3CL1 in synaptic activity and Neuroprotection
  3851. Moxibustion therapy on diabetic peripheral neuropathy in rats for the peripheral Neuroprotection
  3852. Structure–Nongenomic Neuroprotection Relationship of Estrogens and Estrogen‐Derived Compounds
  3853. The Influence of G-CSF on the Expression of VEGF and Neuroprotection in Rats’ brain s After Ischemia/reperfusion Injury [J]
  3854. Relationship between oestrogen and cholesterol in Neuroprotection
  3855. Pharmacological Neuroprotection : that long, long road from idea to practice
  3856. Neuroprotection and cognitive Enhancing Training Strategies: Environmental Enrichment and Motor Skills Training
  3857. A10 SIRT2 inhibition achieves Neuroprotection by decreasing sterol biosynthesis
  3858. Neuroprotection and axonal regeneration after peripheral nerve injury
  3859. Neuroprotection against excitotoxicity and oxidative stress by hypothermia and alkalinization
  3860. Neuroprotection in multiple sclerosis
  3861. Reply to Bell et al.: Nrf2-dependent and-independent mechanisms of astrocytic Neuroprotection
  3862. Secreted amyloid precursor protein-α mediates Neuroprotection and gene expression
  3863. Role of calcium binding proteins in the Neuroprotection of hippocampal CA1 neurons
  3864. Hippocampus Neuroprotection during lactation: a model to study neuroendocrine-immune interactions
  3865. Xenon Neuroprotection against hypoxia–ischaemia is mediated by the N-methyl-D-aspartate receptor glycine site.
  3866. Neuroapoptosis and Neuroprotection by NMDA-receptors antagonists
  3867. Neuroprotection in glaucoma
  3868. Protein transduction technique and its application in Neuroprotection
  3869. The role of oxygen radicals-scavenger in Neuroprotection -induced by normobaric hyperoxia on infarct volume in the rat brain
  3870. Membrane-initiated signaling of estrogen related to Neuroprotection .“Social networks” are required
  3871. Foetal hypoxia is an important determinant of birth asphyxia and subsequent adverse outcome: antenatal Neuroprotection at term
  3872. Efficacy of topiramate against soman intoxication: attenuation of seizures without Neuroprotection
  3873. Neuroprotection in Parkinson’s
  3874. Alpha1A-Adrenergic Receptors in Neuroprotection
  3875. Effects of lithium chloride on behavior and Neuroprotection of dopaminergic neurons in a mice model of MPTP-induced Parkinsons disease
  3876. The Neuroprotection of edaravone and GM1 on the rat model of parkinson disease
  3877. Neuroprotection in Parkinson’s Disease
  3878. Mechanism of Neuroprotection of Estrogen [J]
  3879. Neuroprotection in the Newborn Infant
  3880. CHALLENGES TO OBTAINING Neuroprotection IN PARKINSON’S DISEASE
  3881. Magnetic resonance biomarkers of hypothermic rescue Neuroprotection following neonatal encephalopathy in a south indian neonatal unit
  3882. Effects of ischemic postconditioning on hippocampal Neuroprotection in different cerebral ischemia models at the same” time window” in tree shrews
  3883. Autologous Mononuclear Progenitor Cell Injection for Traumatic brain Injury (TBI): The Effect of Injury Cavity Volume on Potential Neuroprotection
  3884. Neuroprotection in Parkinson’s Disease
  3885. DNA damage and repair in the brain : implications for seizure-induced neuronal injury, endangerment, and Neuroprotection
  3886. Purine nucleoside mediated Neuroprotection in the 6-hydroxydopamine rodent model of Parkinson’s disease
  3887. Neuroprotection in the treatment of multiple sclerosis
  3888. Neurovascular unit and poststroke Neuroprotection
  3889. STUDIES ON Neuroprotection IN TRAUMA AND STROKE MODELS
  3890. The Neuroprotection role of heat shock protein 70 (HSP70) against microwave radiation induced DNA damage in male Wistar rat brain
  3891. Liposome-mediated transfer of the HGF gene results in Neuroprotection in adult rat brain after cerebral ischemia [J]
  3892. Direct VEGF-A Mediated Neuroprotection : Mechanistic Studies in RGCs
  3893. Neuroprotection in the therapy of the brain injury: 7AP5–4
  3894. Experimental studies on ischemic Neuroprotection : criteria for translational significance.
  3895. The Design and Methodology of Clinical Studies of Neuroprotection in Cardiac Surgery
  3896. Neuroprotection of Retinal Ganglion Cells
  3897. Uncovering Novel Therapeutic Targets Promoting Neuroprotection Against Oxidative Stress
  3898. Smoking and Mental Disorders: Focus on Neuroprotection
  3899. Leptin Neuroprotection in the Central Nervous System
  3900. Neuroprotection during pediatric cardiac anesthesia
  3901. Mechanisms of estrogen Neuroprotection in stroke
  3902. Autophagy and its Neuroprotection in neurodegenerative diseases
  3903. Oxidative damage in brain genome and Neuroprotection
  3904. Antenatal brain injury and prospects for Neuroprotection
  3905. A Mechanistic Investigation of STAT3 Regulated Neuroprotection
  3906. Future Perspective: Directions for Future Development on Various Aspects of Neurodegeneration and Neuroprotection in Neurological Disorders
  3907. Dopaminergic Neuroprotection and reconstruction of neural network tiara
  3908. Anti-inflammatory and anti-oxidant Neuroprotection in the prevention of Alzheimer’s disease
  3909. Effects of Sanguisorbae Radix on Neuroprotection in an In Vitro Parkinson’s Disease Model
  3910. Editorial [Hot topic: Neuroprotection in ALS: From Pathology to Treatment (Guest Editors: Gabriele Siciliano and Luigi Murri)]
  3911. Role of Serpinin in Granule Biogenesis and Neuroprotection
  3912. Neuroprotection and Antioxidative Constituents in Sesame (Sesamum indicum L.)
  3913. Investigating the Role of the Prion Protein Polybasic Domain in PrPSc Formation and Neuroprotection
  3914. Local rock-inhibition as a novel therapeutic approach for Neuroprotection of retinal ganglion cells (FRO)
  3915. Mechanism of estrogen-mediated Neuroprotection : regulation of mitochondrial function
  3916. The Corticotropin‐Releasing Hormone in Neuroprotection
  3917. Neuroprotection of Mouse Retina Ganglion Cells by N-Acylethanolamines
  3918. MS pipeline flowing, but niche remains for Neuroprotection
  3919. Neuroprotection with Anesthetics in Two Models of Cerebral Ischemia
  3920. Bench to bedside, tertiary centres to developing world–” tailoring” best available Neuroprotection in high and low resource settings
  3921. Pharmacological Neuroprotection in cervical spinal cord injury
  3922. THE RATIONALE FOR Neuroprotection IN EPILEPSY: STEPS FORWARD FOR NEW THERAPEUTIC AND PREVENTIVE STRATEGIES
  3923. Neuroprotection by estrogen under hypoglycemic condition with special emphasis on AKT_GSK pathway
  3924. by Crystallography on Three Enzymes-Implication on Anesthesia and Neuroprotection Mechanisms
  3925. The effect of estrogen receptor alpha36 involved in Neuroprotection of estrogen
  3926. Tailoring the heterogeneous macrophage response to spinal cord injury towards Neuroprotection
  3927. Neuroprotection by S-PBN in hyperglycemic ischemic brain injury
  3928. Neuroprotection and cell-based therapy in retinal degeneration
  3929. MSK-1 and CREB were involved in HPC-induced Neuroprotection against cerebral ischemic injuries of mice
  3930. Role of α7 nicotinic acetylcholine receptor subtype in Neuroprotection : An overview
  3931. Elucidating Mechanisms of Retinal Ganglion Cell Neuroprotection by Mesenchymal Stem Cell Transplantation
  3932. LEPTIN INDUCES NEUROGENESIS AND Neuroprotection IN A MOUSE MODEL OF ALZHEIMERS DISEASE
  3933. The Neuroprotection of nicotine to the cerebral ischemia/reperfusion injury of rats
  3934. Mechanisms of Erythropoietin-induced Neuroprotection in: in-vivo and in-vitro Models of hypoxia Ischema
  3935. Genetic Ablation or Pharmacological Inhibition of Cell Cycle Pathways Provides Neuroprotection in Experimental TBI
  3936. Cellular mechanisms of neurodegeneration and Neuroprotection in the mammalian cortex
  3937. Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
  3938. Dhea-Analogue Neuroprotection In An Experimental Model Of Retinal Detachment
  3939. Magnesium sulphate in women at risk of preterm birth for Neuroprotection of the fetus
  3940. Therapeutic Hypothermia for Neuroprotection in Adults after Cardiopulmonary Resuscitation
  3941. Modulation of Crystallin Network by Lipin1 is Associated With Neuroprotection in the Mouse Retina
  3942. Amyloid Precursor Protein-mediated Neuroprotection In The Aged Retina
  3943. Study of telmisartan on the c-fos expression and Neuroprotection on MCAO rats
  3944. Progestins and Neuroprotection : Why the Choice of Progestin Matters
  3945. The Neuroprotection role of hypervolemic hemodilution on rat brain suffered from cerebral ischemia-reperfusion insults
  3946. Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
  3947. Neuroprotection in Sepsis by Complement Inhibition and Immunoglobulin Therapy
  3948. Neuroprotection BY GDNF AND A PHYSICAL EXERCISE THERAPY IN THE 3XTGAD MOUSE MODEL
  3949. Real-time monitoring of potential effects of Neuroprotection by acupuncture in global ischemic model of hyperglycemic rats
  3950. brain CYP2D6 and its role in Neuroprotection against Parkinson’s Disease
  3951. Siglec-F receptor and Neuroprotection in mouse central nervous system
  3952. Palmitoyl-proteins: regulators of neuronal functions and potential targets for Neuroprotection
  3953. Neuroprotection and mechanism of 17β-estradiol in ovariectomized female rats with cerebral ischemia
  3954. Intracellular Accumulation of A2E in Retinal Microglia Influences Neuroprotection and Cellular Migration
  3955. Investigation of neurodegeneration and Neuroprotection in secondary progressive multiple sclerosis using volumetric MRI measures
  3956. Neuroprotection ‐A role played by Acorus calamus in experimental temporal lobe epilepsy
  3957. Neuroprotection of Retinal Ganglion Cells in P23H Rats: A Way to Improve Resolution in Retinal Prosthesis or Optogenic Approach
  3958. Neuroprotection effect of FLOS ROSAE RUGOSAE extracts on PC12 cells against Aβ25-35-induced cytotoxity.
  3959. A Possible Role of Microglia in Igf-Mediated Neuroprotection of Rd10 Mouse Retina
  3960. Nrf2 Mediated Neuroprotection in In Vitro Models of Parkinson’s Disease
  3961. Common Gene Expression Profiles Of Induced Neuroprotection By Preconditioning And By Injection Of Leukemia Inhibitory Factor
  3962. Mechanisms of Ipsapirone-Mediated Neuroprotection of Ethanol-Treated Fetal Rhombencephalic Neurons: Role of Endogenous Antioxidants
  3963. Chemically-induced anoxia in retinal cell cultures: mechanisms of injury and Neuroprotection
  3964. Effects of recombine human granuloctye cololny-stimulating factor on Neuroprotection and influence on expression of Fas protein of brain tissue in cerebral infarction …
  3965. Mechanisms of Bone-Marrow Stem Cell-Mediated Delayed Ischemic Neuroprotection in Rat Retina
  3966. Role of-Opioid-Receptor Activation in Retina Neuroprotection Against Ischemic Retinal Injury
  3967. Neuroprotection and Neurorestoration in the MPTP Model for Parkinson’s Disease
  3968. The Mechanisms of Neuroprotection by Melatonin in Cerebral Ischaemia Reperfusion
  3969. S44–Rapid development and implementation of guidelines for infant Neuroprotection with antenatal magnesium sulfate (MgSO4)
  3970. Therapeutic hypothermia for Neuroprotection after off-hospital cardiac arrest: Too cool for school?
  3971. Neuroprotection against ischemic injury induced by morphine preconditioning in different time in mice
  3972. Neuroprotection by estrogen on hypoglycemic injury on hypothalamic cells at the cellular and molecular level
  3973. Adenosine A2A antagonists: Neuroprotection and autophagy induction by a new compound
  3974. Effect of Acacetin on Neuroprotection in MPTPinduced Parkinson’s Disease Model via Anti-inflammatory Actions
  3975. Neuroprotection of minocycline on chronic ocular hypertension rat retina
  3976. The human NT2 cell line as in vitro test system for Neuroprotection and developmental neurotoxicity
  3977. Sevoflurane postconditioning provides Neuroprotection up to 7 days after ischemia/reperfusion via mitoKATP: BAPCAP2–5
  3978. Neuroprotection of Exenatide in rats with diabetic peripheral nerve injury
  3979. Neuroprotection of erythropoietin on rabbit retinal ganglion cells in chronic ocular hypertension
  3980. MOLECULAR MECHANISMS OF NCX1 AND NCX3-INDUCED Neuroprotection IN ANOXIC brain PRECONDITIONOING
  3981. The Regulatory Role of Visfatin in Neuronal Differentiation and Neuroprotection through Activation of Vigin Signaling Pathway
  3982. Signaling in retinal degeneration and Neuroprotection -the role of JAK/STAT and HIF
  3983. … BASICS OF ACUTE brain ISCHEMIA MODERN PHARMACOTHERAPY. NOOTROPICS AND ANTIOXIDANTS’ROLE IN Neuroprotection
  3984. Involvement of the NMDA Receptor in Moderate Ethanol Preconditioning-Dependent Neuroprotection From Amyloid-Beta in Vitro
  3985. Neurology: vitamin E Neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial
  3986. Engineered superparamagnetic Mn₀. ₅Zn₀. ₅Fe₂O₄ nanoparticles as a heat shock protein induction agent for ocular Neuroprotection in glaucoma
  3987. Erratum to: T-cell-based vaccination for morphological and functional Neuroprotection in a rat model of chronically elevated intraocular pressure
  3988. In vivo Neuroprotection through M-type K+ Channels after Cerebrovascular Stroke
  3989. Neuroprotection mediated by P2 receptors of NMDA-dependent toxicity in hippocampal slices
  3990. NQO2: A Novel Target to Mediate Neuroprotection Against Retinal Degeneration
  3991. Influence of therapeutic hypothermia on Neuroprotection and post-ischemic plasticity in a rat model of global ischemia
  3992. Mechanisms of Neuroprotection of silent information regulation 2 homolog 3 against hypoxic injury in hypoxic preconditioning
  3993. Mechanisms of action of Methylthioadenosine: pathways implicated in Neuroprotection in models of Multiple Sclerosis and other neurological diseases
  3994. Cold enhances Neuroprotection in hippocampal slices from hibernating Syrian hamsters
  3995. Beta-lactam antibiotic offers Neuroprotection in a spinal muscular atrophy model by multiple mechanisms
  3996. Review on the Endogenous Neuroprotection Mechanisms of the Cerebellar Fastigial Nucleus Stimulation in Rats with Ischemic [J]
  3997. Mitochondrial potassium sequestration and Neuroprotection is mediated by connexin43
  3998. APPL1 mediates synaptic NMDA receptor-dependent Neuroprotection
  3999. Neuroprotection EFFECT OF FEMALE SEX STEROIDS AFTER TRAUMATIC brain INJURY IN RATS: THE ROLE OF INFLAMMATORY CYTOKINES
  4000. Evaluation of NMDA receptor-mediated Neuroprotection in the endothelin-1 model of upper extremity impairment in stroke
  4001. Neuroprotection against nerve agent using a blood glutamate scavenging system in rats
  4002. Mechanisms of Observed Neuroprotection of Dopaminergic Neurons in Wallerian Degeneration Slow (WldS) Mice
  4003. … Spectral Domain Optical Coherence Tomography Evaluation During Retinal Neurodegeneration Has Quantitative Predictive Value for Studies of Neuroprotection in …
  4004. HIF-1α-Mediated Neuroprotection on MPP+-Induced Apoptosis in SH-SY5Y Cells
  4005. GSK-3b-Nrf2 Signaling Pathway for Neuroprotection in Alzheimer’s Disease
  4006. Identification of the Receptor Tyrosine Kinase Inibitor Sunitinib, and Related Analogues, as Candidate Molecules for Glaucoma Neuroprotection
  4007. The Neuroprotection of Psoralen on βamyloid-induced Cholinergic System Injury in Hippocampal Neuron Cultures
  4008. … in Optic Nerve Axotomy, Manipulation of the p75 Neurotrophin Receptor Signals Activate Neuro-Gial Mechanisms Causing RGC Neuroprotection or Increased RGC …
  4009. The Neuroprotection and cognition -amelioration after G-CSF treatment in chronic cerebral ischemic aged rats
  4010. Fast nongenomic Neuroprotection mediated by GPR30-dependent depression of NR2B-containing NMDA receptors
  4011. OECs transplantation in spinal cord prolongs the survival of mutant SOD1 (G93A) ALS rats through Neuroprotection
  4012. Roles of nuclear receptors LXRs and ERs in the Neuroprotection of dopaminergic neurons in the midbrain
  4013. Newly synthesized radical-containing nanoparticles (RNP) enhance Neuroprotection after cerebral ischemia-reperfusion injury
  4014. Light Reduction, Neuroprotection , And Subretinal Gene Therapy In A Mouse Model Of Bardet Biedl Syndrome
  4015. Retinoic acid receptor‐mediated Neuroprotection and its implications for amyotrophic lateral sclerosis
  4016. The role of Peroxisome Proliferator Activated Receptors in Amyotrophic Lateral Sclerosis: potential mechanisms for Neuroprotection
  4017. The Neuroprotection of SIRT1 on NMDA-induce excitotoxicity in cultured cortical cell
  4018. Neuroprotection with Melatonin and the Caspase-2 Inhibitor TRP601: Novel Aspects by Analysis of the Metabolome in Excitotoxic brain Injury
  4019. NEUROSCIENCES AND NEUROANAESTHESIA-Small temperature variations alter edaravone-induced Neuroprotection of cortical cultures exposed to …
  4020. Boosting endogenous Neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon b in relapsing–remitting Multiple Sclerosis (ASIIMS) trial
  4021. Pregnancy-associated Effects on Immune Modulation and Neuroprotection in Experimental Autoimmune Encephalomyelitis: Role of T Cells and Serum Exosomes
  4022. Exosomes: Mediators of Pregnancy-associated Immune Modulation and Neuroprotection in a Model of Multiple Sclerosis
  4023. The Effects of Paraquat Exposure on Serial Reaction Time Performance in Rats (Rattus norvegicus) and Neuroprotection by Water-Soluble COQ10
  4024. Hippocampal Alterations in Rats Submitted to Streptozotocin-Induced Dementia Model: Neuroprotection with Aminoguanidine
  4025. Improved Neuroprotection with melatonin-augmented hypothermia versus hypothermia alone in a perinatal asphyxia model
  4026. First clinical use of a novel neurovascular access and Neuroprotection system demonstrates complete absence of emboli by transcranial Doppler during carotid artery …
  4027. Calpain Inhibition Confers Histological and Functional Neuroprotection to Retinal Ganglion Cells in Experimental Optic Neuritis
  4028. Neuroprotection of adenoassociated vira-mediated brain -derived neurotrophic factor on retinal ganglion cells in DBA/2J mice with glaucoma
  4029. … of blood glutamate into peripheral tissues is increased by stress response and adrenaline administration, providing Neuroprotection following traumatic brain injury …
  4030. Neuroprotection of Retinal Ganglion Cells and Their Axons With Gdnf & Vit E Loaded Biodegradable Microparticles in Rat Experimental Glaucoma Model
  4031. Docosahexaenoic Acid Pretreatment Confers Neuroprotection in a Rat Model of Perinatal Cerebral Hypoxia-Ischemia
  4032. Hydrogen is Neuroprotective and preserves cerebrovascular reactivity in asphyxiated newborn pigs Running title: Neuroprotection by hydrogen
  4033. 3.2. 2. Retinal Neuroprotection by hypoxic preconditioning is independent of hypoxia-inducible factor-1α expression in photoreceptors
  4034. Intracellular calcium concentration alteration during H202 induced primary cultured retinal neurons injury and 17β-Estradiol Neuroprotection
  4035. In Experimental Glaucoma Using Agonists or Antagonists of TrkA, TrkB, or TrkC Reveal Neuro-Glial Mechanisms of Action and Novel Approaches to Neuroprotection
  4036. Stress, adrenaline and CRH provide Neuroprotection in traumatic brain injury by enhancing the brain -to-blood glutamate driving force: 7AP5–7
  4037. The mechanism of Neuroprotection mediated by nicotinamide mononucleotide adenylyl transferase (NMNAT)
  4038. NR4A orphan nuclear receptors in immediate early regulation of retinoid signaling and Neuroprotection
  4039. Broccoli sprout supplementation during placental insufficiency confers structural and functional Neuroprotection to the fetal rat
  4040. Sulforaphane inhibits redox-regulated permeability transition and provides Neuroprotection following cardiac arrest
  4041. Neurodegeneration and Neuroprotection in glaucoma retinopathy-probing the role of endothelin-1, RAGE, A {221} and lycium barbarum
  4042. Neuroprotection of ischemic postconditioning on spinal cord ischemia reperfusion injury might be related to PI3K/AKT pathway in rabbit
  4043. Transient Lack of Glucose but Not Oxygen is Involved in Ischemic Postconditioning-Induced Neuroprotection in Mouse Corticostriatal Slices by Regulating Glutamate …
  4044. The changes of acid-sensing ion channel 1a in focal cerebral ischemic diabetes rats and Neuroprotection of fasudil
  4045. Gene expression profiles of sevoflurane and isoflurane in a rat model of focal cerebral ischemia: Preconditioning provide Neuroprotection by inhibition of apoptosis …
  4046. … of Poly (triethylene glycol methyl acrylate-co-α-tocopheryl acrylate): a Water Soluble Antioxidant Polymer Derivative to Enable Localized Neuroprotection
  4047. Olfactory ensheathing cells (OECs) transplantation in spinal cord prolongs the survival of mutant SOD1 (G93A) ALS rats through Neuroprotection and remyelination
  4048. Effects Of The Advanced Glycation End Products-Inductor Glyoxal On Mouse Retinal Explants And Neuroprotection By Memantine And Erythropoietin
  4049. Agrin C20 peptide provides Neuroprotection by activating a Na, K‐ATPase/Inositol 1, 4, 5‐Trisphosphate receptor signaling pathway
  4050. 193 The Rna-Binding Protein Rbm3 is Involved in Hypothermia Induced Neuroprotection
  4051. COX-2/PGI2 pathway is involved in Neuroprotection induced by N1-methylnicotinamide in hypoxia/ischemia of newborn rats
  4052. 8-OH DPAT-Mediated Neuroprotection in a mouse model of atrophic age-related macular degeneration
  4053. Morphological insight into new opportunities using Bcl-2 and P53 in studies of neurotrophicity, Neuroprotection and neuroplasticity in brain ischemia
  4054. Abstract# 2: Diffusion Tensor Imaging As a Neuroprotection Outcome Metric in Multiple Sclerosis: Clinical Trial Sample Size Estimates
  4055. Aroclor 1254 Disturbs Estrogen Receptor-mediated Neuroprotection Against Beta-amyloid Toxicity in Cholinergic SN56 Cells
  4056. Status of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and Neuroprotection in children with Ataxia …
  4057. FK506 Binding Protein 51 (FKBP51) Mediated Neuroprotection Against Glutamate Excitotoxicity in 661w and HT22 Cell Culture
  4058. Roles of reactive oxygen species and phosphatidyl-inositol 3-kinase-Akt in Neuroprotection against spinal cord ischemia-reperfusion injury by ischemic …
  4059. 194: MEMANTINE PROVIDES SUPERIOR MOLECULAR Neuroprotection COMPARED TO MK801 AFTER TRAUMATIC brain INJURY IN IMMATURE RATS
  4060. Sphingosine-1-Phosphate Has A Key Role In Müller Glia Proliferation, Migration And Neuroprotection
  4061. HIF-1 Neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors
  4062. Carcinine Has Antioxidant and 4-Hydroxynonenal Scavenging Properties Offering Strong Neuroprotection From Oxidative Damage in Mouse Retina
  4063. Interleukin-6-type cytokines in Neuroprotection and neuromodulation Moidunny, Shamsudheen; Dias, Raquel Baptista; Wesseling, Evelyn; Sekino, Yuko; …
  4064. Effects of chronic, systemic treatment with metabotropic glutamate receptor 5 antagonist on behavioral activity and Neuroprotection in a preclinical rat model of …
  4065. The Anti-NgR Blocking Protein, NgR (310) ecto-Fc, Has a Potential Role for Neuroprotection in an EVC Rat Model of Glaucoma
  4066. Hypoxic preconditioning by HIF‐1 accumulation not angiogenesis provides Neuroprotection in rats following MCAO
  4067. The roles of postsynaptic density-95 protein (PSD-95) and its interactor, cypin, in the regulation of microtubule organization, dendrite morphology, and Neuroprotection
  4068. Role of PPAR< img src=’/image/spc_char/gamma2. gif’border= 0>, a Nuclear Hormone Receptor in Neuroprotection
  4069. 18 Neuroprotection in Parkinson’s
  4070. 113 The Apoptotic Effect of Propofol in Immature Rat brain and Possible Neuroprotection by Erythropoietin
  4071. 247 Neuroprotection with Rhepo in Cyantoic Neonatal Mice
  4072. From the bench to the bedside: Emerging science in Parkinson’s disease, cholesterol metabolism, and Neuroprotection
  4073. Roles of angiotensin type 1 receptor signaling in Neuroprotection
  4074. 717. Broad Spectrum Activity of the HSV-2 Vector∆ RR Enhances Neuroprotection and Includes Crosstalk between Neurons and Glial Cells
  4075. Adenosine A^ sub 2^ A antagonists: Neuroprotection and autophagy induction by a new compound
  4076. Neuroprotection : lessons from hibernators
  4077. Neuroprotection for stroke: current status and future perspectives
  4078. Neuroprotection and repair in multiple sclerosis
  4079. Ischemic stroke and Neuroprotection
  4080. Novel mitochondrial targets for Neuroprotection
  4081. Neuroprotection for ischaemic stroke: translation from the bench to the bedside
  4082. An antagomir to microRNA Let7f promotes Neuroprotection in an ischemic stroke model
  4083. Neurometabolic mechanisms for memory enhancement and Neuroprotection of methylene blue
  4084. Neuroprotection in diabetic retinopathy
  4085. Effects of dimethyl fumarate on Neuroprotection and immunomodulation
  4086. Neuroprotection and estrogen receptors
  4087. Inhibition of Drp1 provides Neuroprotection in vitro and in vivo
  4088. Wine polyphenols: potential agents in Neuroprotection
  4089. Estrogen Neuroprotection and the critical period hypothesis
  4090. A review of Neuroprotection pharmacology and therapies in patients with acute traumatic brain injury
  4091. Microvascular protection is essential for successful Neuroprotection in stroke
  4092. Progesterone receptors: a key for Neuroprotection in experimental stroke
  4093. Hypoxic-ischemic encephalopathy and novel strategies for Neuroprotection
  4094. Nonhuman primate models of stroke for translational Neuroprotection research
  4095. Maximizing Neuroprotection : where do we stand?
  4096. Clinical trials for glaucoma Neuroprotection are not impossible
  4097. Neuroprotection from stroke in the absence of MHCI or PirB
  4098. Neuroprotection of apelin and its signaling pathway
  4099. Kynurenine pathway inhibition as a therapeutic strategy for Neuroprotection
  4100. Neuroprotection and its molecular mechanism following spinal cord injury
  4101. Translational Neuroprotection research in glaucoma: a review of definitions and principles
  4102. Erythropoietin for Neuroprotection in neonatal encephalopathy: safety and pharmacokinetics
  4103. Induction of autophagy contributes to the Neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia
  4104. Neural stem cell transplantation in central nervous system disorders: from cell replacement to Neuroprotection
  4105. Neuroprotection by GDNF in the ischemic brain
  4106. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease
  4107. Lipopolysaccharide-induced microglial activation and Neuroprotection against experimental brain injury is independent of hematogenous TLR4
  4108. Enteric glia and Neuroprotection : basic and clinical aspects
  4109. Resveratrol Neuroprotection in a chronic mouse model of multiple sclerosis
  4110. Blood glutamate scavenging: insight into Neuroprotection
  4111. Expression patterns of histone deacetylases in experimental stroke and potential targets for Neuroprotection
  4112. Phytochemical characteristics, free radical scavenging activities, and Neuroprotection of five medicinal plant extracts
  4113. Transplantation of human central nervous system stem cells–Neuroprotection in retinal degeneration
  4114. Oestrogen signalling and Neuroprotection in cerebral ischaemia
  4115. Neuroprotection in vascular dementia: a future path
  4116. Neuroprotection in metabolism-based therapy
  4117. Gene therapy for retinal ganglion cell Neuroprotection in glaucoma
  4118. Multifaces of neuropeptide Y in the brain –Neuroprotection , neurogenesis and neuroinflammation
  4119. Minocycline-preconditioned neural stem cells enhance Neuroprotection after ischemic stroke in rats
  4120. Nanowired drug delivery to enhance Neuroprotection in spinal cord injury
  4121. Sirt1 mediates Neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway
  4122. Roles of amyloid precursor protein family members in Neuroprotection , stress signaling and aging
  4123. Cytochrome c Oxidase and Its Role in Neurodegeneration and Neuroprotection
  4124. Role of mTOR in Neuroprotection and axon regeneration after inflammatory stimulation
  4125. Silencing of miR20a is crucial for Ngn1-mediated Neuroprotection in injured spinal cord
  4126. Erythropoietin: still on the Neuroprotection road
  4127. Translational potential of preclinical trials of Neuroprotection through pharmacotherapy for spinal cord injury
  4128. Sex differences in mechanisms and outcome of neonatal hypoxia-ischemia in rodent models: implications for sex-specific Neuroprotection in clinical neonatal …
  4129. Inhibition of autophagy contributes to ischemic postconditioning-induced Neuroprotection against focal cerebral ischemia in rats
  4130. Glycyrrhizic acid affords robust Neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion
  4131. Different magnesium sulphate regimens for Neuroprotection of the fetus for women at risk of preterm birth
  4132. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson’s disease
  4133. Monoamine oxidase inhibitors and Neuroprotection : a review
  4134. Neuroprotection targeting ischemic penumbra and beyond for the treatment of ischemic stroke
  4135. Ex vivo and in vivo Neuroprotection induced by argon when given after an excitotoxic or ischemic insult
  4136. The soluble isoform of CX3CL1 is necessary for Neuroprotection in a mouse model of Parkinson’s disease
  4137. Carvacrol, a food-additive, provides Neuroprotection on focal cerebral ischemia/reperfusion injury in mice
  4138. Seizure suppression and Neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice
  4139. Metabotropic glutamate receptors in neurodegeneration/Neuroprotection : still a hot topic?
  4140. Neuroglobin, a novel target for endogenous Neuroprotection against stroke and neurodegenerative disorders
  4141. Autophagy activation is associated with Neuroprotection against apoptosis via a mitochondrial pathway in a rat model of subarachnoid hemorrhage
  4142. Neuroprotection against iron-induced cell death by perineuronal nets-an in vivo analysis of oxidative stress
  4143. New strategies in Neuroprotection and neurorepair
  4144. Taurine provides Neuroprotection against retinal ganglion cell degeneration
  4145. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, Neuroprotection and angiogenesis in a rat model of stroke
  4146. N-Acetylserotonin: Neuroprotection , Neurogenesis, and the Sleepy brain
  4147. Antenatal magnesium sulfate and Neuroprotection
  4148. Neuroprotection by urate on 6‐OHDA‐lesioned rat model of Parkinson’s disease: linking to Akt/GSK 3β signaling pathway
  4149. The metastasis-promoting S100A4 protein confers Neuroprotection in brain injury
  4150. Functional analysis of VPS41-mediated Neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson’s disease
  4151. Targeting mitochondria for Neuroprotection in Parkinson’s disease
  4152. Human neuroglobin functions as an oxidative stress-responsive sensor for Neuroprotection
  4153. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust Neuroprotection in the postischemic brain
  4154. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes Neuroprotection and glial engulfment of Aβ
  4155. Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons
  4156. Xenon Neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage
  4157. Immunopathogenesis of neurodegenerative diseases: current therapeutic models of Neuroprotection with special reference to natural products.
  4158. A natural coumarin derivative esculetin offers Neuroprotection on cerebral ischemia/reperfusion injury in mice
  4159. Manipulating kynurenic acid levels in the brain –on the edge between Neuroprotection and cognitive dysfunction
  4160. ATP-dependent potassium channel blockade strengthens microglial Neuroprotection after hypoxia–ischemia in rats
  4161. Human embryonic stem cell derived astrocytes mediate non-cell-autonomous Neuroprotection through endogenous and drug-induced mechanisms
  4162. A Spirulina-Enhanced diet provides Neuroprotection in an α-synuclein model of Parkinson’s disease
  4163. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson’s disease
  4164. Strong Neuroprotection with a novel platinum nanoparticle against ischemic stroke-and tissue plasminogen activator-related brain damages in mice
  4165. New agents promote Neuroprotection in Parkinson’s disease models
  4166. Therapeutic effect of mesenchymal stem cells in rats with intracerebral hemorrhage: reduced apoptosis and enhanced Neuroprotection
  4167. Non-analgesic effects of opioids: Neuroprotection in the retina
  4168. Phosphorylation of HSP27 by protein kinase D is essential for mediating Neuroprotection against ischemic neuronal injury
  4169. Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury
  4170. brain ‐derived neurotrophic factor‐mediated effects on mitochondrial respiratory coupling and Neuroprotection share the same molecular signalling pathways
  4171. Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats
  4172. α7 nicotinic acetylcholine receptor-mediated Neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
  4173. Neuroprotection provided by dietary restriction in rats is further enhanced by reducing glucocortocoids
  4174. Nanowired drug delivery for Neuroprotection in central nervous system injuries: modulation by environmental temperature, intoxication of nanoparticles, and …
  4175. … abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer’s disease: implications for Neuroprotection and lifespan extension
  4176. Mitochondrial biogenesis contributes to ischemic Neuroprotection afforded by LPS pre‐conditioning
  4177. Treatment of alloxan-induced diabetic rats with metformin or glitazones is associated with amelioration of hyperglycaemia and Neuroprotection
  4178. … expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted Neuroprotection against hippocampal neurone cell …
  4179. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: up-regulated pAkt, pGSK and pCREB, down-regulated NF-κB …
  4180. Cerebrolysin, a mixture of neurotrophic factors induces marked Neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals
  4181. Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson’s disease
  4182. α7 nicotinic acetylcholine receptor mediated Neuroprotection in Parkinson’s disease
  4183. Acetyl‐L‐carnitine‐mediated Neuroprotection during hypoxia is attributed to ERK1/2‐Nrf2‐regulated mitochondrial biosynthesis
  4184. Multimodal Neuroprotection induced by PACAP38 in oxygen–glucose deprivation and middle cerebral artery occlusion stroke models
  4185. Curcumin-mediated Neuroprotection against amyloid-β-induced mitochondrial dysfunction involves the inhibition of GSK-3β
  4186. New evidence of Neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous …
  4187. Interrelation between inflammation, thrombosis, and Neuroprotection in cerebral ischemia
  4188. Neurotrophin production in brain pericytes during hypoxia: a role of pericytes for Neuroprotection
  4189. Sevoflurane and isoflurane preconditioning provides Neuroprotection by inhibition of apoptosis-related mRNA expression in a rat model of focal cerebral ischemia
  4190. B‐vitamins for Neuroprotection : Narrowing the evidence gap
  4191. Ischemic Neuroprotection by TRPV1 receptor-induced hypothermia
  4192. Quercetin in hypoxia-induced oxidative stress: novel target for Neuroprotection
  4193. Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for Neuroprotection
  4194. α7 nicotinic acetylcholine receptor agonism confers Neuroprotection through GSK-3β inhibition in a mouse model of intracerebral hemorrhage
  4195. Role of secondary mediators in caffeine-mediated Neuroprotection in maneb-and paraquat-induced Parkinson’s disease phenotype in the mouse
  4196. Ginkgo extract EGb761 confers Neuroprotection by reduction of glutamate release in ischemic brain
  4197. CR8, a selective and potent CDK inhibitor, provides Neuroprotection in experimental traumatic brain injury
  4198. Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a …
  4199. Neuroprotection by Manganese Superoxide Dismutase (M n SOD) Mimics: Antioxidant Effect and Oxidative Stress Regulation in Acute Experimental Stroke
  4200. Estrogen, Neuroprotection and neurogenesis after ischemic stroke
  4201. Neuroprotection and hypothermia in infants and children
  4202. Preconditioning induces sustained Neuroprotection by downregulation of adenosine 5′-monophosphate-activated protein kinase
  4203. Combined inhibition of cell death induced by apoptosis inducing factor and caspases provides additive Neuroprotection in experimental traumatic brain injury
  4204. Valproic acid-mediated Neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation
  4205. Allosteric modulation of the group III mGlu4 receptor provides functional Neuroprotection in the 6‐hydroxydopamine rat model of Parkinson’s disease
  4206. Neuroprotection by urokinase plasminogen activator in the hippocampus
  4207. AKT/GSK 3β‐Dependent Autophagy Contributes to the Neuroprotection of Limb Remote Ischemic Postconditioning in the Transient Cerebral Ischemic Rat Model
  4208. AIF depletion provides Neuroprotection through a preconditioning effect
  4209. Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory Neuroprotection following reperfused stroke
  4210. Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated Neuroprotection
  4211. Increased neuronal glutathione and Neuroprotection in GTRAP3-18-deficient mice
  4212. The Neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive …
  4213. Curcumin has Neuroprotection effect on homocysteine rat model of Parkinson
  4214. The mitochondrial calcium regulator cyclophilin D is an essential component of oestrogen-mediated Neuroprotection in amyotrophic lateral sclerosis
  4215. Challenging the Role of Adaptive Immunity in Neurotrauma: Rag1−/− Mice Lacking Mature B and T Cells Do Not Show Neuroprotection after Closed Head Injury
  4216. Functional and molecular evidence of myelin‐and Neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis
  4217. Modulation of microglial activation enhances Neuroprotection and functional recovery derived from bone marrow mononuclear cell transplantation after cortical …
  4218. Riluzole Neuroprotection in a Parkinson’s disease model involves suppression of reactive astrocytosis but not GLT-1 regulation
  4219. Health benefits of wine and alcohol from Neuroprotection to heart health.
  4220. Neuroprotection of VEGF-expression neural stem cells in neonatal cerebral palsy rats
  4221. Role of magnesium sulfate in Neuroprotection in acute ischemic stroke
  4222. Mechanisms of neuronal damage and Neuroprotection underlying ischemia/reperfusion injury after physical exercise
  4223. The Neuroprotection effect of pretreatment with olive leaf extract on brain lipidomics in rat stroke model
  4224. Dopaminergic Neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system
  4225. Coordination between proteasome impairment and caspase activation leading to TAU pathology: Neuroprotection by cAMP
  4226. Cyclin D1 gene ablation confers Neuroprotection in traumatic brain injury
  4227. Role of mammalian target of rapamycin in hypoxic or ischemic brain injury: potential Neuroprotection and limitations
  4228. A priming role of local estrogen on exogenous estrogen-mediated synaptic plasticity and Neuroprotection
  4229. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood–brain barrier …
  4230. A derivative of the CRMP2 binding compound lanthionine ketimine provides Neuroprotection in a mouse model of cerebral ischemia
  4231. Direct protection of neurons and astrocytes by matrine via inhibition of the NF-κB signaling pathway contributes to Neuroprotection against focal cerebral ischemia
  4232. Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson’s model: A promising candidate for the treatment of Parkinson’s …
  4233. Specific inhibition of the JNK pathway promotes locomotor recovery and Neuroprotection after mouse spinal cord injury
  4234. Feasibility of implementing magnesium sulphate for Neuroprotection in a tertiary obstetric unit
  4235. Muscone exerts Neuroprotection in an experimental model of stroke via inhibition of the fas pathway
  4236. TMP prevents retinal neovascularization and imparts Neuroprotection in an oxygen-induced retinopathy model
  4237. Interrupted intracarotid artery cold saline infusion as an alternative method for Neuroprotection after ischemic stroke
  4238. Galantamine elicits Neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation
  4239. Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock
  4240. Overexpression of CB2 cannabinoid receptors results in Neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of …
  4241. Inhibition of E2F1/CDK1 pathway attenuates neuronal apoptosis in vitro and confers Neuroprotection after spinal cord injury in vivo
  4242. Neuroprotection of the leaf and stem of Vitis amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons
  4243. Neuronal growth-promoting and inhibitory cues in Neuroprotection and neuroregeneration
  4244. Neuroprotection from tissue inhibitor of metalloproteinase-1 and its nanoparticles
  4245. Neuroprotection of lipoic acid treatment promotes angiogenesis and reduces the glial scar formation after brain injury
  4246. Pizotifen activates ERK and provides Neuroprotection in vitro and in vivo in models of Huntington’s disease
  4247. Blocking of connexin-mediated communication promotes Neuroprotection during acute degeneration induced by mechanical trauma
  4248. Prospective, multicenter European study of the GORE flow reversal system for providing Neuroprotection during carotid artery stenting
  4249. Activation of Akt/FoxO and inactivation of MEK/ERK pathways contribute to induction of Neuroprotection against transient global cerebral ischemia by delayed hypoxic …
  4250. Evaluation of sirtuin role in Neuroprotection of retinal ganglion cells in hypoxia
  4251. Therapeutic hypothermia after cardiac arrest in adults: mechanism of Neuroprotection , phases of hypothermia, and methods of cooling
  4252. … utilization of lactate satisfy increased energy demands upon neuronal activation in hippocampal slices and provide Neuroprotection against oxidative stress
  4253. Intranasal delivery of HMGB1-binding heptamer peptide confers a robust Neuroprotection in the postischemic brain
  4254. Combination treatment of hypothermia and mesenchymal stromal cells amplifies Neuroprotection in primary rat neurons exposed to hypoxic-ischemic-like …
  4255. Long‐lasting Neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly (ADP‐ribose) polymerase
  4256. Dietary therapy to promote Neuroprotection in chronic spinal cord injury
  4257. Neurogenic Neuroprotection : clinical perspectives
  4258. Striatal pleiotrophin overexpression provides functional and morphological Neuroprotection in the 6-hydroxydopamine model
  4259. Combined treatment with capsaicin and resveratrol enhances Neuroprotection against glutamate-induced toxicity in mouse cerebral cortical neurons
  4260. Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy
  4261. Glaucoma 2.0: Neuroprotection , neuroregeneration, neuroenhancement
  4262. Gene expression analysis to identify molecular correlates of pre-and post-conditioning derived Neuroprotection
  4263. Neuroprotection and neurodegeneration in Alzheimer’s disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention …
  4264. Toll-like receptor 7 preconditioning induces robust Neuroprotection against stroke by a novel type I interferon-mediated mechanism
  4265. Pegylated granulocyte colony-stimulating factor conveys long-term Neuroprotection and improves functional outcome in a model of Parkinson’s disease
  4266. Neuroprotection afforded by antagonists of endothelin-1 receptors in experimental stroke
  4267. Sevoflurane-induced delayed Neuroprotection involves mitoKATP channel opening and PKC ε activation
  4268. Delayed Neuroprotection induced by sevoflurane via opening mitochondrial ATP-sensitive potassium channels and p38 MAPK phosphorylation
  4269. Neuroprotection or increased brain damage mediated by temperature in stroke is time dependent
  4270. The omega‐6 fatty acid derivative 15‐deoxy‐Δ12,14‐prostaglandin J2 is involved in Neuroprotection by enteric glial cells against oxidative stress
  4271. Swim training attenuates oxidative damage and promotes Neuroprotection in cerebral cortical slices submitted to oxygen glucose deprivation
  4272. Vascular Neuroprotection via TrkB‐and Akt‐dependent cell survival signaling
  4273. Edaravone offers Neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress
  4274. Alzheimer’s disease, Neuroprotection , and CNS immunosenescence
  4275. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to Neuroprotection
  4276. Inhibition of neuron-specific CREB dephosphorylation is involved in propofol and ketamine-induced Neuroprotection against cerebral ischemic injuries of mice
  4277. 6-Shogaol, a ginger product, modulates neuroinflammation: a new approach to Neuroprotection
  4278. Neuroprotection afforded by adenosine A2A receptor blockade is modulated by corticotrophin‐releasing factor (CRF) in glutamate injured cortical neurons
  4279. Neuroprotection of neurotrophin-3 against focal cerebral ischemia/reperfusion injury is regulated by hypoxia-responsive element in rats
  4280. Neuroprotection by hypoxic preconditioning involves upregulation of hypoxia‐inducible factor‐1 in a prenatal model of acute hypoxia
  4281. Neuroprotection by lowering cholesterol: a decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve …
  4282. Upregulation of heme oxygenase-1 by acteoside through ERK and PI3 K/Akt pathway confer Neuroprotection against beta-amyloid-induced neurotoxicity
  4283. Potential role of glucagon-like peptide-1 (GLP-1) in Neuroprotection
  4284. Co-administration of apocynin with lipoic acid enhances Neuroprotection in a rat model of ischemia/reperfusion
  4285. Controlled release of rasagiline mesylate promotes Neuroprotection in a rotenone-induced advanced model of Parkinson’s disease
  4286. … ) mouse model of Parkinson’s disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for Neuroprotection …
  4287. Neuroprotection in glaucoma
  4288. Glutathione-mediated Neuroprotection against methylmercury neurotoxicity in cortical culture is dependent on MRP1
  4289. Estrogen receptors in lipid raft signalling complexes for Neuroprotection
  4290. The complexity of sporadic Alzheimer’s disease pathogenesis: the role of RAGE as therapeutic target to promote Neuroprotection by inhibiting neurovascular …
  4291. The role of the DNA damage response kinase ataxia telangiectasia mutated in Neuroprotection
  4292. The effects of hemodialysis on blood glutamate levels in chronic renal failure: implementation for Neuroprotection
  4293. Pro-cellular survival and Neuroprotection of citrus flavonoid: the actions of hesperetin in PC12 cells
  4294. Neuroprotection of co-activation of GABA receptors by preventing caspase-3 denitrosylation in KA-induced seizures
  4295. Neuroprotection in Parkinson’s disease: a systematic review of the preclinical data
  4296. Specific conditions for resveratrol Neuroprotection against ethanol-induced toxicity
  4297. Mitochondrial inhibition in rat retinal cell cultures as a model of metabolic compromise: mechanisms of injury and Neuroprotection
  4298. Preconditioning with Ginkgo biloba (EGb 761®) provides Neuroprotection through HO1 and CRMP2
  4299. Methylene blue administration fails to confer Neuroprotection in two amyotrophic lateral sclerosis mouse models
  4300. Neuroprotection of Ilex latifolia and caffeoylquinic acid derivatives against excitotoxic and hypoxic damage of cultured rat cortical neurons
  4301. Caffeic acid ester fraction from Erigeron breviscapus inhibits microglial activation and provides Neuroprotection
  4302. Platelet-derived growth factor CC-mediated Neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta
  4303. Rapid conditioning with oxygen oscillation: Neuroprotection by intermittent normobaric hyperoxia after transient focal cerebral ischemia in rats
  4304. Anti-amnesic effect of neurosteroid PREGS in Aβ25–35-injected mice through σ1 receptor-and α7nAChR-mediated Neuroprotection
  4305. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for Neuroprotection
  4306. Nanowired drug delivery of antioxidant compound H-290/51 enhances Neuroprotection in hyperthermia-induced neurotoxicity
  4307. Role of the pituitary–adrenal axis in granulocyte-colony stimulating factor-induced Neuroprotection against hypoxia–ischemia in neonatal rats
  4308. Kinin-B2 receptor mediated Neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists
  4309. Association of Neuroprotection and Oxidative Stress Gene Polymorphism With Neurodevelopmental Outcomes After Preterm Birth
  4310. Nonadditive Neuroprotection with early glutamate receptor blockade and delayed hypothermia after asphyxia in preterm fetal sheep
  4311. State of the art in Neuroprotection during acute type A aortic dissection repair
  4312. Neuroprotection by nicotine against colchicine-induced apoptosis is mediated by PI3-kinase–Akt pathways
  4313. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice
  4314. G-protein coupled estrogen receptor 1 mediated estrogenic Neuroprotection against spinal cord injury
  4315. SHPS‐1 deficiency induces robust Neuroprotection against experimental stroke by attenuating oxidative stress
  4316. TLR9 bone marrow chimeric mice define a role for cerebral TNF in Neuroprotection induced by CpG preconditioning
  4317. Rodent spinal cord injury model and application of neurotrophic factors for Neuroprotection
  4318. Glycosaminoglycans and Neuroprotection
  4319. Resveratrol potentiates cytochrome P450 2 d22-mediated Neuroprotection in maneb-and paraquat-induced parkinsonism in the mouse
  4320. Oroxylin A induces BDNF expression on cortical neurons through adenosine A2A receptor stimulation: a possible role in Neuroprotection
  4321. Neurodegeneration and Neuroprotection in multiple sclerosis
  4322. Role of electrical activity of neurons for Neuroprotection
  4323. … -activated protein kinase–induced nuclear factor kappa-light-chain-enhancer of activated B cell activity is required for Neuroprotection in retinal ischemia …
  4324. Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for Neuroprotection
  4325. HDAC 6 at the Intersection of Neuroprotection and Neurodegeneration
  4326. The multimodal strategy for the Neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL
  4327. Molecular and Cellular Biology of Neuroprotection in the CNS
  4328. Mechanisms of Neuroprotection underlying physical exercise in ischemia-reperfusion injury
  4329. Neuroglobin upregulation offers Neuroprotection in traumatic brain injury
  4330. Neuroprotection and sex steroid hormones: evidence of estradiol-mediated protection in hypertensive encephalopathy
  4331. Endogenous neural precursors influence grafted neural stem cells and contribute to Neuroprotection in the parkinsonian rat
  4332. Negative modulation of NMDA receptor channel function by DREAM/calsenilin/KChIP3 provides Neuroprotection ?
  4333. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated Neuroprotection against 1-methyl-4-phenyl pyridinium-induced …
  4334. The C-terminal domain of the heavy chain of tetanus toxin given by intramuscular injection causes Neuroprotection and improves the motor behavior in rats treated …
  4335. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and Neuroprotection by gene delivery of antioxidant enzymes
  4336. Time course of Neuroprotection induced by normobaric hyperoxia in focal cerebral ischemia
  4337. Valproic acid Neuroprotection in 6-OHDA lesioned rat, a model for parkinson’s disease
  4338. Plate reader-based assays for measuring cell viability, Neuroprotection and calcium in primary neuronal cultures
  4339. A ketogenic diet may offer Neuroprotection in glaucoma and mitochondrial diseases of the optic nerve
  4340. Neuroprotection by NMDA preconditioning against glutamate cytotoxicity is mediated through activation of ERK 1/2, inactivation of JNK, and by prevention of …
  4341. Nanoerythropoietin is 10-times more effective than regular erythropoietin in Neuroprotection in a neonatal rat model of hypoxia and ischemia
  4342. Piperphentonamine (PPTA) attenuated cerebral ischemia-induced memory deficits via Neuroprotection associated with anti-apoptotic activity
  4343. Angiotensin II type 2 receptor stimulation initiated after stroke causes Neuroprotection in conscious rats
  4344. Time dependent Neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation
  4345. Lymphocyte cell kinase activation mediates Neuroprotection during ischemic preconditioning
  4346. NAD+-converting enzymes in neuronal and glial cells: CD38 as a novel target for Neuroprotection
  4347. Co-regulation of survival of motor neuron and Bcl-xL expression: implications for Neuroprotection in spinal muscular atrophy
  4348. Renin inhibitor aliskiren exerts Neuroprotection against amyloid beta-peptide toxicity in rat cortical neurons
  4349. CD4+ T cell-mediated Neuroprotection is independent of T cell-derived BDNF in a mouse facial nerve axotomy model
  4350. Cyclin‐Dependent Kinase Inhibition With Roscovitine: Neuroprotection in Acute Ischemic Stroke
  4351. Contribution of microRNA-203 to the isoflurane preconditioning-induced Neuroprotection
  4352. Long-term behavioral and biochemical effects of an ultra-low dose of Δ 9-tetrahydrocannabinol (THC): Neuroprotection and ERK signaling
  4353. Neuroprotection of green tea catechins on surgical menopause-induced overactive bladder in a rat model
  4354. Endothelin B receptor agonist, IRL-1620, provides long-term Neuroprotection in cerebral ischemia in rats
  4355. Pre, intra and post-ischemic hypothermic Neuroprotection in temporary focal cerebral ischemia in rats: morphometric analysis
  4356. Neuroprotection for premature infants?: another perspective on caffeine
  4357. Sigma-1 receptor agonists provide Neuroprotection against gp120 via a change in bcl-2 expression in mouse neuronal cultures
  4358. Transcriptional regulation of specific protein 1 (SP1) by hypoxia-inducible factor 1 alpha (HIF-1α) leads to PRNP expression and Neuroprotection from toxic prion …
  4359. An in-silico strategy to explore Neuroprotection by quercetin in cerebral ischemia: a novel hypothesis based on inhibition of matrix metalloproteinase (MMPs) and acid …
  4360. New perspectives of central nervous system injury and Neuroprotection
  4361. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting Neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia
  4362. Is cerebrospinal fluid drainage of benefit to Neuroprotection in patients undergoing surgery on the descending thoracic aorta or thoracoabdominal aorta?
  4363. C5a receptor (CD88) inhibition improves hypothermia-induced Neuroprotection in an in vitro ischemic model
  4364. Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration
  4365. Chiral mercaptoacetamides display enantioselective inhibition of histone deacetylase 6 and exhibit Neuroprotection in cortical neuron models of oxidative stress
  4366. Benzothiazepine CGP37157 and its isosteric 2′-methyl analogue provide Neuroprotection and block cell calcium entry
  4367. Post‐ischemic vascular adhesion protein‐1 inhibition provides Neuroprotection in a rat temporary middle cerebral artery occlusion model
  4368. Tau and caspase 3 as targets for Neuroprotection
  4369. Comprehensive strategy for retinal Neuroprotection . Challenging the clinical application
  4370. Neuropeptides in Neuroprotection and neuroregeneration
  4371. Cerebroside-A provides potent Neuroprotection after cerebral ischaemia through reducing glutamate release and Ca2+ influx of NMDA receptors
  4372. Novel route to Neuroprotection
  4373. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on Neuroprotection treatment
  4374. Pharmacological enhancement of ex vivo gene therapy Neuroprotection in a rodent model of retinal degeneration
  4375. Neuroprotection in epilepsy
  4376. Supra-additive Neuroprotection by renexin, a mixed compound of ginkgo biloba extract and cilostazol, against apoptotic white matter changes in rat after chronic …
  4377. Early antioxidant treatment and delayed hypothermia after hypoxia-ischemia have no additive Neuroprotection in newborn pigs
  4378. Selective cerebral perfusion using moderate flow in complex cardiac surgery provides sufficient Neuroprotection . Are children young adults?
  4379. Toll-like receptor 4 signaling is involved in PACAP-induced Neuroprotection in BV2 microglial cells under OGD/reoxygenation
  4380. Neuroprotection by mefenamic acid against d-serine: Involvement of oxidative stress, inflammation and apoptosis
  4381. Neuroprotection supports signal processing in the hippocampus of Syrian hamsters, a facultative hibernator
  4382. A novel mechanism for sevoflurane preconditioning-induced Neuroprotection
  4383. Selective regulation of NR2B by protein phosphatase-1 for the control of the NMDA receptor in Neuroprotection
  4384. UPEI-100, a conjugate of lipoic acid and apocynin, mediates Neuroprotection in a rat model of ischemia/reperfusion
  4385. Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived …
  4386. Mesenchymal stromal cell Neuroprotection of hydrogen peroxide-challenged pheochromocytoma cells through reducing apoptosis and releasing cytokines
  4387. Flurbiprofen axetil promotes Neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats
  4388. Hypoxic preconditioning induces an AT2-R/VEGFR-2 (Flk-1) interaction in the neonatal brain microvasculature for Neuroprotection
  4389. Small molecule anticonvulsant agents with potent in vitro Neuroprotection
  4390. Recent approaches towards selected lamiaceae plants for their prospective use in Neuroprotection
  4391. Modes of action of taurine and granulocyte colony-stimulating factor in Neuroprotection
  4392. Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to Neuroprotection in the peri …
  4393. Myelin repair and Neuroprotection in multiple sclerosis
  4394. A new alternative NF-ΚB Pathway mediated the Neuroprotection of GDNF on 6-OHDA-induced DA neurons neurotoxicity
  4395. Editorial Comment: Re: Selective cerebral perfusion using moderate flow in complex cardiac surgery provides sufficient Neuroprotection . Are children young adults?
  4396. Relationship between glutamate, GOT and GPT levels in maternal and fetal blood: a potential mechanism for fetal Neuroprotection
  4397. SNP-mediated Neuroprotection under glucose deprivation is enhanced by hypericum perforatum
  4398. The critical role of adrenomedullin and its binding protein, AMBP-1, in Neuroprotection
  4399. In vitro neurotoxic Fe (III) and Fe (III)-chelator activities in rat hippocampal cultures. From neurotoxicity to Neuroprotection prospects
  4400. Neuroprotection in animal models of global cerebral ischemia
  4401. Neurogenic Neuroprotection : Future perspectives
  4402. Window of Opportunity for Neuroprotection with an Antioxidant, A llene O xide S ynthase, after Hypoxia–Ischemia in Adult Male Rats
  4403. Galectin-1 for Neuroprotection ?
  4404. Urinary erythropoietin concentrations after early short-term infusion of high-dose recombinant epo for Neuroprotection in preterm neonates
  4405. Neuroprotection on multiple sclerosis: A BDNF perspective
  4406. Involvement of molecular chaperones and the transcription factor Nrf2 in Neuroprotection mediated by para-substituted-4, 5-diaryl-3-thiomethyl-1, 2, 4-triazines
  4407. Effect of 710-nm visible light irradiation on Neuroprotection and immune function after stroke
  4408. Neuroprotection of n-Butanol Extract from Roots of Potentilla anserina on Hypoxic Injury in Primary Hippocampal Neurons
  4409. Neuroprotection and pain management
  4410. Intraoperative hypoxic preconditioning as a method of Neuroprotection in operations on internal carotid arteries
  4411. Time-window of progesterone Neuroprotection after stroke and its underlying molecular mechanisms
  4412. Selenium and selenoproteins in Neuroprotection and neuronal cell death
  4413. Neuroprotection and neurodegeneration in submucosal VIP-IR neurons in the jejunum of ascorbic acid supplemented aging Wistar rats
  4414. Neuroprotection in steroid therapy: a rodent model
  4415. Pharmacological Neuroprotection in blinding eye diseases
  4416. Involvement of K ATP/PI 3 K/AKT/Bcl-2 pathway in hydrogen sulfide-induced Neuroprotection against the toxicity of 1-methy-4-phenylpyridinium ion
  4417. The six gaps in the search of Neuroprotection for Parkinson’s disease
  4418. Neuroprotection of GluK1 kainate receptor agonist ATPA against ischemic neuronal injury through inhibiting GluK2 kainate receptor–JNK3 pathway via GABAA …
  4419. Different Neuroprotection and therapeutic time windows by two specific diazepam regimens on retinal ganglion cells after optic nerve transection in adult rats
  4420. Neuroprotection for patients with stroke moves one step closer to the clinic
  4421. Neuroprotection and Neuroregeneration in Alzheimer’s Disease
  4422. Molecular and cellular preconditiong-powerful strategies for Neuroprotection
  4423. Reviving Neuroprotection using a new approach: targeting postsynaptic density-95 to arrest glutamate excitotoxicity
  4424. Early indicators early treatments Neuroprotection in multiple sclerosis
  4425. Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
  4426. High-dose albumin for Neuroprotection in acute ischemic stroke: from basic investigations to multicenter clinical trial
  4427. β-Carbolines and Neuroprotection : Inhibition of Monoamine Oxidase
  4428. Magnesium and Neuroprotection in subarachnoid haemorrhage
  4429. Neuroprotection by dietary restriction and the PPAR transcription complex
  4430. Neurabin: a key factor in the specific Neuroprotection mediated by Adenosine
  4431. The use of hypothermia to provide Neuroprotection for neonatal hypoxic-ischemic brain injury
  4432. … of human neuroblastoma cells with Alzheimer’s disease brain hallmarks as a promising strategy to investigate the role of Neurosteroidogenesis in Neuroprotection
  4433. Multitarget drugs for stabilization of calcium cycling and Neuroprotection in neurodegenerative diseases and stroke
  4434. Neuroprotection Against Oxidative Injury by a Nucleic Acid–Based Health Product (Squina DNA) Through Enhancing Mitochondrial Antioxidant Status and Functional …
  4435. Magnesium and Neuroprotection in stroke
  4436. Neuroprotection induced by paeoniflorin against cerebral ischemia through mediating muscarinic receptor signaling pathway
  4437. Estrogen-mediated Neuroprotection : hope to combat neuronal degeneration and synaptic plasticity post-menopause
  4438. The role of davunetide in Neuroprotection and microtubule stabilization
  4439. Wine polyphenols: potential agents in Neuroprotection
  4440. Neuroprotection and functional restoration in an animal model of multiple sclerosis
  4441. Exercise-induced Neuroprotection in a hemiparkinsonian 6-hydroxydopamine rat model
  4442. Neuroglobin: a novel target for endogenous Neuroprotection
  4443. Retinal Ischemia in Relation to Glaucoma and Neuroprotection
  4444. Antioxidants and Neuroprotection
  4445. Mechanisms of Neuroprotection in SCN2. 2 Cells
  4446. Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
  4447. Neuroprotection provided by dietary restriction in rats is further enhanced by reducing glucocortocoids
  4448. Neuroprotection in Stroke
  4449. Immune cell-mediated Neuroprotection is independent of estrogen action through estrogen receptor-alpha
  4450. Neuroprotection of sulfuretin is mediated by inhibition of microglial inflammatory activation in BV‐2 cells
  4451. Gene therapy approaches to evaluate Neuroprotection from oxidation stress in experimental models of amyotrophic lateral sclerosis
  4452. Cone photoreceptor Neuroprotection in inherited retinal degenerations
  4453. Ceftriaxone-induced Neuroprotection in glutamate excitotoxicity: one more reason to treat bacterial meningitis with it?
  4454. Granulocyte-stimulating colony factor Neuroprotection for thoracic myelopathy
  4455. Neuroprotection of extract of Ginkgo biloba on the focal cerebral ischemia-reperfusion injury of rats
  4456. A study of neurodegeneration and Neuroprotection in Nothobranchius guentheri
  4457. Enteric Neuroprotection
  4458. Mechanism of Neuroprotection in stroke-related models
  4459. Microglia-conditioned medium promotes locomotor recovery and Neuroprotection after rat spinal cord injury
  4460. Neuroprotection in Parkinson’s
  4461. Neuroprotection and Neuroregeneration in Alzheimer’s Disease
  4462. Effects of ulinastatin on delayed cerebral vasospasm following subarachnoid hemorrahage in rats and its Neuroprotection [J]
  4463. Cellular basis of neurodegeneration-The possible role of ryanodine receptor and potassium channel in neuronal death and Neuroprotection
  4464. Neuroprotection in ischaemic stroke
  4465. Neonatal Neuroprotection : cooling outside trial criteria
  4466. Provides Long-Term Neuroprotection in Rodents
  4467. High dose intravenous melatonin for augmentation of hypothermic Neuroprotection leads to hypotension
  4468. The role of Neuroprotection in complex rehabilitation of patients with ischemic stroke
  4469. Neuroprotection by Erythropoietin
  4470. Vascular Protection Mediates Neuroprotection : Role of VEGF-A and B
  4471. Temperature Management and Hypothermic Neuroprotection
  4472. Searhing for phytochemicals involved in ageing intervention and Neuroprotection
  4473. Ex Vivo and In Vivo Neuroprotection Induced by Argon When Given after an
  4474. Resveratrol+ ethanol preconditioning and Neuroprotection
  4475. Pharmacological Neuroprotection in Severe Traumatic brain Injury
  4476. MECANISMES D’ACTION IMPLIQUANT LES RÉCEPTEURS OESTROGÉNIQUES DANS LA Neuroprotection CHEZ LA SOURIS MPTP
  4477. Neuroprotection In Chronic brain Ischemia: Clinical And Immunological Features
  4478. Exercise and Neuroprotection in an animal model of multiple sclerosis
  4479. Neuroprotection and autoimmunity in glaucoma
  4480. Routine application of Neuroprotection in surgery of intracranial aneurysms
  4481. Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection A Symposium in Abel Lajtha’s Honour
  4482. CSSI workshop in Brazil highlights “Stress Responses in the Nervous System” in relation to neurodegenerative diseases and Neuroprotection
  4483. Recent progress in kalirin of a new Neuroprotection factor [J]
  4484. Autophagy: a new way to retinal Neuroprotection
  4485. Nicotine, neurodegeneration, and Neuroprotection in neuropsychiatric disorders
  4486. Traumatic spinal cord injuries: Neuroprotection and recent outcomes
  4487. Neuroprotection effect of IL-17 in an autoimmune disease mediated neuroinflammation
  4488. brain Aromatase and Neuroprotection in Mammals
  4489. Effects of exercise on Neuroprotection in experimental autoimmune encephalomyelitis
  4490. Using Pimonidazole Delineated Penumbra To Improve Translational Research on Acute Stroke Neuroprotection (P01. 013)
  4491. Multifunctional small molecular weight compounds from Peltiphyllum Peltatum: From antioxicant to Neuroprotection and antidiabetic effects
  4492. Antenatal magnesium sulfate for fetal Neuroprotection
  4493. Soluble IL-6R and Neuroprotection of Retinal Ganglion Cells in Glaucoma
  4494. Enhancement of-Opioidergic-Receptor Activity Provides Retina Neuroprotection Against Glaucomatous Injury
  4495. Clinical Neuroprotection Against Tissue Hypoxia During brain Injuries; The Challenges and the Targets
  4496. Resveratrol Neuroprotection in cerebral ischemia
  4497. Molecular determinants of hypoxic-ischemic injury in developing brain and potential strategies for Neuroprotection
  4498. The Investigation on the Mechanism of Neuroprotection by Adenosine in 1, 3-Dinitrobenzene Toxicity.
  4499. Immunological mechanism of Neuroprotection function of Copolymer 1 in elevated intraocular pressure in rats
  4500. Silencing of miR20a is Crucial for Ngn1-mediating Neuroprotection in Injured Spinal Cord
  4501. Neuroprotection of estrogen on hypoglycemic attack is through AKT/GSK3b pathway
  4502. Nicotine-Induced Neuroprotection in Drosophila Models of Parkinson’s Disease
  4503. Retinal Ganglion Cell Neuroprotection By Mesenchymal Stem Cell-derived Factors
  4504. Direct Neuroprotection by Exogenous and Endogenous VEGF-A in Rodent Models of Glaucoma
  4505. LOCAL ANAESTHETICS: REAPPRAISAL OF THEIR ROLE IN REGIONAL ANAESTHESIA AND PAIN MANAGEMENT–Neuroprotection
  4506. Studies on astrocyte function: potential roles in brain water homeostasis and Neuroprotection
  4507. In vivo imaging of Neuroprotection in stroke: In search of the penumbra
  4508. The Role of Complement Factors in Neurodegeneration, Neuroinflammation and Neuroprotection : Friend or Foe?
  4509. Neuroprotection Effects of Ischemic Postconditioning after Cerebral Ischemia-reperfusion in Rats [J]
  4510. Volatile meets versatile: Does isoflurane strike a new path to Neuroprotection ?
  4511. Calcium-permeable ion channels in cerebral ischemia and Neuroprotection
  4512. P07 Astrocytes affect Neuroprotection : glatiramer acetate in Huntington’s disease therapy
  4513. Role of the Cerebral Vascular Toll-Like Receptor Signaling Pathway in Neuroprotection Induced by Combination Therapy of VELCADE and TPA
  4514. Mechanisms of Bone-Marrow Stem Cell-Mediated Delayed Ischemic Neuroprotection in Rat Retina<!–field:–
  4515. Ischemic Lesion Evolution and Hemorrhagic Transformation After Thrombolysis with Neuroprotection in FAST-MAG
  4516. Hypothermia-induced Neuroprotection in rats: evidence of a blood glutamate scavenging mechanism: 7AP2-1
  4517. Agmatine Produces Neuroprotection and cognitive Improvement in Rat Treated with Streptozotocin
  4518. Proteomic analysis of npkc epsilon-interactingproteins involved in hpc-induced Neuroprotection against cerebral ischemia of mice
  4519. Somatostatin receptors on neuronal cilia: Evidence for Neuroprotection
  4520. TMP Prevents Retinal Neovascularization and Imparts Neuroprotection in an Oxygen-Induced Retinopathy Model
  4521. Functional role of HIF-1α in hypoxic preconditioning-induced Neuroprotection against focal cerebral ischemia
  4522. Investigation of Normobaric Oxygen Neuroprotection in Acute Schemia-Reperfusion Rat Using MR Diffusion Weighted Imaging
  4523. Erythropoietin and C-erythropoietin Neuroprotection in mouse models of middle cerebral artery occlusion
  4524. Neuroprotection of progesterone against cerebral ischemia-reperfusion injury on rats and the effect on IP3 content
  4525. Role of the prolyl isomerase Pin1 in the pathogenesis of Parkinson’s disease and Neuroprotection by novel targeted compounds in pre-clinical animal models of the …
  4526. Effects of maternal milk lactoferrin supplementation on neurodevelopment and Neuroprotection
  4527. FTOX037 Cisplatin-induced DNA damage and neurotoxicity: Neuroprotection by coenzyme Q10
  4528. Tropisetron as a Neuroprotective Agent Against Glutamate-Induced Excitotoxicity: Potential Mechanisms of Neuroprotection
  4529. Neuroprotection of high concentration normobaric oxygen in stroke rat model observed with MR diffusion-weighted imaging
  4530. The Neuroprotection of SIRT1 on NMDA-induced excitotoxicity in cultured cortical cell
  4531. Neuroprotection and Inhibition of Blood-Retinal Barrier Breakdown In a Transgenic Model of Conditional Müller Cell Ablation
  4532. Adoptive Transfer Of Regulatory T Cells Confers Long Term Neuroprotection Against Cerebral Ischemic Stroke
  4533. Stressed-Induced Neuroprotection through the LIF/GP130/STAT3 Pathway is Mediated by TLR2 Signaling
  4534. brain -Derived Neurotrophic Factor and Exercise-Induced Neuroprotection in the spastic Han-Wistar rat, a model of ataxia
  4535. Behavioral Effects of Calcium Channel Blockers: Acute Exposures and Neuroprotection Against Methylmercury Neurotoxicity
  4536. A study of excitotoxicity as pathological process responsible for spinal cord injury: insight from an in vitro rat spinal cord model with a focus on Neuroprotection
  4537. A study of excitotoxicity as pathological process responsible for spinal cord injury: insight from an in vitro rat spinal cord model with a focus on Neuroprotection
  4538. Neuroprotection And Neurotoxicity Of The Sustained Intraocular Delivery Of Gdnf In Retinal Degeneration
  4539. Role of AMP-activated protein kinase in the Neuroprotection against hypoxia injury in hypoxic preconditioning
  4540. Differential expression of genes involved in Neuroprotection conferred by blackberry polyphenols after simulated gastrointestinal digestion
  4541. Bystander effect of adipose-derived stem cell extracts on neurogenesis, Neuroprotection and β-amyloid claearing
  4542. Inhibition of GSK-3β by valproic acid confers Neuroprotection to key Alzheimer processes and cognitive impairment
  4543. Neuroprotection of Sodium Valproate against Rotenone induced Mitochondrial Dysfunction in SH-SY5Y Cells
  4544. The Combination Therapy of Chemical Chaperone and n-NOS inhibitor Affords Enhanced Neuroprotection in a Rodent model of Ischemic Stroke associated with …
  4545. Granulocyte‐Colony Stimulating Factor Exerts Neuroprotection in the Neonatal Hypoxia‐Ischemia Rat Model via the Hypothalamic‐Pituitary‐Adrenal Axis
  4546. Histamine enhances excitability and may augment Neuroprotection in the Syrian hamster hippocampus
  4547. Kinin-B2 Receptor Mediated Neuroprotection after NMDA Excitotoxicity Is
  4548. The Akt/NFκB Pathway in Postconditioning Induced Neuroprotection through TLR5 in Cerebral Ischemia
  4549. An in vitro model for assessment of excitotoxicity induced by glutamate and Neuroprotection using digitized fluorescent imaging of mitochondrial potentials
  4550. Neuroprotection for Stroke Using Glial Cell Line-Derived Neurotrophic Factor/Neural Stem Cells Grafting
  4551. Neuroprotection by peptides designed to block interactions between glutamate receptors and neuronal activity regulated pentraxin
  4552. ATP-dependent potassium channel blockade strengthens microglial Neuroprotection after hypoxia-ischemia in rats.
  4553. Purinergic control of neuroinflammation and Neuroprotection by the blockade of P2 receptors under excitotoxic conditions in the hippocampus
  4554. Neuroprotection of the leaf and stem of vids amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons
  4555. Local Induction of Heat Shock Proteins using Magnetic Fluid hyperthermia for Ocular-Neuroprotection in Glaucoma
  4556. Expression of brain -derived neurotrophic factor in reactive astrocytes provides Neuroprotection to SH-SY5Y cells against six-hydroxydopamine toxicity invitro
  4557. 190: IRL-1620, ETB RECEPTOR AGONIST, PROVIDES Neuroprotection AND PROMOTES ANGIOGENESIS FOLLOWING CEREBRAL ISCHEMIA IN RATS
  4558. … of inflammation signaling by DNA “Decoy” treatment improves sensory and motor recovery after spinal cord injury in rats by Neuroprotection and microglial inhibition
  4559. Neuroprotection of Active Principles from the Leaves of Laurus nobilis and Mori Cortex Radicis in Neuronal Cell Culture and Rodent Models of Parkinson’s Disease …
  4560. 338 Nutrient for Neuroprotection : MRI Assessment of Lactoferrin Supplementation after HI Injury in the P3 Rat brain
  4561. 191: ESTROGEN-MEDIATED Neuroprotection DEMONSTRATES GENDER SPECIFICITY IN JUVENILE MICE AFTER CARDIAC ARREST …
  4562. 56 Safety of High-Dose Erythopoietin for Neuroprotection in Preterm Infants
  4563. 1111 Pilot Case Series on the Use of Magnesium Sulphate as Neuroprotection in HIE Babies in the Cooling Era
  4564. LOXblock-1 Provides Efficient, Specific, And Long-lasting Neuroprotection Against Transient Focal Ischemia In Mice By Inhibiting 12/15-Lipoxygenase
  4565. 189: ACETYL-L-CARNITINE (ALCAR) PROVIDES LONG-TERM Neuroprotection AFTER TRAUMATIC brain INJURY IN IMMATURE RATS
  4566. Transfection of IGF-1 and IGFBPL-1 in Neuronal Progenitor Cells from Human Persistent Fetal Vascular for Neuroprotection
  4567. AS06-03-Lithium: neuroimaging evidence of Neuroprotection and its implication for bipolar disorder
  4568. 10 Angiotensin II Receptors and Neuroprotection
  4569. 799 ANGIOTENSIN AT2 RECEPTOR STIMULATION INITIATED AFTER STROKE CAUSES Neuroprotection IN CONSCIOUS RATS
  4570. Interaction between estrogen receptor and metabotropic glutamate receptor 1 mediates the dual effect of estrogen in Neuroprotection and neurodegeneration
  4571. Estrogen receptor-alpha-36, not ER-α66, contribute to Neuroprotection of low concentration of E2 against OGD in PC12 cells
  4572. 193: PROGESTERONE FOR Neuroprotection IN PEDIATRIC TRAUMATIC brain INJURY IN IMMATURE RATS
  4573. Progesterone’s role in Neuroprotection , a review of the evidence
  4574. Neuroprotection in stroke: past, present, and future
  4575. Progesterone and Neuroprotection
  4576. Traumatic brain injury: oxidative stress and Neuroprotection
  4577. Excitotoxicity and stroke: identifying novel targets for Neuroprotection
  4578. Emerging roles of Nrf2 and phase II antioxidant enzymes in Neuroprotection
  4579. Animal models of Parkinson’s disease: limits and relevance to Neuroprotection studies
  4580. Parkinson’s disease, insulin resistance and novel agents of Neuroprotection
  4581. Mechanisms of hypothermic Neuroprotection
  4582. Therapeutic hypothermia for Neuroprotection : history, mechanisms, risks, and clinical applications
  4583. Carboxyfullerene Neuroprotection postinjury in Parkinsonian nonhuman primates
  4584. APOE2 enhances Neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
  4585. Pharmacological perioperative brain Neuroprotection : a qualitative review of randomized clinical trials
  4586. Preconditioning provides Neuroprotection in models of CNS disease: paradigms and clinical significance
  4587. Exosomes: mediators of neurodegeneration, Neuroprotection and therapeutics
  4588. Novel approaches to Neuroprotection trials in acute ischemic stroke
  4589. Neurodegeneration and Neuroprotection in diabetic retinopathy
  4590. VEGF-A is necessary and sufficient for retinal Neuroprotection in models of experimental glaucoma
  4591. The role of citicoline in Neuroprotection and neurorepair in ischemic stroke
  4592. Neuroprotection of microRNA in neurological disorders
  4593. The failure of animal models of Neuroprotection in acute ischemic stroke to translate to clinical efficacy
  4594. Erythropoietin Neuroprotection with traumatic brain injury
  4595. The science of cerebral ischemia and the quest for Neuroprotection : navigating past failure to future success: A review
  4596. Aerobic exercise effects on Neuroprotection and brain repair following stroke: a systematic review and perspective
  4597. Heme oxygenase in Neuroprotection : from mechanisms to therapeutic implications
  4598. Resveratrol: new avenues for a natural compound in Neuroprotection
  4599. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to Neuroprotection
  4600. Neuroprotection in glaucoma: present and future
  4601. Food, nutrigenomics, and neurodegeneration—Neuroprotection by what you eat!
  4602. Lithium and Neuroprotection : translational evidence and implications for the treatment of neuropsychiatric disorders
  4603. Immune regulation toward immunomodulation for Neuroprotection in glaucoma
  4604. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival
  4605. Antioxidant drug therapy approaches for Neuroprotection in chronic diseases of the retina
  4606. Perspectives of drug-based Neuroprotection targeting mitochondria
  4607. Mitochondrial respiration as a target for Neuroprotection and cognitive enhancement
  4608. Estrogen receptors and ischemic Neuroprotection : who, what, where, and when?
  4609. Clinical application of preconditioning and postconditioning to achieve Neuroprotection
  4610. Microglial displacement of inhibitory synapses provides Neuroprotection in the adult brain
  4611. Magnesium sulphate for women at term for Neuroprotection of the fetus
  4612. Lipid rafts in neurodegeneration and Neuroprotection
  4613. Melatonin augments hypothermic Neuroprotection in a perinatal asphyxia model
  4614. Retinal cell death and current strategies in retinal Neuroprotection
  4615. Progesterone–estrogen interactions in synaptic plasticity and Neuroprotection
  4616. Erythropoietin: emerging role of erythropoietin in neonatal Neuroprotection
  4617. Can we switch microglia’s phenotype to foster Neuroprotection ? Focus on multiple sclerosis
  4618. Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for Neuroprotection
  4619. Perinatal Neuroprotection
  4620. GPR30 mediates estrogen rapid signaling and Neuroprotection
  4621. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress
  4622. Statins and Neuroprotection : basic pharmacology needed
  4623. Tsc1 (hamartin) confers Neuroprotection against ischemia by inducing autophagy
  4624. Stem cell transplantation for Neuroprotection in stroke
  4625. Olive oil phenols and Neuroprotection
  4626. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and Neuroprotection
  4627. Small-molecule activator of glutamate transporter EAAT2 translation provides Neuroprotection
  4628. Stroke Neuroprotection : targeting mitochondria
  4629. Progesterone, brain -derived neurotrophic factor and Neuroprotection
  4630. Neonatal encephalopathy: pre-clinical studies in Neuroprotection
  4631. Neuroprotection and lifespan extension in Ppt1−/− mice by NtBuHA: therapeutic implications for INCL
  4632. Neuroprotection signaling of nuclear akt in neuronal cells
  4633. Exercise-induced Neuroprotection of hippocampus in APP/PS1 transgenic mice via upregulation of mitochondrial 8-oxoguanine DNA glycosylase
  4634. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of Neuroprotection with amiloride
  4635. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to Neuroprotection , neurogenesis, and angiogenesis
  4636. Magnesium treatment for Neuroprotection in ischemic diseases of the brain
  4637. Bcl-xL in Neuroprotection and plasticity
  4638. Luteolin provides Neuroprotection in models of traumatic brain injury via the Nrf2–ARE pathway
  4639. Neuroprotection by astrocytes in brain ischemia: importance of microRNAs
  4640. Hypothermia and erythropoietin for Neuroprotection after neonatal brain damage
  4641. Implication of GPER1 in Neuroprotection in a mouse model of Parkinson’s disease
  4642. Calcium‐sensing receptor (CaSR) as a novel target for ischemic Neuroprotection
  4643. XENON in medical area: emphasis on Neuroprotection in hypoxia and anesthesia
  4644. Dual effects of ketamine: neurotoxicity versus Neuroprotection in anesthesia for the developing brain
  4645. Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for Neuroprotection
  4646. Immunomodulation Neuroprotection and remyelination–The fundamental therapeutic effects of glatiramer acetate: A critical review
  4647. Squalenoyl adenosine nanoparticles provide Neuroprotection after stroke and spinal cord injury
  4648. BDNF–TrkB signaling and Neuroprotection in schizophrenia
  4649. Saffron and retina: Neuroprotection and pharmacokinetics
  4650. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway
  4651. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct Neuroprotection
  4652. Docosahexaenoic acid confers enduring Neuroprotection in experimental stroke
  4653. Differential mechanisms underlying Neuroprotection of hydrogen sulfide donors against oxidative stress
  4654. Fingolimod may support Neuroprotection via blockade of astrocyte nitric oxide
  4655. Identification of retinal ganglion cell Neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome
  4656. Neuroprotection in a novel mouse model of multiple sclerosis
  4657. Estrogen mediates Neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or …
  4658. Sex steroids and Neuroprotection in spinal cord injury: a review of preclinical investigations
  4659. Greatly improved survival and Neuroprotection in aquaporin‐4‐knockout mice following global cerebral ischemia
  4660. School-age outcomes following a randomized controlled trial of magnesium sulfate for Neuroprotection of preterm infants
  4661. Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events
  4662. Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and Neuroprotection after brain injury
  4663. Modulation of mitochondrial function and autophagy mediates carnosine Neuroprotection against ischemic brain damage
  4664. Multinutrient diets improve cerebral perfusion and Neuroprotection in a murine model of Alzheimer’s disease
  4665. Simvastatin Induces Neuroprotection in 6‐OHDA‐Lesioned PC 12 via the PI 3K/AKT/Caspase 3 Pathway and Anti‐Inflammatory Responses
  4666. Neuroprotection after cerebral ischemia
  4667. Cell transplantation approaches to retinal ganglion cell Neuroprotection in glaucoma
  4668. Neuroprotection of medical IOP-lowering therapy
  4669. Doxycycline restrains glia and confers Neuroprotection in a 6‐OHDA Parkinson model
  4670. Ursolic acid promotes the Neuroprotection by activating Nrf2 pathway after cerebral ischemia in mice
  4671. N-acetylcysteine amide confers Neuroprotection , improves bioenergetics and behavioral outcome following TBI
  4672. Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia
  4673. Mechanisms of cannabidiol Neuroprotection in hypoxic–ischemic newborn pigs: Role of 5HT1A and CB2 receptors
  4674. Role of growth hormone (GH) in the treatment on neural diseases: from Neuroprotection to neural repair
  4675. Calcitriol imparts Neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression
  4676. Paracrine-mediated Neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: comparison with human bone …
  4677. Astaxanthin offers Neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage
  4678. Acute metformin preconditioning confers Neuroprotection against focal cerebral ischaemia by pre‐activation of AMPK‐dependent autophagy
  4679. PreImplantation factor promotes Neuroprotection by targeting microRNA let-7
  4680. Sigma receptors as potential therapeutic targets for Neuroprotection
  4681. Antioxidant activity, genotoxicity and cytotoxicity evaluation of lemon balm (Melissa officinalis L.) ethanolic extract: Its potential role in Neuroprotection
  4682. NeuroAiD: properties for Neuroprotection and neurorepair
  4683. Intravitreally transplanted dental pulp stem cells promote Neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury
  4684. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1α
  4685. Acute and subacute IL-1β administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for Neuroprotection and …
  4686. Klotho upregulation contributes to the Neuroprotection of ligustilide in an Alzheimer’s disease mouse model
  4687. Microglia trigger astrocyte-mediated Neuroprotection via purinergic gliotransmission
  4688. Guanosine controls inflammatory pathways to afford Neuroprotection of hippocampal slices under oxygen and glucose deprivation conditions
  4689. Distinct roles for μ-calpain and m-calpain in synaptic NMDAR-mediated Neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration
  4690. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms
  4691. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and Neuroprotection
  4692. Hydrogen sulfide offers Neuroprotection on traumatic brain injury in parallel with reduced apoptosis and autophagy in mice
  4693. Research advances on the usage of traditional Chinese medicine for Neuroprotection in glaucoma
  4694. Autophagy activation contributes to the Neuroprotection of remote ischemic perconditioning against focal cerebral ischemia in rats
  4695. Hypothermia-induced Neuroprotection is associated with reduced mitochondrial membrane permeability in a swine model of cardiac arrest
  4696. Dexmedetomidine provides Neuroprotection : impact on ketamine‐induced neuroapoptosis in the developing rat brain
  4697. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
  4698. Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson’s disease
  4699. Isoflurane provides Neuroprotection in neonatal hypoxic ischemic brain injury
  4700. Dock GEFs and their therapeutic potential: Neuroprotection and axon regeneration
  4701. … formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for Neuroprotection
  4702. Role of crystallins in ocular Neuroprotection and axonal regeneration
  4703. Progesterone-induced Neuroprotection : factors that may predict therapeutic efficacy
  4704. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and Neuroprotection share a PPAR-alpha-mediated mechanism
  4705. EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates Neuroprotection in in vitro and in vivo models of Parkinson’s disease
  4706. Can medical herbs stimulate regeneration or Neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy?
  4707. Neuroprotection by acetyl-11-keto-β-boswellic acid, in ischemic brain injury involves the Nrf2/HO-1 defense pathway
  4708. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and Neuroprotection and natural history in …
  4709. N-acetyl-serotonin offers Neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury
  4710. Neuroprotection against Traumatic brain Injury by Xenon, but Not Argon, Is Mediated by Inhibition at the N-Methyl-d-Aspartate Receptor Glycine Site
  4711. Stroke Neuroprotection : oestrogen and insulin‐like growth factor‐1 interactions and the role of microglia
  4712. Feasibility and safety of erythropoietin for Neuroprotection after perinatal arterial ischemic stroke
  4713. Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and Neuroprotection
  4714. mGlu3 receptor and astrocytes: partners in Neuroprotection
  4715. Melatonin-based therapeutics for Neuroprotection in stroke
  4716. Resveratrol induced Neuroprotection is mediated via both estrogen receptor subtypes, ERα and ERβ
  4717. Curcumin inhibits microglia inflammation and confers Neuroprotection in intracerebral hemorrhage
  4718. Amyloid-beta Neuroprotection mediated by a targeted antioxidant
  4719. Targeting Wnt signaling at the neuroimmune interface for dopaminergic Neuroprotection /repair in Parkinson’s disease
  4720. Survivin is a transcriptional target of STAT3 critical to estradiol Neuroprotection in global ischemia
  4721. Neuroprotection against Aβ25–35-induced apoptosis by Salvia miltiorrhiza extract in SH-SY5Y cells
  4722. NADPH oxidase as a therapeutic target for Neuroprotection against ischaemic stroke: future perspectives
  4723. New synaptic and molecular targets for Neuroprotection in Parkinson’s disease
  4724. Creatine for women in pregnancy for Neuroprotection of the fetus
  4725. Activation of the phase II enzymes for Neuroprotection by ginger active constituent 6-dehydrogingerdione in PC12 cells
  4726. Inhibition of autophagy contributes to melatonin-mediated Neuroprotection against transient focal cerebral ischemia in rats
  4727. Neuroprotection of antioxidant enzymes against transient global cerebral ischemia in gerbils
  4728. Sex hormones and biomarkers of Neuroprotection and neurodegeneration: implications for female reproductive events in bipolar disorder
  4729. Ligand-gated ion channel interacting proteins and their role in Neuroprotection
  4730. Indirect application of near infrared light induces Neuroprotection in a mouse model of parkinsonism–an abscopal Neuroprotective effect
  4731. Dual effects of Neuroprotection and neurotoxicity by general anesthetics: role of intracellular calcium homeostasis
  4732. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer’s disease models: the control of neuroinflammation
  4733. … actors in astrocyte–neuron crosstalk in P arkinson’s disease: the W nt/β‐catenin signaling cascade as the common final pathway for Neuroprotection and self‐repair
  4734. The Microglial α7-Acetylcholine Nicotinic Receptor Is a Key Element in Promoting Neuroprotection by Inducing Heme Oxygenase-1 via Nuclear Factor Erythroid-2 …
  4735. Unraveling the mechanism of Neuroprotection of curcumin in arsenic induced cholinergic dysfunctions in rats
  4736. Isoflurane postconditioning reduces ischemia-induced nuclear factor-κB activation and interleukin 1β production to provide Neuroprotection in rats and mice
  4737. Developmental changes in the transcriptome of the rat choroid plexus in relation to Neuroprotection
  4738. Formononetin mediates Neuroprotection against cerebral ischemia/reperfusion in rats via downregulation of the Bax/Bcl-2 ratio and upregulation PI3K/Akt signaling …
  4739. Molecular Chaperone Mediated Late-Stage Neuroprotection in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis
  4740. The endoplasmic reticulum stress inhibitor salubrinal inhibits the activation of autophagy and Neuroprotection induced by brain ischemic preconditioning
  4741. Autophagy activation and Neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis
  4742. Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress
  4743. Mitochondrial-targeted human catalase affords Neuroprotection from proton irradiation
  4744. Anti-inflammatory effect of tanshinone I in Neuroprotection against cerebral ischemia–reperfusion injury in the gerbil hippocampus
  4745. Sildenafil mediates blood-flow redistribution and Neuroprotection after neonatal hypoxia-ischemia
  4746. Neuroprotection Induced by N-acetylcysteine and Selenium Against Traumatic brain Injury-Induced Apoptosis and Calcium Entry in Hippocampus of Rat
  4747. Mitochondrial Neuroprotection in traumatic brain injury: rationale and therapeutic strategies
  4748. Citicoline (CDP‐choline) increases S irtuin1 expression concomitant to Neuroprotection in experimental stroke
  4749. Early Neuroprotection after cardiac arrest
  4750. Hypoxia-inducible factor 1α mediates Neuroprotection of hypoxic postconditioning against global cerebral ischemia
  4751. Lesional-targeting of Neuroprotection to the inflammatory penumbra in experimental multiple sclerosis
  4752. Molecular targets underlying SUMO‐mediated Neuroprotection in brain ischemia
  4753. Saffron pre-treatment offers Neuroprotection to Nigral and retinal dopaminergic cells of MPTP-Treated mice
  4754. Downregulation of miR‐181b in mouse brain following ischemic stroke induces Neuroprotection against ischemic injury through targeting heat shock protein A5 and …
  4755. Astrocyte-derived growth factors and estrogen Neuroprotection : role of transforming growth factor-α in estrogen-induced upregulation of glutamate transporters in …
  4756. Mechanisms of Neuroprotection by hemopexin: modeling the control of heme and iron homeostasis in brain neurons in inflammatory states
  4757. Exogenous T3 administration provides Neuroprotection in a murine model of traumatic brain injury
  4758. Hypoxia-inducible factor prolyl hydroxylases as targets for Neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke
  4759. Post-stroke infections exacerbate ischemic brain injury in middle-aged rats: immunomodulation and Neuroprotection by progesterone
  4760. Ginsenoside Rg1 provides Neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through …
  4761. Membrane-mediated Neuroprotection by curcumin from amyloid-β-peptide-induced toxicity
  4762. nNOS and p-ERK involvement in the Neuroprotection exerted by remote postconditioning in rats subjected to transient middle cerebral artery occlusion
  4763. Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors
  4764. Temporal activation of Nrf2 in the penumbra and Nrf2 activator-mediated Neuroprotection in ischemia–reperfusion injury
  4765. The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and Neuroprotection in cerebral ischemia
  4766. Neuroprotection conferred by post‐ischemia ethanol therapy in experimental stroke: an inhibitory effect on hyperglycolysis and NADPH oxidase activation
  4767. Improved Neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann–Pick disease type C1 mice
  4768. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson’s disease
  4769. Reprint of” GPR30 mediates estrogen rapid signaling and Neuroprotection ”
  4770. Phosphorylation of p38 MAPK mediates hypoxic preconditioning-induced Neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL in …
  4771. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease
  4772. Activation of K2P channel–TREK1 mediates the Neuroprotection induced by sevoflurane preconditioning
  4773. Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions
  4774. Effect of HDAC inhibitors on Neuroprotection and neurite outgrowth in primary rat cortical neurons following ischemic insult
  4775. brain -targeting delivery for RNAi Neuroprotection against cerebral ischemia reperfusion injury
  4776. Notoginsenoside R1-mediated Neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: a novel mechanism of Nrf2/ARE …
  4777. Anesthetic Neuroprotection : antecedents and an appraisal of preclinical and clinical data quality
  4778. Transplants of adult mesenchymal and neural stem cells provide Neuroprotection and behavioral sparing in a transgenic rat model of Huntington’s disease
  4779. Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for Neuroprotection in stroke
  4780. Activation of STAT3 is involved in Neuroprotection by electroacupuncture pretreatment via cannabinoid CB1 receptors in rats
  4781. Magnesium sulfate provides Neuroprotection in lipopolysaccharide-activated primary microglia by inhibiting NF-κB pathway
  4782. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in Neuroprotection ?
  4783. Prophylactic Neuroprotection by blueberry-enriched diet in a rat model of light-induced retinopathy
  4784. Neuroprotection by rat Müller glia against high glucose-induced neurodegeneration through a mechanism involving ERK1/2 activation
  4785. Possible roles of astrocytes in estrogen Neuroprotection during cerebral ischemia
  4786. Delta opioid receptor and its peptide: a receptor-ligand Neuroprotection
  4787. Gap junction-mediated death of retinal neurons is connexin and insult specific: a potential target for Neuroprotection
  4788. Activations of GABAergic signaling, HSP70 and MAPK cascades are involved in baicalin’s Neuroprotection against gerbil global ischemia/reperfusion injury
  4789. Bone marrow mononuclear cells exert long-term Neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and angiogenesis
  4790. Ceruloplasmin and β-amyloid precursor protein confer Neuroprotection in traumatic brain injury and lower neuronal iron
  4791. Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous Neuroprotection –design and MRI measurements
  4792. SIRT1 silencing confers Neuroprotection through IGF‐1 pathway activation
  4793. Melatonin renders Neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia
  4794. Harmine mediated Neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia
  4795. Granulocyte-colony stimulating factor in combination with stem cell factor confers greater Neuroprotection after hypoxic–ischemic brain damage in the neonatal rats …
  4796. A dietary polyphenol resveratrol acts to provide Neuroprotection in recurrent stroke models by regulating AMPK and SIRT 1 signaling, thereby reducing energy …
  4797. TLR4 inhibitor resatorvid provides Neuroprotection in experimental traumatic brain injury: implication in the treatment of human brain injury
  4798. Inhibition of the NLRP3 inflammasome provides Neuroprotection in rats following amygdala kindling-induced status epilepticus
  4799. Docosahexaenoic acid complexed to albumin provides Neuroprotection after experimental stroke in aged rats
  4800. Dual role of astrocytes in perinatal asphyxia injury and Neuroprotection
  4801. Enhanced Neuroprotection by local intra-arterial infusion of human albumin solution and local hypothermia
  4802. Neuroprotection following mild hypothermia after spinal cord ischemia in rats
  4803. The role of ghrelin in Neuroprotection after ischemic brain injury
  4804. Phenelzine mitochondrial functional preservation and Neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4 …
  4805. Role of histidine/histamine in carnosine-induced Neuroprotection during ischemic brain damage
  4806. Pharmacologically induced hypothermia via TRPV1 channel agonism provides Neuroprotection following ischemic stroke when initiated 90 min after reperfusion
  4807. Mesenchymal stem cells transplantation for Neuroprotection in preterm infants with severe intraventricular hemorrhage
  4808. The Neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and …
  4809. Altered selenium status in Huntington’s disease: Neuroprotection by selenite in the N171-82Q mouse model
  4810. Magnesium sulphate for fetal Neuroprotection : a cost-effectiveness analysis
  4811. Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways
  4812. Neuroprotection elicited by P2Y13 receptors against genotoxic stress by inducing DUSP2 expression and MAPK signaling recovery
  4813. Ghrelin is Neuroprotective in Parkinson’s disease: molecular mechanisms of metabolic Neuroprotection
  4814. Dexamethasone-induced Neuroprotection in hypoxic-ischemic brain injury in newborn rats is partly mediated via Akt activation
  4815. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of Neuroprotection by sodium salicylate in a chronic rotenone model of …
  4816. The proton permeability of self-assembled polymersomes and their Neuroprotection by enhancing a Neuroprotective peptide across the blood–brain barrier after …
  4817. [Gly14]-Humanin offers Neuroprotection through glycogen synthase kinase-3β inhibition in a mouse model of intracerebral hemorrhage
  4818. Probucol affords Neuroprotection in a 6-OHDA mouse model of Parkinson’s disease
  4819. Neuroprotection induced by N-acetylcysteine against cytosolic glutathione depletion-induced Ca2+ influx in dorsal root ganglion neurons of mice: role of TRPV1 …
  4820. 5‐Hydroxytryptamine type 7 receptor Neuroprotection against NMDA‐induced excitotoxicity is PDGFβ receptor dependent
  4821. Erythropoietin Neuroprotection in neonatal cardiac surgery: a phase I/II safety and efficacy trial
  4822. Hippocampal neuronal metal ion imbalance related oxidative stress in a rat model of chronic aluminum exposure and Neuroprotection of meloxicam
  4823. A novel in vivo model of focal light emitting diode-induced cone-photoreceptor phototoxicity: Neuroprotection afforded by brimonidine, BDNF, PEDF or bFGF
  4824. Normobaric hyperoxia combined with minocycline provides greater Neuroprotection than either alone in transient focal cerebral ischemia
  4825. Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for Neuroprotection
  4826. … refilling and mitochondrial calcium extrusion promoted in neurons by NCX1 and NCX3 in ischemic preconditioning are determinant for Neuroprotection
  4827. Neuroprotection after traumatic brain injury in heat-acclimated mice involves induced neurogenesis and activation of angiotensin receptor type 2 signaling
  4828. Enhanced neurotrophic distribution, cell signaling and Neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
  4829. BDNF mediates Neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin
  4830. Zinc in traumatic brain injury: from Neuroprotection to neurotoxicity
  4831. Synergistical Neuroprotection of rofecoxib and statins against malonic acid induced Huntington’s disease like symptoms and related cognitive dysfunction in rats
  4832. Functional Neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson’s disease
  4833. Biomarkers for trials of Neuroprotection in Parkinson’s disease
  4834. Calmodulin Kinase IV–dependent CREB activation is required for Neuroprotection via NMDA receptor‐PSD 95 disruption
  4835. Dose dependent Neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by KATP—Channel opening
  4836. Carboxypeptidase E (NF-α1): a new trophic factor in Neuroprotection
  4837. Mechanisms of Neuroprotection from hypoxia-ischemia (HI) brain injury by up-regulation of cytoglobin (CYGB) in a neonatal rat model
  4838. Potential benefits of therapeutic use of β2-adrenergic receptor agonists in Neuroprotection and Parkinson’s disease
  4839. Neuroprotection by inhaled nitric oxide in a murine stroke model is concentration and duration dependent
  4840. Urate and Neuroprotection trials
  4841. Light activation of the insulin receptor regulates mitochondrial hexokinase. A possible mechanism of retinal Neuroprotection
  4842. Neurotrophin strategies for Neuroprotection : are they sufficient?
  4843. NCX as a key player in the Neuroprotection exerted by ischemic preconditioning and postconditioning
  4844. Hyperbaric oxygen therapy provides Neuroprotection following spinal cord injury in a rat model
  4845. A peroxisome proliferator-activated receptor-δ agonist provides Neuroprotection in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s …
  4846. Decreased extracellular adenosine levels lead to loss of hypoxia-induced Neuroprotection after repeated episodes of exposure to hypoxia
  4847. Mechanisms of ocular Neuroprotection by antioxidant molecules in animal models.
  4848. N-Acetylserotonin: Circadian Activation of the BDNF Receptor and Neuroprotection in the Retina and brain
  4849. Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated Neuroprotection in an MPTP-induced model of Parkinson’s disease
  4850. Serum exosomes in pregnancy-associated immune modulation and Neuroprotection during CNS autoimmunity
  4851. L‐theanine administration results in Neuroprotection and prevents glutamate receptor agonist‐mediated injury in the rat model of cerebral ischemia‐reperfusion
  4852. Synergetic Neuroprotection of normobaric oxygenation and ethanol in ischemic stroke through improved oxidative mechanism
  4853. Overview of immunotherapy in Alzheimer’s disease (AD) and mechanisms of IVIG Neuroprotection in preclinical models of AD
  4854. Endoplasmic reticulum stress is associated with Neuroprotection against apoptosis via autophagy activation in a rat model of subarachnoid hemorrhage
  4855. Neuroprotection in multiple sclerosis: a therapeutic approach
  4856. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic Neuroprotection against amyloid-beta toxicity
  4857. Reactive oxygen species scavenging activities in a chemiluminescence model and Neuroprotection in rat pheochromocytoma cells by astaxanthin, beta …
  4858. Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent Neuroprotection following traumatic brain injury in mice
  4859. Neuroprotection effect of interleukin (IL)‐17 secreted by reactive astrocytes is emerged from a high‐level IL‐17‐containing environment during acute …
  4860. Trichilia catigua (Catuaba) bark extract exerts Neuroprotection against oxidative stress induced by different neurotoxic agents in rat hippocampal slices
  4861. Valproic acid potentiates curcumin-mediated Neuroprotection in lipopolysaccharide induced rats
  4862. Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats
  4863. Bacillus Calmette‐Guerin vaccine‐mediated Neuroprotection is associated with regulatory T‐cell induction in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine …
  4864. … pentylenetetrazol-induced seizures and associated oxidative stress, inflammation, and cognitive impairment in rats: possible mechanisms of Neuroprotection
  4865. The systemic administration of oleoylethanolamide exerts Neuroprotection of the nigrostriatal system in experimental Parkinsonism
  4866. Mediator lipidomics in ophthalmology: targets for modulation in inflammation, Neuroprotection and nerve regeneration
  4867. Simulated microgravity facilitates cell migration and Neuroprotection after bone marrow stromal cell transplantation in spinal cord injury
  4868. Both Creatine and Its Product Phosphocreatine Reduce Oxidative Stress and Afford Neuroprotection in an In Vitro Parkinson’s Model
  4869. Hinokitiol, a natural tropolone derivative, offers Neuroprotection from thromboembolic stroke in vivo
  4870. Early transplantation of bone marrow mononuclear cells promotes Neuroprotection and modulation of inflammation after status epilepticus in mice by paracrine …
  4871. Neuroprotection mediated by the EP4 receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury
  4872. PI3K/Akt and NF-κB activation following intravitreal administration of 17β-estradiol: Neuroprotection of the rat retina from light-induced apoptosis
  4873. Mitochondria: prospective targets for Neuroprotection in Parkinson’s disease
  4874. Hypothermia for Neuroprotection in children after cardiopulmonary arrest
  4875. Neuroprotection by steroids after neurotrauma in organotypic spinal cord cultures: A key role for progesterone receptors and steroidal modulators of GABAA receptors
  4876. Effective Neuroprotection by ischemic postconditioning is associated with a decreased expression of RGMa and inflammation mediators in ischemic rats
  4877. A case for Neuroprotection in ophthalmology: developments in translational research
  4878. Preconditioning to mild oxidative stress mediates astroglial Neuroprotection in an IL-10-dependent manner
  4879. TAT-Hsp70 induces Neuroprotection against stroke via anti-inflammatory actions providing appropriate cellular microenvironment for transplantation of neural …
  4880. In search of new targets for retinal Neuroprotection : is there a role for autophagy?
  4881. Catalpol induces Neuroprotection and prevents memory dysfunction through the cholinergic system and BDNF
  4882. Intra-carotid cold magnesium sulfate infusion induces selective cerebral hypothermia and Neuroprotection in rats with transient middle cerebral artery occlusion
  4883. Caffeoylquinic acid-rich purple sweet potato extract, with or without anthocyanin, imparts Neuroprotection and contributes to the improvement of spatial learning and …
  4884. … role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARγ in retinal Neuroprotection
  4885. Neuroprotection for retinal detachment
  4886. Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal Neuroprotection
  4887. Norepinephrine provides short-term Neuroprotection against Aβ1–42 by reducing oxidative stress independent of Nrf2 activation
  4888. Co-administration of resveratrol and lipoic acid, or their synthetic combination, enhances Neuroprotection in a rat model of ischemia/reperfusion
  4889. Inhibition of cysteine cathepsin B and L activation in astrocytes contributes to Neuroprotection against cerebral ischemia via blocking the tBid‐mitochondrial apoptotic …
  4890. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early Neuroprotection against MPP+
  4891. Endogenous ghrelin’s role in hippocampal Neuroprotection after global cerebral ischemia: does endogenous ghrelin protect against global stroke?
  4892. Novel protective properties of auranofin: inhibition of human astrocyte cytotoxic secretions and direct Neuroprotection
  4893. The effects of peritoneal dialysis on blood glutamate levels: implementation for Neuroprotection
  4894. WISP1 Neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1
  4895. Neuroprotection by argon ventilation after perinatal asphyxia: a safety study in newborn piglets
  4896. Sevoflurane postconditioning provides Neuroprotection against brain hypoxia–ischemia in neonatal rats
  4897. Electrical stimulation of cerebellar fastigial nucleus: mechanism of Neuroprotection and prospects for clinical application against cerebral ischemia
  4898. Hemopexin induces Neuroprotection in the rat subjected to focal cerebral ischemia
  4899. Globular adiponectin elicits Neuroprotection by inhibiting NADPH oxidase-mediated oxidative damage in ischemic stroke
  4900. Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7
  4901. Neuroprotection or neurotoxicity? New insights into the effects of Acanthopanax senticosus harms on nervous system through cerebral metabolomics analysis
  4902. New perspective on the dual functions of indirubins in cancer therapy and Neuroprotection
  4903. Microglial ion channels as potential targets for Neuroprotection in Parkinson’s disease
  4904. Preconditioning with the traditional Chinese medicine Huang-Lian-Jie-Du-Tang initiates HIF-1α-dependent Neuroprotection against cerebral ischemia in rats
  4905. Transient Neuroprotection by SRY upregulation in dopamine cells following injury in males
  4906. Neuroprotection by genipin against reactive oxygen and reactive nitrogen species-mediated injury in organotypic hippocampal slice cultures
  4907. Neuroprotection against degeneration of SK-N-MC cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin
  4908. Alterations in energy metabolism, Neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys
  4909. The roles of p38 MAPK/MSK1 signaling pathway in the Neuroprotection of hypoxic postconditioning against transient global cerebral ischemia in adult rats
  4910. Neamine induces Neuroprotection after acute ischemic stroke in type one diabetic rats
  4911. Challenges in the development of glaucoma Neuroprotection therapy
  4912. MyD88 is a critical regulator of hematopoietic cell-mediated Neuroprotection seen after stroke
  4913. Neuroprotection and axonal regeneration after lumbar ventral root avulsion by re-implantation and mesenchymal stem cells transplant combined therapy
  4914. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides Neuroprotection in two rat models of temporal lobe epilepsy
  4915. Neuroprotection of dietary virgin olive oil on brain lipidomics during stroke
  4916. … acid, but not arachidonic acid, activates glutathione and thioredoxin antioxidant systems in murine hippocampal HT22 cells: potential implications in Neuroprotection
  4917. p-ERK involvement in the Neuroprotection exerted by ischemic preconditioning in rat hippocampus subjected to four vessel occlusion
  4918. Neonatal serum magnesium concentrations are determined by total maternal dose of magnesium sulfate administered for Neuroprotection
  4919. Chronic ibuprofen administration reduces neuropathic pain but does not exert Neuroprotection after spinal cord injury in adult rats
  4920. Translational strategies for Neuroprotection in ischemic stroke—focusing on acid-sensing ion channel 1a
  4921. Fast Neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now
  4922. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated Neuroprotection after oxygen and glucose deprivation: role of vascular …
  4923. The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell Neuroprotection in a rat model of optic nerve axotomy
  4924. The extent of neurodegeneration and Neuroprotection in two chemical in vitro models related to Parkinson’s disease is critically dependent on cell culture conditions
  4925. Decreased brain K ATP Channel Contributes to Exacerbating Ischemic brain Injury and the Failure of Neuroprotection by Sevoflurane Post-Conditioning in …
  4926. Combined antiapoptotic and antioxidant approach to acute Neuroprotection for stroke in hypertensive rats
  4927. ERKs and mitochondria-related pathways are essential for glycyrrhizic acid-mediated Neuroprotection against glutamate-induced toxicity in differentiated …
  4928. Marine-derived bioactive materials for Neuroprotection
  4929. Prevention of JNK phosphorylation as a mechanism for rosiglitazone in Neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase
  4930. Chlorpromazine confers Neuroprotection against brain ischemia by activating BKCa channel
  4931. Emerging novel roles of neuropeptide Y in the retina: from neuromodulation to Neuroprotection
  4932. Neuroprotection with erythropoietin in preterm and/or low birth weight infants
  4933. p38 MAPK signaling acts upstream of LIF-dependent Neuroprotection during photoreceptor degeneration
  4934. … role of functionalized magnetic iron oxide nanoparticles in the central nervous system injury and repair: new potentials for Neuroprotection with Cerebrolysin therapy
  4935. Involvement of p-CREB and phase II detoxifying enzyme system in Neuroprotection mediated by the flavonoid calycopterin isolated from Dracocephalum kotschyi
  4936. Targeted delivery of erythropoietin by transcranial focused ultrasound for Neuroprotection against ischemia/reperfusion-induced neuronal injury: a long-term …
  4937. Phosphorylation enhances recombinant HSP27 Neuroprotection against focal cerebral ischemia in mice
  4938. Induction of ischemic stroke in awake freely moving mice reveals that isoflurane anesthesia can mask the benefits of a Neuroprotection therapy
  4939. Aquaporin-4 inhibition mediates piroxicam-induced Neuroprotection against focal cerebral ischemia/reperfusion injury in rodents
  4940. Knocking out DJ-1 attenuates astrocytes Neuroprotection against 6-hydroxydopamine toxicity
  4941. Docosahexaenoic acid augments hypothermic Neuroprotection in a neonatal rat asphyxia model
  4942. Daphnetin, a natural coumarin derivative, provides the Neuroprotection against glutamate-induced toxicity in HT22 cells and ischemic brain injury
  4943. Engineered N-cadherin and L1 biomimetic substrates concertedly promote neuronal differentiation, neurite extension and Neuroprotection of human neural stem cells
  4944. Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate Neuroprotection independent of HDAC inhibition
  4945. Neural repair and Neuroprotection with stem cells in ischemic stroke
  4946. Glycyrrhizic acid confers Neuroprotection after subarachnoid hemorrhage via inhibition of high mobility group box-1 protein: a hypothesis for novel therapy of …
  4947. Neuroprotection in glaucoma
  4948. ARRB1/β-arrestin-1 mediates Neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia
  4949. Crosstalk between delta opioid receptor and nerve growth factor signaling modulates Neuroprotection and differentiation in rodent cell models
  4950. Regulated expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its Neuroprotection on dopaminergic cells in …
  4951. Neuroprotection of atractylenolide III from Atractylodis macrocephalae against glutamate-induced neuronal apoptosis via inhibiting caspase signaling pathway
  4952. Structure and function of Parkin, PINK1, and DJ-1, the three musketeers of Neuroprotection
  4953. Neuroprotection by the kappa-opioid receptor agonist, BRL52537, is mediated via up-regulating phosphorylated signal transducer and activator of transcription-3 in …
  4954. Estimated cerebral oxyhemoglobin as a useful indicator of Neuroprotection in patients with post-cardiac arrest syndrome: a prospective, multicenter …
  4955. GluN2B N‐methyl‐D‐aspartic acid receptor subunit mediates atorvastatin‐Induced Neuroprotection after focal cerebral ischemia
  4956. Spatiotemporal resolution of BDNF Neuroprotection against glutamate excitotoxicity in cultured hippocampal neurons
  4957. Neuroprotection by docosahexaenoic acid in brain injury
  4958. Ischemic preconditioning-induced Neuroprotection against transient cerebral ischemic damage via attenuating ubiquitin aggregation
  4959. Mechanisms of Neuroprotection by glucose in rat retinal cell cultures subjected to respiratory inhibition
  4960. Hemin‑mediated neuroglobin induction exerts Neuroprotection following ischemic brain injury through PI3K/Akt signaling
  4961. Neuroprotection by 6-(methylsulfinyl) hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳ s disease
  4962. Effects of tetrahydrohyperforin in mouse hippocampal slices: Neuroprotection , long-term potentiation and TRPC channels
  4963. Partial Neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep
  4964. Sildenafil promotes Neuroprotection of the pelvic ganglia neurones after bilateral cavernosal nerve resection in the rat
  4965. The role of neuroglobin in the Neuroprotection of limb ischemic preconditioning in rats
  4966. Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer Neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis
  4967. Neuroprotection of S-nitrosoglutathione against ischemic injury by down-regulating Fas S-nitrosylation and downstream signaling
  4968. The divergence–convergence model of acquired Neuroprotection
  4969. Inhibition of brain ischemia-caused notch activation in microglia may contribute to isoflurane postconditioning-induced Neuroprotection in male rats
  4970. Treatment with lutein provides Neuroprotection in mice subjected to transient cerebral ischemia
  4971. Anti-seizure medications and estradiol for Neuroprotection in epilepsy: the 2013 update
  4972. The potential Neuroprotection mechanism of GDNF in the 6-OHDA-induced cellular models of Parkinson’s disease
  4973. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits Neuroprotection in rat model of ischaemic stroke
  4974. Omega-3 fatty acids and traumatic neurological injury: from Neuroprotection to neuroplasticity?
  4975. Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia
  4976. Cell penetrating peptide (CPP)-conjugated desferrioxamine for enhanced Neuroprotection : Synthesis and in vitro evaluation
  4977. Cudarflavone B provides Neuroprotection against glutamate-induced mouse hippocampal HT22 cell damage through the Nrf2 and PI3K/Akt signaling pathways
  4978. Interleukin-10 mediates the Neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice
  4979. Intravenous administration of Honokiol provides Neuroprotection and improves functional recovery after traumatic brain injury through cell cycle inhibition
  4980. … treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: the role of BDNF/TrkB/Erk1/2 signaling in Neuroprotection
  4981. Coumestrol treatment prevents Na+, K+-ATPase inhibition and affords histological Neuroprotection to male rats receiving cerebral global ischemia
  4982. The G Protein‐Coupled Receptor 55 Ligand l‐α‐Lysophosphatidylinositol Exerts Microglia‐Dependent Neuroprotection After Excitotoxic Lesion
  4983. When human immunodeficiency virus meets chemokines and microglia: Neuroprotection or neurodegeneration?
  4984. Targeting mitochondria for Neuroprotection in Parkinson disease
  4985. TrkB receptor agonist 7, 8 dihydroxyflavone triggers profound gender-dependent Neuroprotection in mice after perinatal hypoxia and ischemia
  4986. Sustained Neuroprotection from a single intravitreal injection of PGJ2 in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy
  4987. Studies of (±)-3, 4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to Neuroprotection and neurotoxicity profile
  4988. Neuroprotection of posttreatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a …
  4989. Drug-induced hypothermia by 5HT1A agonists provide Neuroprotection in experimental stroke: new perspectives for acute patient treatment
  4990. GPR30 activation is neither necessary nor sufficient for acute Neuroprotection by 17β-estradiol after an ischemic injury in organotypic hippocampal slice cultures
  4991. The Neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by …
  4992. The early stage formation of PI3K-AMPAR GluR2 subunit complex facilitates the long term Neuroprotection induced by propofol post-conditioning in rats
  4993. Neuroprotection against permanent focal cerebral ischemia by ginkgolides A and B is associated with obstruction of the mitochondrial apoptotic pathway via inhibition …
  4994. Astrocyte‐like cells derived from human oral mucosa stem cells provide Neuroprotection in vitro and in vivo
  4995. Neuroprotection by bilobalide in ischemia: improvement of mitochondrial function
  4996. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes Neuroprotection in conscious hypertensive rats
  4997. Neuroprotection of a novel cyclopeptide C* HSDGIC* from the cyclization of PACAP (1–5) in cellular and rodent models of retinal ganglion cell apoptosis
  4998. RTCB-1 mediates Neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway
  4999. Differential effects of synthetic progestagens on neuron survival and estrogen Neuroprotection in cultured neurons
  5000. Intermittent hypobaric hypoxia induces Neuroprotection in kainate-induced oxidative stress in rats
  5001. Effect of heparin on Neuroprotection against spinal cord ischemia and reperfusion in rats
  5002. Electroacupuncture preconditioning-induced Neuroprotection may be mediated by glutamate transporter type 2
  5003. Differential pattern of Neuroprotection in lumbar, cervical and thoracic spinal cord segments in an organotypic rat model of glutamate-induced excitotoxicity
  5004. Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated Neuroprotection in stroke for middle-aged female rats
  5005. Albumin induces Neuroprotection against ischemic stroke by altering Toll-like receptor 4 and regulatory T cells in mice
  5006. FGF-2 released from degenerating neurons exerts microglial-induced Neuroprotection via FGFR3-ERK signaling pathway
  5007. Influence of delivery method on Neuroprotection by bone marrow mononuclear cell therapy following ventral root reimplantation with fibrin sealant
  5008. Current advances in neurotrauma research: diagnosis, Neuroprotection , and neurorepair
  5009. Copper-zinc superoxide dismutase (SOD1) is released by microglial cells and confers Neuroprotection against 6-OHDA neurotoxicity
  5010. The Neuroprotection of Rattin against amyloid β peptide in spatial memory and synaptic plasticity of rats
  5011. A military-centered approach to Neuroprotection for traumatic brain injury
  5012. Neuroprotection of ischemic postconditioning by downregulating the postsynaptic signaling mediated by kainate receptors
  5013. Bone marrow-derived mononuclear cells do not exert acute Neuroprotection after stroke in spontaneously hypertensive rats
  5014. The essential role of endothelial nitric oxide synthase activation in insulin-mediated Neuroprotection against ischemic stroke in diabetes
  5015. Intranasal pyrrolidine dithiocarbamate decreases brain inflammatory mediators and provides Neuroprotection after brain hypoxia–ischemia in neonatal rats
  5016. Hypothermia plus erythropoietin for neonatal Neuroprotection ? Commentary on Fan et al. and Fang et al.
  5017. Prophylactic Neuroprotection with A91 improves the outcome of spinal cord injured rats
  5018. RNAi screening identifies GSK3β as a regulator of DRP1 and the Neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1
  5019. Hypoxia-inducible factor 1 is essential for spontaneous recovery from traumatic brain injury and is a key mediator of heat acclimation induced Neuroprotection
  5020. PACAP signaling exerts opposing effects on Neuroprotection and neuroinflammation during disease progression in the SOD1 (G93A) mouse model of amyotrophic …
  5021. 2‐Methoxyestradiol confers Neuroprotection and inhibits a maladaptive HIF‐1α response after traumatic brain injury in mice
  5022. P2X7 receptor inhibition increases CNTF in the subventricular zone, but not neurogenesis or Neuroprotection after stroke in adult mice
  5023. Neuroprotection with non-feminizing estrogen analogues: An overlooked possible therapeutic strategy
  5024. Neuroprotection & mechanism of ethanol in stroke and traumatic brain injury therapy: new prospects for an ancient drug
  5025. Neuroprotection and neuroregeneration for retinal diseases
  5026. Antioxidant agents in Neuroprotection treatment of glaucoma
  5027. … sensitivity of acid-sensitive outwardly rectifying (ASOR) anion channels in cortical neurons is involved in hypothermic Neuroprotection against acidotoxic necrosis
  5028. Statin-induced T-lymphocyte modulation and Neuroprotection following experimental subarachnoid hemorrhage
  5029. Paraoxonase-2 (PON2) in brain and its potential role in Neuroprotection
  5030. The role of fatty acids in the regulation of cerebral vascular function and Neuroprotection in ischemia
  5031. Sustained Neuroprotection from a single intravitreal injection of PGJ2 in a rodent model of anterior ischemic optic neuropathy
  5032. … normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for Neuroprotection
  5033. Dose-dependent Neuroprotection of VEGF165 in Huntington’s disease striatum
  5034. Electroacupuncture-induced Neuroprotection against cerebral ischemia in rats: role of the dopamine D2 receptor
  5035. Lymphocyte-mediated Neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways
  5036. Neuroprotection by monocarbonyl dimethoxycurcumin C: ameliorating the toxicity of mutant TDP-43 via HO-1
  5037. Spinal cord injury Neuroprotection and the promise of flexible adaptive clinical trials
  5038. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia
  5039. Involvement of TREK-1 activity in astrocyte function and Neuroprotection under simulated ischemia conditions
  5040. Emulsion-core and polyelectrolyte-shell nanocapsules: biocompatibility and Neuroprotection against SH-SY5Y cells
  5041. Histone deacetylase inhibition leads to Neuroprotection through regulation on glial function
  5042. Functions of the CB1 and CB2 Receptors in Neuroprotection at the Level of the Blood–brain Barrier
  5043. Mitochondrial mechanisms of neuroglobin’s Neuroprotection
  5044. Modulation of neuronal nicotinic receptor by quinolizidine alkaloids causes Neuroprotection on a cellular Alzheimer model
  5045. The future of ischemic stroke: flow from prehospital Neuroprotection to definitive reperfusion
  5046. Hemin offers Neuroprotection through inducing exogenous neuroglobin in focal cerebral hypoxic-ischemia in rats
  5047. Minocycline mechanism of Neuroprotection involves the Bcl-2 gene family in optic nerve transection
  5048. Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent Neuroprotection in rats after stroke
  5049. Fatty acid methyl esters and Solutol HS 15 confer Neuroprotection after focal and global cerebral ischemia
  5050. Are there cognitive and neurobehavioural correlates of hormonal Neuroprotection for women after TBI?
  5051. Neuroprotection and repair of 3′-blocking DNA ends by glaikit (gkt) encoding Drosophila tyrosyl-DNA phosphodiesterase 1 (TDP1)
  5052. Magnesium sulphate at 30 to 34 weeks’ gestational age: Neuroprotection trial (MAGENTA)-study protocol
  5053. Canadian journal of ophthalmology lecture: translational research advances in glaucoma Neuroprotection
  5054. Neuroprotection of a novel synthetic caffeic acid-syringic acid hybrid compound against experimentally induced transient cerebral ischemic damage
  5055. Neuroprotection for acute optic neuritis—Can it work?
  5056. Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal Neuroprotection : the IRIS randomised trial
  5057. Prophylactic angiotensin type 1 receptor antagonism confers Neuroprotection in an aged rat model of postoperative cognitive dysfunction
  5058. Rosiglitazone attenuates cerebral vasospasm and provides Neuroprotection in an experimental rat model of subarachnoid hemorrhage
  5059. A Chinese medicine preparation induces Neuroprotection by regulating paracrine signaling of brain microvascular endothelial cells
  5060. Inhibition of N-myc Downstream–regulated Gene-2 Is Involved in an Astrocyte-specific Neuroprotection Induced by Sevoflurane Preconditioning
  5061. PPAR-γ activator induces Neuroprotection in hypercholesterolemic rats subjected to global cerebral ischemia/reperfusion injury: In vivo and in vitro inhibition of …
  5062. Is cholesterol and amyloid-β stress induced CD147 expression a protective response? Evidence that extracellular cyclophilin a mediated Neuroprotection is reliant on …
  5063. Inhibition of transforming growth factor beta-activated kinase 1 confers Neuroprotection after traumatic brain injury in rats
  5064. IL-6, A1 and A2aR: A crosstalk that modulates BDNF and induces Neuroprotection
  5065. Nicotine-induced Neuroprotection against ischemic injury involves activation of endocannabinoid system in rats
  5066. An active component of Achyranthes bidentata polypeptides provides Neuroprotection through inhibition of mitochondrial-dependent apoptotic pathway in …
  5067. Vehicles for lipophilic drugs: implications for experimental design, Neuroprotection , and drug discovery
  5068. Lack of resveratrol Neuroprotection in developing rats treated with kainic acid
  5069. Sesamin suppresses activation of microglia and p44/42 MAPK pathway, which confers Neuroprotection in rat intracerebral hemorrhage
Related Posts

Lipid Droplets

Inhibits Lipid Droplet Accumulation

Conditioned Place Preference

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping